<SEC-DOCUMENT>0001564590-21-026534.txt : 20210511
<SEC-HEADER>0001564590-21-026534.hdr.sgml : 20210511
<ACCEPTANCE-DATETIME>20210511160549
ACCESSION NUMBER:		0001564590-21-026534
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		53
CONFORMED PERIOD OF REPORT:	20210331
FILED AS OF DATE:		20210511
DATE AS OF CHANGE:		20210511

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARCA biopharma, Inc.
		CENTRAL INDEX KEY:			0000907654
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				363855489
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-22873
		FILM NUMBER:		21911260

	BUSINESS ADDRESS:	
		STREET 1:		10170 CHURCH RANCH WAY
		STREET 2:		SUITE 100
		CITY:			WESTMINSTER
		STATE:			CO
		ZIP:			80021
		BUSINESS PHONE:		7209402200

	MAIL ADDRESS:	
		STREET 1:		10170 CHURCH RANCH WAY
		STREET 2:		SUITE 100
		CITY:			WESTMINSTER
		STATE:			CO
		ZIP:			80021

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUVELO INC
		DATE OF NAME CHANGE:	20030203

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HYSEQ INC
		DATE OF NAME CHANGE:	19970610
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>abio-10q_20210331.htm
<DESCRIPTION>10-Q
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
abio-10q_20210331.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="border-top:Solid 0.75pt #000000;padding-top:0pt;text-align:center;margin-top:1pt;line-height:1pt;margin-bottom:0pt;text-indent:0%;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;border-top:Solid 1pt;padding-top:1pt;margin-top:1pt;line-height:1pt;margin-bottom:0pt;text-indent:0%;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">WASHINGTON, D.C. 20549 </p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;line-height:4pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM 10-Q </p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;line-height:4pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Mark One) </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Segoe UI Symbol;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">&#9746;</p></td>
<td valign="top"  style="width:96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2021 </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">OR </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:4%;">
<p style="margin-bottom:0pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Segoe UI Symbol;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
<td valign="top"  style="width:96%;">
<p style="margin-bottom:0pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FOR THE TRANSITION PERIOD FROM <font style="text-decoration:underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> TO <font style="text-decoration:underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Commission File Number 000-22873 </p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;line-height:4pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:3pt;text-indent:0%;font-weight:bold;font-size:24pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARCA BIOPHARMA, INC. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Exact Name of Registrant as Specified in Its Charter) </p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;line-height:4pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:49%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Delaware</p></td>
<td valign="bottom"  style="width:2%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:49%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">36-3855489</p></td>
</tr>
<tr>
<td valign="top"  style="width:49%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(State or Other Jurisdiction of<br />Incorporation or Organization)</p></td>
<td valign="bottom"  style="width:2%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:49%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(I.R.S. Employer<br />Identification Number)</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td colspan="2" valign="middle"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:49%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">10170 Church Ranch Way, Suite 100, Westminster, CO</p></td>
<td valign="bottom"  style="width:2%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:49%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">80021</p></td>
</tr>
<tr>
<td valign="top"  style="width:49%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Address of Principal Executive Offices)</p></td>
<td valign="bottom"  style="width:2%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:49%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Zip Code)</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(720) 940-2200 </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Registrant&#8217;s Telephone Number, including Area Code) </p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;line-height:4pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:4pt;margin-bottom:6pt;text-indent:5.06%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section 12(b) of the Act:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:86.67%;">
<tr>
<td style="width:25.83%;"></td>
<td style="width:20%;"></td>
<td style="width:40.83%;"></td>
</tr>
<tr style="height:12.65pt;">
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title of each class</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Trading Symbol(s)</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name of each exchange on which registered</p></td>
</tr>
<tr style="height:16.6pt;">
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common Stock, par value $0.001 per share</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ABIO</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nasdaq Capital Market</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:5.87%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;Yes&#160;&#160;<font style="font-family:Segoe UI Symbol;">&#9746;</font>&#160;&#160;&#160;&#160;No&#160;&#160;<font style="font-family:Segoe UI Symbol;">&#9744;</font> </p>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:5.87%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;Yes&#160;&#160;<font style="font-family:Segoe UI Symbol;">&#9746;</font>&#160;&#160;&#160;&#160;No&#160;&#160;<font style="font-family:Segoe UI Symbol;">&#9744;</font> </p>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:5.87%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr style="height:10.8pt;">
<td valign="top"  style="width:19.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Large&#160;accelerated&#160;filer</p></td>
<td valign="top"  style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:55.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
<td valign="top"  style="width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="width:20.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accelerated&#160;filer</p></td>
<td valign="top"  style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
</tr>
<tr style="height:3.75pt;">
<td valign="top"  style="width:19.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:56.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:21.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:2.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-accelerated filer</p></td>
<td valign="top"  style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:55.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9746;&#160;&#160;</p></td>
<td valign="top"  style="width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="width:20.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Smaller&#160;reporting&#160;company</p></td>
<td valign="top"  style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9746;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="top"  style="width:55.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="top"  style="width:20.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="top"  style="width:2.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emerging growth company</p></td>
<td valign="top"  style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:55.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
<td valign="top"  style="width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:20.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:2.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.33%;font-size:4pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.33%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;<font style="font-family:Segoe UI Symbol;">&#9744;</font></p>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:5.06%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;<font style="font-family:Segoe UI Symbol;">&#9744;</font>&#160;&#160;&#160;&#160;No&#160;&#160;<font style="font-family:Segoe UI Symbol;">&#9746;</font> </p>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:5.06%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate the number of shares outstanding of each of the issuer&#8217;s classes of common stock, as of the latest practicable date. </p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%; border-bottom:solid 1pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Class</p></td>
<td valign="bottom"  style="width:2%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:48%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number&#160;of<br />Shares&#160;Outstanding</p></td>
</tr>
<tr>
<td valign="top"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common Stock, par value $0.001 per share</p></td>
<td valign="bottom"  style="width:2%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="width:48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On May 10, 2021: 14,410,143</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:10pt;border-top:Solid 0.75pt #000000;padding-top:0pt;text-align:center;line-height:1pt;margin-bottom:0pt;text-indent:0%;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;border-top:Solid 1pt;padding-top:1pt;margin-top:1pt;line-height:1pt;margin-bottom:0pt;text-indent:0%;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARCA BIOPHARMA, INC. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM 10-Q </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FOR THE QUARTER ENDED MARCH 31, 2021 </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:auto;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PAGE</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_I"><font style="text-decoration:underline;">Part&#160;I Financial Information</font></a></p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:36pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1"><font style="text-decoration:underline;">Item&#160;1. Financial Statements (unaudited)</font></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="bottom"  style="width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:36pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_2"><font style="text-decoration:underline;">Item&#160;2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p></td>
<td valign="bottom"  style="width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:36pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_3"><font style="text-decoration:underline;">Item&#160;3. Quantitative and Qualitative Disclosures about Market Risk</font></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td>
<td valign="bottom"  style="width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:36pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_4"><font style="text-decoration:underline;">Item&#160;4. Controls and Procedures</font></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td>
<td valign="bottom"  style="width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_II"><font style="text-decoration:underline;">Part&#160;II Other Information</font></a></p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:36pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1_LEGAL"><font style="text-decoration:underline;">Item&#160;1. Legal Proceedings</font></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p></td>
<td valign="bottom"  style="width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:36pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Item_1A_Risk"><font style="text-decoration:underline;">Item&#160;1A. Risk Factors</font></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p></td>
<td valign="bottom"  style="width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:36pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_2_UNREGISTERED"><font style="text-decoration:underline;">Item&#160;2. Unregistered Sales of Equity Securities and Use of Proceeds</font></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</p></td>
<td valign="bottom"  style="width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:36pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_3_DEFAULTS"><font style="text-decoration:underline;">Item&#160;3. Defaults Upon Senior Securities</font></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</p></td>
<td valign="bottom"  style="width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:36pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_4_MINE"><font style="text-decoration:underline;">Item&#160;4. Mine Safety Disclosures</font></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</p></td>
<td valign="bottom"  style="width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:36pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_5_OTHER"><font style="text-decoration:underline;">Item&#160;5. Other Information</font></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</p></td>
<td valign="bottom"  style="width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:36pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_6_EXHIBITS"><font style="text-decoration:underline;">Item 6. Exhibits</font></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</p></td>
<td valign="bottom"  style="width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#SIGNATURE"><font style="text-decoration:underline;">Signature</font></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</p></td>
<td valign="bottom"  style="width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="PART_I"></a><a name="PART_I"></a>PART I. FINANCIAL INFORMATION </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:9.06%;text-indent:-9.06%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_1"></a><a name="ITEM_1"></a>ITEM&#160;1. FINANCIAL STATEMENTS </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARCA BIOPHARMA, INC. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">BALANCE SHEETS </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited) </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.16%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.08%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.08%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except share</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">and per share amounts)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ASSETS</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current assets:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66,933</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,071</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other current assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,797</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">897</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68,730</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,968</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use asset - operating</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.08%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">414</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.08%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">428</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.08%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69,183</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.08%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,429</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.08%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.08%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current liabilities:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,578</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,773</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued compensation and employee benefits</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">255</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">815</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses and other liabilities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,047</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">911</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current liabilities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,880</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,499</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liability, net of current portion</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">394</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">409</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,274</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,908</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commitments and contingencies</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.08%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.08%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Stockholders&#8217; equity:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock, $0.001 par value; 100 million shares authorized</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; at March 31, 2021 and December 31, 2020; 14,410,143</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; and 9,548,150 shares issued and outstanding at</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;March 31, 2021 and December 31, 2020, respectively</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional paid-in capital</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">224,149</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">200,665</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated deficit</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(158,254</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(154,154</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total stockholders&#8217; equity</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65,909</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46,521</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities and stockholders&#8217; equity</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.08%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69,183</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.08%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,429</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See accompanying Notes to Financial Statements </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARCA BIOPHARMA, INC. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">STATEMENTS OF OPERATIONS</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(unaudited) </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except share</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">and per share amounts)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Costs and expenses:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,876</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">365</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,226</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">975</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total costs and expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,102</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,340</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,102</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,340</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest and other income</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,100</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,320</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic and diluted</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.33</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.83</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average shares outstanding:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic and diluted</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,356,928</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,594,070</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See accompanying Notes to Financial Statements </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARCA BIOPHARMA, INC. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(unaudited) </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="18" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stockholders&#8217; Equity</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.44%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Additional</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.24%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Paid-In</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.72%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.44%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Capital</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.26%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deficit</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="18" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except share amounts)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance, December 31, 2019</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1,594,070</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">152,024</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(144,416</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">7,610</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Share-based compensation</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,320</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,320</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance, March 31, 2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1,594,070</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">152,040</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(145,736</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">6,306</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock and exercise</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; of prefunded warrants for cash,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; net of offering costs</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">673,500</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,297</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,297</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Share-based compensation</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,302</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,302</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance, June 30, 2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2,267,570</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">157,341</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(147,038</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">10,305</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock for cash,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; net of offering costs</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,018,054</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,129</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,136</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Share-based compensation</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,991</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,991</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance, September 30, 2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">9,285,624</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">9</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">199,475</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(149,029</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">50,455</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock for cash,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; net of offering costs</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">262,526</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,172</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,173</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Share-based compensation</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,125</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,125</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance, December 31, 2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">9,548,150</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">10</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">200,665</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(154,154</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">46,521</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock for cash,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; net of offering costs</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,861,993</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,343</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,347</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Share-based compensation</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">141</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">141</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,100</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,100</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.58%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance, March 31, 2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">14,410,143</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">14</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">224,149</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(158,254</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">65,909</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See accompanying Notes to Financial Statements</p>
<p style="text-align:center;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:10pt;margin-top:0pt;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;letter-spacing:-0.1pt;">ARCA BIOPHARMA, INC.</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:3pt;text-indent:0%;font-weight:bold;font-size:9pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">STATEMENTS OF CASH FLOWS </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:9pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(unaudited) </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.74%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.74%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.74%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.74%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.74%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.74%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.6%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash flows from operating activities:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,100</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,320</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adjustments to reconcile net loss to net cash used</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; in operating activities:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization of right-of-use asset - operating</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Share-based compensation</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">141</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in operating assets and liabilities:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other current assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(840</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(75</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(293</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued compensation and employee benefits</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(560</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses and other liabilities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(99</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in operating activities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,225</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,686</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash flows from investing activities:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.74%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.74%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchases of property and equipment</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in investing activities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash flows from financing activities:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.74%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.74%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from the issuance of common stock</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,070</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock offering costs</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(977</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,093</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Net increase (decrease) in cash and cash equivalents</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.74%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,862</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.74%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,689</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents, beginning of period</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,071</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,363</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents, end of period</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66,933</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,674</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Supplemental cash flow information:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.74%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.74%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest paid</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.74%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.74%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax refund received</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.74%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.74%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Supplemental disclosure of noncash investing and financing</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; transactions:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.74%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.74%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchases of property and equipment in accounts payable</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.74%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.74%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vendor finance agreement</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.74%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.74%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">408</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leased assets obtained in exchange for operating lease liabilities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.74%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.74%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See accompanying Notes to Financial Statements </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;;font-size:4pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARCA BIOPHARMA, INC. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTES TO FINANCIAL STATEMENTS </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(unaudited) </p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(1) The Company and Summary of Significant Accounting Policies </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Description of Business </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARCA biopharma, Inc. (the Company or ARCA), a Delaware corporation, is headquartered in Westminster, Colorado. The Company is a clinical-stage biopharmaceutical company applying a precision medicine approach to the development and commercialization of genetically targeted therapies for cardiovascular diseases. The Company&#8217;s lead product candidates are rNAPc2 (AB201) as a potential treatment for diseases caused by ribonucleic acid, or RNA, viruses, initially focusing on COVID-19, the disease caused by SARS-CoV-2 virus, and Gencaro&#8482; (bucindolol hydrochloride) for the treatment of atrial fibrillation (AF) in patients with chronic heart failure (HF).&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rNAPc2 is a protein therapeutic in clinical development as a potential treatment for patients hospitalized with COVID-19. Based on its unique mechanism of action, development history and the clinical evidence from the SARS&#8209;CoV-2 pandemic, the Company believes rNAPc2 has potential to be a beneficial therapy for patients with this serious viral disease. The Company initiated the Phase 2b clinical trial of rNAPc2 as a potential treatment for patients hospitalized with COVID-19 in the fourth quarter of 2020.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk496097166"></a>The Company continues to evaluate the feasibility and potential timing for initiating PRECISION-AF relative to the COVID-19 pandemic and prioritizing the development of rNAPc2.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk512436189"></a>The Company&#8217;s other product candidate, AB171, is a thiol-substituted isosorbide mononitrate, which ARCA plans to develop as a genetically-targeted treatment for HF and peripheral arterial disease. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2020, the World Health Organization declared the outbreak of COVID-19, a novel strain of Coronavirus, a global pandemic. This outbreak is causing major disruptions to businesses and markets worldwide as the virus spreads. The Company does not expect a material financial effect as a result of the pandemic. However, if the pandemic continues to be a severe worldwide crisis, it could have a material adverse effect on the Company&#8217;s business, results of operations, financial condition and cash flows.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Liquidity and Going Concern </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company devotes substantially all of its efforts towards obtaining regulatory approval and raising capital necessary to fund its operations and it is subject to a number of risks associated with clinical research and development, including dependence on key individuals, the development of and regulatory approval of commercially viable products, the need to raise adequate additional financing necessary to fund the development and commercialization of its products, and competition from larger companies. The Company has not generated revenue to date and has incurred substantial losses and negative cash flows from operations since its inception.&nbsp;&nbsp;The Company has historically funded its operations through issuances of common and preferred stock.&nbsp;&nbsp; </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company believes that its current cash and cash equivalents as of March 31, 2021<font style="Background-color:#FFFFFF;color:#000000;"> </font>will be sufficient to fund its operations through <font style="Background-color:#FFFFFF;color:#000000;">the end of fiscal year </font>2022. <font style="Background-color:#FFFFFF;color:#000000;">Conducting a Phase 3 rNAPc2 clinical trial or the Phase 3 PRECISION-AF trial would likely require additional financing</font>. <font style="Background-color:#FFFFFF;color:#000000;">However, changing circumstances may cause us to consume capital significantly faster or slower than currently anticipated. The Company has based these estimates on assumptions that may prove to be wrong, and the Company could exhaust its available financial resources sooner than the Company currently anticipates. Therefore, the Company may have to raise additional capital for clinical trials of </font>rNAPc2<font style="Background-color:#FFFFFF;color:#000000;"> and will have to raise additional capital for clinical trials of Gencaro. The Company may not be able to raise sufficient capital on acceptable terms, or at all, to continue development of </font>rNAPc2<font style="Background-color:#FFFFFF;color:#000000;"> or Gencaro or to otherwise continue operations and may not be able to execute any strategic transaction</font>.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s liquidity, and its ability to raise additional capital or complete any strategic transaction, depends on a number of factors, including, but not limited to, the following: </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;"></font>&#9679;</p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the costs and timing for the potential additional clinical trials in order to gain possible regulatory approval for rNAPc2, Gencaro or any other product candidate; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;"></font>&#9679;</p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the market price of the Company&#8217;s stock and the availability and cost of additional equity capital from existing and potential new investors; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;"></font>&#9679;</p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the Company&#8217;s ability to retain the listing of its common stock on the Nasdaq Capital Market; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;"></font>&#9679;</p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">general economic and industry conditions affecting the availability and cost of capital, including as a result of the COVID-19 pandemic; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;"></font>&#9679;</p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;"></font>&#9679;</p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the terms and conditions of the Company&#8217;s existing collaborative and licensing agreements. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The sale of additional equity or convertible debt securities would likely result in substantial additional dilution to the Company&#8217;s stockholders. If the Company raises additional funds through the incurrence of indebtedness, the obligations related to such indebtedness would be senior to rights of holders of the Company&#8217;s capital stock and could contain covenants that would restrict the Company&#8217;s operations. The Company also cannot predict what consideration might be available, if any, to the Company or its stockholders, in connection with any strategic transaction. Should strategic alternatives or additional capital not be available to the Company, or not be available on acceptable terms, the Company may be unable to realize value from its assets and discharge its liabilities in the normal course of business which may, among other alternatives, cause the Company to further delay, substantially reduce or discontinue operational activities to conserve its cash resources.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Basis of Presentation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying unaudited financial statements of the Company were prepared in accordance with generally accepted accounting principles for interim financial information and instructions to Form 10-Q and pursuant to Regulation S-X.&nbsp;&nbsp;Accordingly, these financial statements do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America (GAAP) for complete financial statements.&#160; In the opinion of management, these financial statements include all normal and recurring adjustments considered necessary for a fair presentation of these interim financial statements.&nbsp;&nbsp;The results of operations for the three months ended March 31, 2021 are not necessarily indicative of results expected for the full year ending December&#160;31, 2021.&#160; The Company has generated no revenue to date and its activities have consisted of seeking regulatory approval, research and development, exploring strategic alternatives for further developing and commercializing rNAPc2 and Gencaro, and raising capital. These unaudited financial statements should be read in conjunction with the audited financial statements and footnotes thereto for the year ended December&#160;31, 2020 included in the Company&#8217;s Annual Report on Form 10-K filed with the Securities and Exchange Commission. Amounts presented are rounded to the nearest thousand, where indicated, except per share data and par values.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentrations of Credit Risk </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company has no off-balance-sheet concentrations of credit risk, such as foreign exchange contracts, option contracts, or foreign currency hedging arrangements. The Company maintains cash and cash equivalent balances in the form of bank demand deposits and money market fund accounts with financial institutions that management believes are creditworthy. Such balances may at times exceed the insured amount. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Comprehensive Loss</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive loss is defined as the change in equity during a period from transactions and other events and/or circumstances from non-owner sources. If the Company had comprehensive gains (losses), they would be reflected in the statement of operations and comprehensive loss and as a separate component in the statement of stockholders&#8217; equity. There were no elements of comprehensive loss during the three months ended March 31, 2021&#160;and&#160;2020.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Leases</font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determines if an arrangement is a lease at inception.&nbsp;&nbsp;Operating leases are included in right-of-use (ROU) asset &#8211; operating and lease obligations are included in accrued expenses and other liabilities and operating lease liability on the Company&#8217;s March 31, 2021 and December&#160;31, 2020 balance sheets.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ROU lease assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease obligations represent the Company&#8217;s obligation to make lease payments arising from the lease. Operating ROU lease assets are recognized at the commencement date based on the present value of lease payments over the lease term. As the Company&#8217;s lease does not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments.&nbsp;&nbsp;The Company&#8217;s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Accrued Outsourcing Expenses </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of the process of preparing its financial statements, the Company is required to estimate accrued outsourcing expenses. This process involves identifying services that third parties have performed on the Company&#8217;s behalf and estimating the level of service performed and the associated cost incurred for these services as of the balance sheet date. Examples of estimated accrued outsourcing expenses include contract service fees, such as fees payable to contract manufacturers in connection with the production of materials related to the Company&#8217;s drug product, and service fees and pass through costs from clinical research organizations. The Company develops estimates of liabilities using its judgment based upon the facts and circumstances known at the time. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Recent Accounting Pronouncements</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company reviewed recently issued accounting pronouncements and concluded that they were either not applicable or not expected to have a significant impact to the financial statements.</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(2) Net Loss Per Share </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company calculates basic earnings per share by dividing net loss by the weighted average common shares outstanding during the period. Diluted earnings per share is computed by dividing net loss by the weighted average number of common shares outstanding during the period increased to include, if dilutive, the number of additional common shares that would have been outstanding if the potential common shares had been issued. The Company&#8217;s potentially dilutive shares include stock options and warrants for common stock<font style="letter-spacing:-0.1pt;">. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because the Company reported a net loss for the three months ended March 31, 2021 and 2020, all potentially dilutive shares of common stock have been excluded from the computation of the dilutive net loss per share for all periods presented.<font style="font-size:12pt;">&nbsp;&nbsp;</font>Such potentially dilutive shares of common stock consist of the following:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.8%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Potentially dilutive securities, excluded:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding stock options</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">596,497</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,890</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants to purchase common stock</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">133,401</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">133,401</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.18%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">729,898</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">164,291</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(3) Fair Value Disclosures </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There were no marketable securities as of March 31, 2021 or December 31, 2020.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). Inputs used to measure fair value are classified into the following hierarchy: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;"></font>&#9679;</p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Level 1&#8212;Unadjusted quoted prices in active markets for identical assets or liabilities.&nbsp;&nbsp;The Company&#8217;s Level 1 assets consist of money market investments.&nbsp;&nbsp;The Company does not have any Level 1 liabilities.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;"></font>&#9679;</p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Level 2&#8212;Unadjusted quoted prices in active markets for similar assets or liabilities; unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active; or inputs other than quoted prices that are observable for the asset or liability.&nbsp;&nbsp;The Company does not have any Level 2 assets or liabilities. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;"></font>&#9679;</p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Level 3&#8212;Unobservable inputs for the asset or liability.&nbsp;&nbsp;The Company does not have any Level 3 assets or liabilities. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March 31, 2021 and December 31, 2020, the Company had $66.9 million and $49.1 million, respectively, of cash equivalents consisting of money market funds with original maturities of 90 days or less. The Company has the ability to liquidate these investments without restriction. The Company determines fair value for these money market funds with Level 1 inputs through quoted market prices. There were no transfers of assets between fair value hierarchy levels during the three-month period ended March&#160;31,&#160;2021. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"> Fair Value of Other Financial Instruments </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The carrying amount of other financial instruments, including accounts payable and a vendor finance agreement, which are included in accounts payable and accrued expenses and other liabilities, approximated fair value due to their short maturities. </p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(4) Property and Equipment</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment consist of the following (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Estimated Life</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.1%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 years</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lab equipment</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5 years</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">146</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">146</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and fixtures</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5 years</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer software</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:20.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 years</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">280</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">271</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated depreciation and amortization</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:20.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(253</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(250</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.52%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:20.1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the three months ended March 31, 2021 and 2020, depreciation and amortization expense was $3,000 and $3,000, respectively. </p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(5) Related Party Arrangements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Transactions with the Company&#8217;s President and Chief Executive Officer </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has entered into unrestricted research grants with its President and Chief Executive Officer&#8217;s academic research laboratory at the University of Colorado. Funding of any unrestricted research grants is contingent upon the Company&#8217;s financial condition, and can be deferred or terminated at the Company&#8217;s discretion. Total expense under these arrangements for the three months ended March 31, 2021 and 2020 was $107,000 and $70,000 respectively.&nbsp;&nbsp; </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(6) Commitments and Contingencies </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has or is subject to the following commitments and contingencies. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Employment Agreements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company maintains employment agreements with several key executive employees. The agreements may be terminated at any time by the Company with or without cause upon written notice to the employee, and entitle the employee to wages in lieu of notice for periods not exceeding one calendar year from the date of termination without cause or by the employee for good reason. Certain of these agreements also provide for payments to be made under certain conditions related to a change in control of the Company. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Operating Lease </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On August&#160;1, 2013 the Company entered into a lease agreement for approximately 5,300 square feet of office facilities in Westminster, Colorado which served as the Company&#8217;s primary business office from October&#160;1, 2013 until September 30, 2020.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On August&#160;29, 2020 the Company entered into a lease agreement for approximately 5,200 square feet of office facilities in Westminster, Colorado which serves as the Company&#8217;s primary business office effective October&#160;1, 2020 (October 2020 Lease). The lease term is 42 months beginning October 1, 2020 and includes an option to renew for an additional 36 month term at the then prevailing rental rate. The exercise of the lease renewal option is at the Company&#8217;s sole discretion.&nbsp;&nbsp;The amounts recorded assume the Company will exercise its renewal option. The lease includes real estate taxes and insurance, which is not a lease component and is not included in the lease obligation.&nbsp;&nbsp;In addition, common area maintenance charges are based on actual costs incurred and are a non-lease component that is not included in the lease obligation.  </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Future minimum commitments due under the October 2020 Lease agreement as of March 31, 2021 are as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:55.82%;">
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Remainder of 2021</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">125</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total remaining lease payments</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.56%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">556</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: imputed lease interest</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(106</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: Current portion</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(56</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.78%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liability, net of current portion</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">394</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rent expense, which is included in general and administrative expense, for the three months ended March 31, 2021 and 2020 was $22,000 and $23,000, respectively. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March 31, 2021, the lease liability was $450,000, and the current portion is included in accrued expenses and other liabilities and the non-current portion is in operating lease liability, net of current portion in the accompanying balance sheet. Cash paid for amounts included in the measurement of lease liabilities and the operating cash flows from operating leases for the three months ended March 31, 2021 and 2020 were $7,000 and $25,000, respectively. The weighted-average remaining lease term for the operating lease as of March&#160;31, 2021 is 6.0&#160;years. The discount rate for the operating lease is 7%.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(7) <font style="font-style:italic;">Equity Financings and Warrants</font> </p>
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Registered Direct Financing</p>
<p style="margin-bottom:12pt;margin-top:6pt;line-height:11pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On June 3, 2020, the Company closed a registered direct offering with certain institutional and accredited investors of 348,000 shares of the Company&#8217;s common stock, at a purchase price of $9.00 per share, and pre-funded warrants to purchase 325,500 shares of common stock at a purchase price of $8.999 per warrant. All warrants were exercised by the closing date. The net proceeds were approximately $5.3 million, after deducting placement agent fees and other offering expenses. The Company paid JonesTrading a placement agent fee equal to 8.0% of the aggregate gross proceeds and agreed to provide JonesTrading with customary indemnification and contribution rights.&nbsp;&nbsp;<font style="font-size:12pt;"> </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">At the Market Equity Financing </p>
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January&#160;11, 2017, the Company entered into a Capital on Demand<font style="font-size:8.5pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top"> TM</sup></font>&#160;Sales Agreement (the Sales Agreement) with JonesTrading Institutional Services LLC, as agent (JonesTrading), pursuant to which the Company may offer and sell, from time to time through JonesTrading, shares of the Company&#8217;s common stock, par value $0.001 per share (the Common Stock), having an aggregate offering price of up to $7.3&#160;million.&nbsp;&nbsp;On August&#160;21, 2017, January 25, 2019, March 11, 2019, May 9, 2019, May 20, 2019, June 28, 2019, July&#160;2, 2020 and July 14, 2020, the Company amended its Capital on Demand Sales Agreement. The amendments, among other things, increased the maximum aggregate offering value of shares of the Company&#8217;s common stock which the Company may issue and sell from time to time under the Sales Agreement<font style="font-size:12pt;">&#160;</font>from $7.3 million to $32.4&#160;million (the Shares).&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the amended Sales Agreement, JonesTrading may sell the Shares by any method permitted by law and deemed to be an &#8220;at the market offering&#8221; as defined in Rule 415 promulgated under the Securities Act of 1933, as amended, including sales made directly on or through the Nasdaq Capital Market, on any other existing trading market for the Common Stock or to or through a market maker. In addition, under the amended Sales Agreement, JonesTrading may sell the Shares by any other method permitted by law, including in negotiated transactions. The Company may instruct JonesTrading not to sell Shares if the sales cannot be effected at or above the price designated by the Company from time to time. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is not obligated to make any sales of the Shares under the amended Sales Agreement. The offering of Shares pursuant to the amended Sales Agreement will terminate upon the earlier of (a)&#160;the sale of all of the Shares subject to the amended Sales Agreement or (b)&#160;the termination of the amended Sales Agreement by JonesTrading or the Company, as permitted therein. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company paid JonesTrading a commission rate equal to 3.0% of the aggregate gross proceeds from each sale of Shares and agreed to provide JonesTrading with customary indemnification and contribution rights. The Company will also reimburse JonesTrading for certain specified expenses in connection with entering into and amending the Sales Agreement. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the amended Sales Agreement, the Company sold an aggregate of 2,214,301 <font style="font-size:6pt;">&#160;</font>shares of Common Stock, for net proceeds of approximately $14.4 million, during the year ended December 31, 2020, including initial expenses for executing the &#8220;at the market offering&#8221; and commissions to the placement agent. This sales agreement terminated in July 2020.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;line-height:11pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July 22, 2020, the Company entered into a new Capital on Demand<font style="font-size:8.5pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top"> TM</sup></font>&#160;Sales Agreement (the 2020 Sales Agreement) with JonesTrading, pursuant to which the Company may offer and sell, from time to time through JonesTrading, shares of the Company&#8217;s Common Stock, having an aggregate offering price of up to $54.0&#160;million. During the three months ended March 31, 2021 and the year ended December 31, 2020, the Company had sold an aggregate of 4,861,993 and 5,066,279 shares of its Common Stock pursuant to the terms of the 2020 Sales Agreement for net proceeds of approximately $23.3 million and $28.9&#160;million, respectively, after deducting expenses for executing the &#8220;at the market offering&#8221; and commissions paid to the placement agent.</p>
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk46826700"></a><a name="_Hlk46826720"></a>In April 2021, the Company amended the 2020 Sales Agreement and has $50.0<a name="_Hlk46826720"></a> million available for the offering under its prospectus to the Company&#8217;s registration statement on Form S-3 (No. 333-254585).</p>
<p style="margin-bottom:0pt;margin-top:16pt;line-height:11pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Warrants </p>
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants to purchase shares of common stock were previously granted as part of various financing and business agreements.&nbsp;&nbsp;All outstanding warrants were recorded in additional paid-in capital at their estimated fair market value at the date of grant using a Black-Scholes option-pricing model. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 31</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, 202</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, these warrants, by year of expiration, are summarized below:</font></p>
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:60%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.16%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year of Expiration</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.36%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Number</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">of Warrants</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.62%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Weighted Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exercise Price</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.16%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.36%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">133,401</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.62%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109.80</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;line-height:11pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(8) Share-based Compensation </p>
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the three month periods ended March 31, 2021 and 2020, the Company recognized the following non-cash, share-based compensation expense in the statements of operations (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Three Months</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Ended March 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.88%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">141</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock option transactions for the three month period ended March 31, 2021 under the Company&#8217;s stock incentive plans were as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Number</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">of Options</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Weighted Average Exercise Price</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Term</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(in years)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options outstanding at December&#160;31, 2020</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">531,238</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.71</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.68</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67,200</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.30</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited and cancelled</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,941</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72.33</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options outstanding at March 31, 2021</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">596,497</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.01</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.51</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options exercisable at March 31, 2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66,125</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38.02</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.68</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options vested and expected to vest</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">595,774</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.01</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.51</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(9) Income Taxes </p>
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In accordance with GAAP, a valuation allowance should be provided if it is more likely than not that some or all of the Company&#8217;s deferred tax assets will not be realized.&nbsp;&nbsp;The Company&#8217;s ability to realize the benefit of its deferred tax assets will depend on the generation of future taxable income. Due to the uncertainty of future profitable operations and taxable income, the Company has recorded a full valuation allowance against its net deferred tax assets.&nbsp;&nbsp;The Company believes its tax filing positions and deductions related to tax periods subject to examination will be sustained upon audit and, therefore, has no reserve for uncertain tax positions.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_2"></a><a name="ITEM_2"></a>ITEM&#160;2. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">This Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations contains &#8220;forward-looking statements&#8221; within the meaning of Section&#160;27A of the Securities Act of 1933, as amended, or the Securities Act, Section&#160;21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and the Private Securities Litigation Reform Act of 1995. Examples of these statements include, but are not limited to, statements regarding the following: potential future development plans for rNAPc2 (AB201) and Gencaro, including the potential for rNAPc2 to treat COVID-19, our ability to secure sufficient financing to support our anticipated clinical trials of rNAPc2 and Gencaro, the likelihood that any Phase 3 clinical trial results for Gencaro will satisfy the requirements of our Special Protocol Assessment agreement, the expected features and characteristics of Gencaro, including the potential for genetic variations to predict individual patient response to Gencaro or AB171, Gencaro&#8217;s potential to treat atrial fibrillation, or AF, future vaccines and treatment options for patients with COVID-19, future treatment options for patients with AF, the potential for Gencaro to be the first genetically-targeted AF prevention treatment, statements regarding potential Phase&#160;3 development plans for Gencaro, including the timing and results thereof, the expected features and characteristics of AB171 as a potential genetically-targeted treatment for peripheral arterial disease, or PAD, and for heart failure, or HF, the potential timeline for development of AB171, including any Investigational New Drug, or IND, application submission related thereto, and the ability of ARCA&#8217;s financial resources to support its operations through the end of fiscal year 2022, the sufficiency of our current capital to reach certain of our corporate objectives, our ability to obtain additional funding when needed or enter into a strategic or other transaction, including our ability to raise sufficient capital to fund any clinical trials for rNAPc2 and Gencaro and our other operations, the extent to which our issued and pending patents may protect our products and technology, the potential of such product candidates to lead to the development of safe or effective therapies, our ability to enter into collaborations, our ability to maintain listing of our common stock on a national exchange, our future operating expenses, our future losses, our future expenditures, and the sufficiency of our cash resources to maintain operations. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors discussed herein and elsewhere. These and other factors are identified and described in more detail in ARCA&#8217;s filings with the U.S. Securities and Exchange Commission, or the SEC, including without limitation our annual report on Form 10-K for the year ended December&#160;31,&#160;2019, and subsequent filings. Forward-looking statements may be identified by words including &#8220;will,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;intend,&#8221; &#8220;estimates,&#8221; &#8220;expect,&#8221; &#8220;should,&#8221; &#8220;may,&#8221; &#8220;potential&#8221; and similar expressions. We disclaim any intent or obligation to update these forward-looking statements. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The terms &#8220;ARCA,&#8221; &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; and similar terms refer to ARCA biopharma, Inc. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Overview </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a clinical-stage biopharmaceutical company applying a precision medicine approach to the development and commercialization of targeted therapies for cardiovascular diseases. Precision medicine refers to the tailoring of medical treatment to the individual characteristics of patients, using genomic, non-genomic biomarker and other information that extends beyond routine diagnostic categorization. We believe that when implemented correctly precision medicine can enhance therapeutic response, improve patient outcomes, and reduce healthcare costs. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our lead product candidates are rNAPc2 (AB201) as a potential treatment for diseases caused by ribonucleic acid, or RNA, viruses, initially focusing on COVID-19, the disease syndrome caused by the SARS-CoV-2 virus, and Gencaro&#8482; (bucindolol hydrochloride) for the treatment of atrial fibrillation, or AF, in patients with chronic heart failure, or HF. rNAPc2 targets COVID-19 patients with biomarker evidence of coagulopathy, while Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">rNAPc2 (AB201) for treatment of COVID-19</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Recombinant Nematode Anticoagulant Protein c2, or rNAPc2 (AB201), is a protein therapeutic in clinical development as a potential treatment for patients with COVID-19. Based on its unique mechanism of action, development history and the clinical evidence from the SARS-CoV-2 pandemic, we believe rNAPc2 has potential to be a beneficial therapy for patients with this serious viral disease. We initiated a Phase 2 clinical trial of rNAPc2 as a potential treatment for patients hospitalized with COVID-19 in the fourth quarter of 2020 and are currently enrolling patients. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain patients with severe COVID-19 disease exhibit thrombotic complications and other inflammatory responses suggesting potential dysregulation of the coagulation and immune systems. rNAPc2 is a potent inhibitor of tissue factor, a cellular receptor responsible for initiation of the primary coagulation pathway and appears to be the major activator of the coagulation cascade during viral infection. Tissue factor is also implicated in the immune system inflammatory response to viral infections and in the process of viral dissemination during infection. We believe that evidence from the pandemic implicates tissue factor pathways as an important part of the COVID-19 disease process, and provides a rationale to test rNAPc2 as a potential therapeutic for COVID&#8209;19 for its anticoagulant and potential anti-inflammatory properties.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rNAPc2</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> was originally developed for potential use as an anticoagulant due to its inhibition of the TF-initiated coagulation process. It was evaluated for the prevention of thrombosis in Phase 1 and Phase 2 clinical studies involving over 800 subjects and demonstrated both safety and efficacy in these studies. </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rNAPc2</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> has also been investigated as a potential therapeutic for severe viral infections other than COVID-19. Research has shown that viral infections can provoke dysregulated activation of the TF pathway, resulting in abnormal systemic coagulation and related inflammation, leading to potential organ failure and mortality. For this reason, </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rNAPc2</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> was tested as a therapeutic in non-human primates, or NHPs, in studies against lethal doses of the Ebola and Marburg viruses, where it showed evidence of efficacy in the form of mortality reduction, decreases in inflammatory biomarkers and, evidence of reduced disseminated intravascular coagulation, or DIC. DIC is a serious condition that causes abnormal blood&#160;clotting&#160;throughout the body's blood vessels.</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SARS-CoV-2 is a new coronavirus identified in late 2019 that belongs to a family of enveloped RNA viruses that include Middle East Respiratory Syndrome (MERS) and Severe Acute Respiratory Syndrome (SARS-CoV-1), both of which caused serious human infections of the respiratory system. The disease caused by the SARS-CoV-2 virus has been designated COVID-19. Since this outbreak was first reported in late 2019, there have been over 157 million confirmed cases of COVID-19 and over 3&#160;million deaths worldwide attributed to the virus (as of May 2021).</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">COVID-19 is associated with a high incidence of both arterial and venous coagulation-related adverse events in large and small blood vessels. These include, stroke, myocardial infarction, or MI, (i.e., heart attack) and pulmonary emboli; as well as, blockage of the smaller peripheral blood vessels in the fingers/toes (COVID-digit). This syndrome is so frequently observed in COVID-19 that it has received the name of COVID-19 Associated Coagulopathy, or CAC. The underlying pathology of CAC is believed to result from thrombo-inflammatory processes triggered by the viral infection. A commonly used biomarker for assessing the presence of abnormal coagulation is a D-dimer test, which is elevated (greater than 0.5) in nearly 70% of hospitalized COVID-19 patients and is associated with adverse clinical outcomes. Some researchers believe that this and other evidence points to dysregulation of TF pathways in COVID-19 patients that result in the development of thrombotic complications.&nbsp;&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rNAPc2 has shown potential in addressing the coagulation disorder caused by severe viral infections. In preliminary, non-human studies in NHPs against lethal doses of the Ebola and Marburg virus, rNAPc2 lowered D-dimer levels, reduced mortality and exhibited anti-inflammatory effects. We believe more recent research supports our belief that rNAPc2 has the ability to inhibit the activity of TF in multiple processes that contribute to severe viral disease. Taken together, we believe this evidence suggests that rNAPc2 may have therapeutic benefits for patients with serious COVID-19 infections and the accompanying high risk of thrombosis. To our knowledge, rNAPc2 is the only NME anticoagulant, and the only tissue factor inhibitor, currently under evaluation for COVID-19.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a therapeutic aimed at a host response to a disease syndrome, we believe rNAPc2 potentially could be used in combination with other antiviral drugs. We believe its potential efficacy is not linked to a specific viral genome and may not be diminished by genetic drift or the development of new strains of the SARS-CoV-2 virus. As a therapeutic addressing a disease, we believe rNAPc2 may have broad spectrum potential against multiple pathogens that have disease elements in common with COVID&#8209;19, such as other coronaviruses and other RNA viruses. Therefore, we believe that rNAPc2 has therapeutic potential for future viral outbreaks beyond the current pandemic.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rNAPc2 is a single-chain, 85 amino acid, recombinant protein administered subcutaneously, that has previously been evaluated under three FDA Investigational New Drug, or IND, applications in six Phase 1 and three Phase 2 clinical studies in the United States and Europe. These clinical trials primarily examined the safety, dosing and anticoagulation effects of rNAPc2 in patients with acute coronary syndromes, in patients undergoing knee replacement surgery and in patients undergoing percutaneous coronary interventions. In these trials, involving more than 800 human patients with over 700 exposed to drug, rNAPc2 was generally well-tolerated with a safety profile comparable to commercially available anticoagulants. rNAPc2 is manufactured in an engineered yeast strain by an established methodology following current Good Manufacturing Practices, or cGMP, and we believe this process can be readily scaled to commercial quantities. FDA granted rNAPc2 Orphan Drug Designation status in 2014 for the treatment of viral hemorrhagic fever post-exposure to Ebola virus, but human clinical trials were not conducted. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2020, FDA approved the IND application for rNAPc2 as a potential treatment for patients hospitalized with COVID-19 and it received a Fast-Track designation in November 2020. We initiated the Phase 2b clinical trial of rNAPc2 (AB201), ASPEN-COVID-19, in patients hospitalized with COVID-19 in the fourth quarter of 2020. We anticipate announcing topline data from this approximately 100 patient Phase 2b clinical trial in the third quarter of 2021. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are evaluating rNAPc2 as a treatment for patients hospitalized with COVID-19 who are at high risk for thrombotic complications, as indicated by elevated D-dimer levels. The Phase 2b clinical trial is designed to be a randomized comparison of two-dose regimens of rNAPc2 versus heparin prescribed per local standard of care. The primary endpoint of the clinical trial is the change in D-dimer level from baseline to Day 8. If Phase 2b results indicate a favorable effect on D-dimer levels and safety is confirmed, following FDA review of the data and identification of the proposed Phase&#160;3 rNAPc2 dose, we anticipate that clinical investigative sites will begin enrolling patients in a planned Phase 3 clinical trial. The primary endpoint of Phase 3 is planned to be clinical recovery as measured by the Adaptive COVID-19 Treatment Trial ordinal scale, with secondary endpoints that include D-dimer levels and the number of </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">thrombotic events. We believe the Phase 3 clinical trial will be event driven, with an estimated requirement of 450 patients. We believe that favorable results from this Phase 2b/3 clinical trial program could support use of </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rNAPc2</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> in COVID-19 patients, given its potential efficacy both as an anticoagulant and an anti-viral agent that we believe counters the dysregulatory immune response and improves clinical recovery.</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The clinical trial is being managed in collaboration with the Colorado Prevention Center, or CPC, the University of Colorado's Academic Research Organization with extensive experience in managing vascular and anticoagulation clinical trials. <font style="margin-left:36pt;"></font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have financed the development of rNAPc2 through public equity sales. Our rNAPc2 development plans, including the timeline, depend on our ability to enroll patients during the COVID-19 pandemic, the results of our Phase 2b clinical trial, FDA guidance, and availability of drug product, all of which are currently uncertain.&nbsp;&nbsp; <font style="margin-left:36pt;"></font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We own the clinical development program of rNAPc2, including Phase 2 clinical trials.&#160; If rNAPc2 is successfully developed, we believe it will have intellectual property protection, including 12 years of market exclusivity as an innovative biologic product under FDA law in the United States, 10 years data protection exclusivity in the European Union, or EU, and potentially patent protection in addition to this. We plan to pursue strategic co-development and partnering opportunities for rNAPc2 development and commercialization.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Gencaro&#8482; (bucindolol hydrochloride) for Atrial Fibrillation </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gencaro&#8482; (bucindolol hydrochloride) is a pharmacogenetically-targeted beta-adrenergic receptor antagonist with mild vasodilator properties that we are developing for the treatment of atrial fibrillation in patients with heart failure. We believe the pharmacology of Gencaro is unique and its efficacy can be enhanced by prescribing it to patients with a common genotypic variant that is present in approximately 50% of the North American and European general populations. This gene can be detected with a simple genetic test. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are developing Gencaro to treat atrial fibrillation, or AF, in patients with chronic heart failure, or HF. AF is the most common form of cardiac arrhythmia, a disruption of the heart&#8217;s normal rhythm or rate. HF is a chronic condition in which the heart is unable to pump enough blood to meet the body&#8217;s needs. AF and HF commonly occur together. In HF patients, the development of AF leads to worsening symptoms, and increased risk of hospitalization and death. Current treatment options for AF in HF patients are limited, and can be invasive, costly and dangerous.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our development plan for Gencaro focuses on the treatment of AF in patients with higher ejection fraction HF, those who have an ejection fraction, or EF, of 40% and higher who also have the genotype we believe is optimal for Gencaro efficacy. This population of HF encompasses more than half of all HF patients in the United States and Europe. There are currently few approved or effective drug therapies to treat AF or HF in this patient population.&nbsp;&nbsp; </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our development plan for Gencaro is based on our recent analysis of the Phase 2b clinical trial of Gencaro for the prevention of AF in HF patients, known as GENETIC-AF. This analysis showed novel results for Gencaro in patients in the clinical trial with EF&#8217;s of 40% and higher. We are planning a new design for a Phase 3 pivotal clinical trial of Gencaro based on this analysis that addresses what we believe are important clinical assessments, including the total amount of time that a patient experiences AF, known as AF burden, maintenance of normal sinus rhythm, rhythm control interventions such as electrical cardioversion, catheter ablation and use of anti-arrhythmic drugs and drug-related complications such as bradycardia. Based on these analyses, we were issued a United States patent in February 2021 for the use of Gencaro in this patient population. We believe this patent will substantially extend the patent protection for our planned development of Gencaro into 2039. We are seeking similar patent protection in other countries. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently have an agreement with the FDA, known as a Special Protocol Assessment, or SPA, for the requirements of a Gencaro Phase 3 clinical trial that would support approval of Gencaro if successful.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that patients with HF and AF represent a major unmet medical need, and this need is most pronounced in patients with EF values of 40% and above. This EF range constitutes more than half of all chronic HF in the United States and Europe, as well as in Japan and China, and there are currently few approved, effective or guideline-recommended therapies for these patients to treat either their AF or HF. AF is a very common complication in these patients, with estimates of AF incidence ranging from 40% to 60%. Beta-blockers approved for HF are commonly used off-label to control heart rate in these patients, but they are not considered effective in preventing AF and none are approved for patients with EF &#8805; 40%. Other anti-arrhythmic drugs approved for the treatment of AF have adverse side effects and in HF patients are either contraindicated or have label warnings for use due to an increased risk of mortality. Interventional procedures for AF, such as catheter ablation and electrical cardioversion, are invasive, expensive, and often temporary; these interventions also typically require the continued use of beta blockers and other anti-arrhythmic drugs post-intervention.&nbsp;&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that Gencaro, if approved, may be a safe and more effective therapy for the treatment of higher ejection fraction HF patients with AF. We believe there are several potentially important attributes that would differentiate Gencaro from existing therapies, including:</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">More effective rhythm control compared to the current standard of care;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Reduction in the need for catheter ablation, electrical cardioversion, or toxic anti-arrhythmic drugs;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Maintenance of rhythm control after a successful AF catheter ablation;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Effective rate control with lower risk of treatment-limiting bradycardia;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Reduction in symptoms and improvement in quality of life;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Reduced health care burden;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Foundational beta-blocker benefits for HF and unique evidence of efficacy in HF patients with AF;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">One of the only drug therapies approved and shown effective for AF in HF patients with EF &#8805; 40%, and the only one in its drug class.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have an international patent portfolio for Gencaro in the United States, the EU, and other major markets, as well as new chemical entity status, including a new patent that we believe will give us a strong intellectual property position to at least approximately 2039 in the United States; we have filed applications similar to this new patent in international territories. We have developed a laboratory platform for the diagnostic test that would be used to prescribe Gencaro; this platform was approved by FDA for use in the Phase 2B clinical trial. We retain all rights to this test platform; we expect to use it in future clinical trials, and we believe it could be one of multiple diagnostic platforms used for commercialization. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">To support the continued development of </font><font style="color:#000000;">rNAPc2</font><font style="Background-color:#FFFFFF;"> and Gencaro, we will need additional financing to fully fund the planned </font>clinical trials, <font style="Background-color:#FFFFFF;">and our general and administrative costs through the clinical trials&#8217; projected completion and potential commercialization. Considering the substantial time and costs associated with the development of </font><font style="color:#000000;">rNAPc2</font><font style="Background-color:#FFFFFF;"> and Gencaro and the risk that we may be unable to raise a significant amount of capital on acceptable terms, we are also pursuing co-development and commercialization partnering opportunities with large pharmaceutical and/or specialty pharmaceutical companies and may pursue a strategic combination or other strategic transactions. If we are unable to obtain sufficient financing or are unable to complete a strategic transaction, we may discontinue our development activities on </font><font style="color:#000000;">rNAPc2</font><font style="Background-color:#FFFFFF;"> or Gencaro or discontinue our operations</font><font style="color:#000000;">.&#160;&#160;</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">We believe our cash and cash equivalents as of March&#160;31, 2021 will be sufficient to fund our operations through the end of fiscal year 2022, including the projected costs for the </font><font style="color:#000000;">rNAPc2 (</font><font style="Background-color:#FFFFFF;">AB201) Phase 2b clinical trial. Conducting a Phase 3 rNAPc2 clinical trial or the Phase&#160;3 PRECISION-AF trial would likely require additional financing. However, changing circumstances may cause us to consume capital significantly faster or slower than currently anticipated. We have based these estimates on assumptions that may prove to be wrong, and we could exhaust our available financial resources sooner than we currently anticipate; therefore, we may have to raise additional capital for other clinical trials of </font><font style="color:#000000;">rNAPc2</font><font style="Background-color:#FFFFFF;">. Initiating any Phase 3 clinical trial of </font><font style="Background-color:#FFFFFF;">Gencaro is dependent on sustained improvement in the COVID-19 pandemic and will require additional financing</font><font style="Background-color:#FFFFFF;">.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2017, we entered into a sales agreement with a placement agent to sell, from time to time, our common stock having an aggregate offering price of up to $10.2 million, in an &#8220;at the market offering.&#8221; In 2020, we further amended the sales agreement to increase the maximum aggregate value of shares which we may issue and sell from time to time under this sales agreement to $32.4&#160;million. This sales agreement terminated in July 2020. Under this sales agreement, we had sold an aggregate of 3,302,159 shares of our common stock pursuant to the terms of such sales agreement, as amended, for aggregate gross proceeds of approximately $32.3&#160;million. Net proceeds received in this offering were approximately $30.8&#160;million, after deducting expenses for executing the &#8220;at the market offering&#8221; and commissions paid to the placement agent. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2020, we entered into a new sales agreement with a placement agent to sell, from time to time, our common stock having an aggregate offering price of up to $54.0 million, in an &#8220;at the market offering.&#8221; As of February 2021, we had sold an aggregate of 9,928,272&#160;shares of our common stock pursuant to the terms of such sales agreement for aggregate gross proceeds of approximately $54.0&#160;million. Net proceeds received in this offering were approximately $52.2&#160;million, after deducting expenses for executing the &#8220;at the market offering&#8221; and commissions paid to the placement agent.<font style="Background-color:#FFFFFF;color:#000000;"> </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">In April 2021, we amended the new sales agreement and have $50.0 million available for the offering under our prospectus to our registration statement on Form S-3 (No. 333-254585)</font><font style="color:#000000;">.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2020, the World Health Organization declared the outbreak of COVID-19, a novel strain of Coronavirus, a global pandemic. This outbreak is causing major disruptions to businesses and markets worldwide as the virus spreads. We do not expect a material financial effect as a result of the pandemic. However, if the pandemic continues to be a severe worldwide crisis, it could have a material adverse effect on our business, results of operations, financial condition and cash flows</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="margin-bottom:16pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Results of Operations </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research and Development Expenses </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development, or R&amp;D, expense is comprised primarily of personnel costs, clinical development, manufacturing process development, and regulatory activities and costs. Our R&amp;D expense continues to be almost entirely generated by our activities relating to the development of Gencaro. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">R&amp;D expense for the three months ended March 31, 2021 was $2.9 million compared to $0.4 million for the corresponding period of 2020, an increase of $2.5 million. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical expense increased approximately $1.7 million for the three months ended March 31, 2021, as compared to the corresponding periods of 2020. Manufacturing process development costs increased approximately $0.6 million for the three months ended March&#160;31, 2021, as compared to the corresponding periods of 2020. The increase was related to the initiation of our rNAPc2 (AB201) clinical trial in the second half of 2020. The remaining increase is primarily a result of higher outside services and consulting costs.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">R&amp;D personnel costs increased approximately $0.2 million for the three months ended March 31, 2021, as compared to the corresponding period of 2020. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">R&amp;D expense in 2021 is expected to be higher than 2020, as we continue our rNAPc2 (AB201) Phase 2b clinical trial.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;line-height:11pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">General and Administrative Expenses </p>
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative, or G&amp;A, expenses primarily consist of personnel costs, consulting and professional fees, insurance, facilities and depreciation expenses, and various other administrative costs. </p>
<p style="margin-bottom:0pt;margin-top:12pt;line-height:11pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">G&amp;A expenses were $1.2 million for the three months ended March 31, 2021 compared to $1.0 million for the corresponding period of 2020, an increase of $0.3 million. The $0.3 million increase was primarily a result of higher personnel costs in 2021. &nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">G&amp;A expenses in 2021 are expected to be consistent with those in 2020 as we maintain administrative activities to support our ongoing operations. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Interest and Other Income </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest and other income was $2,000 and $24,000 in the three months ended March 31, 2021 and 2020, respectively. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Interest Expense </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense was $4,000 for the three months ended March 31, 2020. Based on our current capital structure, interest expense for the remainder of 2021 is expected to be negligible. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Liquidity and Capital Resources </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Cash and Cash Equivalents </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk68792473"></a>&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66,933</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,071</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March 31, 2021, we had total cash and cash equivalents of $66.9 million, as compared to $49.1&#160;million as of December&#160;31,&#160;2020. The net increase of $17.9 million primarily reflects the net proceeds of $23.0 million from the issuance of common stock, offset by $5.2&#160;million of cash used in operating activities during the three months ended March 31, 2021. &nbsp;&nbsp;&nbsp;&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cash Flows from Operating, Investing and Financing Activities </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.26%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended March 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash (used in) provided by:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating activities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,225</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,686</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investing activities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financing activities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,093</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net increase (decrease) in cash and cash equivalents</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,862</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.4%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,689</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in operating activities for the three months ended March 31, 2021 increased $3.5 million compared with the same period in 2020. This was primarily due to higher outflows related to changes in operating assets and liabilities and a higher net loss in 2021, as discussed in Results of Operations above. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in investing activities for the three months ended March 31, 2021 was $6,000 for the purchase of property and equipment. Net cash used in investing activities for the three months ended March 31, 2020 was $3,000 for the purchase of property and equipment.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities was $23.0&#160;million for the three months ended March 31, 2021 related to net proceeds from sales of our common stock in our &#8220;at the market&#8221; equity offering in the period. There were no financing activities for the three months ended March 31, 2020. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Sources and Uses of Capital </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our primary sources of liquidity to date have been capital raised from issuances of shares of our preferred and common stock. The primary uses of our capital resources to date have been to fund operating activities, including research, clinical development and drug manufacturing expenses, license payments, and spending on capital items. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2020, we entered into a new sales agreement with a placement agent to sell, from time to time, our common stock having an aggregate offering price of up to $54.0 million, in an &#8220;at the market offering.&#8221; As of February 2021, we had sold an aggregate of 9,928,272&#160;shares of our common stock pursuant to the terms of such sales agreement for aggregate gross proceeds of approximately $54.0&#160;million. Net proceeds received in this offering were approximately $52.2&#160;million, after deducting expenses for executing the &#8220;at the market offering&#8221; and commissions paid to the placement agent.<font style="Background-color:#FFFFFF;color:#000000;"> </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2021, we amended the new sales agreement and have $50.0 million available for the offering under our prospectus to our registration statement on Form S-3 (No. 333-254585<font style="font-size:12pt;">).</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2020, the World Health Organization declared the outbreak of COVID-19, a novel strain of Coronavirus, a global pandemic. This outbreak is causing major disruptions to businesses and markets worldwide as the virus spreads. We do not expect a material financial effect as a result of the pandemic. However, if the pandemic continues to be a severe worldwide crisis, it could have a material adverse effect on our business, results of operations, financial condition and cash flows.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our ability to execute our development program</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> in accordance with our projected time line depends on a number of factors, including, but not limited to, the following: </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the costs and timing for the potential additional clinical trials in order to gain possible regulatory approval for rNAPc2, Gencaro or any other product candidate; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the market price of our stock and the availability and cost of additional equity capital from existing and potential new investors;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">our ability to retain the listing of our common stock on the Nasdaq Capital Market; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">our ability to control costs associated with its operations; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">general economic and industry conditions affecting the availability and cost of capital, including as a result of the COVID-19 pandemic; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the terms and conditions of our existing collaborative and licensing agreements.&nbsp;&nbsp;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:7.87%;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">We believe our cash and cash equivalents balance as of March 31, 2021 will be sufficient to fund our operations </font><font style="color:#000000;">through </font><font style="Background-color:#FFFFFF;">the end of fiscal year </font><font style="color:#000000;">2022.</font><font style="Background-color:#FFFFFF;"> Conducting a Phase 3 rNAPc2 clinical trial or the Phase&#160;3 PRECISION-AF trial would likely require additional financing</font><font style="color:#000000;">. </font><font style="Background-color:#FFFFFF;">However, changing circumstances may cause us to consume capital significantly faster or slower than currently anticipated. We have based these estimates on assumptions that may prove to be wrong, and we could exhaust our available financial resources sooner than we currently anticipate; therefore, we may have to raise additional capital for clinical trials of </font><font style="color:#000000;">rNAPc2</font><font style="Background-color:#FFFFFF;">. Initiating any Phase 3 clinical trial of Gencaro is dependent on our obtaining additional financing. </font><font style="color:#000000;">We may not be able to raise sufficient capital on acceptable terms, or at all, to continue development and potential commercialization of rNAPc2 or Gencaro or to otherwise continue operations and may not be able to execute any strategic transaction.&nbsp;&nbsp;</font><font style="font-style:italic;color:#000000;"> </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;line-height:11pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Critical Accounting Policies and Estimates </p>
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A critical accounting policy is one that is both important to the portrayal of our financial condition and results of operation and requires our management&#8217;s most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. Our significant accounting policies are described in Note 1 of &#8220;Notes to Financial Statements&#8221; included within our 2020 Annual Report on Form 10-K filed with the SEC. Following is a discussion of the accounting policies that we believe involve the most difficult, subjective or complex judgments and estimates. </p>
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Accrued Outsourcing Expenses </p>
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of the process of preparing our financial statements, we are required to estimate accrued outsourcing expenses. This process involves identifying services that third parties have performed on our behalf and estimating the level of service performed and the associated cost incurred for these services as of the balance sheet date. Examples of estimated accrued outsourcing expenses include contract service fees, such as fees payable to contract manufacturers in connection with the production of materials related to our drug product, and service fees from clinical research organizations. We develop estimates of liabilities using our judgment based upon the facts and circumstances known at the time. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Off-Balance Sheet Arrangements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have not participated in any transactions with unconsolidated entities, such as special purpose entities, which would have been established for the purpose of facilitating off-balance sheet arrangements. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Indemnifications </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the ordinary course of business, we enter into contractual arrangements under which we may agree to indemnify certain parties from any losses incurred relating to the services they perform on our behalf or for losses arising from certain events as defined within the particular contract. Such indemnification obligations may not be subject to maximum loss clauses. We have entered into indemnity agreements with each of our directors, officers and certain employees. Such indemnity agreements contain provisions, which are in some respects broader than the specific indemnification provisions contained in Delaware law. We also maintain an insurance policy for our directors and executive officers insuring against certain liabilities arising in their capacities as such. </p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_3"></a><a name="ITEM_3"></a>ITEM&#160;3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable. </p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_4"></a><a name="ITEM_4"></a>ITEM&#160;4. CONTROLS AND PROCEDURES </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Evaluation of Disclosure Controls and Procedures </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in the reports that we file under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosures. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As required by Rule 13a-15(b) of the Securities Exchange Act of 1934, an evaluation was carried out under the supervision and with the participation of management, including our principal executive officer and principal financial officer, of the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934) as of the end of the quarter covered by this report. Based on the foregoing, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective at a reasonable level of assurance. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Changes in Internal Control over Financial Reporting </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There has been no change in our internal control over financial reporting during our most recent fiscal quarter that would materially affect or is reasonably likely to materially affect, our internal control over financial reporting.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="PART_II"></a><a name="PART_II"></a>PART II. OTHER INFORMATION </p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_1_LEGAL"></a><a name="ITEM_1_LEGAL"></a>ITEM&#160;1. LEGAL PROCEEDINGS </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None </p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="Item_1A_Risk"></a><a name="Item_1A_Risk"></a>Item&#160;1A. Risk Factors </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">An investment in our securities involves certain risks, including those set forth below and elsewhere in this report. In addition to the risks set forth below and elsewhere in this report, other risks and uncertainties not known to us, that are beyond our control or that we deem to be immaterial may also materially adversely affect our business operations. You should carefully consider the risks described below as well as other information and data included in this report. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Summary of Risk Factors</p>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Below is a summary of the principal factors that make an investment in our common stock speculative or risky. This summary does not address all of the risks that we face. Additional discussion of the risks summarized in this risk factor summary, and other risks that we face, can be found below under the heading &#8220;Risk Factors&#8221; and should be carefully considered, together with other information in this Form 10-Q and our other filings with the SEC, before making an investment decision regarding our common stock.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;"></font>&#9679;</p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">if we are not able to successfully develop, obtain FDA approval for, and provide for the commercialization of rNAPc2 or Gencaro in a timely manner, we may not be able to continue our business operations;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;"></font>&#9679;</p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">if we encounter difficulties enrolling patients in our clinical trials, any potential enrollment milestones or potential regulatory approvals could be delayed or otherwise adversely affected; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;"></font>&#9679;</p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">our clinical trials for our product candidates may not yield results that will enable us to further develop our products and obtain regulatory approvals necessary to sell them;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;"></font>&#9679;</p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">we may not achieve our projected development goals in the time frames we announce and expect;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;"></font>&#9679;</p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">we expect the PRECISION-AF clinical trial will require substantially more capital to complete, and we cannot guarantee when or if we will be able to secure such additional financing; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;"></font>&#9679;</p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">we will need to raise substantial additional funds through public or private equity or debt transactions and/or complete one or more strategic transactions, to continue development of rNAPc2, Gencaro or any of our other product candidates. If we are unable to raise such financing or complete such a transaction, we may not be able to continue operations;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;"></font>&#9679;</p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">if we are not able to maintain the requirements for listing on the Nasdaq Capital Market, we could be delisted, which could have a material adverse effect on our ability to raise additional funds as well as the price and liquidity of our common stock;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;"></font>&#9679;</p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">our business could be adversely affected by the effects of health epidemics, including the ongoing COVID-19 global pandemic, in regions where we or third parties on which we rely may have clinical trial sites or other business operations. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;"></font>&#9679;</p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">we depend or may depend on third parties to conduct clinical trials and provide diagnostic information, as well as to develop, commercialize and/or manufacture our product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;"></font>&#9679;</p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">unless we are able to generate sufficient product revenue, we will continue to incur losses from operations and will not achieve or maintain profitability. We are years away from commercializing a product and generating product revenue;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;"></font>&#9679;</p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">our product candidates are subject to extensive regulation, which can be costly and time-consuming, and unsuccessful or delayed regulatory approvals could increase our future development costs or impair our future revenue;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;"></font>&#9679;</p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">if our product candidates receive regulatory approval, we would be subject to ongoing regulatory obligations and restrictions, which may result in significant expenses and limit our ability to develop and commercialize other potential products;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;"></font>&#9679;</p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">transitioning from a clinical development stage company will require successful completion of a number of steps, many of which are outside of our control and, consequently, we can provide no assurance of our successful and timely transition from a clinical development stage company;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;"></font>&#9679;</p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">if approved by the FDA, rNAPc2 or Gencaro will be entering a competitive marketplace and may not succeed;</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;"></font>&#9679;</p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">if we fail to identify and license or acquire other products or product candidates, then we may be unable to expand our business, and the acquisition or licensing of other products or product candidates may put a strain on our operations and will likely require us to seek additional financing;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;"></font>&#9679;</p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the loss of any rights to market key products would significantly impair our operating results;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;"></font>&#9679;</p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">third parties may own or control patents or patent applications that we may be required to license to commercialize our product candidates or that could result in litigation that would be costly and time consuming;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;"></font>&#9679;</p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">our intellectual property rights may not preclude competitors from developing competing products and our business may suffer.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our Business and Financial Condition </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we are not able to successfully develop, obtain FDA approval for, and provide for the commercialization of rNAPc2 or Gencaro in a timely manner, we may not be able to continue our business operations. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently have no products that have received regulatory approval for commercial sale. The process to develop, obtain regulatory approval for and commercialize potential product candidates is long, complex and costly. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Failure to demonstrate that a product candidate, including rNAPc2 or Gencaro, is safe and effective, or significant delays in demonstrating such safety and efficacy, would adversely affect our business. Failure to obtain marketing approval of rNAPc2 or Gencaro from appropriate regulatory authorities, or significant delays in obtaining such approval, would also adversely affect our business and could, among other things, preclude us from completing a strategic transaction or obtaining additional financing necessary to continue as a going concern. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if approved for sale, a product candidate must be successfully commercialized to generate value. We do not currently have the capital resources or management expertise to commercialize rNAPc2, Gencaro or any of our other product candidates and, as a result, will need to complete a strategic transaction, or, alternatively, raise substantial additional funds to enable commercialization of rNAPc2, Gencaro or any of our other product candidates, if approved. Failure to successfully provide for the commercialization of rNAPc2, Gencaro or any other product candidate, if approved, would damage our business. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we encounter difficulties enrolling patients in our clinical trial of rNAPc2, any potential enrollment milestones or potential regulatory approvals could be delayed or otherwise adversely affected.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may encounter difficulty enrolling a sufficient number of patients in the trial, due to circumstances which are outside our control, including improvements in the COVID-19 pandemic resulting from the development of vaccines and therapies, as well as other clinical trials or capacity constraints at potential COVID-19 clinical trial sites, that may limit the availability of study participants. As a result, we may need to delay or terminate our trial, which would have a negative impact on our business. Delays in enrolling patients in the clinical trial of <font style="color:#000000;">rNAPc2</font> would also adversely affect our ability to meet projected enrollment milestones or timelines for completing the study and obtaining regulatory approval. Development of other COVID-19 targeted therapies may mean there are no patients who need <font style="color:#000000;">rNAPc2</font> as a therapy.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">rNAPc2 may not yield results that will enable us to further develop it as a therapy and obtain regulatory approvals necessary to be used as a drug.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will receive regulatory approval for our product candidates only if we can demonstrate, in carefully designed and conducted clinical trials, that the product candidate is safe and effective. We do not know whether any future clinical trials for <font style="color:#000000;">rNAPc2, Gencaro or any other product candidate</font> will demonstrate sufficient safety and efficacy to obtain the requisite regulatory approvals or will result in marketable products. <font style="color:#000000;">rNAPc2</font> has never been tested for safety or efficacy in any <font style="color:#000000;">pre-clinical COVID-19 models or any patients diagnosed with COVID-19. It may not be effective for any COVID-19 associated diseases.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The results from preclinical testing and early clinical trials may not be predictive of results from later studies, including our studies of <font style="color:#000000;">rNAPc2</font>. We may suffer significant setbacks in advanced clinical trials, even after seeing promising results in earlier studies. Based on results at any stage of clinical trials, we may decide to repeat or redesign a trial or discontinue development of one or more of our product candidates, including <font style="color:#000000;">rNAPc2</font>. If we fail to adequately demonstrate the safety and efficacy of our <font style="color:#000000;">rNAPc2, or other</font> product candidates, we will not be able to obtain the required regulatory approvals to commercialize it and our business, results of operations and financial condition would be materially adversely affected.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU29"></a><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, administering </font><font style="color:#000000;">rNAPc2</font><font style="color:#000000;">, or other product candidates,</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> to humans may produce undesirable side effects. These side effects could interrupt, delay or halt clinical trials of </font><font style="color:#000000;">rNAPc2</font><font style="color:#000000;">, or other product candidates,</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and could result in the FDA or other regulatory authorities denying approval of </font><font style="color:#000000;">rNAPc2</font><font style="color:#000000;">, or other product candidates</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU29"></a> for any or all targeted indications</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may not achieve our projected development goals in the time frames we announce and expect.</p>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We set goals for, and make public statements regarding, the timing of certain accomplishments, such as the initiation of our clinical trials, including <font style="color:#000000;">rNAPc2</font>, the duration of the planned <font style="color:#000000;">rNAPc2 </font>Phase 2b clinical trial, the steps for commencing and continuing our clinical trials, the disclosure of trial results, the obtainment of regulatory approval and the sale of drug products, which we sometimes refer to as milestones. These milestones may not be achieved, and the actual timing of these events can vary dramatically due to a number of factors such as delays or failures in our clinical trials, disagreements with any collaborative partners, the uncertainties inherent in the regulatory approval process and manufacturing scale-up, delays in achieving manufacturing or marketing arrangements sufficient to commercialize our products or our inability to obtain sufficient financing in a timely manner. There can be no assurance that we will make regulatory submissions or receive regulatory approvals as planned. If we fail to achieve one or more of these milestones as planned, our business will be materially adversely affected<font style="color:#000000;">.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We expect the PRECISION-AF clinical trial will require substantially more capital to complete, and we cannot guarantee when or if we will be able to secure such additional financing. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have put the potential initiation of the PRECISION-AF trial on hold due to the ongoing COVID-19 pandemic and prioritizing the development of rNAPc2. Initiation of the PRECISION-AF clinical trial will depend on receiving additional funding and an abatement of the COVID-19 pandemic to the point of being able to recruit patients for a cardiovascular clinical trial. We will need to secure additional financing in order to initiate enrollment of our Phase 3 PRECISION-AF clinical trial. Even if we can<font style="font-weight:bold;font-style:italic;"> </font>begin enrolling patients, we expect to have to raise significant additional capital to continue enrollment.<font style="font-weight:bold;font-style:italic;"> </font>If we are not able to obtain financing in the future or on acceptable terms, we may have to terminate the clinical trial early, which could adversely affect our business. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We will need to raise substantial additional funds through public or private equity or debt transactions and/or complete one or more strategic transactions, to continue development of rNAPc2, Gencaro or any of our other product candidates. If we are unable to raise such financing or complete such a transaction, we may not be able to continue operations. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In light of the expected development timeline to potentially obtain FDA approval for rNAPc2 or Gencaro, if at all, the substantial additional costs associated with the development of our product candidates, including the costs associated with clinical trials related thereto, and the substantial cost of commercializing rNAPc2 or Gencaro, if approved, we will need to raise substantial additional funding through public or private equity or debt transactions or a strategic combination or partnership. If we are delayed in obtaining funding or are unable to complete a strategic transaction, we may discontinue our development activities on rNAPc2, Gencaro and our other product candidates or discontinue our operations. Even if we are able to fund continued development of rNAPc2, Gencaro or any of our other product candidates is approved, we expect that we will need to complete a strategic transaction or raise substantial additional funding through public or private equity or debt securities to successfully commercialize rNAPc2, Gencaro or any other product candidate.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">We believe our cash and cash equivalents as of March 31, 2021 will be sufficient to fund our </font><font style="color:#000000;">operations through </font><font style="Background-color:#FFFFFF;">the end of fiscal year </font><font style="color:#000000;">2022.</font><font style="Background-color:#FFFFFF;"> Conducting a Phase 3 rNAPc2 clinical trial or the Phase 3 PRECISION-AF trial would likely require additional financing</font><font style="color:#000000;">. On July 22, 2020, we entered into a new sales agreement with a placement agent to sell, from time to time, our common stock having an aggregate offering price of up to $54.0 million, in an &#8220;at the market offering.&#8221; As of March&#160;31,&#160;2021, we sold an aggregate of 9,928,272&#160;shares of our common stock pursuant to the terms of such sales agreement for aggregate gross proceeds of approximately $54.0&#160;million. Net proceeds received in this offering were approximately $52.2&#160;million, after deducting expenses for executing the &#8220;at the market offering&#8221; and commissions paid to the placement agent. </font><font style="Background-color:#FFFFFF;">In April 2021, we amended the new sales agreement and have $50.0 million available for the offering under our prospectus to our registration statement on Form S-3 (No. 333-254585). </font><font style="color:#000000;">Sales of our common stock dilute the ownership interest of our stockholders and may cause the price per share of our common stock to decrease. Changing circumstances may cause us to consume capital significantly faster or slower than we currently anticipate. We have based these estimates on assumptions that may prove to be wrong, and we could exhaust our available financial resources sooner than we currently anticipate</font><font style="font-family:Calibri;color:#000000;">.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, in March 2020, the World Health Organization declared the outbreak of COVID-19 a global pandemic. This outbreak is causing major disruptions to businesses and markets worldwide as the virus spreads. The economic uncertainty surrounding the COVID-19 pandemic may dramatically reduce our ability to secure equity or debt financing necessary to support our operations. We are unable to currently estimate the financial effect of the pandemic. If the pandemic continues to be a severe worldwide crisis, economic conditions may cause capital not to be available to us, or not be available on acceptable terms, regardless of our business efforts. </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have put </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the potential </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">initiation of the PRECISION-AF</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> clinical</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> trial on hold due to the ongoing COVID-19 pandemic</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and prioritizing the development of </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rNAPc2</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">nitiation of the PRECISION-AF </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">clinical </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">trial will depend on receiving additional funding and an abatement of the COVID-19 pandemic </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to the point of being able to recruit patients for a cardiovascular clinical trial</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our liquidity, and our ability to raise additional capital or complete any strategic transaction, depends on a number of factors, including, but not limited to, the following: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;"></font>&#9679;</p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the costs and timing for potential additional clinical trials in order to gain possible regulatory approval for rNAPc2, Gencaro and our other product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;"></font>&#9679;</p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the market price of our stock and the availability and cost of additional equity capital from existing and potential new investors; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;"></font>&#9679;</p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">our ability to retain the listing of our common stock on the Nasdaq Capital Market; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;"></font>&#9679;</p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">general economic and industry conditions affecting the availability and cost of capital, including as a result of the COVID&#8209;19 pandemic; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;"></font>&#9679;</p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">our ability to control costs associated with our operations; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;"></font>&#9679;</p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;"></font>&#9679;</p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the terms and conditions of our existing collaborative and licensing agreements. </font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The sale of additional equity or convertible debt securities would likely result in substantial dilution to our stockholders. If we raise additional funds through the incurrence of indebtedness, the obligations related to such indebtedness would be senior to rights of holders of our capital stock and could contain covenants that would restrict our operations. We also cannot predict what consideration might be available, if any, to us or our stockholders, in connection with any strategic transaction. Should strategic alternatives or additional capital not be available to us, or not be available on acceptable terms, we may be unable to realize value from our assets and discharge our liabilities in the normal course of business which may, among other alternatives, cause us to further delay, substantially reduce or discontinue operational activities to conserve our cash resources. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="S166610219"></a>We have received an SPA agreement from the FDA relating to our planned Phase 3 program for&#160;Gencaro.&#160;This SPA agreement does not guarantee approval of&#160;Gencaro&#160;or any other particular outcome from regulatory review. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2019, we received an SPA agreement from the FDA for our planned Phase 3 clinical trial of&#160;Gencaro<font style="color:#000000;">. </font>The FDA&#8217;s SPA process is designed to facilitate the FDA&#8217;s review and approval of drugs by allowing the FDA to evaluate the proposed design and size of certain clinical trials that are intended to form the primary basis for determining a drug product&#8217;s efficacy. Upon specific request by a clinical trial sponsor, the FDA will evaluate the protocol and respond to a sponsor&#8217;s <font style="Background-color:#FFFFFF;">questions regarding, among other things, primary efficacy endpoints, trial conduct and data analysis, within 45 days of receipt of the request. The FDA ultimately assesses whether the protocol design and planned analysis of the trial are acceptable to support regulatory approval of the product candidate with respect to the effectiveness of the indication studied. All agreements and disagreements between the FDA and the sponsor regarding a SPA must be clearly documented in a SPA letter or the minutes of a meeting between the sponsor and the FDA.</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">However, an SPA agreement does not guarantee approval of a product candidate, even if the trial is conducted in accordance with the protocol. Moreover, the FDA may revoke or alter our SPA agreement in certain circumstances. In particular, a SPA agreement is not binding on the FDA if public health concerns emerge that were unrecognized at the time of the SPA agreement, other new scientific concerns regarding product safety or efficacy arise, we fail to comply with the agreed upon trial protocols, or the relevant data, assumptions or information provided by us in our request for the SPA change or are found to be false or omit relevant facts. In addition, even after an SPA agreement is finalized, the SPA agreement may be modified, and such modification will be deemed binding on the FDA review division, except under the circumstances described above, if the FDA and the sponsor agree in writing to modify the protocol and such modification is intended to improve the study. The FDA retains significant latitude and discretion in interpreting the terms of the SPA agreement and the data and results from any study that is the subject of the SPA agreement.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Even though we obtained an agreement on our SPA, we cannot assure you that our planned Phase 3 clinical trial will succeed, will be deemed binding by the FDA under our SPA agreement, or will result in any FDA approval for&#160;Gencaro.&#160;</font><font style="Background-color:#FFFFFF;">We may also alter the design of the trial to focus on endpoints that are not covered by the SPA. </font><font style="Background-color:#FFFFFF;">Moreover, if the FDA revokes or alters its agreement under our SPA, or interprets the data collected from the clinical trial differently than we do, the FDA may not deem the data sufficient to support an application for regulatory approval, which could materially adversely affect our business, financial condition and results of operations</font><font style="Background-color:#FFFFFF;">.</font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we are not able to maintain the requirements for listing on the Nasdaq Capital Market, we could be delisted, which could have a material adverse effect on our ability to raise additional funds as well as the price and liquidity of our common stock. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Our common stock is currently listed on the Nasdaq Capital Market. To maintain the listing of our common stock on the Nasdaq Capital Market we are required to meet certain listing requirements, including, among others, (i) a minimum closing bid price of $1.00 per share, (ii) a market value of publicly held shares (excluding shares held by our executive officers, directors and 10% or more stockholders) of at least $1 million and (iii) either: (x) stockholders&#8217; equity of at least $2.5 million; or (y) a total market value of listed securities of at least $35 million. </font></p>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have received three potential delisting notices from Nasdaq since 2012. In each of 2012, 2015 and 2018, we received notification from Nasdaq of potential delisting of our shares from the Nasdaq Capital Market because the closing bid price of our common stock had not met the minimum closing bid price of $1.00 per share during the preceding 30 business days. We subsequently regained compliance with Nasdaq&#8217;s minimum closing bid price requirements related to the 2012, 2015 and 2018 notices, by effecting a 1&#8209;for&#8209;6 reverse split of our common stock in March 2013, a 1&#8209;for&#8209;7 reverse split of our common stock in September 2015 and a 1-for-18 reverse split of our common stock in April 2019. Despite effecting a 1-for-18 reverse split of our common stock in April 2019, there can be no assurance that the market price per share of our common stock will remain in excess of the $1.00 minimum bid price for a sustained period of time. The continuing effect of our reverse stock split on the market price of our common stock cannot be predicted with any certainty, and the history of similar stock split combinations for companies in like circumstances is varied. It is possible that the per share price of our common stock after the reverse stock split will not rise in proportion to the reduction in the number of shares of common stock outstanding resulting from the reverse stock split, effectively reducing our market capitalization, and there can be no assurance that the market price per post-reverse split share will either exceed or remain in excess of the $1.00 minimum bid price for a sustained period of time. The market price of our common stock may vary based on other factors that are unrelated to the number of shares outstanding, including our future performance.</p>
<p style="margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The delisting of our common stock from a national exchange could impair the liquidity and market price of the common stock. It could also materially, adversely affect our access to the capital markets, and any limitation on market liquidity or reduction in the price of the common stock as a result of that delisting could adversely affect our ability to raise capital on terms acceptable to us, or at all. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In future periods, if we do not meet the minimum stockholders&#8217; equity, minimum closing bid price requirements, or any other listing requirements, we would be subject to delisting from the Nasdaq Capital Market. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of May 10, 2021, the closing price of our common stock was $3.06&#160;per share, and the total market value of our listed securities was approximately $44.1 million. As of March 31, 2021, we had stockholders&#8217; equity of $65.9&#160;million. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our financial statements for the quarter ended March&#160;31, 2021 were prepared assuming that we will continue as a going concern.<font style="font-weight:normal;font-style:normal;"> </font>Our management has concluded that due to our need for additional capital, and the uncertainties surrounding our ability to raise such funding, there may be uncertainty about our ability to continue as a going concern in future years.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our financial statements for the quarter ended March 31, 2021 were prepared assuming that we will continue as a going concern. The going concern basis of presentation assumes that we will continue in operation for the foreseeable future and will be able to realize our assets and discharge our liabilities and commitments in the normal course of business and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from our inability to continue as a going concern. As of December&#160;31,&#160;2019, our management and our independent registered public accounting firm concluded that, due to our need for additional capital and the uncertainties surrounding our ability to raise such funding, substantial doubt existed as to our ability to continue as a going concern for a period from one year after our annual financial statements had been issued. <font style="Background-color:#FFFFFF;color:#000000;">We believe our cash and cash equivalents as of March&#160;31,&#160;2021 will be sufficient to fund our </font>operations through <font style="Background-color:#FFFFFF;color:#000000;">the end of fiscal year </font>2022.<font style="Background-color:#FFFFFF;color:#000000;"> Conducting a Phase 3 rNAPc2 clinical trial or the Phase 3 PRECISION-AF trial would likely require additional financing</font>. We cannot be certain that we will be able to make any other sale of our common stock in any future offering to cover our future capital needs, or at all. Changing circumstances may cause us to consume capital significantly faster or slower than we currently anticipate. If we are delayed in completing or are unable to complete additional funding and/or a strategic transaction, we may discontinue our development activities or operations, but there are no assurances that these reductions would be sufficient to allow us to continue to operate as a going concern. Therefore, even if we resolve this uncertainty, our independent registered public accountants and/or management could conclude that uncertainty as to our ability to continue as a going concern could exist at a future date.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have based these estimates on assumptions that may prove to be wrong, and we could exhaust our available financial resources sooner than we currently anticipate. We may be forced to reduce our operating expenses and raise additional funds to meet our working capital needs, principally through the additional sales of our securities or debt financings. However, we cannot guarantee that we will be able to obtain sufficient additional funds when needed or that such funds, if available, will be obtainable on terms satisfactory to us. If we are unable to raise sufficient additional capital or complete a strategic transaction, we may be unable to continue to fund our operations, develop rNAPc2, Gencaro or our other product candidates, or realize value from our assets and discharge our liabilities in the normal course of business. If we cannot raise sufficient funds, we may have to liquidate our assets, and might realize significantly less than the values at which they are carried on our financial statements, and stockholders may lose all or part of their investment in our securities. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our business could be adversely affected by the effects of health epidemics, including the ongoing COVID-19 global pandemic, in regions where we or third parties on which we rely may have clinical trial sites or other business operations. We anticipate having clinical trial sites in countries that have been directly affected by COVID-19 and depend on third party manufacturing operations for various stages of our supply chain. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our business could be adversely affected by health epidemics, including the ongoing COVID-19 pandemic, in regions where we may have concentrations of future clinical trial sites or other business operations.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the recent COVID-19 outbreak continues to spread, we may need to further limit operations or implement limitations, including work-from-home policies. There is a risk that other countries or regions may be less effective at containing COVID-19, or it may be more difficult to contain if the outbreak reaches a larger population or broader geography, in which case the risks described herein could be elevated significantly.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, third party manufacturing of our drug product candidates and suppliers of the materials used in the production of our drug product candidates may be impacted by significant delays or restrictions resulting from the COVID-19 outbreak which may disrupt our supply chain or limit our ability to manufacture drug product candidates for our clinical trials. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The ultimate impact of the COVID-19 outbreak or a similar future health epidemic is highly uncertain and subject to change. We do not yet know the full extent of potential delays or impacts on our business, our clinical trials, healthcare systems or the global economy as a whole. However, these effects could have a material impact on our operations, and we will continue to monitor the COVID-19 situation closely.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we encounter difficulties enrolling patients in any future clinical trials, our future trials could be delayed or otherwise adversely affected. </font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we have difficulty enrolling a sufficient number of patients in any future clinical trial, we may need to delay or terminate our trial, which would have a negative impact on our business. Delays in enrolling patients in any future clinical trials would also adversely affect our ability to generate any product, milestone and royalty revenues under collaboration agreements, if any, and could impose significant additional costs on us or on any future collaborators.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development beyond our control may impact our ability to enroll patients in an rNAPc2 (AB201) Phase 2b clinical trial, such as the development of vaccines for the SARS-CoV-2 virus or the development of other therapies for COVID-19 disease.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The GENETIC-AF clinical trial required that we identify and enroll a large number of patients with the condition under investigation and the trial enrolled only those patients having a specific genotype, and certain patients who have or are willing to have a Medtronic device implanted for monitoring and recording AFB data. As a result, enrollment for GENETIC-AF was slower than expected, with our first patient enrolled in June 2014 and enrollment completed in August 2017. Because of the rigorous enrollment criteria, our clinical trial timelines were delayed from our original projections. We anticipate that any future Phase 3 clinical trial of Gencaro, including PRECISION-AF, may have similar enrollment criteria, and we cannot guarantee that we will not have similar enrollment issues in any future clinical trials.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may also encounter difficulty enrolling a sufficient number of patients in any future clinical trial, due to circumstances which are outside our control, including as a result of the ongoing COVID-19 pandemic. See &#8220;Our business could be adversely affected by the effects of health epidemics, including the ongoing COVID-19 global pandemic, in regions where we or third parties on which we rely have clinical trial sites or other business operations. We anticipate having clinical trial sites in countries that have been directly affected by COVID-19 and depend on third party manufacturing operations for various stages of our supply chain&#8221; for a discussion of the risks that the COVID-19 pandemic poses to, among other things, our anticipated clinical trials.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We will rely on contract research organizations to conduct substantial portions of our clinical trials, including any future clinical trial of rNAPc2 or Gencaro, and as a result, we will be unable to directly control the timing, conduct and expense of all aspects of our clinical trials. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not currently have sufficient staff with the requisite experience to conduct our clinical trials and therefore will rely on third parties to conduct certain aspects of any future clinical trials. We previously contracted with a CRO to conduct components of our GENETIC-AF clinical trial and anticipate contracting with a CRO to conduct components of any future clinical trial for Gencaro and components of the clinical study of rNAPc2 or any future clinical trials for our other product candidates. As a result, we will have less control over many details and steps of any clinical trial, the timing and completion of any clinical trial, the required reporting of adverse events and the management of data developed through any clinical trial than would be the case if we were relying entirely upon our own staff. Communicating with outside parties can also be challenging, potentially leading to mistakes as well as difficulties in coordinating activities. Outside parties, such as CROs, may have staffing difficulties, may undergo changes in priorities or may become financially distressed, adversely affecting their willingness or ability to conduct our clinical trial. We may experience unexpected cost increases that are beyond our control. Problems with the timeliness or quality of the work of a CRO may lead us to seek to terminate the relationship and use an alternative service provider. However, making any change may be costly and may delay ongoing trials, if any, and contractual restrictions may make such a change difficult or impossible. Additionally, it may be impossible to find a replacement organization that can conduct clinical trials in an acceptable manner and at an acceptable cost.&#160;&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even though we anticipate relying on CROs in the future, we will likely have to devote substantial resources and rely on the expertise of our employees to manage the work being done by the CROs. Due to our limited experience in managing clinical trials, we cannot guarantee our employees will do so effectively. </p>
<p style="margin-top:18pt;line-height:11pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We expect to depend on existing and future collaborations with third parties for the development of some of our product candidates. If those collaborations are not successful, we may not be able to complete the development of these product candidates. </p>
<p style="margin-top:6pt;line-height:11pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We intend to collaborate with one or more clinical trial networks in our development program for rNAPc2. As a result, we will lack direct control over certain aspects of the development program and the amount and timing of resources that these collaborators devote to the project.&nbsp;&nbsp;</p>
<p style="margin-top:6pt;line-height:11pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We had a collaboration agreement with Medtronic that supported our GENETIC-AF clinical trial. If our arrangement with Medtronic, as amended, is continued as part of our future development of Gencaro, we will have limited control over the amount and timing of resources that they dedicate to the development of Gencaro. This is also likely to be true in any future collaboration with third parties and we may seek additional third party collaborators for the development of rNAPc2, Gencaro or any other product candidates. Our ability to benefit from these arrangements will depend on our collaborators&#8217; abilities to successfully perform the functions assigned to them in these arrangements<font style="letter-spacing:-0.1pt;">. </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Collaborations involving our product candidates pose the following risks to us: </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;"></font>&#9679;</p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;"></font>&#9679;</p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">collaborators may not pursue development and commercialization of our product candidates or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborator&#8217;s strategic focus or available funding, or external factors such as an acquisition that diverts resources or creates competing priorities; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;"></font>&#9679;</p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;"></font>&#9679;</p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;"></font>&#9679;</p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our proprietary information or expose us to potential litigation; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;"></font>&#9679;</p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">disputes may arise between the collaborators and us that result in the delay or termination of the research, development or commercialization of our product candidates or that result in costly litigation or arbitration that diverts management attention and resources; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;"></font>&#9679;</p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;"></font>&#9679;</p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">collaborators may elect to take over manufacturing rather than retain us as manufacturers and may encounter problems in starting up or gaining approval for their manufacturing facility and so be unable to continue development of product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;"></font>&#9679;</p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">we may be required to undertake the expenditure of substantial operational, financial and management resources in connection with any collaboration; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;"></font>&#9679;</p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">we may be required to issue equity securities to collaborators that would dilute our existing stockholders&#8217; percentage ownership; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;"></font>&#9679;</p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">we may be required to assume substantial actual or contingent liabilities; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;"></font>&#9679;</p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">collaborators may not commit adequate resources to the marketing and distribution of our product candidates, limiting our potential revenues from these products; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;"></font>&#9679;</p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">collaborators may experience financial difficulties. </font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We face a number of challenges in seeking additional collaborations. Collaborations are complex and any potential discussions may not result in a definitive agreement for many reasons. For example, whether we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration, and the proposed collaborator&#8217;s evaluation of a number of factors, such as the design or results of our clinical trials, the potential market for our product candidates, the costs and complexities of manufacturing and delivering our product candidates to patients, the potential of competing products, the existence of uncertainty with respect to ownership or the coverage of our intellectual property, and industry and market conditions generally. If we were to determine that additional collaborations for our Gencaro development is necessary and were unable to enter into such collaborations on acceptable terms, we might elect to delay or scale back the development or commercialization of Gencaro in order to preserve our financial resources or to allow us adequate time to develop the required physical resources and systems and expertise ourselves<font style="font-family:Calibri;">. </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Collaboration agreements may not lead to development or commercialization of our product candidates in the most efficient manner, or at all. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators. If a present or future collaborator of ours were to be involved in a business combination, the continued pursuit and emphasis on our product development or commercialization program could be delayed, diminished or terminated. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Any future clinical trial for Gencaro will require the use of a third-party diagnostic services provider to administer a genetic test needed to identify the patient receptor genotypes of clinical trial participants, and as a result, we will be unable to directly control the timing, conduct and expense of the genetic test. </font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We anticipate that any future clinical trial of Gencaro, if any, will require a companion diagnostic test that identifies the patient&#8217;s receptor genotype. The trial would only enroll those patients with the receptor that has the potential for enhanced efficacy, the beta-1 389 Arg receptor as detected by a beta-1 389 Arg/Arg genotype. Accordingly, we anticipate that any future clinical trial for Gencaro will require the use of a third-party diagnostic service to perform the genetic testing. There has been limited experience in our industry in prospective development of companion diagnostics required to perform the required molecular profiling. We entered into an agreement with LabCorp to provide the diagnostic services of the genetic test needed to support our GENETIC-AF clinical trial. To provide those services, LabCorp obtained from the FDA an investigational device exemption, or IDE, for the companion diagnostic test being used in our GENETIC-AF clinical trial. We would expect a similar agreement and approval would be necessary for any companion diagnostic used in any future clinical trials for Gencaro.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA and similar regulatory authorities outside the United States regulate companion diagnostics. Companion diagnostics require separate or coordinated regulatory approval prior to commercialization.&#160;Changes to regulatory advice could delay our development programs or delay or prevent eventual marketing approval for our product candidates that may otherwise be approvable. In July 2011, the FDA issued draft guidance that stated that if safe and effective use of a therapeutic depends on an <font style="font-style:italic;">in vitro</font> diagnostic, the FDA generally will not approve the therapeutic unless the FDA approves or clears this &#8220;<font style="font-style:italic;">in vitro</font> companion diagnostic device&#8221; at the same time that the FDA approves the therapeutic. The approval or clearance of the companion diagnostic would occur through the FDA&#8217;s Center for Devices and Radiological Health. In 2014, the FDA issued guidance on in vitro companion diagnostic devices. The guidance allows for flexibility by the FDA in the case of therapeutic products to treat serious conditions for which no alternative treatment exists and the benefits of using the companion diagnostic outweigh the risk, but it is unclear how this discretion may be applied by the agency with respect to the companion diagnostic test related to any Gencaro clinical trials. The FDA&#8217;s evolving position on the topic of companion diagnostics could affect our clinical development programs that utilize companion diagnostics. In particular, the FDA may limit our ability to use retrospective data, otherwise disagree with our approaches to trial design, biomarker qualification, clinical and analytical validity, and clinical utility, or make us repeat aspects of a trial or initiate new trials. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Given our limited experience in developing diagnostics, we expect to rely primarily on third parties for the design and manufacture of the companion diagnostics for our product candidates. If we, or any third parties that we engage to assist us, are unable to successfully develop companion diagnostics for our product candidates that require such diagnostics, or experience delays in doing so, the development of our product candidates may be adversely affected, our product candidates may not receive marketing approval and we may not realize the full commercial potential of any products that receive marketing approval. As a result, our business could be materially harmed. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We will need to establish a collaborative arrangement with a third-party diagnostics services provider to obtain marketing clearance or approval of the companion genetic test. There is no guarantee that the FDA will grant timely clearance or approval of the genetic test, if at all, and failure to obtain such timely clearance or approval would adversely affect our ability to market Gencaro. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The drug label we intend to seek for Gencaro would identify the patient receptor genotype for which the drug is approved. Accordingly, we believe developing a genetic test that is simple to administer and widely available will be critical to the successful commercialization of Gencaro. The genetic test will be subject to regulation by the FDA and by comparable agencies in various foreign countries. The process of complying with the requirements of the FDA and comparable agencies is costly, time consuming and burdensome. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Despite the time and expense expended, regulatory clearance or approval is never guaranteed. If regulatory clearance or approval is delayed, or if one or more third-party diagnostic services providers are unable to obtain FDA approval of the genetic test at all or in parallel with the approval of Gencaro, or are unable to commercialize the test successfully and in a manner that effectively supports the commercial efforts for Gencaro, or if the information concerning the differential response to Gencaro resulting from certain genetic variation is not included in the approval label for Gencaro, the commercial launch of Gencaro may be significantly and adversely affected. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Regulatory approval is required for the genetic test to be used in our Gencaro clinical trials and to support the commercialization of the test, if approved. Delays or failures in obtaining such regulatory approval, including any required validation analyses may prevent a third-party diagnostics provider from commercializing such genetic test and will adversely affect our business, operating results and prospects. </font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Before a genetic test can be used commercially, including in conjunction with Gencaro, if it is approved for marketing, the third-party diagnostics provider must obtain FDA Premarket Approval, or PMA, for such test. The FDA may require additional validation of the genetic test we used in GENETIC-AF prior to any approval of Gencaro or the genetic test or prior to the use of such test in any future clinical trials for Gencaro. We anticipate the genetic test will be required as a condition to prescribing Gencaro. There is no guarantee the FDA will approve the anticipated PMA submission for the genetic test. Even if the genetic test is eventually approved, performing additional validation work necessary to support the PMA, if required, for current or future genetic test products, including one associated with Gencaro, would require additional time and expense and the outcome would be uncertain. Moreover, such delays or increased costs or failures could adversely affect our business, operating results and prospects for commercializing the genetic test.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If a third-party diagnostics provider responsible for the genetic test or certain of its third-party suppliers fails to comply with ongoing FDA or other foreign regulatory authority requirements, or if there are unanticipated problems with the genetic test, these products could be subject to restrictions or withdrawal from use in a trial or from the market. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any diagnostic for which a third-party diagnostics provider obtains clearance or approval, and the manufacturing processes, reporting requirements, post-approval clinical data and promotional activities for such product, will be subject to continued regulatory review, oversight and periodic inspections by the FDA and other domestic and foreign regulatory bodies. With respect to the genetic test, to the extent applicable, any third-party diagnostics provider and certain of its suppliers will be required to comply with the FDA&#8217;s Quality System Regulation, or QSR, and International Standards Organization, or ISO, requirements which cover the methods and documentation of the design, testing, production, control, quality assurance, labeling, packaging, storage and shipping of any product for which clearance or approval is obtained. Regulatory bodies, such as the FDA, enforce the QSR and other regulations through periodic inspections. The failure by a third-party diagnostics provider, or certain of its third-party manufacturers or suppliers, as the case may be, to comply with applicable statutes and regulations administered by the FDA and other regulatory bodies, or the failure to timely and adequately respond to any adverse inspectional observations or product safety issues, could result in, among other things, enforcement actions. If any of these actions were to occur, it could harm our reputation and cause product sales and profitability of Gencaro, if approved, to suffer and may prevent us from generating revenue or utilizing the genetic test further in any clinical trial. Even if regulatory clearance or approval is granted, such clearance or approval may be subject to limitations on the intended uses for which the product may be marketed and reduce our potential to successfully commercialize the product and generate revenue from the product. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Future sales of Gencaro may suffer if its marketplace acceptance is negatively affected by the genetic test. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The genetic test is an important component of the commercial strategy for Gencaro in addition to being required for our clinical trials. We believe that the genetic test helps predict patient response to Gencaro, and that this aspect of the drug is important to its ability to compete effectively with current therapies. The genetic test adds an additional step in the prescribing process, an additional cost for the patient and payors, the risk that the test results may not be rapidly available and the possibility that it may not be available at all to hospitals and medical centers. Although we anticipate that Gencaro, if approved in a timely manner, would be the first genetically-targeted cardiovascular drug, Gencaro will be one of a number of successful drugs in the beta-blocker class currently on the market. Prescribers may be more familiar with these other beta-blockers, and may be resistant to prescribing Gencaro as an AF therapy in patients with HF. For instance, the top-line results of our Phase 2B GENETIC-AF clinical trial indicated that Gencaro demonstrated a similar treatment benefit compared to the active comparator, metoprolol succinate (TOPROL-XL). If our future clinical trials in Gencaro do not show that Gencaro has a clear therapeutic benefit as compared to other drugs in the beta-blocker class currently on the market, then prescribers may be unlikely to prescribe Gencaro to patients, even if approved. Any one of these factors could affect prescriber behavior, which in turn may substantially impede market acceptance of the genetic test, which could cause significant harm to Gencaro&#8217;s ability to compete, and in turn harm our business. </p>
<p style="margin-top:18pt;line-height:11pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Unless we are able to generate sufficient product revenue, we will continue to incur losses from operations and will not achieve or maintain profitability. We are years away from commercializing a product and generating product revenue. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our historical losses have had and will continue to have an adverse effect on our stockholders&#8217; equity and working capital, among other things. We are years away from commercializing a product and generating any product revenue. As a result, we expect to continue to incur significant operating losses for the foreseeable future. Even if we ultimately receive regulatory approval for rNAPc2, Gencaro or our other product candidates, sales of such products may not generate sufficient revenue for it to achieve or maintain profitability. Because of the numerous risks and uncertainties associated with developing therapeutic drugs, we may experience larger than expected future losses and may never reach profitability. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:18pt;line-height:11pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our product candidates are subject to extensive regulation, which can be costly and time-consuming, and unsuccessful or delayed regulatory approvals could increase our future development costs or impair our future revenue. </font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preclinical and clinical development, testing, manufacture, safety, efficacy, labeling, storage, recordkeeping, and subsequent advertising, promotion, sale, marketing, and distribution, if approved, of our product candidates are subject to extensive regulation by the FDA and other regulatory authorities in the United States and elsewhere. These regulations also vary in important, meaningful ways from country to country. We are not permitted to market a potential drug in the United States until we receive approval of an NDA from the FDA for such drug. We have not received an NDA approval from the FDA for rNAPc2, Gencaro or any of our other product candidates. There can be no guarantees with respect to our product candidates that clinical studies will adequately support an NDA, that the products will receive necessary regulatory approvals, or that they will prove to be commercially successful. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To receive regulatory approval for the commercial sale of any product candidates, we must demonstrate safety and efficacy in humans to the satisfaction of regulatory authorities through preclinical studies and adequate and well-controlled clinical trials of the product candidates. This process is expensive and can take many years, and failure can occur at any stage of the testing. Our failure to adequately demonstrate the safety and efficacy of our product candidates will prevent regulatory approval and commercialization of such products. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2008, we submitted and the FDA accepted our NDA filing for Gencaro for the treatment of chronic HF. In 2009, the FDA issued a Complete Response Letter, or CRL, in which the FDA stated that it could not approve the Gencaro NDA in its current form and specified actions required for approval of the NDA, including conducting an additional Phase 3 clinical trial of Gencaro in patients with HF. We completed a Phase 2B clinical study of Gencaro in HF patients to assess its efficacy in reducing or preventing AF. We enrolled 267 HF patients with AF in the Phase 2B clinical trial. We reported top-line Phase 2B data in February 2018. In the third quarter of 2018, we submitted a SPA to the FDA for a Phase 3 clinical trial. In 2019, the FDA approved our SPA request for a Phase 3 clinical trial of Gencaro. Even though the FDA approved our SPA, this product candidate will require years of additional clinical development. Even if we conduct additional studies in accordance with our SPA agreement or further FDA guidance and submit or file a new or amended NDA, the FDA may ultimately decide that the NDA does not satisfy the criteria for approval. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the event that we or our collaborators conduct preclinical studies that do not comply with Good Laboratory Practices, or GLP, or incorrectly design or carry out human clinical trials in accordance with Good Clinical Practices, or GCP, or those clinical trials fail to demonstrate clinical significance, it is unlikely that we will be able to obtain FDA approval for product development candidates. Our inability to successfully initiate and effectively complete clinical trials for any product candidate on schedule, or at all, will severely harm our business. Significant delays in clinical development could materially increase product development costs or allow our competitors to bring products to market before we do, impairing our ability to effectively commercialize any future product candidate. We do not know whether planned clinical trials will begin on time, will need to be redesigned or will be completed on schedule, if at all. Clinical trials can be delayed for a variety of reasons, including: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">delays or failures in obtaining regulatory authorization to commence a trial because of safety concerns of regulators relating to our product candidates or similar product candidates of our competitors or failure to follow regulatory guidelines; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">delays or failures in obtaining clinical materials and manufacturing sufficient quantities of the product candidates for use in trials; </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">failure of clinical materials to meet pre-established specifications at product release or during ongoing stability studies; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">delays or failures in reaching agreement on acceptable terms with prospective study sites; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">delays or failures in obtaining approval of our clinical trial protocol from an institutional review board to conduct a clinical trial at a prospective study site; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">delays in recruiting patients to participate in a clinical trial, which may be due to the size of the patient population, eligibility criteria, protocol design, perceived risks and benefits of the drug, availability of other approved and standard of care therapies or, availability of clinical trial sites; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">other clinical trials seeking to enroll subjects with similar profile; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">failure of our clinical trials and clinical investigators to be in compliance with GCP; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">unforeseen safety issues, including negative results from ongoing preclinical studies; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">inability to monitor patients adequately during or after treatment; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">difficulty recruiting and monitoring multiple study sites;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100.26%;">
<tr style="height:7.2pt;">
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">failure of our third-party contract research organizations, clinical site organizations and other clinical trial managers, to satisfy their contractual duties, comply with regulations or meet expected deadlines; and </p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">an insufficient number of patients who have, or are willing to have, a Medtronic device implanted for monitoring and recording AF burden data.</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, any approvals we may obtain may not cover all of the clinical indications for which we seek approval or permit us to make claims of superiority over currently marketed competitive products. Also, an approval might contain significant limitations in the form of narrow indications, warnings, precautions or contraindications with respect to conditions of use. If the FDA determines that a risk evaluation and mitigation strategy, or REMS, is necessary to ensure that the benefits of the drug outweigh the risks, we may be required to include as part of the NDA a proposed REMS that may include a package insert directed to patients, a plan for communication with healthcare providers, restrictions on a drug&#8217;s distribution, or a Medication Guide, to provide better information to consumers about the drug&#8217;s risks and benefits. Finally, an approval could be conditioned on our commitment to conduct further clinical trials, which we may not have the resources to conduct or which may negatively impact our financial situation. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The manufacture and analytical testing of rNAPc2 and Gencaro is performed by third party suppliers, who must also meet cGMP requirements and pass a pre-approval inspection of their facilities before we can obtain marketing approval. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All of our product candidates are prone to the risks of failure inherent in drug development. The results from preclinical animal testing and early human clinical trials may not be predictive of results obtained in later human clinical trials. Further, although a new product may show promising results in preclinical or early human clinical trials, it may subsequently prove unfeasible or impossible to generate sufficient safety and efficacy data to obtain necessary regulatory approvals. The data obtained from preclinical and clinical studies are susceptible to varying interpretations that may delay, limit or prevent regulatory approval, and the FDA and other regulatory authorities in the United States and elsewhere exercise substantial discretion in the drug approval process. The numbers, size and design of preclinical studies and clinical trials that will be required for FDA or other regulatory approval will vary depending on the product candidate, the disease or condition for which the product candidate is intended to be used and the regulations and guidance documents applicable to any particular product candidate. The FDA or other regulators can delay, limit or deny approval of any product candidate for many reasons, including, but not limited to: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">side effects; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">safety and efficacy; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">defects in the design of clinical trials; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the fact that the FDA or other regulatory officials may not approve our or our third party manufacturer&#8217;s processes or facilities; or </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the fact that new regulations may be enacted by the FDA or other regulators may change their approval policies or adopt new regulations requiring new or different evidence of safety and efficacy for the intended use of a product candidate. </p></td>
</tr>
</table></div>
<p style="margin-top:12pt;line-height:11pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In light of widely publicized events concerning the safety of certain drug products, regulatory authorities, members of Congress, the Government Accountability Office, medical professionals and the general public have raised concerns about potential drug safety issues. These events have resulted in the withdrawal of certain drug products, revisions to certain drug labeling that further limit use of the drug products and establishment of risk management programs that may, for instance, restrict distribution of drug products. The increased attention to drug safety issues may result in a more cautious approach by the FDA to clinical trials and approval. Data from clinical trials may receive greater scrutiny with respect to safety and the product&#8217;s risk/benefit profile, which may make the FDA or other regulatory authorities more likely to terminate clinical trials before completion, or require longer or additional clinical trials that may result in substantial additional expense, and a delay or failure in obtaining approval or approval for a more limited indication than originally sought. Aside from issues concerning the quality and sufficiency of submitted preclinical and clinical data, the FDA may be constrained by limited resources from reviewing and determining the approvability of the Gencaro NDA in a timely manner. </p>
<p style="margin-top:12pt;line-height:11pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In pursuing clinical development of Gencaro for an AF indication, we will be required to amend the Gencaro HF NDA or prepare a new NDA. The FDA could approve Gencaro, but without including some or all of the prescribing information that we have requested. For instance, the FDA could approve Gencaro for AF in a more limited patient population or include additional warnings in the drug&#8217;s label. This, in turn, could substantially and detrimentally impact our ability to successfully commercialize Gencaro and effectively protect our intellectual property rights in Gencaro.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:12pt;line-height:11pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If our product candidates receive regulatory approval, we would be subject to ongoing regulatory obligations and restrictions, which may result in significant expenses and limit our ability to develop and commercialize other potential products. </font></p>
<p style="margin-top:6pt;line-height:11pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If a product candidate of ours is approved by the FDA or by another regulatory authority, we would be held to extensive regulatory requirements over product manufacturing, testing, distribution, labeling, packaging, adverse event reporting and other reporting to regulatory authorities, storage, advertising, marketing, promotion, distribution, and record keeping. Regulatory approvals may also be subject to significant limitations on the indicated uses or marketing of the product candidates. Potentially costly follow-up or post-marketing clinical studies may be required as a condition of approval to further substantiate safety or efficacy, or to investigate specific issues of interest to the regulatory authority. Previously unknown problems with the product candidate, including adverse events of unanticipated severity or frequency, may result in additional regulatory controls or restrictions on the marketing or use of the product or the need for post marketing studies, and could include suspension or withdrawal of the products from the market. </p>
<p style="margin-top:12pt;line-height:11pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, our third-party manufacturers and the manufacturing facilities that they use to make our product candidates are regulated by the FDA. Quality control and manufacturing procedures must continue to conform to cGMP after approval. Drug manufacturers and their subcontractors are required to register their facilities and products manufactured annually with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA, state and/or other foreign authorities. Any subsequent discovery of problems with a product, or a manufacturing or laboratory facility used by us or our collaborators, may result in restrictions on the product, or on the manufacturing or laboratory facility, including a withdrawal of the drug from the market or suspension of manufacturing. Any changes to an approved product, including the way it is manufactured or promoted, often require FDA approval before the product, as modified, can be marketed. We and our third-party manufacturers will also be subject to ongoing FDA requirements for submission of safety and other post-market information. </p>
<p style="margin-top:12pt;line-height:11pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The marketing and advertising of our drug products by our collaborators or us will be regulated by the FDA, certain state agencies or foreign regulatory authorities. Violations of these laws and regulations, including promotion of our products for unapproved uses or failing to disclose risk information, are punishable by criminal and civil sanctions and may result in the issuance of enforcement letters or other enforcement action by the FDA, U.S. Department of Justice, state agencies, or foreign regulatory authorities that could jeopardize our ability to market the product. </p>
<p style="margin-top:12pt;line-height:11pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the FDA, state or foreign regulations, the marketing of our drug products by us or our collaborators will be regulated by federal, state or foreign laws pertaining to health care &#8220;fraud and abuse,&#8221; such as the federal anti-kickback law prohibiting bribes, kickbacks or other remuneration for the order or recommendation of items or services reimbursed by federal health care programs. Many states have similar laws applicable to items or services reimbursed by commercial insurers. Violations of these laws are punishable by criminal and civil sanctions, including, in some instances, imprisonment and exclusion from participation in federal and state health care programs, including the Medicare, Medicaid and Veterans Affairs healthcare programs. Because of the far-reaching nature of these laws, we may be required to discontinue one or more of our practices to be in compliance with these laws. Healthcare fraud and abuse regulations are complex, and even minor irregularities can potentially give rise to claims that a statute or prohibition has been violated. Any violations of these laws, or any action against us for violations of these laws, even if we successfully defend against it, could have a material adverse effect on our business, financial condition and results of operations. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We could also become subject to false claims litigation under federal statutes, which can lead to civil money penalties, restitution, criminal fines and imprisonment, and exclusion from participation in Medicare, Medicaid and other federal and state health care programs. These false claims statutes include the False Claims Act, which allows any person to bring a suit on behalf of the federal government alleging submission of false or fraudulent claims, or causing to present such false or fraudulent claims, under federal programs or contracts claims or other violations of the statute and to share in any amounts paid by the entity to the government in fines or settlement. These suits against pharmaceutical companies have increased significantly in volume and breadth in recent years. Some of these suits have been brought on the basis of certain sales practices promoting drug products for unapproved uses. This new growth in litigation has increased the risk that a pharmaceutical company will have to defend a false claim action, pay fines or restitution, or be excluded from the Medicare, Medicaid, Veterans Affairs and other federal and state healthcare programs as a result of an investigation arising out of such action. We may become subject to such litigation and, if we are not successful in defending against such actions, those actions may have a material adverse effect on our business, financial condition and results of operations. We could also become subject to false claims litigation and consumer protection claims under state statutes, which also could lead to civil monetary penalties, restitution, criminal fines and imprisonment, and exclusion from participation in state health care programs. Of note, over the past few years there has been an increased focus on the sales and marketing practices of the pharmaceutical industry at both the federal and state level. Additionally, the law or regulatory policies governing pharmaceuticals may change. New statutory requirements may be enacted or additional regulations may be adopted that could prevent or delay regulatory approval of our product candidates or limit our ability to commercialize our products. We cannot predict the likelihood, nature or extent of adverse government regulation that may arise from future legislation or administrative action, either in the United States or elsewhere. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we, our collaborators or our third-party manufacturers fail to comply with applicable continuing regulatory requirements, our business could be seriously harmed because a regulatory agency may: </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">issue untitled or warning letters; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">suspend or withdraw our regulatory approval for approved products; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">seize or detain products or recommend a product recall of a drug or medical device, or issue a mandatory recall of a medical device; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">refuse to approve pending applications or supplements to approved applications filed by us; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">suspend our ongoing clinical trials; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">restrict our operations, including costly new manufacturing requirements, or restrict the sale, marketing and/or distribution of our products; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">seek an injunction; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pursue criminal prosecutions; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">close the facilities of our contract manufacturers; or </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">impose civil or criminal penalties. </p></td>
</tr>
</table></div>
<p style="margin-top:18pt;line-height:11pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Reliance on third parties to commercialize rNAPc2, Gencaro or our other product candidates could negatively impact our business. If we are required to establish a direct sales force in the United States and are unable to do so, our business may be harmed. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercialization of rNAPc2, Gencaro or any other product candidate, if approved, particularly the establishment of a sales organization, will require substantial additional capital resources. We currently intend to pursue a strategic partnership alternative for the commercialization of rNAPc2 or Gencaro, if it is approved, and we have suspended our efforts to build internal sales, marketing and distribution capabilities. If we elect to rely on third parties to sell rNAPc2, Gencaro and any other products, then we may receive less revenue than if we sold such products directly. In addition, we may have little or no control over the sales efforts of those third parties. If we are unable to complete a strategic transaction, we would be unable to commercialize rNAPc2, Gencaro or any other product candidate without substantial additional capital. Even if such capital were secured, we would be required to build internal sales, marketing and distribution capabilities to market rNAPc2 or Gencaro in the United States. None of our current employees have experience in establishing and managing a sales force. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the event we are unable to sell rNAPc2, Gencaro and other selected product candidates, either directly or through third parties via a strategic transaction, the commercialization of rNAPc2 or Gencaro, if approved, may be delayed indefinitely.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We are dependent on our key personnel. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The success of our business is highly dependent on the principal members of our board of directors and executive management, including our President and Chief Executive Officer, Michael R. Bristow. The loss of the services of any such individual might seriously harm our product development, partnering and financing efforts. Recruiting and training personnel with the requisite skills is challenging and we compete for talent with companies that are larger and have more financial resources. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We have no manufacturing capacity which puts us at risk of lengthy and costly delays of bringing our products to market.</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not currently operate manufacturing facilities for clinical or commercial production of our product candidates, including their drug substance or active pharmaceutical ingredients, or API. We have no experience in drug formulation or manufacturing, and we lack the resources and the capabilities to manufacture any of our product candidates on a clinical or commercial scale. We do not intend to develop facilities for the manufacture of product candidates for clinical trials or commercial purposes in the foreseeable future. We have contracted with several third-party manufacturing organizations for production and analytical testing of our product candidates. These contract manufacturers may not perform as agreed or may not remain in the contract manufacturing business for the time required to successfully produce, store and distribute our products. In addition, these manufacturers may have staffing difficulties, may experience delays due to key material or component availability, may not be able to manufacture our products on a timely basis or may become financially distressed. In the event of errors in forecasting production quantities required to meet demand, natural disaster, equipment malfunctions or failures, technology malfunctions, strikes, lock-outs or work stoppages, regional power outages, product tampering, war or terrorist activities, actions of regulatory authorities, business failure, strike or other difficulty, we may be unable to find an alternative third-party manufacturer in a timely manner and the production of our product candidates would be interrupted, resulting in delays and additional costs, which could impact our ability to commercialize and sell our product candidates. We or our contract manufacturers may also fail to achieve and maintain required manufacturing standards, which could result in patient injury or death, product recalls or withdrawals, an order by governmental authorities to halt production, delays or failures in product testing or delivery, stability testing failures, cost overruns or other problems that could seriously hurt our business. Contract manufacturers also often encounter difficulties involving production yields, quality control and quality assurance, as well as shortages of qualified personnel. In addition, our contract manufacturers are subject to ongoing inspections and regulation by the FDA, the U.S. Drug Enforcement Agency and corresponding foreign and state agencies and they may fail to meet these agencies&#8217; acceptable standards of compliance. If our contract manufacturers fail to comply with applicable governmental regulations, such as quality control, quality assurance and the maintenance of records and documentation, we may not be able to continue production of the API or finished product. If the safety of any API or product supplied is compromised due to failure to adhere to applicable laws or for other reasons, this may jeopardize our regulatory approval for rNAPc2, Gencaro and other product candidates, and we may be held liable for any injuries sustained as a result. Upon the occurrence of one of the aforementioned events, the ability to switch manufacturers may be difficult for a number of reasons, including: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the number of potential manufacturers is limited and we may not be able to negotiate agreements with alternative manufacturers on commercially reasonable terms, if at all; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">long lead times are often needed to manufacture drugs; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the manufacturing process is complex and may require a significant learning curve; and </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the FDA must approve any replacement prior to manufacturing, which requires new testing and compliance inspections. </p></td>
</tr>
</table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Transitioning from a clinical development stage company will require successful completion of a number of steps, many of which are outside of our control and, consequently, we can provide no assurance of our successful and timely transition from a clinical development stage company. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a clinical development stage biopharmaceutical company with a limited operating history. To date we have not generated any product revenue and have historically funded our operations through investment capital. Our future growth depends on our ability to emerge from the clinical development stage and successfully commercialize or provide for the commercialization of rNAPc2, Gencaro and our other product candidates which in turn, will depend, among other things, on our ability to: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">conduct additional clinical trials and develop and obtain regulatory approval for rNAPc2, Gencaro or other product candidates; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">successfully partner a companion genetic test with the commercial launch of rNAPc2 or Gencaro; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">enter into a strategic transaction enabling the continued development and commercialization of rNAPc2 or Gencaro, or alternatively, raise significant additional capital to enable these activities; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pursue additional indications for rNAPc2 or Gencaro and develop other product candidates, including other cardiovascular therapies; and </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">obtain commercial quantities of rNAPc2, Gencaro or other product candidates at acceptable cost levels. </p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any one of these factors or other factors discussed in this report could affect our ability to successfully commercialize Gencaro and other product candidates, which could impact our ability to earn sufficient revenues to transition from a clinical development stage company and continue our business.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If approved by the FDA, </font><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">rNAPc2</font><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"> or Gencaro will be entering a competitive marketplace and may not succeed. </font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not yet know what the commercial opportunity will be, if any, for rNAPc2 if it is approved for treating COVID-19 disease. We do not know how and to whom rNAPc2 would be marketed and what the commercial arrangements would be for its sales and reimbursement. While we anticipate that rNAPc2, if approved, could potentially be used in combination with antiviral drugs and other therapies, there are other<font style="color:#000000;"> vaccines and therapies under development</font>. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gencaro is a new type of beta-blocker and vasodilator being developed for AF. While we anticipate that this drug, if approved, would be the first genetically-targeted cardiovascular drug, and potentially the only beta-blocker approved for AF, Gencaro will be one of a number of accepted treatments for AF. In addition, our proposed prescribing information for Gencaro is expected to include a requirement for genetic testing of the patient to ascertain if they have the genotype that we believe responds best to Gencaro. This additional step will add incremental cost and procedures to prescribing Gencaro, which could make it more difficult to compete against existing therapies. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our commercial opportunity may be reduced or eliminated if competitors develop and commercialize products that are safer, more effective, have fewer side effects, are more convenient or are less expensive than Gencaro. If products with any of these properties are developed, or any of the existing products are better marketed, then prescriptions of Gencaro by physicians and patient use of Gencaro could be significantly reduced or rendered obsolete and noncompetitive. Further, public announcements regarding the development of any such competing drugs could adversely affect the market price of our common stock and the value of our assets. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Future sales of our products may suffer if they are not accepted in the marketplace by physicians, patients and the medical community. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rNAPc2, Gencaro or our other product candidates may not gain market acceptance among physicians, patients and the medical community. The degree of market acceptance of rNAPc2, Gencaro or our other product candidates will depend on a number of factors, such as its effectiveness and tolerability, as compared with competitive drugs. For instance, if rNAPc2 is approved, by that time there may be superior alternatives in terms of vaccines and/or therapeutics that may significantly impact the relative medical benefits offered by rNAPc2. If our future clinical trials for rNAPc2 do not show that rNAPc2 has a clear therapeutic benefit as compared to other therapies or vaccines that are approved in the interim, then there may be a limited or no commercial market for rNAPc2. Also, prevalence and severity of side-effects could negatively affect market acceptance of rNAPc2. Failure to achieve market acceptance of rNAPc2 or Gencaro would significantly harm our business. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we are unable to obtain acceptable prices or adequate reimbursement from third-party payors for rNAPc2, Gencaro, or any other product candidates that we may seek to commercialize, then our revenues and prospects for profitability will suffer. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our or any strategic partner&#8217;s ability to commercialize rNAPc2, Gencaro, or any other product candidates that we may seek to commercialize, is highly dependent on the extent to which coverage and reimbursement for these product candidates will be available from: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">governmental payors, such as Medicare and Medicaid; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">private health insurers, including managed-care organizations; and </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">other third-party payors. </p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many patients will not be capable of paying for our potential products themselves and will rely on third-party payors to pay for their medical needs. A primary current trend in the U.S. health care industry is toward cost containment. Large private payors, managed-care organizations, group purchasing organizations and similar organizations are exerting increasing influence on decisions regarding the use of, and reimbursement levels for, particular treatments. Such third-party payors, including Medicare, are challenging the prices charged for medical products and services, and many third-party payors limit reimbursement for newly approved health care products. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost-control initiatives could decrease the price we might establish for products, which could result in product revenues lower than anticipated. If the prices for our product candidates decrease, or if governmental and other third-party payors do not provide adequate coverage and reimbursement levels, then our revenue and prospects for profitability will suffer.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Health care reform measures could materially and adversely affect our business. </font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The business and financial condition of pharmaceutical and biotechnology companies are affected by the efforts of governmental and third-party payors to contain or reduce the costs of health care. The U.S. Congress has enacted legislation to reform the health care system. While we anticipate that this legislation may, over time, increase the number of patients who have insurance coverage for pharmaceutical products, it also imposes cost containment measures that may adversely affect the amount of reimbursement for pharmaceutical products. These measures include increasing the minimum rebates for products covered by Medicaid programs and extending such rebates to drugs dispensed to Medicaid beneficiaries enrolled in Medicaid managed care organizations as well as expansion of the 340(B) Public Health Services drug discount program. In addition, such legislation contains a number of provisions designed to generate the revenues necessary to fund the coverage expansion, including new fees or taxes on certain health-related industries, including medical device manufacturers. Each medical device manufacturer has to pay an excise tax (or sales tax) in an amount equal to 2.3% of the price for which such manufacturer sells its medical devices. Such excise taxes may impact any potential sales of the genetic test if it is approved for marketing. On January 22, 2018, legislation was enacted suspending the medical device tax in 2018 and 2019. In December 2019, a permanent repeal of the medical device tax was enacted. The Gencaro Test is likely to be subject to this tax if this tax is reinstated in the future. In foreign jurisdictions there have been, and we expect that there will continue to be, a number of legislative and regulatory proposals aimed at changing the health care system. For example, in some countries other than the United States, pricing of prescription drugs is subject to government control and we expect to see continued efforts to reduce healthcare costs in international markets. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Some states are also considering legislation that would control the prices of drugs, and state Medicaid programs are increasingly requesting manufacturers to pay supplemental rebates and requiring prior authorization by the state program for use of any drug for which supplemental rebates are not being paid. Managed care organizations continue to seek price discounts and, in some cases, to impose restrictions on the coverage of particular drugs. Government efforts to reduce Medicaid expenses may lead to increased use of managed care organizations by Medicaid programs. This may result in managed care organizations influencing prescription decisions for a larger segment of the population and a corresponding constraint on prices and reimbursement for drugs. It is likely that federal and state legislatures and health agencies will continue to focus on additional health care reform in the future although we are unable to predict what additional legislation or regulation, if any, relating to the health care industry or third-party coverage and reimbursement may be enacted in the future or what effect such legislation or regulation would have on our business. We or any strategic partner&#8217;s ability to commercialize rNAPc2, Gencaro, or any other product candidates that we may seek to commercialize, is highly dependent on the extent to which coverage and reimbursement for these product candidates will be available from government payors, such as Medicare and Medicaid, private health insurers, including managed care organizations, and other third-party payors, and any change in reimbursement levels could materially and adversely affect our business. Further, the pendency or approval of future proposals or reforms could result in a decrease in our stock price or limit our ability to raise capital or to obtain strategic partnerships or licenses. </p>
<p style="margin-top:18pt;line-height:11pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our competitors may be better positioned in the marketplace and thereby may be more successful than us at developing, manufacturing and marketing approved products. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many of our competitors currently have significantly greater financial resources and expertise in conducting clinical trials, obtaining regulatory approvals, managing manufacturing and marketing approved products than us. Other early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. In addition, these third parties compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring therapies and therapy licenses complementary to our programs or advantageous to our business. We expect that our ability to compete effectively will depend upon our ability to: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">successfully and rapidly complete clinical trials for any product candidates and obtain all requisite regulatory approvals in a cost-effective manner; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">build an adequate sales and marketing infrastructure, raise additional funding, or enter into strategic transactions enabling the commercialization of our products; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">develop competitive formulations of our product candidates; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">attract and retain key personnel; and </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">identify and obtain other product candidates on commercially reasonable terms. </p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we fail to identify and license or acquire other products or product candidates, then we may be unable to expand our business, and the acquisition or licensing of other products or product candidates may put a strain on our operations and will likely require us to seek additional financing. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">One of our strategies is to license or acquire clinical-stage products or product candidates and further develop them for commercialization. The market for licensing and acquiring products and product candidates is intensely competitive and many of our competitors may have greater resources than we do. If we undertake any additional acquisitions, whether of product candidates or other biopharmaceutical companies, the process of integrating an acquired product candidate or complementary company into our business may put a strain on our operations, divert personnel, financial resources and management&#8217;s attention. In 2020, our research and development activities were dedicated to initiating the clinical trial of rNAPc2. If we are not able to substantially expand our research and development efforts, or identify, or license or acquire other products or product candidates or complete future acquisitions, then we will likely be unable expand our pipeline of product candidates. In addition, any future acquisition would give rise to additional operating costs and will likely require us to seek additional financing. Future acquisitions could result in additional issuances of equity securities that would dilute the ownership of existing stockholders. Future acquisitions could also result in the incurrence of debt, contingent liabilities or the amortization of expenses related to other intangible assets, any of which could adversely affect our operating results.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We would be subject to applicable regulatory approval requirements of the foreign countries in which we market our products, which are costly and may prevent or delay us from marketing our products in those countries. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to regulatory requirements in the United States, we would be subject to the regulatory approval requirements in each foreign country where we market our products. In addition, we might be required to identify one or more collaborators in these foreign countries to develop, seek approval for and manufacture our products and any companion genetic test for Gencaro. If we decide to pursue regulatory approvals and commercialization of our product candidates internationally, we may not be able to obtain the required foreign regulatory approvals on a timely basis, if at all, and any failure to do so may cause us to incur additional costs or prevent us from marketing our products in foreign countries, which may have a material adverse effect on our business, financial condition and results of operations. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If our internal control over financial reporting is not considered effective, our business and stock price could be adversely affected. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section&#160;404 of the Sarbanes-Oxley Act of 2002 requires us to evaluate the effectiveness of our internal control over financial reporting as of the end of each fiscal year, and to include a management report assessing the effectiveness of our internal control over financial reporting in our annual report on Form 10-K for that fiscal year. Our management, including our principal executive officer and principal financial officer, does not expect that our internal control over financial reporting will prevent all error and all fraud. We continue to operate with a small staff for financial reporting. Though the process and design of our internal controls over financial reporting have not been altered, the small number of staff involved in financial reporting may limit our ability to properly segregate internal control procedures which could result in deficiencies or material weaknesses in our internal controls in the future. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#8217;s objectives will be met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud involving a company have been, or will be, detected. The design of any system of controls is based in part on certain assumptions about the&#160;likelihood of future events, and we cannot assure you that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become ineffective because of changes in conditions or deterioration in the degree of compliance with policies or procedures. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected. We cannot assure you that we or our independent registered public accounting firm will not identify a material weakness in our internal control over financial reporting in the future. A material weakness in our internal control over financial reporting would require management to consider our internal control over financial reporting as ineffective. If our internal control over financial reporting is not considered effective, we may experience a loss of public confidence, which could have an adverse effect on our business and on the market price of our common stock. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Changes in tax laws or regulations that are applied adversely to us or our customers may have a material adverse effect </font><font style="color:#000000;">on our business, cash flow, financial condition or results of operations.</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">New income, sales, use or other tax laws, statutes, rules, regulations or ordinances could be enacted at any time, which could affect the tax treatment of our domestic and foreign earnings. Any new taxes could adversely affect our domestic and international business operations, and our business and financial performance. Further, existing tax laws, statutes, rules, regulations or ordinances could be interpreted, changed, modified or applied adversely to us. For example, legislation enacted in 2017, informally titled the Tax Cuts and Jobs Act, significantly revised the Internal Revenue Code of 1986, as amended, or the Code. <font style="Background-color:#FFFFFF;color:#000000;">Future guidance from the Internal Revenue Service and other tax authorities with respect to the Tax Cuts and Jobs Act may affect us, and certain aspects of the Tax Cuts and Jobs Act could be repealed or modified in future legislation. In addition, it is uncertain if and to what extent various states will conform to the Tax Cuts and Jobs Act or any newly enacted federal tax legislation. Changes in corporate tax rates, the realization of net deferred tax assets relating to our operations, the taxation of foreign earnings, and the deductibility of expenses under the Tax Cuts and Jobs Act or future reform legislation could have a material impact on the value of our deferred tax assets, could result in significant one-time charges, and could increase our future U.S. tax expense.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our ability to use our net operating losses to offset future taxable income may be subject to certain limitations. </p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, we had net operating loss, or NOL, carryforwards of approximately $179.5 million, and approximately $1.9&#160;million of research and development credits that may be used to offset future taxable income. Our net operating loss carryforwards generated prior to 2018 will expire beginning in 2025 if not utilized. Under the Tax Cuts and Jobs Act, U.S. federal NOLs incurred in tax years ending after December 31, 2017, may be carried forward indefinitely, but the deductibility of federal NOLs generated in tax years beginning after December 31, 2017, may be limited. In general, under Section 382 of the Code, a corporation that undergoes an &#8220;ownership change&#8221; (as defined under Section 382 of the Code and applicable Treasury Regulations) is subject to limitations on its ability to utilize its pre-change NOLs to offset future taxable income. We have not determined whether we have experienced an ownership change in the past, and we may experience ownership changes in the future as a result of subsequent shifts in our stock ownership, some of which may be outside of our control. There is also a risk that due to regulatory changes, such as suspensions on the use of NOLs or other unforeseen reasons, our existing NOLs could expire or otherwise be unavailable to reduce future income tax liabilities, including for state tax purposes. For these reasons, we may not be able to utilize a material portion of the NOLs reflected on our balance sheet, even if we attain profitability, which could potentially result in increased future tax liability to us and could adversely affect our operating results and financial condition.<font style="color:#000000;"> </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Security breaches, cyber-attacks, or other disruptions or incidents could expose us to liability and affect our business and reputation. </p>
<p style="margin-top:4pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are increasingly dependent on our information technology systems and infrastructure for our business. We, our collaborators and our service providers collect, store, and transmit sensitive information including intellectual property, proprietary business information, clinical trial data and personal information in connection with our business operations. The secure maintenance of this information is critical to our operations and business strategy. Some of this information could be an attractive target of criminal attack by third parties with a wide range of motives and expertise, including organized criminal groups, &#8220;hacktivists,&#8221; patient groups, disgruntled current or former employees, nation-state and nation-state supported actors, and others. Cyber-attacks are of ever-increasing levels of sophistication, and despite our security measures, our information technology and infrastructure may be vulnerable to such attacks or may be breached, including due to employee error or malfeasance. </p>
<p style="margin-top:4pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have implemented information security measures to protect our systems, proprietary information and sensitive data against the risk of inappropriate and unauthorized external use and disclosure and other types of compromise. However, despite these measures, and due to the ever changing information cyber-threat landscape, we cannot guarantee that these measures will be adequate to detect, prevent or mitigate security breaches and other incidents and we may be subject to data breaches through cyber-attacks, malicious code (such as viruses and worms), phishing attacks, social engineering schemes, and insider theft or misuse. Any such breach could compromise our networks and the information stored there could be accessed, modified, destroyed, publicly disclosed, lost or stolen. If our systems become compromised, we may not promptly discover the intrusion. </p>
<p style="margin-top:4pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any security breach of other incident, whether real or perceived, could cause us to suffer reputational damage. Such incidents could result in costs to respond to, investigate and remedy such incidents, notification obligations to affected individuals, government agencies, credit reporting agencies and other third parties, legal claims or proceedings, and liability under our contracts with other parties and federal and state laws that protect the privacy and security of personal information. Any one of these events could cause our business to be materially harmed and our results of operations would be adversely impacted.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Failure to comply with data protection laws and regulations could lead to government enforcement actions (which could include civil or criminal penalties), private litigation, and/or adverse publicity and could negatively affect our operating results and business.</font><font style="font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"> </font></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We and our partners may be subject to federal, state, and foreign data protection laws and regulations (i.e., laws and regulations that address privacy and data security). In the United States, numerous federal and state laws and regulations, including state data breach notification laws, state health information privacy laws, and federal and state consumer protection laws and regulations (e.g., Section 5 of the FTC Act), that govern the collection, use, disclosure, and protection of health-related and other personal information could apply to our operations or the operations of our partners. In addition, we may obtain health information from third parties (including research institutions from which we obtain clinical trial data) that are subject to privacy and security requirements under the Health Insurance Portability and Accountability Act of 1996, as amended, or HIPAA. Depending on the facts and circumstances, we could be subject to criminal penalties if we knowingly obtain, use, or disclose individually identifiable health information maintained by a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA.</p>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the California Consumer Privacy Act, or the CCPA, became effective on January 1, 2020. The CCPA gives California residents expanded rights to access and delete their personal information, opt out of certain personal information sharing and receive detailed information about how their personal information is used by requiring covered companies to provide new disclosures to California consumers (as that term is broadly defined) and provide such consumers new ways to opt-out of certain sales of personal information. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. Although there are limited exemptions for clinical trial data and the CCPA&#8217;s implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future, the CCPA may increase our compliance costs and potential liability. <font style="color:#000000;">Many similar privacy laws have been proposed at the federal level and in other states.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign data protection laws, including, without limitation, the European Union Directive 95/46/EC, or the Directive, and the European Union&#8217;s General Data Protection Regulation, or the GDPR, that became effective in May 2018, and member state data protection legislation, may also apply to health-related and other personal information obtained outside of the United States. <font style="color:#000000;">These laws impose strict obligations on the ability to process health-related and other personal information of data subjects in the European Union and the United Kingdom, including in relation to use, collection, analysis, and transfer (including cross-border transfer) of such personal information. These laws include several requirements relating to the consent of the individuals to whom the personal data relates, limitations on data processing, establishing a legal basis for processing, notification of data processing obligations or security incidents to appropriate data protection authorities or data subjects, the security and confidentiality of the personal data and various rights that data subjects may exercise.&nbsp;&nbsp;</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Directive and the GDPR prohibit, without an appropriate legal basis, the transfer of personal data to countries outside of the European Economic Area, or EEA, such as the United States, which are not considered by the European Commission to provide an adequate level of data protection. Switzerland has adopted similar restrictions. Although there are legal mechanisms to allow for the transfer of personal data from the EEA and Switzerland to the United States, uncertainty about compliance with European Union data protection laws remains. For example, ongoing legal challenges in Europe to the mechanisms allowing companies to transfer personal data from the EEA to the United States could result in further limitations on the ability to transfer personal data across borders, particularly if governments are unable or unwilling to reach new or maintain existing agreements that support cross-border data transfers, such as the European Union-U.S. and Swiss-U.S. Privacy Shield framework. Additionally, other countries have passed or are considering passing laws requiring local data residency.</p>
<p style="margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the GDPR, regulators may impose substantial fines and penalties for non-compliance. Companies that violate the GDPR can face fines of up to the greater of 20 million Euros or 4% of their worldwide annual turnover (revenue). The GDPR increases our responsibility and potential liability in relation to personal data that we process, and we may be required to put in place additional mechanisms to ensure compliance with the GDPR and other EU and international data protection rules<font style="color:#000000;">.</font></p>
<p style="margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Compliance with U.S. and foreign privacy and security laws, rules and regulations could require us to take on more onerous obligations in our contracts, require us to engage in costly compliance exercises, restrict our ability to collect, use and disclose data, or in some cases, impact our or our partners&#8217; or suppliers&#8217; ability to operate in certain jurisdictions. Each of these constantly evolving laws can be subject to varying interpretations. Failure to comply with U.S. and foreign data protection laws and regulations could result in government investigations and enforcement actions (which could include civil or criminal penalties), fines, private litigation, and/or adverse publicity and could negatively affect our operating results and business. Moreover, patients about whom we or our partners obtain information, as well as the providers who share this information with us, may contractually limit our ability to use and disclose the information. Claims that we have violated individuals&#8217; privacy rights, failed to comply with data protection laws, or breached our contractual obligations, even if we are not found liable, could be expensive and time-consuming to defend and could result in adverse publicity that could harm our business.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Intellectual Property and Other Legal Matters </font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If product liability lawsuits are successfully brought against us, then we will incur substantial liabilities and may be required to limit commercialization of rNAPc2, Gencaro or other product candidates. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We face product liability exposure related to the testing of our product candidates in human clinical trials, and may face exposure to claims by an even greater number of persons once we begin marketing and distributing our products commercially. If we cannot successfully defend against product liability claims, then we will incur substantial liabilities. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Regardless of merit or eventual outcome, liability claims may result in: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">decreased demand for our products and product candidates; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">injury to our reputation; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">withdrawal of clinical trial participants; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">costs of related litigation; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">substantial monetary awards to patients and others; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">loss of revenues; and </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the inability to commercialize our products and product candidates. </p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have obtained limited product liability insurance coverage. Such coverage, however, may not be adequate or may not continue to be available to us in sufficient amounts or at an acceptable cost, or at all. We may not be able to obtain commercially reasonable product liability insurance for any product candidate.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Defending against claims relating to improper handling, storage or disposal of hazardous chemicals, radioactive or biological materials could be time consuming and expensive. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our research and development of product candidates may involve the controlled use of hazardous materials, including chemicals, radioactive and biological materials. We cannot eliminate the risk of accidental contamination or discharge and any resultant injury from the materials. Various laws and regulations govern the use, manufacture, storage, handling and disposal of hazardous materials. We may be sued or be required to pay fines for any injury or contamination that results from our use or the use by third parties of these materials. Compliance with environmental laws and regulations may be expensive, and current or future environmental regulations may impair our research, development and production efforts. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The loss of any rights to market key products would significantly impair our operating results. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our patent portfolios relating to Gencaro, including a patent that issued in 2021, are either owned by us or are subject to licenses that impose no royalty obligations or milestone payments relating to the further development, approval and commercialization of Gencaro. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Termination of our license agreements could result in the loss of our further rights to develop and commercialize Gencaro for any indication. The termination of any such license, or of any other agreement which enables us to market a key product or product candidate, could significantly and adversely affect our business.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain intellectual property licensed by us is the subject of additional licensing arrangements to which the party that has licensed rights to us is subject. If such parties were to breach the terms of such licenses or such licenses were otherwise to terminate, our and our partners&#8217; rights to use such technology and develop and commercialize their products such as the genetic test may terminate and our business would be materially harmed. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Third parties may own or control patents or patent applications that we may be required to license to commercialize our product candidates or that could result in litigation that would be costly and time consuming. </font></p>
<p style="margin-top:6pt;line-height:11pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our or any strategic partner&#8217;s ability to commercialize rNAPc2, Gencaro and other product candidates depends upon our ability to develop, manufacture, market and sell these drugs without infringing the proprietary rights of third parties. A number of pharmaceutical and biotechnology companies, universities and research institutions have or may be granted patents that cover technologies similar to the technologies owned by or licensed to us. We may choose to seek, or be required to seek, licenses under third party patents, which would likely require the payment of license fees or royalties or both. We may also be unaware of existing patents that may be infringed by rNAPc2 or Gencaro, the genetic testing we intend to use in connection with Gencaro or our other product candidates. Because patent applications can take many years to issue, there may be other currently pending applications that may later result in issued patents that are infringed by rNAPc2, Gencaro or our other product candidates. Moreover, a license may not be available to us on commercially reasonable terms, or at all. </p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There is a substantial amount of litigation involving patent and other intellectual property rights in the biotechnology and biopharmaceutical industries generally. If a third party claims that we are infringing on its technology, then our business and results of operations could be harmed by a number of factors, including: </p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">infringement and other intellectual property claims, even if without merit, are expensive and time-consuming to litigate and can divert management&#8217;s attention from our core business; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">monetary damage awards for past infringement can be substantial; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a court may prohibit us from selling or licensing product candidates unless the patent holder chooses to license the patent to us; and </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">if a license is available from a patent holder, we may have to pay substantial royalties. </p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may also be forced to bring an infringement action if we believe that a competitor is infringing our protected intellectual property. Any such litigation will be costly, time-consuming and divert management&#8217;s attention, and the outcome of any such litigation may not be favorable to us.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our intellectual property rights may not preclude competitors from developing competing products and our business may suffer. </p>
<p style="margin-top:6pt;line-height:11pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our competitive success will depend, in part, on our ability to obtain and maintain patent protection for our inventions, technologies and discoveries, including intellectual property that we license. The patent positions of biotechnology companies involve complex legal and factual questions, and we cannot be certain that our patents and licenses will successfully preclude others from using our technology. Consequently, we cannot be certain that any of our patents will provide significant market protection or will not be circumvented or challenged and found to be unenforceable or invalid. In some cases, patent applications in the United States and certain other jurisdictions are maintained in secrecy until patents issue, and since publication of discoveries in the scientific or patent literature often lags behind actual discoveries, we cannot be certain of the priority of inventions covered by pending patent applications. Moreover, we may have to participate in interference proceedings declared by the U.S. Patent and Trademark Office to determine priority of invention, in opposition proceedings in a foreign patent office, or in a post-grant challenge proceeding such as an <font style="font-style:italic;">ex parte</font> reexamination or <font style="font-style:italic;">inter partes</font> review at the U.S. Patent and Trademark Office, any of which could result in substantial cost to us, even if the eventual outcome is favorable. There can be no assurance that a court of competent jurisdiction would hold any claims in any issued patent to be valid. An adverse outcome could subject us to significant liabilities to third parties, require disputed rights to be licensed from third parties or require us to cease using such technology. </p>
<p style="margin-top:6pt;line-height:11pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We own the clinical development program of rNAPc2, including Phase 2 clinical trials.&#160; If rNAPc2 is successfully developed, we believe it will have intellectual property protection, including 12 years of market exclusivity as an innovative biologic product under FDA law in the United States, 10 years data protection exclusivity in the EU, and potentially patent protection in addition to this. However, another competitor could develop a compound with similar biological properties to rNAPc2 that may not be barred by our exclusivity. We have also filed a provisional patent application for rNAPc2 and its use for COVID-19 disease, but there is no assurance that this provisional application will ultimately result in an issued patent.</p>
<p style="margin-top:6pt;line-height:11pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Regardless of merit, the listing of patents in the FDA Orange Book for Gencaro may be challenged as being improperly listed. We may have to defend against such claims and possible associated antitrust issues. We could also incur substantial costs in seeking to enforce our proprietary rights against infringement. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:6pt;line-height:11pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While the composition of matter patents on the compound that comprises Gencaro have expired, we hold the intellectual property concerning the interaction of Gencaro with the polymorphisms of the beta-1 and alpha-2C receptors. We have obtained patents that claim methods involving Gencaro after a patient&#8217;s receptor genotype has been determined. We anticipate that any NDA for Gencaro will request a label including a claim that efficacy varies based on receptor genotype and a recommendation in the prescribing information that prospective patients be tested for their receptor genotype. We believe that under applicable law, a generic bucindolol label would likely be required to include this recommendation as it pertains directly to the safe or efficacious use of the drug. Such a label may be considered as inducing infringement, carrying the same liability as direct infringement. If the label with the genotype information for Gencaro is not approved, or if generic labels are not required to copy the approved label, competitors could have an easier path to introduce competing products and our business may suffer. The approved label may not contain language covered by the patents, or we may be unsuccessful in enforcing them. </font></p>
<p style="margin-top:6pt;line-height:11pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may not be able to effectively protect our intellectual property rights in some foreign countries, as our patents are limited by jurisdiction and many countries do not offer the same level of legal protection for intellectual property as the United States. </p>
<p style="margin-top:6pt;line-height:11pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We require our employees, consultants, business partners and members of our scientific advisory board to execute confidentiality agreements upon the commencement of employment, consulting or business relationships with us. These agreements provide that all confidential information developed or made known during the course of the relationship with us be kept confidential and not disclosed to third parties except in specific circumstances. In the case of employees, the agreements provide that all inventions resulting from work performed for us, utilizing the property or relating to our business and conceived or completed by the individual during employment shall be our exclusive property to the extent permitted by applicable law. </p>
<p style="margin-top:6pt;line-height:11pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third parties may breach these and other agreements with us regarding our intellectual property and we may not have adequate remedies for the breach. Third parties could also fail to take necessary steps to protect our licensed intellectual property, which could seriously harm our intellectual property position. </p>
<p style="margin-top:6pt;line-height:11pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we are not able to protect our proprietary technology, trade secrets and know-how, then our competitors may develop competing products. Any issued patent may not be sufficient to prevent others from competing with us. Further, we have trade secrets relating to rNAPc2 and Gencaro, and such trade secrets may become known or independently discovered. Our issued patents and those that may issue in the future, or those licensed to us, may be challenged, opposed, invalidated or circumvented, which could allow competitors to market similar products or limit the patent protection term of our product candidates. All of these factors may affect our competitive position. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If the manufacture, use or sale of our products infringe on the intellectual property rights of others, we could face costly litigation, which could cause us to pay substantial damages or licensing fees and limit our ability to sell some or all of our products. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Extensive litigation regarding patents and other intellectual property rights has been common in the biopharmaceutical industry. Litigation may be necessary to assert infringement claims, enforce patent rights, protect trade secrets or know-how and determine the enforceability, scope and validity of certain proprietary rights. Litigation may even be necessary to defend disputes of inventorship or ownership of proprietary rights. The defense and prosecution of intellectual property lawsuits, U.S. Patent and Trademark Office interference proceedings, and related legal and administrative proceedings (e.g., a reexamination, <font style="font-style:italic;">inter partes</font> review, or post-grant review) in the United States and internationally involve complex legal and factual questions. As a result, such proceedings are costly and time-consuming to pursue, and their outcome is uncertain. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Regardless of merit or outcome, our involvement in any litigation, interference or other administrative proceedings could cause us to incur substantial expense and could significantly divert the efforts of our technical and management personnel. Any public announcements related to litigation or interference proceedings initiated or threatened against us could cause our stock price to decline. Adverse outcomes in patent litigation may potentially subject us to antitrust litigation which, regardless of the outcome, would adversely affect our business. An adverse determination may subject us to the loss of our proprietary position or to significant liabilities, or require us to seek licenses that may include substantial cost and ongoing royalties. Licenses may not be available from third parties, or may not be obtainable on satisfactory terms. An adverse determination or a failure to obtain necessary licenses may restrict or prevent us from manufacturing and selling our products, if any. These outcomes could materially harm our business, financial condition and results of operations. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Ownership of our Common Stock and Stock Price Volatility </font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our stock price has been and is expected to be volatile. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our common stock has in the past been and in the future could be subject to significant fluctuations. Market prices for securities of early-stage pharmaceutical, biotechnology and other life sciences companies have historically been particularly volatile. Some of the factors that may cause the market price of our common stock to fluctuate include: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the regulatory status of rNAPc2, Gencaro and the genetic test, and whether and when they are approved for sale, if at all, and the labeling or other conditions of use imposed by the FDA; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our ability to secure additional funding or complete a strategic transaction or to complete development of and commercialize rNAPc2 or Gencaro; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">progress of any future clinical trials for rNAPc2, Gencaro or our other product candidate, including enrollment and any data that may become available;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the results of our future clinical trials and any future NDAs of our current and future product candidates; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the entry into, or termination of, key agreements, including key strategic alliance agreements; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the results and timing of regulatory reviews relating to our product candidates; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">failure of any of our product candidates, if approved, to achieve commercial success; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">general and industry-specific economic conditions that may affect our research and development expenditures; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the results of clinical trials conducted by others on drugs that would compete with our product candidates; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">issues in manufacturing our product candidates or any approved products; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the initiation of or material developments in or the conclusion of litigation to enforce or defend any of our intellectual property rights; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the loss of key employees; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the introduction of technological innovations or new commercial products by our competitors; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">changes in estimates or recommendations by securities analysts, if any, who cover our common stock; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">future sales of our common stock; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">changes in the structure of health care payment systems; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">period-to-period fluctuations in our financial results; and </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our ability to retain the listing of our common stock on the Nasdaq Capital Market. </p></td>
</tr>
</table></div>
<p style="margin-top:12pt;line-height:11pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, the stock markets in general have experienced substantial volatility that has often been unrelated to the operating performance of individual companies, including as a result of the ongoing COVID-19 pandemic. These broad market fluctuations may also adversely affect the trading price of our common stock. In the past, following periods of volatility in the market price of a company&#8217;s securities, stockholders have often instituted class action securities litigation against those companies. Such litigation, if instituted, could result in substantial costs and diversion of management attention and resources, which could significantly harm our profitability and reputation.</p>
<p style="margin-top:12pt;line-height:11pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Future sales or the possibility of future sales of our common stock may depress the market price of our common stock. </p>
<p style="margin-top:6pt;line-height:11pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales in the public market of substantial amounts of our common stock could depress prevailing market prices of our common stock. As of March 31, 2021, approximately 14.4&#160;million shares of common stock were outstanding, and all of these shares are freely transferable without restriction or further registration under the Securities Act of 1933, as amended, or the Securities Act, except for shares held by our directors, officers and other affiliates and unregistered shares held by non-affiliates. The sale of these additional shares, or the perception that such sales may occur, could depress the market price of our common stock. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:12pt;line-height:11pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 3</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, 202</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, approximately 133,000 shares of our common stock were issuable upon the exercise of outstanding warrants. Once a warrant is exercised, if the shares of our common stock issued upon the exercise of any such warrant are not available for sale in the open market without further registration under the Securities Act, then the holder can arrange for the resale of shares either by invoking any applicable registration rights, causing the shares to be registered under the Securities Act and thus freely transferable, or by relying on an exemption to the Securities Act. For instance, in July 2015, we filed a registration statement on Form&#160;S-3 which registered for resale an aggregate of 0.1 million shares of our common stock issuable upon exercise of outstanding warrants. If these registration rights, or similar registration rights that may apply to securities we may issue in the future, are exercised, it could result in additional sales of our common stock in the market, which may have an adverse effect on our stock price. </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March 31, 2021, there were approximately 596,000 shares of our common stock which may be issued upon the exercise of outstanding stock options, and we anticipate that we will continue to issue stock option awards to our employees and consultants in the fiscal year ended December 31, 2021 and thereafter. If and when these options are exercised, such shares will be available for sale in the open market without further registration under the Securities Act. The existence of these outstanding options may negatively affect our ability to complete future equity financings at acceptable prices and on acceptable terms. The exercise of those options, and the prompt resale of shares of our common stock received, may also result in downward pressure on the price of our common stock. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the absence of a significant strategic transaction, we will need to raise significant additional capital to finance the research, development and commercialization of rNAPc2, Gencaro and our other product candidate. If future securities offerings occur, they would dilute our current stockholders&#8217; equity interests and could reduce the market price of our common stock. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We do not expect to pay cash dividends, and accordingly, stockholders must rely on stock appreciation for any return on their investment. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We anticipate that we will retain our earnings, if any, for future growth and therefore do not anticipate paying cash dividends in the future. As a result, only appreciation of the price of our common stock will provide a return to stockholders. Investors seeking cash dividends should not invest in our common stock. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We have implemented anti-takeover provisions that could discourage, prevent or delay a takeover, even if the acquisition would be beneficial to our stockholders. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provisions of our certificate of incorporation and bylaws, as well as provisions of Delaware law, could make it more difficult for a third party to acquire us, even if doing so would benefit our stockholders. These provisions: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">establish a classified board of directors so that not all members of our board may be elected at one time; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">authorize the issuance of up to approximately 5&#160;million additional shares of preferred stock that could be issued by our board of directors to increase the number of outstanding shares and hinder a takeover attempt; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">limit who may call a special meeting of stockholders; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">prohibit stockholder action by written consent, thereby requiring all stockholder actions to be taken at a meeting of our stockholders; and </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">establish advance notice requirements for nominations for election to our board of directors or for proposing matters that can be acted upon at a stockholder meeting. </p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Specifically, our certificate of incorporation provides that all stockholder action must be effected at a duly called meeting and not by a written consent. The bylaws provide, however, that our stockholders may call a special meeting of stockholders only upon a request of stockholders owning at least 50% of our outstanding common stock. These provisions of our certificate of incorporation and bylaws could discourage potential acquisition proposals and could delay or prevent a change in control. We designed these provisions to reduce our vulnerability to unsolicited acquisition proposals and to discourage certain tactics that may be used in proxy fights. These provisions, however, could also have the effect of discouraging others from making tender offers for our shares. As a consequence, they also may inhibit fluctuations in the market price of our shares that could result from actual or rumored takeover attempts. Such provisions also may have the effect of preventing changes in our management. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are permitted to issue shares of our preferred stock without stockholder approval upon such terms as our board of directors determines. Therefore, the rights of the holders of our common stock are subject to, and may be adversely affected by, the rights of the holders of our preferred stock that may be issued in the future. In addition, the issuance of preferred stock could have a dilutive effect on the holdings of our current stockholders. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to the Delaware anti-takeover laws regulating corporate takeovers. These anti-takeover laws prevent a Delaware corporation from engaging in a merger or sale of more than 10% of its assets with any stockholder, including all affiliates and associates of the stockholder, who owns 15% or more of the corporation&#8217;s outstanding voting stock, for three years following the date that the stockholder acquired 15% or more of the corporation&#8217;s stock unless: </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the board of directors approved the transaction where the stockholder acquired 15% or more of the corporation&#8217;s stock; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">after the transaction in which the stockholder acquired 15% or more of the corporation&#8217;s stock, the stockholder owned at least 85% of the corporation&#8217;s outstanding voting stock, excluding shares owned by directors, officers and employee stock plans in which employee participants do not have the right to determine confidentially whether shares held under the plan will be tendered in a tender or exchange offer; or </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on or after this date, the merger or sale is approved by the board of directors and the holders of at least two-thirds of the outstanding voting stock that is not owned by the stockholder. </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The provisions of our governing documents and current Delaware law may, collectively: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">lengthen the time required for a person or entity to acquire control of us through a proxy contest for the election of a majority of our board of directors; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">discourage bids for our common stock at a premium over market price; and </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">generally deter efforts to obtain control of us. </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_2_UNREGISTERED"></a><a name="ITEM_2_UNREGISTERED"></a>ITEM&#160;2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable. </p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_3_DEFAULTS"></a><a name="ITEM_3_DEFAULTS"></a>ITEM&#160;3. DEFAULTS UPON SENIOR SECURITIES </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable. </p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_4_MINE"></a><a name="ITEM_4_MINE"></a>ITEM&#160;4. MINE SAFETY DISCLOSURES </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable. </p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_5_OTHER"></a><a name="ITEM_5_OTHER"></a>ITEM&#160;5. OTHER INFORMATION </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mr.&#160;C. Jeff Dekker entered into an employment agreement that is effective as of May 10, 2021. As of May 10, 2021, Mr.&#160;Dekker executed an indemnification agreement in substantially the form filed as Exhibit 10.29 to our Annual Report on Form 10-K for the year ended December&#160;31, 2013.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under his employment agreement, Mr.&#160;Dekker is entitled to receive an annual base salary of $270,000, subject to annual increases if approved by our Board of Directors or Compensation Committee and is eligible to receive an annual target bonus of 35% of his base salary as determined by the Board of Directors or Compensation Committee in their sole discretion. On May&#160;10,&#160;2021, the Compensation Committee approved an incentive stock option grant of 55,000 common stock options to Mr. Dekker pursuant to our 2020 Equity Incentive Plan.&nbsp;&nbsp;The option has an exercise price of $3.06 per share, representing the closing price of our common stock on the Nasdaq Capital Market on May 10, 2021.&nbsp;&nbsp;The option vests 25% after one year, then in 36 equal monthly installments, measured from May 10, 2021, subject to partial acceleration upon the occurrence of specified events. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we terminate Mr.&#160;Dekker&#8217;s employment without &#8220;cause,&#8221; or if Mr.&#160;Dekker terminates his employment with &#8220;good reason&#8221; (as these terms are defined in his employment agreement), we have agreed to pay Mr.&#160;Dekker a severance payment equivalent to (i)&#160;12 months of his base salary (if such termination occurs on the same day as or within thirteen months after a change of control of the Company), (ii)&#160;a pro rata portion of any bonus compensation under any employee bonus plan that has been approved by the Board of Directors payable to him for the fiscal year in which his employment terminated to be paid at the same time that such incentive bonus </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">would have been paid had the termination not occurred, and (iii)&#160;reimbursement to cover out-of-pocket costs to continue group</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> health insurance benefits under COBRA for 12 months, whether he elects or is eligible to receive COBRA (provided, that even if he does not elect or is not eligible to receive COBRA, he will receive the equivalent of such out-of-pocket expenses paid by him</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> not to exceed the costs that the benefits would equal under COBRA if he were so eligible). In addition, </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may elect in </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> sole discretion, to pay additional severance equal to up to 12 months of base salary, which additional payment would extend</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> the covenants and obligations under Mr.&#160;Dekker&#8217;s </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">employee </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">intellectual </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">property</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">confidentiality </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">non</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">compete </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">agreement </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for such additional period. The severance payment is conditioned </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on the execution by Mr.&#160;Dekker of a legal release in a form acceptable to </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">us</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_6_EXHIBITS"></a><a name="ITEM_6_EXHIBITS"></a>ITEM&#160;6. EXHIBITS </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT INDEX </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following documents are filed as part of this quarterly report on Form 10-Q. The Company will furnish a copy of any exhibit listed to requesting stockholders upon payment of the Company&#8217;s reasonable expenses in furnishing those materials. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:auto;">
<tr>
<td style="width:0.73%;"></td>
<td style="width:10.88%;"></td>
<td style="width:1.93%;"></td>
<td style="width:45.33%;"></td>
<td style="width:0.96%;"></td>
<td style="width:6.74%;"></td>
<td style="width:0.96%;"></td>
<td style="width:16.83%;"></td>
<td style="width:0.96%;"></td>
<td style="width:1%;"></td>
<td style="width:7.32%;"></td>
<td style="width:0.96%;"></td>
<td style="width:7.71%;"></td>
<td style="width:0.44%;"></td>
</tr>
<tr>
<td colspan="2" valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom"  style=" border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Incorporated by Reference (1)</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td colspan="2" valign="bottom"  style=" border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit<br />No.</p></td>
<td valign="bottom" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style=" border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description </p></td>
<td valign="bottom" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style=" border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Form</p></td>
<td valign="bottom" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style=" border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Filing<br />Date</p></td>
<td valign="bottom" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style=" border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style=" border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Filed<br />Herewith </p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1</p></td>
<td valign="bottom" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000119312509064819/dex31.htm"><font style="text-decoration:underline;">Amended and Restated Certificate of Incorporation of the Registrant, as amended</font></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /><font style="font-size:10pt;">10-K</font></p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /><font style="font-size:10pt;">3/27/2009</font></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /><font style="font-size:10pt;">3.1</font></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />&#160;</p></td>
<td colspan="2" valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1(a)</p></td>
<td valign="bottom" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000119312513090814/d498361dex51.htm"><font style="text-decoration:underline;">Certificate of Amendment to Restated Certificate of Incorporation</font></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /><font style="font-size:10pt;">8-K</font></p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /><font style="font-size:10pt;">3/5/2013</font></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /><font style="font-size:10pt;">5.1</font></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />&#160;</p></td>
<td colspan="2" valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1(b)</p></td>
<td valign="bottom" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000156459015007723/abio-ex31_74.htm"><font style="text-decoration:underline;">Certificate of Amendment to Restated Certificate of Incorporation</font></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /><font style="font-size:10pt;">8-K</font></p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /><font style="font-size:10pt;">9/3/2015</font></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /><font style="font-size:10pt;">3.1</font></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />&#160;</p></td>
<td colspan="2" valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1(c)</p></td>
<td valign="bottom" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000156459019010715/abio-ex31_7.htm"><font style="text-decoration:underline;">Certificate of Amendment to Restated Certificate of Incorporation</font></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /><font style="font-size:10pt;">8-K</font></p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /><font style="font-size:10pt;">4/3/2019</font></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /><font style="font-size:10pt;">3.1</font></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />&#160;</p></td>
<td colspan="2" valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.2</p></td>
<td valign="bottom" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000119312509235710/dex32.htm"><font style="text-decoration:underline;">Second Amended and Restated Bylaws of the Registrant, as amended</font></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /><font style="font-size:10pt;">10-Q</font></p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /><font style="font-size:10pt;">11/16/2009</font></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /><font style="font-size:10pt;">3.2</font></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />&#160;</p></td>
<td colspan="2" valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1</p></td>
<td valign="bottom" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000119312509064819/dex31.htm"><font style="text-decoration:underline;">Reference is made to Exhibits 3.1, 3.1(a), 3.1(b) and 3.2</font></a></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />&#160;</p></td>
<td colspan="2" valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /><font style="font-size:10pt;">&#160;</font></p></td>
</tr>
<tr style="height:14.4pt;">
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.2</p></td>
<td valign="bottom" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000156459019017210/abio-ex42_106.htm"><font style="text-decoration:underline;">Form of Common Stock Certificate</font></a><font style="text-decoration:none;">.</font></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5/8/2019</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.2</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />&#160;</p></td>
<td colspan="2" valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="bottom" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000156459021017811/abio-ex101_6.htm"><font style="text-decoration:underline;">Amendment No. 1 to Capital on Demand</font><font style="font-size:8.5pt;text-decoration:underline;"><sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup></font><font style="text-decoration:underline;">&#160;Sales Agreement, dated April 6, 2021, by and between ARCA biopharma, Inc. and JonesTrading Institutional Services LLC</font></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /><font style="font-size:10pt;">8-K</font></p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /><font style="font-size:10pt;">4/6/2021</font></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /><font style="font-size:10pt;">10.1</font></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.2</p></td>
<td valign="bottom" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="abio-ex102_75.htm"><font style="text-decoration:underline;">Employment Agreement, dated April 21, 2021, by and between ARCA biopharma, Inc. and C. Jeff Dekker</font></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /><font style="font-size:10pt;">&#160;</font></p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /><font style="font-size:10pt;">&#160;</font></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /><font style="font-size:10pt;">&#160;</font></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />&#160;</p></td>
<td colspan="2" valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /><font style="font-size:10pt;">X</font></p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31.1</p></td>
<td valign="bottom" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="abio-ex311_7.htm"><font style="text-decoration:underline;">Certification of Principal Executive Officer pursuant to Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</font></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /><font style="font-size:10pt;">&#160;</font></p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /><font style="font-size:10pt;">&#160;</font></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /><font style="font-size:10pt;">&#160;</font></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />&#160;</p></td>
<td colspan="2" valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /><font style="font-size:10pt;">X</font></p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31.2</p></td>
<td valign="bottom" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="abio-ex312_6.htm"><font style="text-decoration:underline;">Certification of Principal Financial Officer pursuant to Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</font></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /><font style="font-size:10pt;">&#160;</font></p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /><font style="font-size:10pt;">&#160;</font></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /><font style="font-size:10pt;">&#160;</font></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />&#160;</p></td>
<td colspan="2" valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /><font style="font-size:10pt;">X</font></p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32.1</p></td>
<td valign="bottom" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="abio-ex321_8.htm"><font style="text-decoration:underline;">Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. sec. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</font></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /><font style="font-size:10pt;">&#160;</font></p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /><font style="font-size:10pt;">&#160;</font></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /><font style="font-size:10pt;">&#160;</font></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />&#160;</p></td>
<td colspan="2" valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /><font style="font-size:10pt;">X</font></p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.INS</p></td>
<td valign="bottom" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Instance Document (filed electronically herewith)</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /><font style="font-size:10pt;">&#160;</font></p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /><font style="font-size:10pt;">&#160;</font></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /><font style="font-size:10pt;">&#160;</font></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />&#160;</p></td>
<td colspan="2" valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /><font style="font-size:10pt;">X</font></p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.SCH</p></td>
<td valign="bottom" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Schema Document (filed electronically herewith)</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /><font style="font-size:10pt;">&#160;</font></p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /><font style="font-size:10pt;">&#160;</font></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /><font style="font-size:10pt;">&#160;</font></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />&#160;</p></td>
<td colspan="2" valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /><font style="font-size:10pt;">X</font></p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.CAL</p></td>
<td valign="bottom" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Calculation Linkbase Document (filed electronically herewith)</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /><font style="font-size:10pt;">&#160;</font></p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /><font style="font-size:10pt;">&#160;</font></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /><font style="font-size:10pt;">&#160;</font></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />&#160;</p></td>
<td colspan="2" valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /><font style="font-size:10pt;">X</font></p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.LAB</p></td>
<td valign="bottom" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Label Linkbase Document (filed electronically herewith)</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /><font style="font-size:10pt;">&#160;</font></p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /><font style="font-size:10pt;">&#160;</font></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /><font style="font-size:10pt;">&#160;</font></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />&#160;</p></td>
<td colspan="2" valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /><font style="font-size:10pt;">X</font></p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:auto;">
<tr>
<td style="width:0.73%;"></td>
<td style="width:10.88%;"></td>
<td style="width:1.93%;"></td>
<td style="width:45.33%;"></td>
<td style="width:0.96%;"></td>
<td style="width:6.74%;"></td>
<td style="width:0.96%;"></td>
<td style="width:16.83%;"></td>
<td style="width:0.96%;"></td>
<td style="width:1%;"></td>
<td style="width:7.32%;"></td>
<td style="width:0.96%;"></td>
<td style="width:7.71%;"></td>
<td style="width:0.44%;"></td>
</tr>
<tr>
<td colspan="2" valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom"  style=" border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Incorporated by Reference (1)</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td colspan="2" valign="bottom"  style=" border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit<br />No.</p></td>
<td valign="bottom" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style=" border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description </p></td>
<td valign="bottom" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style=" border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Form</p></td>
<td valign="bottom" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style=" border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Filing<br />Date</p></td>
<td valign="bottom" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style=" border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style=" border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Filed<br />Herewith </p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.PRE</p></td>
<td valign="bottom" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Presentation Linkbase Document (filed electronically herewith)</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /><font style="font-size:10pt;">&#160;</font></p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /><font style="font-size:10pt;">&#160;</font></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /><font style="font-size:10pt;">&#160;</font></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />&#160;</p></td>
<td colspan="2" valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /><font style="font-size:10pt;">X</font></p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.DEF</p></td>
<td valign="bottom" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Definition Linkbase Document (filed electronically herewith)</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /><font style="font-size:10pt;">&#160;</font></p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /><font style="font-size:10pt;">&#160;</font></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /><font style="font-size:10pt;">&#160;</font></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />&#160;</p></td>
<td colspan="2" valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /><font style="font-size:10pt;">X</font></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gubvrvugbnha000001.jpg" title="" alt="" style="width:162px;height:1px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.67%;text-indent:-6.67%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:0.83%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.83%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(1)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:normal;color:#000000;">The SEC file number for all items incorporated by reference herein from reports on Forms 10-K, 10-Q and 8-K is 000-22873.</font></p></td></tr></table></div>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="SIGNATURE"></a><a name="SIGNATURE"></a>SIGNATURE </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:39.12%;">
<tr>
<td colspan="3" valign="bottom"  style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARCA biopharma, Inc. (Registrant)</p></td>
</tr>
<tr style="height:12pt;">
<td valign="middle"  style="width:7.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td colspan="2" valign="middle"  style="width:92.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:7.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  style="width:1.28%; border-bottom:solid 0.75pt #000000;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:91.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ C. Jeffrey Dekker</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:7.22%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:1.28%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:91.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">C. Jeffrey Dekker</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:7.22%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:1.28%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:91.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Principal Financial and Accounting Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dated: May 11, 2021 </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>2
<FILENAME>abio-ex102_75.htm
<DESCRIPTION>EX-10.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
abio-ex102_75.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.2</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gneflb3r2gmg000001.jpg" title="" alt="" style="width:209px;height:76px;"></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">April 21, 2021</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">C. Jeff Dekker</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1265 Eldorado Drive</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Superior, CO. 80027</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Re:<font style="margin-left:36pt;">Employment Agreement</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dear Jeff:</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARCA biopharma, Inc. (the &#8220;<font style="font-weight:bold;">Company</font>&#8221;) is pleased to offer you this agreement regarding your employment as the Company&#8217;s Chief Financial Officer (the &#8220;<font style="font-weight:bold;">Agreement</font>&#8221;).&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Employment.</font><font style="font-weight:normal;color:#000000;">&nbsp;&nbsp;The Company hereby agrees to employ you and you hereby accept such employment upon the terms and conditions set forth herein and agree to perform such duties.&nbsp;&nbsp;Your start date will be on or before May 10, 2021 (the &#8220;</font><font style="color:#000000;">Start Date</font><font style="font-weight:normal;color:#000000;">&#8221;).</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">2.</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Duties.</font><font style="font-weight:normal;color:#000000;">&nbsp;&nbsp;You shall render exclusive services as a full-time employee to the Company as its Chief Financial Officer and shall report to the Company&#8217;s Chief Executive Officer.&nbsp;&nbsp;Your responsibilities, title, working conditions, duties, reporting relationship and/or any other aspect of your employment may be changed, added to or eliminated during your employment at the sole discretion of the Company.&nbsp;&nbsp;During the term of your employment hereunder, you shall devote your best efforts and your full business time, skill and attention to the performance of your duties on behalf of the Company; provided, however, that the Company recognizes that you may continue to provide reasonably acceptable, as determined by the Company, transition services to GlobeImmune, Inc. for a period of up to [12 months] after the Start Date.&nbsp;&nbsp;</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Your primary responsibility in this position will be to provide overall leadership for the financial operations of the company, and in this role you will collaborate closely with the CEO, COO and other members of the Senior Leadership Team.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">3.</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Compensation.</font><font style="font-weight:normal;color:#000000;">&nbsp;&nbsp;</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font><font style="font-weight:normal;">For all services to be rendered hereunder, the Company agrees to pay you, and you agree to accept a salary of $22,500 per month.&nbsp;&nbsp;Such salary will be subject to review and adjustment in accordance with the procedures set forth by the Company&#8217;s Board of Directors (the &#8220;</font>Board<font style="font-weight:normal;">&#8221;) or the Compensation Committee thereof.&nbsp;&nbsp;Any such salary shall be payable pursuant to the Company&#8217;s payroll procedures which may be changed by the Company from time to time and shall be subject to such deductions or withholdings as the Company is required to make pursuant to law, or by further agreement with you. In addition to your base salary, you</font> <font style="font-weight:normal;">may be eligible to receive a bonus pursuant to an employee bonus plan as approved by the Board of Directors in its sole discretion.&nbsp;&nbsp;You will also be eligible to participate in the Company&#8217;s benefit plans based on </font></p>
<p style="text-align:left;margin-top:12pt;line-height:10pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="font-size:12pt;">1</font></a></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<p style="line-height:10pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">249091796 v1</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:10pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">the eligibility criteria for each of those plans, which plans will remain subject to change from time to time at the Company&#8217;s discretion.</font><font style="font-weight:normal;"> </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">4.</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Termination.</font><font style="font-weight:normal;color:#000000;">&nbsp;&nbsp;You and the Company each acknowledge that your employment relationship with the Company is at-will and that either party has the right to terminate your employment with the Company at any time for any reason whatsoever, with or without cause or advance notice pursuant to the following provisions. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font>Termination by Death or Disability.<font style="font-weight:normal;">&nbsp;&nbsp;In the event you shall die during the period of your employment hereunder or become permanently disabled, which shall mean you are unable to perform each of the essential duties of your position by reason of a medically determinable physical or mental impairment which is potentially permanent in character or which can be expected to last for a continuous period of not less than twelve (12) months, your employment and the Company&#8217;s obligation to make payments hereunder shall terminate on the date of your death, or the date upon which, in the sole reasonable determination of the Board of Directors, you are determined to be permanently disabled.&nbsp;&nbsp;The Company&#8217;s ability to terminate you as a result of any disability shall be to the extent permitted by state and/or federal law.</font><font style="font-weight:normal;color:#000000;"> If your employment terminates under this section you shall not be eligible for any severance pay or other severance benefits.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Resignation Without Good Reason.</font><font style="font-weight:normal;color:#000000;">&nbsp;&nbsp;In the event you resign from your employment with the Company without Good Reason (as defined below), the Company&#8217;s obligation to make payments hereunder shall cease upon such resignation, and you shall not be entitled to any severance pay or other severance benefits, pay in lieu of notice or any other such compensation, except the Company shall pay you (i) any salary earned but unpaid prior to the resignation and all accrued but unused vacation, if any, and (ii)&#160;any business expenses incurred by you in connection with your performance of your duties, according to the policies of the Company, that were incurred but not reimbursed as of the date of resignation.&nbsp;&nbsp;Vesting of any of your stock options outstanding on the date of resignation shall cease on the date of resignation.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Termination for Cause.</font><font style="font-weight:normal;color:#000000;">&nbsp;&nbsp;In the event you are terminated by the Company for Cause (as defined below), the Company&#8217;s obligation to make payments hereunder shall cease upon the date of receipt by you of written notice of such termination (the &#8220;</font><font style="color:#000000;">Date of Termination</font><font style="font-weight:normal;color:#000000;">&#8221;), and you shall not be entitled to any severance pay or other severance benefits, pay in lieu of notice or any other such compensation, except the Company shall pay you (i) any salary earned but unpaid prior to the Date of Termination and all accrued but unused vacation, if any, and (ii) any business expenses incurred by you in connection with your performance of your duties, according to the policies of the Company, that were incurred but not reimbursed as of the Date of Termination.&nbsp;&nbsp;Vesting of any stock options outstanding on the Date of Termination shall cease on the Date of Termination.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Hlk68120237"></a><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Termination by the Company Without Cause or Resignation for Good Reason.</font><font style="font-weight:normal;color:#000000;">&nbsp;&nbsp;Subject to the terms and conditions of this Agreement, the Company will provide you with Severance Benefits (as defined below) if (i) the Company terminates your employment without Cause or (ii) you resign your employment for Good Reason. You will not be entitled to receive any Severance Benefits if (A)&#160;the Company terminates your employment for Cause, (B)&#160;you resign from your employment with the Company without Good Reason, or (C)&#160;in the event </font></p>
<p style="text-align:left;margin-top:12pt;line-height:10pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="font-size:12pt;">2</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<p style="line-height:10pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">249091796 v1</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:10pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;color:#000000;">of your deat</font><font style="font-weight:normal;color:#000000;">h or </font><font style="font-weight:normal;color:#000000;">termination due to </font><font style="font-weight:normal;color:#000000;">disability</font><font style="font-weight:normal;color:#000000;"><a name="_Hlk68120237"></a>.&nbsp;&nbsp;</font><font style="font-weight:normal;color:#000000;">In addition, to the extent that any federal, state or local laws, including, without limitation, so-called &#8220;plant closing&#8221; laws, require the Company to give advance notice or make a payment of any kind to you because of your involuntary termination due to a layoff, reduction in force, plant or facility closing, sale of business, change of control, or any other similar event or reason, the Severance Benefits payable under this Agreement shall either be reduced proportionately or eliminated, such that the total amounts paid to you do not exceed the amounts specified herein.&nbsp;&nbsp;</font><font style="font-weight:normal;color:#000000;">The Severance Benefits provided under this Agreement are intended to satisfy any and all statutory obligations that may arise out of your involuntary termination of employment for the foregoing reasons.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">5.</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Description of Severance Benefits.</font><font style="font-weight:normal;color:#000000;">&nbsp;&nbsp;For purposes of this Agreement, &#8220;</font><font style="color:#000000;">Severance Benefits</font><font style="font-weight:normal;color:#000000;">&#8221; are defined as:&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="OLE_LINK5"></a><a name="OLE_LINK6"></a><a name="OLE_LINK7"></a><a name="OLE_LINK8"></a><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">severance pay (the &#8220;</font><font style="color:#000000;">Severance Pay</font><font style="font-weight:normal;color:#000000;"><a name="OLE_LINK5"></a><a name="OLE_LINK6"></a>&#8221;) equivalent to: (A)(i)&#160;twelve (12)</font><font style="color:#000000;"> </font><font style="font-weight:normal;color:#000000;">months of your Base Salary (as defined below) in effect as of your last day of employment with the Company if the Notice Date (as defined below) occurs (a)&#160;on the same day as a Corporate Transaction or (b)&#160;within thirteen (13) months after the effective date of a Corporate Transaction or (ii)&#160;six (6)</font><font style="color:#000000;"> </font><font style="font-weight:normal;color:#000000;">months of your Base Salary (as defined below) in effect as of your last day of full-time employment with the Company if a Corporate Transaction has not occurred on or within thirteen (13) months <a name="OLE_LINK7"></a><a name="OLE_LINK8"></a>before the Notice Date; and (B)&#160;a pro rata portion of any bonus compensation under any employee bonus plan that has been approved by the Board (&#8220;</font><font style="color:#000000;">Bonus Pay</font><font style="font-weight:normal;color:#000000;">&#8221;) payable to you for the fiscal year in which your employment terminated to be paid at the same time that such incentive bonus would have been paid if such termination had not occurred. Your pro rata portion of any Bonus Pay shall be based upon the number of days in such calendar year elapsed through the Notice Date of such termination as a proportion of 365. </font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The date you are notified that your employment with the Company is being terminated without Cause or the date you notify the Company that you are terminating your employment for Good Reason, shall be referred to herein as the &#8220;<font style="font-weight:bold;">Notice Date</font>.&#8221;  The Severance Pay shall be payable in equal installments over the applicable number of months in accordance with the Company&#8217;s then applicable payroll policies, commencing on the first regular payroll date following the effective date of the Release (as defined below); provided, however, that if the consideration period for the Release begins in one calendar year and ends in a second calendar year, the Severance Pay shall begin in the second calendar year; provided, further, that the initial payment shall include a catch-up payment (without interest) to cover amounts retroactive to the date immediately following your last day of employment; provided, further that, any Bonus Pay shall not be payable to you until such time as bonus compensation under the applicable employee bonus plan is paid to other employees of the Company.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">reimbursement of your out-of-pocket costs to continue your group health insurance benefits (and dependent coverage, if applicable) under COBRA at substantially the same level of coverage in effect immediately prior to the Notice Date for (i)&#160;twelve (12) months, if Severance Pay is payable pursuant to paragraph&#160;5(a)(A)(i) above, or (ii)&#160;six (6) months, if Severance Pay is payable pursuant to paragraph&#160;5(a)(A)(ii) above, provided that you timely elect continued coverage under COBRA. This reimbursement shall cease if you become eligible for group health insurance coverage through a new employer or you cease to be eligible for COBRA continuation coverage for any reason, including plan termination. In either such event, you must </font></p>
<p style="text-align:left;margin-top:12pt;line-height:10pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="font-size:12pt;">3</font></a></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<p style="line-height:10pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">249091796 v1</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:10pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;color:#000000;">immediately notify the Company.&nbsp;&nbsp;Notwithstanding the foregoing, if the Company determines, in its sole discretion, that it cannot </font><font style="font-weight:normal;color:#000000;">reimburse </font><font style="font-weight:normal;color:#000000;">your</font><font style="font-weight:normal;color:#000000;"> COBRA </font><font style="font-weight:normal;color:#000000;">p</font><font style="font-weight:normal;color:#000000;">remiums without a substantial risk of violating applicable law, the Company instead shall pay </font><font style="font-weight:normal;color:#000000;">you</font><font style="font-weight:normal;color:#000000;">, on the first day of each calendar month, a fully taxable cash payment equal to the applicable COBRA premiums for that month, subject to applicable tax withholdings, which </font><font style="font-weight:normal;color:#000000;">you </font><font style="font-weight:normal;color:#000000;">may, but </font><font style="font-weight:normal;color:#000000;">are </font><font style="font-weight:normal;color:#000000;">not obligated to, use such toward the cost of COBRA premiums.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To receive any of the Severance Benefits, you must first sign and date a general release of claims in favor of the Company in the form presented by the Company, which will be substantially in the form attached hereto as <font style="font-style:italic;">Exhibit A</font> (the &#8220;<font style="font-weight:bold;">Release</font>&#8221;), and allow such Release to become effective.&nbsp;&nbsp;Such Release shall not be signed or dated until the Notice Date, and, except as otherwise required by applicable law, is not valid (and will not entitle you to Severance Benefits) unless signed and delivered to the Company within the time frame requested by the Company.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">6.</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Parachute Payments.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">Notwithstanding anything in this Agreement to the contrary, if any payment or benefit you would receive pursuant to a Corporate Transaction from the Company or otherwise (&#8220;</font><font style="color:#000000;">Payment</font><font style="font-weight:normal;color:#000000;">&#8221;) (i)&#160;would constitute a &#8220;parachute payment&#8221; within the meaning of Section 280G of the Internal Revenue Code of 1986, as amended (the &#8220;</font><font style="color:#000000;">Code</font><font style="font-weight:normal;color:#000000;">&#8221;), and (ii)&#160;but for this sentence, would be subject to the excise tax imposed by Section 4999 of the Code (the &#8220;</font><font style="color:#000000;">Excise Tax</font><font style="font-weight:normal;color:#000000;">&#8221;), then such Payment shall be equal to the Reduced Amount (as defined below).&nbsp;&nbsp;For the avoidance of doubt, a Payment shall not be considered a parachute payment for purposes of this paragraph if such Payment is approved by the shareholders of the Company in accordance with the procedures set forth in Sections 280G(b)(5)(A)(ii) and (B) of the Code and the regulations thereunder, and at the time of such shareholder approval, no stock of the Company is readily tradeable on an established securities market or otherwise (within the meaning of Section 280G(b)(5)(A)(ii)(I) of the Code) (&#8220;</font><font style="color:#000000;">280G Shareholder Approval</font><font style="font-weight:normal;color:#000000;">&#8221;).&nbsp;&nbsp;The &#8220;</font><font style="color:#000000;">Reduced Amount</font><font style="font-weight:normal;color:#000000;">&#8221; shall be either (i)&#160;the largest portion of the Payment that would result in no portion of the Payment being subject to the Excise Tax, or (ii)&#160;the Payment or a portion thereof after payment of the applicable Excise Tax, whichever amount after taking into account all applicable federal, state and local employment taxes, income taxes, and the Excise Tax (all computed at the highest applicable marginal rate), results in your receipt, on an after-tax basis, of the greatest amount of the Payment to you.&nbsp;&nbsp;If a reduction in payments or benefits constituting &#8220;parachute payments&#8221; is necessary so that the Payment equals the Reduced Amount, reduction shall occur in the following order unless you elect in writing a different order (</font><font style="font-style:italic;font-weight:normal;color:#000000;">provided, however,</font><font style="font-weight:normal;color:#000000;"> that such election shall be subject to Company approval if made on or after the date on which the event that triggers the Payment occurs):&nbsp;&nbsp;reduction of cash payments; cancellation of accelerated vesting of stock awards; reduction of employee benefits.&nbsp;&nbsp;In the event that acceleration of vesting of stock award compensation is to be reduced, such acceleration of vesting shall be cancelled in the reverse order of the date of grant of your stock awards unless you elect in writing a different order for cancellation.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;">The accounting firm engaged by the Company for general audit purposes as of the day prior to the effective date of the event giving rise to the Payment (&#8220;</font>Payment Event<font style="font-weight:normal;">&#8221;) shall perform the foregoing calculations.&nbsp;&nbsp;If the accounting firm so engaged by the Company is serving as accountant or auditor for the individual, entity or group effecting the Payment Event, the Board shall have the discretion to appoint a nationally recognized accounting firm to make the </font></p>
<p style="text-align:left;margin-top:12pt;line-height:10pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="font-size:12pt;">4</font></a></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<p style="line-height:10pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">249091796 v1</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:10pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;">determinations required hereunder.&nbsp;&nbsp;The Company shall bear all expenses with respect to the determinations by such accounting firm required to be made hereunder.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">The accounting firm engaged to make the determinations hereunder shall provide its calculations, together with detailed supporting documentation, to the Company and you within fifteen (15) calendar days after the date on which your right to a Payment is triggered (if requested at that time by the Company or you) or such other time as requested by the Company or you.&nbsp;&nbsp;If the accounting firm determines that no Excise Tax is payable with respect to a Payment, either before or after the application of the Reduced Amount, it shall furnish the Company and you with an opinion reasonably acceptable to you that no Excise Tax will be imposed with respect to such Payment.&nbsp;&nbsp;The Company shall be entitled to rely upon the accounting firm&#8217;s determinations, which shall be final and binding.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">7.</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Compliance with Revenue Code Section 409A.&nbsp;&nbsp;</font><font style="font-weight:normal;color:#000000;">To the extent any Severance Benefits are paid from the date of termination of your employment through March 15 of the calendar year following such termination, such Severance Benefits are intended to constitute separate payments for purposes of Section 1.409A-2(b)(2) of the Treasury Regulations and thus payable pursuant to the &#8220;short-term deferral&#8221; rule set forth in Section 1.409A-1(b)(4) of the Treasury Regulations; (b) are paid following said March 15, such Severance Benefits are intended to constitute separate payments for purposes of Section 1.409A-2(b)(2) of the Treasury Regulations made upon an involuntary separation from service and payable pursuant to Section 1.409A-1(b)(9)(iii) of the Treasury Regulations, to the maximum extent permitted by said provision, and (c) are in excess of the amounts specified in clauses (a) and (b) of this paragraph, shall (unless otherwise exempt under Treasury Regulations) be considered separate payments subject to the distribution requirements of Section 409A(a)(2)(A) of the Code, including, without limitation, the requirement of Section 409A(a)(2)(B)(i) of the Code that payments or benefits be delayed until 6 months after your separation from service (if the Company is publicly traded and you are a &#8220;specified employee&#8221; within the meaning of the aforesaid section of the Code at the time of such separation from service). In the event that a six-month delay of any such separation payments or benefits is required, on the first regularly scheduled pay date following the conclusion of the delay period you shall receive a lump sum payment or benefit in an amount equal to the separation payments and benefits that were so delayed, and any remaining separation payments or benefits shall be paid on the same basis and at the same time as otherwise specified pursuant to this Agreement (subject to applicable tax withholdings and deductions).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">8.</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Description of Corporate Transaction.</font><font style="font-weight:normal;color:#000000;"> For purposes of this Agreement, &#8220;</font><font style="color:#000000;">Corporate Transaction</font><font style="font-weight:normal;color:#000000;">&#8221; is defined as:&nbsp;&nbsp;(i) a sale of all or substantially all of the assets of the Company; (ii)&#160;a merger, consolidation or reorganization involving the Company if, immediately after the consummation of such merger, consolidation or reorganization, the stockholders of the Company immediately prior thereto do not own, directly or indirectly, either (A) outstanding voting securities representing more than fifty percent (50%) of the combined outstanding voting power of the surviving entity in such merger, consolidation or reorganization or (B) more than fifty percent (50%) of the combined outstanding voting power of the parent of the surviving entity in such merger, consolidation or similar transaction; or (iii)&#160;any transaction (including without limitation a merger or reorganization in which the Company is the surviving entity) which results in any person or entity (other than persons who are stockholders or affiliates of the Company immediately prior to the transaction) owning fifty percent (50%) or more of the combined voting </font></p>
<p style="text-align:left;margin-top:12pt;line-height:10pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="font-size:12pt;">5</font></a></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<p style="line-height:10pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">249091796 v1</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:10pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;color:#000000;">power of all classes of stock of the Company, other than the sale by the Company of stock in transactions the primary purpose of which is to raise capital for the Company&#8217;s operations and activities.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">9.</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Salary and Accrued PTO/Vacation.</font><font style="font-weight:normal;color:#000000;">&nbsp;&nbsp;On the next regular payroll date after your last date of employment with the Company, or earlier if required by applicable law, the Company will pay to you all of your accrued salary and all of your accrued but unused paid time off (&#8220;</font><font style="color:#000000;">PTO</font><font style="font-weight:normal;color:#000000;">&#8221;) or vacation, if any, as the case may be earned through your last day of employment.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">10.</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Definition of Base Salary.</font><font style="font-weight:normal;color:#000000;">&nbsp;&nbsp;For purposes of this Agreement, &#8220;</font><font style="color:#000000;">Base Salary</font><font style="font-weight:normal;color:#000000;">&#8221; means your base salary in effect as of your last day of full-time employment with the Company, excluding the following: any type of commissions, incentive payments or any other similar remuneration paid directly to you, or any other income received in connection with stock options, contributions made by the Company under any employee benefit plan, or similar items of compensation.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">11.</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Definition of Cause.</font><font style="font-weight:normal;color:#000000;">&nbsp;&nbsp;For purposes of this Agreement, &#8220;</font><font style="color:#000000;">Cause</font><font style="font-weight:normal;color:#000000;">&#8221; means that you have committed or engaged in: (i) willful misconduct, gross negligence, theft, fraud, or other illegal or dishonest conduct, any of which are considered to be materially harmful to the Company; (ii) refusal, unwillingness, failure, or inability to perform material job duties or habitual absenteeism; or (iii) violation of fiduciary duty, violation of any duty of loyalty, or material breach of any material term of this Agreement or of your Employee Intellectual Property and Confidentiality Agreement (a copy of which is attached hereto as </font><font style="font-style:italic;font-weight:normal;color:#000000;">Exhibit B</font><font style="font-weight:normal;color:#000000;">) (the &#8220;</font><font style="color:#000000;">Employee Intellectual Property Agreement</font><font style="font-weight:normal;color:#000000;">&#8221;) or any other contract between you and the Company.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">12.</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Definition of Good Reason.</font><font style="font-weight:normal;color:#000000;">&nbsp;&nbsp;For purposes of this Agreement, &#8220;</font><font style="color:#000000;">Good Reason</font><font style="font-weight:normal;color:#000000;">&#8221; shall mean the following occurs without your consent (i) the relocation of your normal principal place of work greater than thirty (30) miles from your then current normal work location; (ii) a decrease in your then current base salary of more than fifteen percent (15%), other than any such decrease resulting from a general reduction by the Company in the base salary of all Company executive officers; or (iii) the Company unilaterally makes significant detrimental reductions in your job responsibilities; provided, that you shall give written notice to the Chairman of the Board setting forth your intent to resign for Good Reason and the facts in support of your claim that Good Reason exists within sixty (60) days of the initial existence of any of the foregoing conditions; and the Company shall have thirty (30) days after the applicable party has received such notice to take such actions, if any, as the Company may deem appropriate to eliminate such claimed Good Reason (without thereby admitting that such Good Reason had occurred) (the &#8220;Cure Period&#8221;); and your termination of employment occurs within sixty (60) days following the end of the Cure Period.&nbsp;&nbsp;If the Company acts to eliminate such claimed Good Reason within the thirty (30) day period after receipt of your notice, then you shall not be deemed to be resigning for Good Reason under such facts.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">13.</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">At-Will Employment.</font><font style="font-weight:normal;color:#000000;">&nbsp;&nbsp;</font><font style="font-style:italic;color:#000000;">Nothing in this Agreement alters the at-will nature of your employment relationship with the Company.&nbsp;&nbsp;Any contrary representations or agreements, which may have been made to you, are superseded by this Agreement.&nbsp;&nbsp;Subject to the terms of this Agreement, either you or the Company may terminate your employment relationship at any time, with or without Cause or advance notice.</font><font style="font-weight:normal;color:#000000;">&nbsp;&nbsp;</font></p>
<p style="text-align:left;margin-top:12pt;line-height:10pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="font-size:12pt;">6</font></a></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<p style="line-height:10pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">249091796 v1</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:10pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">14.</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Employee Intellectual Property Agreement.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Execution and Compliance</font><font style="font-weight:normal;color:#000000;">. You acknowledge that you are a member of the Company&#8217;s management personnel and that, as such, you have been and will be privy to extremely sensitive, confidential and valuable commercial information, which constitutes trade secrets of the Company, the disclosure of which would greatly harm the Company. </font><font style="letter-spacing:0.1pt;font-weight:normal;color:#000000;">Your work for the Company is conditioned on your execution of and continued compliance with the Employee Intellectual Property Agreement</font><font style="font-weight:normal;color:#000000;">, which shall continue in full force and effect.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Extension of Time.</font><font style="font-weight:normal;color:#000000;">&nbsp;&nbsp;In the event that you breach any covenant, obligation or duty in </font><font style="font-weight:normal;">the Employee Intellectual Property Agreement </font><font style="font-weight:normal;color:#000000;">or its subparts, any such duty, obligation, or covenants to which you and the Company agreed by </font><font style="font-weight:normal;">the Employee Intellectual Property Agreement </font><font style="font-weight:normal;color:#000000;">and its subparts shall automatically toll from the date of the first breach, and all subsequent breaches, until the resolution of the breach through private settlement, judicial or other action, including all appeals.&nbsp;&nbsp;The duration and length of your duties and obligations as agreed by </font><font style="font-weight:normal;">the Employee Intellectual Property Agreement </font><font style="font-weight:normal;color:#000000;">and its subparts shall continue upon the effective date of any such settlement, or judicial or other resolution.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">15.</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Miscellaneous. </font><font style="font-weight:normal;color:#000000;"> Except as specifically set forth herein, this Agreement constitutes the complete, final and exclusive embodiment of the entire agreement between you and the Company with regard to your employment terms and Severance Benefits.&nbsp;&nbsp;It is entered into without reliance on any promise or representation, written or oral, other than those expressly contained herein, and it supersedes any other such promises, warranties or representations.&nbsp;&nbsp;This Agreement may not be modified or amended except in writing signed by you and a duly authorized officer of the Company.&nbsp;&nbsp;This Agreement will be deemed to have been entered into and will be construed and enforced in accordance with the laws of the State of Colorado as applied to contracts made and to be performed entirely within Colorado.</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*****</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-top:12pt;line-height:10pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="font-size:12pt;">7</font></a></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<p style="line-height:10pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">249091796 v1</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:10pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:8.46%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Please sign below to indicate your understanding and acceptance of this Agreement and return the signed original to me at your earliest convenience.</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Very truly yours,</p>
<p style="text-align:left;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-variant: small-caps;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;">ARCA biopharma, Inc.</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By: <font style="text-decoration:underline;">/s/ Michael R. Bristow</font><font style="text-decoration:underline;margin-left:180pt;"></font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name: <font style="text-decoration:underline;">Michael R. Bristow</font><font style="text-decoration:underline;margin-left:180pt;"></font><font style="text-decoration:underline;margin-left:36pt;"></font></p>
<p style="text-align:left;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title: <font style="text-decoration:underline;">President and Chief Executive Officer</font></p>
<p style="text-align:left;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-variant: small-caps;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;">Understood and Agreed:</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">/s/ C. Jeff Dekker</font><font style="margin-left:180pt;"></font><font style="margin-left:252pt;"></font><font style="text-decoration:underline;">4/21/2021</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">C. Jeff Dekker<font style="font-weight:bold;margin-left:252pt;"></font>Date</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-top:12pt;line-height:10pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="font-size:12pt;">8</font></a></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<p style="line-height:10pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">249091796 v1</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:10pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-variant: small-caps;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;">Exhibit A</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RELEASE</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In exchange for the Severance Benefits provided under the foregoing Employment Agreement with ARCA biopharma, Inc. (the &#8220;<font style="font-weight:bold;">Company</font>&#8221;), dated [_________________], and except as set forth in this release, I, on behalf of my spouse, heirs, executors, administrators, assigns, insurers, attorneys and other persons and entities, acting or purporting to act on my behalf (the &#8220;<font style="font-weight:bold;">Employee Parties</font>&#8221;), hereby generally and completely release, acquit and forever discharge the Company, its parents and subsidiaries, and its and their respective officers, directors, agents, servants, employees, shareholders, predecessors, successors, assigns and affiliates, of and from any and all claims, liabilities, demands, causes of action, costs, expenses, attorneys fees, damages, indemnities and obligations of every kind and nature, in law, equity, or otherwise, known and unknown, suspected and unsuspected, disclosed and undisclosed, arising out of or in any way related to agreements, events, acts or conduct at any time prior to the date I execute this release (the &#8220;<font style="font-weight:bold;">Released Claims</font>&#8221;), including, but not limited to:&nbsp;&nbsp;all such claims and demands directly or indirectly arising out of or in any way connected with my employment with the Company or the termination of that employment, including but not limited to, claims of intentional and negligent infliction of emotional distress, any and all tort claims for personal injury, claims or demands related to salary, bonuses, commissions, stock, stock options, or any other ownership interests in the Company, vacation pay, fringe benefits, expense reimbursements, severance pay, or any other form of compensation; all claims for breach of contract and wrongful termination; claims pursuant to any federal, state or local law or cause of action including, but not limited to, the federal Civil Rights Act of 1964, as amended; the federal Employee Retirement Income Security Act of 1974, as amended; the federal Americans with Disabilities Act of 1990; Colorado anti-discrimination statutes, including but not limited to the Colorado Civil Rights Act (as amended); the Colorado Labor Relations Act; the Colorado Whistleblower Law; tort law; contract law; wrongful discharge; discrimination; fraud; defamation; emotional distress; and breach of the implied covenant of good faith and fair dealing.</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I also hereby acknowledge that I am knowingly and voluntarily waiving and releasing any rights I may have under the federal Age Discrimination in Employment Act of 1967, as amended (&#8220;<font style="font-weight:bold;">ADEA</font>&#8221;).&nbsp;&nbsp;I also acknowledge that the consideration given for the release in the preceding paragraph hereof is in addition to anything of value to which I was already entitled.&nbsp;&nbsp;I further acknowledge that I have been advised by this writing, as required by the ADEA, that: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.77%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(a)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">my waiver and release do not apply to any rights or claims that arise on or after the date I execute this release;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.77%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(b)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">I have the right to consult with an attorney prior to executing this release;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.77%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(c)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">I have twenty-one (21) days to consider this release (although I may choose to voluntarily execute this release earlier);</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.77%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(d)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">I have seven (7) days following my execution of this release to revoke the release; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.77%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(e)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">this release shall not be effective until the date upon which the revocation period has expired, which shall be the eighth day after I execute this release.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notwithstanding the foregoing, the following are not included in the Released Claims (the &#8220;<font style="font-weight:bold;">Excluded Claims</font>&#8221;): <font style="color:#000000;">(a)&#160;any claims for breach of the Agreement arising after the date on which </font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<p style="margin-top:12pt;line-height:10pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">249091796 v1</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:10pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;">I sign this Release; (</font><font style="color:#000000;">b</font><font style="color:#000000;">) claims for reimbursement of properly incurred business expenses prior to and through the </font><font style="color:#000000;">last day of employment</font><font style="color:#000000;"> which are submitted to the Company for reimbursement within </font><font style="color:#000000;">time period required by the Company</font><font style="color:#000000;">; (</font><font style="color:#000000;">c</font><font style="color:#000000;">) all claims for or rights to indemnification pursuant to the certificate of incorporation and bylaws of the Company, any indemnification agreement to which I am a party, or under applicable law; and (</font><font style="color:#000000;">d</font><font style="color:#000000;">) all claims which cannot be waived as a matter of law</font><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I hereby confirm that I have been paid all compensation owed to me by the Company for all hours worked; I have received all the leave and leave benefits and protections for which I was eligible, pursuant to the Company&#8217;s policies, applicable law, or otherwise; and I have not suffered any on-the-job injury or illness for which I have not already filed a workers&#8217; compensation claim.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I agree not to disparage the Company, and its officers, directors, employees, shareholders and agents, in any manner likely to be harmful to them or their business, business reputation or personal reputation; provided that I may respond accurately to any inquiry or request for information when required by legal process.&nbsp;&nbsp;Notwithstanding the foregoing, nothing in this Agreement shall limit my right to voluntarily communicate with the Equal Employment Opportunity Commission, United States Department of Labor, the National Labor Relations Board, the Securities and Exchange Commission, other federal government agency or similar state or local agency or to discuss the terms and conditions of my employment with others to the extent expressly permitted by Section 7 of the National Labor Relations Act.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I hereby certify that I have returned, without retaining any reproductions (in whole or in part), all information, materials and other property of the Company, including but not limited to any such information, materials or property contained on any personally-owned electronic or other storage device (such as computer, cellular phone, PDA, tablet or the like). I also represent that I have been paid all compensation owed and for all hours worked; I have received all the leave and leave benefits and protections for which I am eligible; and I have not suffered any on-the-job injury for which I have not already filed a workers&#8217; compensation claim.&nbsp;&nbsp;I acknowledge and agree that I will continue to abide by my continuing obligations to the Company under any agreement with the Company, including but not limited to the [Employee Intellectual Property Agreement].</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Release constitutes the complete, final and exclusive embodiment of the entire agreement between the Company and me with regard to the subject matter hereof.&nbsp;&nbsp;I am not relying on any promise or representation by the Company that is not expressly stated herein.&nbsp;&nbsp;This Release may only be modified by a writing signed by both me and a duly authorized officer of the Company.&nbsp;&nbsp;This Release will be deemed to have been entered into and will be construed and enforced in accordance with the laws of the State of Colorado as applied to contracts made and to be performed entirely within Colorado. This Release shall be effective on the date I sign and return it to the Company, provided that the Company has also signed it.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I accept and agree to the terms and conditions stated above.</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:53.85%;"><font style="text-decoration:underline;margin-left:36pt;"></font>&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:53.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="color:#000000;">[Name]</font></p></td></tr></table></div>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:-7.69%;">Date:&nbsp;&nbsp;<font style="text-decoration:underline;margin-left:468pt;"></font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<p style="margin-top:12pt;line-height:10pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">249091796 v1</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:10pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:-7.69%;"><font style="font-variant: small-caps;color:#000000;">ARCA biopharma</font><font style="font-variant: small-caps;">, Inc.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:-7.69%;">By:<font style="text-decoration:underline;margin-left:468pt;"></font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:-7.69%;">Name:<font style="text-decoration:underline;margin-left:468pt;"></font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:-7.69%;">Title:<font style="text-decoration:underline;margin-left:468pt;"></font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<p style="margin-top:12pt;line-height:10pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">249091796 v1</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:10pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-variant: small-caps;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;">Exhibit B</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EMPLOYEE INTELLECTUAL PROPERTY, CONFIDENTIALITY AND NON-COMPETE AGREEMENT</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[See attached]</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<p style="margin-top:12pt;line-height:10pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">249091796 v1</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:10pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit A</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gneflb3r2gmg000002.jpg" title="" alt="" style="width:174px;height:63px;"><font style="margin-left:0pt;"></font><font style="margin-left:36pt;">10170 Church Ranch Way, Suite 100</font></p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Westminster, CO&nbsp;&nbsp;80021</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:3pt;margin-top:12pt;font-weight:bold;font-size:16pt;font-family:Calibri Light;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><a name="_AEIOULastRenderedPageBreakAEIOU1"></a><a name="_AEIOULastRenderedPageBreakAEIOU1"></a><font style="font-size:12pt;font-family:Times New Roman Bold;font-variant: small-caps;">Employee Intellectual Property, Confidentiality and Non-Compete Agreement</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div style="width:100%;">
<div style="float:left;width:32%;">
<p style="line-height:12pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a>In consideration of my employment by ARCA biopharma, Inc. or its affiliates (the &#8220;<font style="font-weight:bold;">Company</font>&#8221;) and the salary paid to me, I acknowledge and agree:</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: small-caps;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">I.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-variant: normal;margin-left:18pt;color:#000000;"></font><font style="color:#000000;">Intellectual Property</font></p>
<p style="margin-bottom:12pt;line-height:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A.<font style="margin-left:18pt;">I do hereby assign and agree to assign in the future to the Company all my right, </font>title and interest in and to any and all Intellectual Property (including works not considered &#8220;works made for hire&#8221;) that I may make, conceive, create or author, either alone or jointly with others, during the period of my employment with the Company, regardless of whether the Intellectual Property is patentable, copyrightable or protectable by any other intellectual property right. I further agree that any Intellectual Property disclosed by me to the Company or a third person or described in a patent application filed by me or on my behalf within one year following termination of my employment with the Company shall be presumed to be Intellectual Property subject to the terms of this agreement unless proved by me to have been conceived and first reduced to practice by me following the termination of my employment with the Company.&nbsp;&nbsp;By way of illustration but not limitation, the term &#8220;<font style="font-weight:bold;">Intellectual Property</font>&#8221; includes (a)&#160;data, results, ideas, processes, techniques, formulae, compounds, know-how, improvements, discoveries, developments and designs, (b) tangible and intangible information relating to biological materials such as cell lines, antibodies, tissue samples, proteins, nucleic acids and the like, assays and assay components and media, procedures and formulations for producing any such assays or assay components, and pre-clinical and clinical data, results, developments or experiments, and (c) plans for research, development and new products, marketing and selling information, business plans, budgets and unpublished financial statements, licenses, prices and costs, suppliers and customers, and information regarding the skills and compensation of other employees of the Company.<font style="font-style:italic;"> </font> All copyrightable Intellectual Property are &#8220;works made for hire&#8221; as defined or understood under the United States Copyright Act (17 USC &#167;&#167; 100 <font style="font-style:italic;">et seq.</font>), and the Company will be the author thereof for all purposes of the United States Copyright Act and otherwise.</p></div>
<div style="float:left;width:32%;padding-left:2%">
<p style="margin-bottom:12pt;line-height:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU3"></a>B.<font style="margin-left:18pt;">I will promptly disclose to the Company all Intellectual Property as I make, conceive, </font>create or author it and all patent applications filed by me or in which I am named as an inventor or co-inventor, each during the period of my employment and for one (1) year thereafter.</p>
<p style="margin-bottom:12pt;line-height:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">C.<font style="margin-left:18pt;">I will assist the Company (at its expense) in every proper manner, during and after the term of my employment, to obtain, perfect, protect and enforce its rights in all countries in any Intellectual Property of the Company.</font></p>
<p style="line-height:12pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">D.<font style="margin-left:18pt;">Further, I hereby irrevocably appoint the Company and its duly authorized officers and agents as my attorneys-in-fact, coupled with an interest, to act for and on my behalf and instead of me, to execute all documents and papers, including any application for patent, copyright or mask work, and to do all other lawfully permitted acts reasonably necessary to assign, or otherwise transfer and perfect my right, title and interest in and to the Intellectual Property, to and in the Company, and to obtain, perfect, protect and enforce its rights in the Intellectual Property.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:12pt;line-height:12pt;text-indent:0%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: small-caps;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">II.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-variant: normal;margin-left:18pt;color:#000000;"></font><font style="color:#000000;">Excluded Intellectual Property </font></p></div>
<div style="float:left;width:32%;padding-left:2%">
<p style="margin-bottom:12pt;line-height:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU4"></a>As the Company will own all Intellectual Property, for my own protection of my prior existing rights, I have fully described on <font style="text-decoration:underline;">Annex A</font> all the inventions, improvements, discoveries, writings, art, algorithms, computer codes and programs, mask works, business methods, trade secrets and other intellectual property that may relate to the research or business interests, present or prospective, of the Company which I made, conceived, created or authored, either alone or jointly with others, prior to my term of employment with the Company which I wish to be excluded from this agreement (collectively referred to as &#8220;<font style="font-weight:bold;">Prior Inventions</font>&#8221;).&nbsp;&nbsp;The descriptions in <font style="text-decoration:underline;">Annex A</font> are sufficiently complete to enable qualified persons to distinguish between the intellectual property excluded from this agreement and any Intellectual Property subject to this agreement and include all U.S. and foreign patent and patent application numbers, of which I am aware, corresponding to the described items. </p>
<p style="line-height:12pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If no <font style="text-decoration:underline;">Annex&#160;A</font> is attached, I represent that there are no Prior Inventions.&nbsp;&nbsp;If, in the course of my employment with the Company, I incorporate a Prior Invention into a Company product, process or machine, the Company is hereby granted and shall have a nonexclusive, fully-paid, royalty-free, irrevocable, perpetual, worldwide license (with rights to sublicense through multiple tiers of sublicensees) to reproduce, make derivative works of, distribute, publicly perform, and publicly display in any form or medium, whether now known or later developed, make, have made, modify, use </p></div></div>
<p style="text-align:center;margin-top:12pt; clear:both;margin-bottom:12pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">- 1</a> -</p>
<p style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:0%;font-weight:bold;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">\\\BO - 87877/0001 - 171746 v4  </p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="line-height:12pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and sell such Prior Invention.&nbsp;&nbsp;Notwithstanding the foregoing, I agree that I will not incorporate, or permit to be incorporated, Prior Inventions in any Company Intellectual Property without the Company&#8217;s prior written consent.&nbsp;&nbsp;</font></p>
<div style="width:100%;">
<div style="float:left;width:32%;">
<p style="text-align:left;margin-bottom:12pt;margin-top:12pt;line-height:12pt;text-indent:0%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: small-caps;letter-spacing:0pt;"><a name="_AEIOULastRenderedPageBreakAEIOU5"></a><font style="Background-color:#auto;text-decoration:none;">III.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-variant: normal;margin-left:18pt;color:#000000;"></font><font style="color:#000000;">Confidentiality</font></p>
<p style="margin-bottom:12pt;line-height:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A.<font style="margin-left:18pt;">In addition to the Intellectual Property I may produce, the Company, in reliance on my compliance with the terms of this agreement, will disclose or allow me access to confidential or proprietary technical or business information of the Company, or confidential or proprietary technical or business information of a third party. Neither during the term of my employment, nor at any </font>time thereafter, will I, without prior written authorization from the Company, disclose or use, except as required in my performance of my duties to the Company, any confidential or proprietary information of the Company or of any third party provided to me by the Company.&nbsp;&nbsp;I will obtain the written approval of the Company&#8217;s General Counsel before publishing or submitting for publication any material (written, oral, or otherwise) that relates to my work at Company and/or incorporates any confidential information of the Company or any third party provided to me by the Company.</p>
<p style="margin-bottom:12pt;line-height:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">B.<font style="margin-left:18pt;">Upon termination of my employment, or at any time at the request of the Company, I will return all documents, recorded material in any media, and any property of the Company, and all documents, recorded </font>material and any property of a third party, and all copies thereof, which I acquired from the Company or which I produced during or as a result of my employment.&nbsp;&nbsp;I also will not retain any copies, notes or abstracts of any of the foregoing.</p>
<p style="margin-bottom:12pt;line-height:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">C. <font style="margin-left:18pt;">If at any time during or after my employment, I am uncertain whether any information provided to me by the Company, or produced by me, is confidential or proprietary information of the Company, or of any third party, or if I am solicited to disclose or use confidential or proprietary information, I will inform the Company in writing (by </font>certified mail, if after my employment) and consult with an officer, or designated representative of the Company, to determine whether the information is confidential or proprietary information to the Company or a third party.</p></div>
<div style="float:left;width:32%;padding-left:2%">
<p style="margin-bottom:12pt;line-height:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU6"></a>D. <font style="margin-left:18pt;">The Company may notify any of my future or prospective employers or other third parties of this agreement, without my further consent.</font></p>
<p style="margin-bottom:12pt;line-height:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">E. <font style="margin-left:18pt;">I understand that the unauthorized use or disclosure of confidential or proprietary information of the Company, or of a third party, provided to me by the Company would cause irreparable harm to the Company and therefore the Company is entitled to injunctive relief to preclude or restrain me from disclosing or using, or further disclosing or using, confidential or proprietary information of the Company, or of a third party, provided to me by the Company.</font></p>
<p style="line-height:12pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F.<font style="margin-left:18pt;">I further agree that I will neither disclose to the Company nor use in the performance of my duties to the Company any confidential or proprietary information of any other party, unless permitted by agreement between the Company and the other party.</font></p>
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:12pt;line-height:12pt;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: small-caps;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: small-caps;letter-spacing:0pt;">IV.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:12pt;margin-top:12pt;line-height:12pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: small-caps;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:normal;font-variant: normal;color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman Bold;color:#000000;">Non-Compete and Non-Solicitation</font></p></td></tr></table>
<p style="margin-bottom:12pt;line-height:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A.<font style="margin-left:18pt;">During my term of employment by the Company and for </font>one (1) year period thereafter, I will not engage or participate or assist any person, directly or indirectly, in any individual or representative capacity in any business or enterprise that competes with the business, present or prospective, of the Company without the express written consent of the Company.&nbsp;&nbsp;I may, however, retain personal investments held by me as of the date hereof <font style="text-decoration:underline;">provided</font> <font style="text-decoration:underline;">that</font> by those investments I am not involved in the management or operation of that business.&nbsp;&nbsp;It is agreed that, should I own or control less than five percent (5%) of the issued publicly traded stock of, or equity in, a business, such ownership shall not constitute a violation of this provision. </p>
<p style="margin-bottom:12pt;line-height:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">B.<font style="margin-left:18pt;">I agree further that for the period of my employment by the Company and for 12 months after the date of termination of my employment with the Company I will neither (a)&#160;solicit the business of any client or customer of the Company (other than on behalf of the Company), (b)&#160;either directly or through others, solicit or attempt to solicit any employee, independent contractor or consultant of the Company to terminate his or her relationship with the Company in order to become an employee, consultant or independent contractor to or for any other person or entity, nor (c) directly or indirectly induce any client, customer, supplier, vendor, consultant or independent contractor of the Company to terminate or negatively alter his, her or its relationship with the Company. </font></p></div>
<div style="float:left;width:32%;padding-left:2%">
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU7"></a>C.<font style="margin-left:18pt;">I acknowledge that through my employment with the Company I will acquire access to information suited to immediate application by a business in competition with the Company.&nbsp;&nbsp;I specifically acknowledge that, because of the nature and type of business that the Company engages in, the geographic scope of the covenants in this Article IV shall include all counties, cities and states in the United States</font> and any other city, country, territory or region in which the Company conducts business. I agree and acknowledge that the foregoing restrictions, geographic scope and time limitations set forth in this Article IV are reasonable, and that the provisions in this Article IV are reasonably necessary for the protection of the Company.&nbsp;&nbsp;If any restriction set forth in this Article IV is found by any court of competent jurisdiction to be unenforceable because it extends for too long a period of time or over too great a range of activities or in too broad a geographic area, it shall be interpreted to extend only over the maximum period of time, range of activities or geographic area as to which it may be enforceable.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">D.<font style="margin-left:18pt;">I further acknowledge the following provisions of Colorado</font> law, set forth in Colorado Revised Statutes Section 8-2-113(2):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;Any covenant not to compete which restricts the right of any person to receive </p></div></div>
<p style="margin-top:12pt;line-height:10pt; clear:both;margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:0%;font-weight:bold;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">\\\BO - 87877/0001 - 171746 v4  </p>
<p style="line-height:10pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:8pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">226874 v3/CO</strike></font><font style="font-size:10pt;color:#000000;"> </font></p>
<p style="line-height:10pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:8pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">4v2203!.DOC</strike></font><font style="font-size:10pt;color:#000000;"> </font></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">compensation for performance of skilled or unskilled labor for any employer shall be void, but this subsection (2) shall not apply to:</font></p>
<div style="width:100%;">
<div style="float:left;width:32%;">
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:-13.33%;"><a name="_AEIOULastRenderedPageBreakAEIOU8"></a>(a)<font style="margin-left:36pt;">Any contract for the purchase and sale of a business or the assets of a </font>business;</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:-13.33%;">(b)<font style="margin-left:36pt;">Any contract for the protection of trade </font>secrets;</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:-13.33%;">(c)<font style="margin-left:36pt;">Any contract provision providing for the recovery of the expense of educating and training an employee who has served an employer for a period of less than two </font>years;</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:-13.33%;">(d)<font style="margin-left:36pt;">Executive and management personnel and officers and employees who constitute professional staff to executive and management personnel.&#8221;</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I acknowledge that this agreement is a contract for the protection of trade secrets under Section 8-2-113(2)(b), and is intended to protect the confidential information and trade secrets of the Company; and that I am an executive and management employee or professional staff to executive or management personnel, within the meaning of Section 8-2-113(2)(d).</p>
<p style="line-height:12pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">E.<font style="margin-left:18pt;">I acknowledge and am prepared for the possibility that my standard of living may be reduced during the noncompetition period provided in this Article IV following the termination of my employment, and fully accept any risk associated with that possibility.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:12pt;line-height:12pt;text-indent:0%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: small-caps;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">V.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-variant: normal;margin-left:18pt;color:#000000;"></font><font style="color:#000000;">Prior Employment</font></p>
<p style="line-height:12pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">My performance of my duties to the Company during my employment does not conflict with and will not be constrained in any manner by any prior or current employment or business relationship. I have not entered into any agreement that will prevent my full compliance with the terms of this agreement except as I have fully described on <font style="text-decoration:underline;">Annex B</font> and to which I have attached a true copy of that agreement.</p></div>
<div style="float:left;width:32%;padding-left:2%">
<p style="text-align:left;margin-bottom:12pt;margin-top:12pt;line-height:12pt;text-indent:0%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: small-caps;letter-spacing:0pt;"><a name="_AEIOULastRenderedPageBreakAEIOU9"></a><font style="Background-color:#auto;text-decoration:none;">VI.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-variant: normal;margin-left:18pt;color:#000000;"></font><font style="color:#000000;">Legal and Equitable Remedies. </font></p>
<p style="line-height:12pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In view of the nature of the rights in goodwill, employee relations, trade secrets, and business reputation and prospects of the Company to be protected under this agreement, I understand and agree that the Company could not be reasonably or adequately compensated in damages in an action at law for my breach of my obligations (whether individually or together) hereunder.&nbsp;&nbsp;Accordingly, I specifically agree that the Company shall be entitled to temporary and permanent injunctive relief, specific performance, and other equitable relief to enforce the provisions of this agreement and that such relief may be granted without the necessity of proving actual damages, and without bond.&nbsp;&nbsp;<font style="font-style:italic;">I acknowledge and agree that the provisions in this agreement, and that upon my breach of this agreement, the Company is entitled to withhold payments or consideration, as equitable relief to prevent continued breach, to recover damages and to seek any other remedies available to the Company.</font>&nbsp;&nbsp;This provision with respect to injunctive relief shall not, however, diminish the right of the Company to claim and recover damages or other remedies in addition to equitable relief.</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:12pt;line-height:12pt;text-indent:0%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: small-caps;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">VII.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-variant: normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Miscellaneous</font></p>
<p style="margin-bottom:12pt;line-height:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This agreement sets forth the entire and complete understanding and agreement I have with the Company relating to its subject matter and supersedes all other oral or written representations and understandings.&nbsp;&nbsp;The terms of this agreement may not be waived, amended or superseded except by a written amendment that refers to this agreement and is signed by both me and a duly authorized representative of the Company.&nbsp;&nbsp;The formation, interpretation, compliance and performance of this agreement will be governed by the laws of the State of Colorado, excluding its conflict-of-law rules.&nbsp;&nbsp;I hereby expressly consent to the personal jurisdiction of the state courts located in Denver County, Colorado and the federal courts located in the city and county of Denver, Colorado for any lawsuit filed there against me by the Company arising from or related to this agreement.&nbsp;&nbsp;If any provision of this agreement is found invalid or unenforceable, the remainder of the provisions will remain valid and enforceable. If moreover, any term, word, clause, phrase, provision, restriction, or section of this agreement is more restrictive than permitted by the law of the jurisdiction in which the Company seeks enforcement thereof, the provisions of this agreement shall be limited only to the extent that a judicial determination finds the same to be unreasonable or otherwise unenforceable.</p></div>
<div style="float:left;width:32%;padding-left:2%">
<p style="margin-bottom:12pt;line-height:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU10"></a>This agreement shall survive the termination of my employment and the assignment of this agreement by Company to any successor-in-interest or other assignee and be binding upon my heirs and legal representatives. </p>
<p style="margin-bottom:12pt;line-height:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I agree and understand that nothing in this Agreement shall confer any right with respect to continuation of employment by Company, nor shall it interfere in any way with my right or Company&#8217;s right to terminate my employment at any time, with or without cause and with or without advance notice.</p>
<p style="margin-bottom:12pt;line-height:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I have been furnished with a copy of this agreement prior to my signing. I have carefully read all of the provisions of this agreement and I understand each and all of the provisions. I have had the opportunity to seek independent business advice and legal counsel regarding this agreement and my obligations hereunder. I will fully and faithfully comply with all the provisions and obligations of this agreement.</p></div></div>
<p style="margin-bottom:12pt;line-height:12pt; clear:both;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU11"></a>&nbsp;</p>
<p style="text-align:center;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">* * * * *</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:12pt;margin-top:6pt;font-size:10pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;text-indent:6.67%;">- 3</a> -<font style="margin-left:36pt;"></font><font style="font-size:9pt;">ARCA biopharma, Inc.</font></p>
<p style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:0%;font-weight:bold;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">\\\BO - 87877/0001 - 171746 v4  </p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-variant: small-caps;font-family:Times New Roman;font-style:normal;text-transform:none;">I acknowledge that I have read and understand this agreement and have been given the opportunity to discuss it with independent legal counsel<font style="font-variant: normal;">.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">/s/ C. Jeff Dekker</font><font style="text-decoration:underline;margin-left:48pt;"></font><font style="text-decoration:underline;margin-left:108pt;"></font><font style="margin-left:168pt;"></font><font style="text-decoration:underline;margin-left:192pt;"></font><font style="text-decoration:underline;">4/21/21</font><font style="text-decoration:underline;margin-left:48pt;"></font><font style="text-decoration:underline;margin-left:108pt;"></font></p>
<p style="margin-bottom:12pt;line-height:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Signature<font style="margin-left:108pt;"></font><font style="margin-left:192pt;">Date</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:1.67%;"><font style="text-decoration:underline;"></font><font style="text-decoration:underline;">C. Jeff Dekker</font><font style="text-decoration:underline;margin-left:9pt;"></font><font style="text-decoration:underline;margin-left:108pt;"></font><font style="margin-left:168pt;"></font><font style="text-decoration:underline;margin-left:192pt;"></font><font style="text-decoration:underline;">CFO</font><font style="text-decoration:underline;margin-left:9pt;"></font><font style="text-decoration:underline;margin-left:108pt;"></font><font style="margin-left:168pt;"></font><font style="text-decoration:underline;margin-left:192pt;"></font><font style="text-decoration:underline;margin-left:217pt;"></font></p>
<p style="margin-bottom:12pt;line-height:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name (type or print)<font style="margin-left:108pt;"></font><font style="margin-left:192pt;">Job Title</font><font style="margin-left:288pt;"></font><font style="margin-left:360pt;"></font><font style="margin-left:378pt;"></font></p>
<p style="margin-bottom:12pt;line-height:12pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:5pt;line-height:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;text-transform:uppercase;font-family:Times New Roman;font-style:normal;font-variant: normal;">Company<font style="font-variant: small-caps;text-transform:none;">:&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-variant: small-caps;font-family:Times New Roman;font-style:normal;text-transform:none;">Accepted and agreed:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">/s/ Thomas A. Keuer</font><font style="text-decoration:underline;margin-left:42pt;"></font><font style="text-decoration:underline;margin-left:108pt;"></font><font style="margin-left:168pt;"></font><font style="text-decoration:underline;margin-left:192pt;"></font><font style="text-decoration:underline;">4/21/21</font><font style="text-decoration:underline;margin-left:42pt;"></font><font style="text-decoration:underline;margin-left:108pt;"></font></p>
<p style="margin-bottom:12pt;line-height:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Signature<font style="margin-left:108pt;"></font><font style="margin-left:192pt;">Date</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Thomas A. Keuer</font><font style="text-decoration:underline;margin-left:37pt;"></font><font style="text-decoration:underline;margin-left:108pt;"></font><font style="margin-left:168pt;"></font><font style="text-decoration:underline;margin-left:192pt;">COO</font><font style="text-decoration:underline;margin-left:288pt;"></font><font style="margin-left:354pt;"></font><font style="text-decoration:underline;margin-left:378pt;"></font><font style="text-decoration:underline;margin-left:432pt;"></font></p>
<p style="margin-bottom:12pt;line-height:12pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name (type or print)</p>
<p style="margin-bottom:12pt;line-height:12pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;line-height:12pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Copies to Employee and ARCA biopharma, Inc.</p>
<p style="text-align:center;margin-bottom:12pt;line-height:12pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;line-height:12pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:0%;font-weight:bold;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">\\\BO - 87877/0001 - 171746 v4  </p>
<p style="line-height:10pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:8pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">226874 v3/CO</strike></font><font style="font-size:10pt;color:#000000;"> </font></p>
<p style="line-height:10pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:8pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">4v2203!.DOC</strike></font><font style="font-size:10pt;color:#000000;"> </font></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-variant: small-caps;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;">Annex A</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-variant: small-caps;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;">Prior Inventions</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:478.8pt;;">
<tr>
<td style="width:333.9pt;"></td>
<td style="width:144.9pt;"></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Title</font></p></td>
<td valign="top" >
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Date of Invention/Authorship</font></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.____<font style="text-decoration:underline;">N/A</font>____________________________________________</p></td>
<td valign="top" >
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">________________________</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:36pt;;text-indent:-36pt;;font-size:11pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:36pt;;text-indent:-36pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.___________________________________________________</p></td>
<td valign="top" >
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">________________________</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.___________________________________________________</p></td>
<td valign="top" >
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">________________________</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.___________________________________________________</p></td>
<td valign="top" >
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">________________________</p></td>
</tr>
</table></div>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Signature of Employee:&nbsp;&nbsp;_____________________________</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Print Name of Employee:&nbsp;&nbsp;____________________________</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date:&nbsp;&nbsp;____________________</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:12pt;margin-top:6pt;font-weight:bold;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;text-indent:6.67%;"><font style="margin-left:36pt;"></font><font style="font-size:9pt;">ARCA biopharma, Inc.</font></p>
<p style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:0%;font-weight:bold;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">\\\BO - 87877/0001 - 171746 v4  </p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-variant: small-caps;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;">Annex B</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-variant: small-caps;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;">Prior Employment Agreements</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:86.67%;">
<tr>
<td style="width:28.92%;"></td>
<td style="width:28.99%;"></td>
<td style="width:28.76%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Title of Agreement</font></p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Name of Employer</font></p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Date of Agreement</font></p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-variant: small-caps;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;">Employment Agreement</p></td>
<td valign="top" >
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-variant: small-caps;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;">GlobeImmune, Inc.</p></td>
<td valign="top" >
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-variant: small-caps;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;">7/1/14 Amended 11/15/16, 3/10/17</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:3.5pt;">
<td valign="top" >
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Signature of Employee:&nbsp;&nbsp;/<font style="text-decoration:underline;font-size:10pt;">s/ C. Jeff Dekker</font></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Print Name of Employee:&nbsp;&nbsp;<font style="text-decoration:underline;font-size:10pt;">C. Jeff Dekker</font></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date:&nbsp;&nbsp;4/21/21</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:0%;font-weight:bold;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">\\\BO - 87877/0001 - 171746 v4  </p>
<p style="line-height:10pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:8pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">226874 v3/CO</strike></font><font style="font-size:10pt;color:#000000;"> </font></p>
<p style="line-height:10pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:8pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">4v2203!.DOC</strike></font><font style="font-size:10pt;color:#000000;"> </font></p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>abio-ex311_7.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
abio-ex311_7.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 31.1</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION</p>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Michael R. Bristow, certify that:</p>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1. I have reviewed this quarterly report on Form 10-Q of ARCA biopharma, Inc.;</p>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p>
<p style="margin-bottom:0pt;margin-top:4pt;margin-left:6.67%;text-indent:-2.5%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a)  Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p>
<p style="margin-bottom:0pt;margin-top:4pt;margin-left:6.67%;text-indent:-2.5%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">b)  Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p>
<p style="margin-bottom:0pt;margin-top:4pt;margin-left:6.67%;text-indent:-2.5%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c)  Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p>
<p style="margin-bottom:0pt;margin-top:4pt;margin-left:6.67%;text-indent:-2.5%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d)  Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</p>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</p>
<p style="margin-bottom:0pt;margin-top:4pt;margin-left:6.67%;text-indent:-2.5%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a)  All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</p>
<p style="margin-bottom:0pt;margin-top:4pt;margin-left:6.67%;text-indent:-2.5%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">b)  Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</p>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: May 11, 2021</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:297pt;;">
<tr>
<td style="width:297pt;"></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Michael R. Bristow</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:1pt;border-top:Solid 0.75pt;padding-top:1pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Michael R. Bristow</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">(Principal Executive Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>abio-ex312_6.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
abio-ex312_6.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 31.2</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION</p>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, C. Jeffrey Dekker, certify that:</p>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1. I have reviewed this quarterly report on Form 10-Q of ARCA biopharma, Inc.;</p>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p>
<p style="margin-bottom:0pt;margin-top:4pt;margin-left:6.67%;text-indent:-2.5%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a)  Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p>
<p style="margin-bottom:0pt;margin-top:4pt;margin-left:6.67%;text-indent:-2.5%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">b)  Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p>
<p style="margin-bottom:0pt;margin-top:4pt;margin-left:6.67%;text-indent:-2.5%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c)  Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p>
<p style="margin-bottom:0pt;margin-top:4pt;margin-left:6.67%;text-indent:-2.5%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d)  Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</p>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</p>
<p style="margin-bottom:0pt;margin-top:4pt;margin-left:6.67%;text-indent:-2.5%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a)  All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</p>
<p style="margin-bottom:0pt;margin-top:4pt;margin-left:6.67%;text-indent:-2.5%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">b)  Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</p>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: May 11, 2021</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:301.5pt;;">
<tr>
<td style="width:301.5pt;"></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ <font style="color:#000000;">C. Jeffrey Dekker</font></p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:1pt;border-top:Solid 0.75pt;padding-top:1pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">C. Jeffrey Dekker</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">(Principal Financial and Accounting Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>abio-ex321_8.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
abio-ex321_8.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 32.1</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">ARCA BIOPHARMA, INC.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION PURSUANT TO</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">18 U.S.C. SEC. 1350</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">AS ADOPTED PURSUANT TO</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act") and Section&#160;1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167;1350), Michael R. Bristow, Chief Executive Officer of ARCA biopharma, Inc. (the "Company"), and C. Jeffrey Dekker, Chief Financial Officer of the Company, each hereby certifies that, to the best of his/her knowledge:</p>
<p style="margin-bottom:0pt;margin-top:9pt;margin-left:9.17%;text-indent:-2.5%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1) The Company's Quarterly Report on Form 10-Q for the period ended March 31, 2021, to which this Certification is attached as Exhibit 32.1 (the "Periodic Report") fully complies with the requirements of section 13(a) or 15(d) of the Exchange Act; and</p>
<p style="margin-bottom:0pt;margin-top:9pt;margin-left:9.17%;text-indent:-2.5%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2) The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p>
<p style="margin-bottom:0pt;margin-top:13pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">In Witness Whereof<font style="font-weight:normal;">, the undersigned have set their hands hereto as of the 11th day of May, 2021.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:540pt;;">
<tr>
<td style="width:251.4pt;"></td>
<td style="width:9.3pt;"></td>
<td style="width:4.65pt;"></td>
<td style="width:9.3pt;"></td>
<td style="width:265.35pt;"></td>
</tr>
<tr>
<td valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Michael R. Bristow</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ <font style="color:#000000;">C. Jeffrey Dekker</font></p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;border-top:Solid 0.75pt;padding-top:1pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;border-top:Solid 0.75pt;padding-top:1pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Michael R. Bristow</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">C. Jeffrey Dekker</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">(Principal Executive Officer)</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">(Principal&#160;Financial and Accounting Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A signed original of this written statement required by Section&#160;906 of the Public Company Accounting Reform and Investor Protection Act of 2002 (18 U.S.C. &#167; 1350, as adopted) has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request. This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of ARCA biopharma, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>gneflb3r2gmg000002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gneflb3r2gmg000002.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_[@ .061O8F4 9       _^$ 2D5X:68
M $U- "H    (  ,!&@ %     0   #(!&P %     0   #H!*  #     0 "
M         2P    !   !+     $  /_; $,  0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,#
M __  !0( 38#6 0!$0 "$0 #$0 $$0#_Q  ?    !@(# 0             '
M" 8%! D#"@(!  O_Q "U$  " 0,$ 0,# @,# P(&"74! @,$$042!B$'$R(
M"#$403(C%0E10A9A)#,74G&!&&*1)4.AL? F-'(*&<'1-2?A4S:"\9*B1%1S
M148W1V,H5597&K+"TN+R9(-TDX1EH[/#T^,I.&;S=2HY.DA)2EA96F=H:6IV
M=WAY>H6&AXB)BI25EI>8F9JDI::GJ*FJM+6VM[BYNL3%QL?(R<K4U=;7V-G:
MY.7FY^CIZO3U]O?X^?K_V@ .! $  @ #  0  #\ W^/>_P >]_CWO\>_>_>_
M>_>VO,9O%;?H9,CF:Z"@HX^#+.UB[V)$4,:AI9YF -D168VX'M-[KWAMG8^'
MGSVZ\S183%4_#5-9(0TLI5F6GI*>,/4UM7(JG3%"CR-8V4V]EX^4'RQ^.7PO
MZFS?>'RA[=V?TWUE@OVIMP;LKWCGRN1:&:H@P&U<#0Q5NXMX[HK8:>1J?%XJ
MDK,A4+&QCA8*Q'O9<MT?("9GDIMI8U$C&I?XGEE+R-]1KIZ"*0)'8\JTKO<?
M5![(-V-\XZIY)\?UA@(H8!KC&XMS1F6HDN"OEH,+3SK#!I;U(]1++J'ZH5/'
MO1G_ )@?_"T;=%9D,UL3^6UT5B\-A(_NJ!._OD902Y3/U^I):?\ BFR>G\!F
M*?$X/P3*L]'59[)9/SQL!4XF!@4]^]@ME=^[RS3%LAN/*.I-S#3U+4-+?\'[
M6A^WIKC\'3<>RC;E[L[9W=(SYS?VY)HV;4:2BKWP^.N/TG^&X<4% 67\$QW'
M//)]ZJ?R)_G'_P T?Y4U]16=T_.;Y#9BBJ9O/+M79^^JWJ?8!E6WBE_T==3+
MLC8QFIUN(Y#CS)&&:S#6U_>TH[O(Q>1WD=K7=V+L;  79B2; 6]AE---42--
M42RSRO;7+-(TLC:5"KJ=RS-I50!<\ >ZXLKELKG*^?*YO)Y#,9.J\7W.1RM;
M4Y"OJ/!#'3P^>LJY)JB;PT\*1KJ8Z44*. ![][X>\7MO]^]\@K-] 3_OOZ_3
MWS5&;@ ^_>_>\RT['ZG_ &PO_O/ 'N2E'(WZO3_K_P#%.??O?O>44R_G_>3_
M ,4]R4H1^;DG^@X_WF_OL GZ G_6'OWO(($X%A?_ (*3_O)]R%H!]!&W/^)_
MXCWS$4A^B'W[W+@QXFBK)+A?M*9:C3X@WDU5E)2:+ZAHM]UJOS^FUN;ATHL"
M:NFRU1<Q_P +Q\5<$\9?S^3*XS&>+5J7Q6_B.O59KZ+6YN!!V;U])NW;G;&?
M_B?\._T7]?X[?/VGV7W?\<_B':?6G6G\+\_WE-_#/#_I#^]\^BHU?9^'QCR^
M6+WN*8%'U4#_ ) _XIS[;3C[<F-O]N?]X'L/S#*/[!_V'/OWO@:=/\!_L2/^
M*CWA>@7_ %++_L ?K_O/O@48?53_ +;W[WC:F_H3_O?^]6/N,]"1^D_[ W'^
M]W]\??O>!HG'XN/\/^*?7W%>"1/JIM_7_C?(]^]^]X_>(@CZ^_>_>_>^O?O?
MO;I0YO,XQE;'9;)4#)^DT==4TUK?@>&5!;_#Z>U%A]W[LVZ\<F W/N#"O%;Q
MG%9G(X_3;D "EJ(AIX^GT/L?NI?E=\H>@ZNBK^COD=WMT[5XYD:BFZP[:W[L
M0TXC966.-=L9[&1^'T@&,@HPX((X]^]B;@.[MZ8AD2OFI\_2"P:+(1+'5!!>
MXBKJ98Y-9/\ :E6;_6]F)V3\PNW-KR119NLH=[8Q2JO39RFC@R"Q"Y84V8QR
M4]1YG)Y>I6JL!8#W?U\-_P#A6=_-5^-5?C<7W%NS9OS(ZXIF@@JMO=TX"APN
M_:;'1>5YEP';6PJ+!;@;+5,CKJJ]Q4VYE5%TK"."OO9CMG=I[8W@8Z6&9L9E
MG _W%U[(CRO^115 /AK.?H!IE(Y* >S]]4_)/KKM1X,;2U<FW=T2J!_=S-O%
M%-4R_P!I<17J1293G]*+HJ" 28@/>\Y_+!_X41? #^9M583KO;NYZ[H'Y*9.
M&)!\?^Y*O'8[*;BR14>>FZKWO3R)M?LQ1)J\-+"U%GI(D:5\9%&I8>]B3[,%
M[OD]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]
M^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]
M^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]
M^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]
M^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]
M^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]
M^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]
M^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]
M^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]
M^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]
M^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]
M^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]HG?.^<7L?%BLK :FMJ2\>-QL;A
M9:N50"S,Q#>&EAU R2$&UP "Q (/]R]R[<Z;VXN6RRG(9?(&6# 8""58ZG)U
M,:@R222$/]KCJ76IFF*MIU!5#.RJ:F?YN_\ -W^/_P#*-^/\/9W9T,F^NU]]
M29+"]&=&87)04&XNQ]Q4$$4E=D,A72157]V.O]L?=0/E\N\$P@$T4$$4]7/!
M _O9(-S[KS6[L@^1S-4TSW84],FI*.BB8W\-) 681H+"Y-W>UV)//NG7L3LO
M=_:&=ESV[<F]7+>1:''Q%XL5B*9VU"DQE$7=*>( #4Q+2R$7D=FY]_)0^?/\
MQ7Y6_P RCNO(]W?*;L6LW3E!)6T^R]CXMJK%]9]5[>JYQ,FUNN-H/65=+@L7
M&L<8FGD>HR60>-9:VIJ9[R'WM.>T#[(Y[][][][][][Y*K-]!_L?Q_M_?-(V
M<@*/K[][][EI3CZGG_7^G^P'Y]N,-%_JKD_T'^Q^I_'^P]]@$\ 7/OWMTBHU
MDI994!,M/(AE4V(-/, BRJ@%U6*<!6)N"95''Y4])AEGQM14Q*ZST51&:F,$
M,&H:D+%%.J :XTIZM DC$D,:B,"Q'J$O%;)I<[UON'<V--6=P[*SV,DW)0B6
M&>*;96YDBQ>-S]/1I&E304VVMV4T=#7U#O+%--N''1J(F4^?WOI8+_7_ &W^
MP_H/>2+&C_4W_P 3_P 38V_WGVE*?#RR6M&3S^0?]X]^]YE@ MZ?]Z'_ !OV
MX1X\#@*/]@.1^?P#_O?M\@VW,]KJ1_K"W^PO[][R"#\V_P![/_&O<I<=?^P3
M_L+?[R2?;M%M1F_L$_[ _P#%+>_>W?'4DDM-F_&E_'BEE?A5M&F6Q18^HB]O
MZ#GVI\#AIJC'[N\,!?P[;CJ);-&FF"+<VVS(]F8:M/' N3_3V:'H'J_.[CZ]
M^82X3'/6_P #^,^.W'EOWZ6F^TP>)^3_ ,:I*^M'W=13_<>#R)^U%KF>_I0V
M/OWMI,'^'_)I'^\CVFOX=_M!_P!LM_\ >^?99'VFUOT-_L5-[?X6Y]^]\&@_
M!'^^_P!C[POC_P"JD?ZX(Y_Y.'MNGVO(M[ _ZUO]]?W[WB: <\6^G^'^\CCW
M!DQRG^R#?^@_Z-_XI[9:G 3)>\=_^0?I_OOZ^_>^5-1>>=$>_B DEG9;!UIX
M$::=D)!&M84;2".38>^%#@UK*V*%RZ4RB6HK'0KKCH:2&2JK7BU!E,J4L+Z
M1ZGL/S[477&P8=Y;UQ6&R<E72;?IXLMN/=];1/ E=0;)VAB*[=6]*W&&IBEI
MY<M2[7P]6U'$R,)ZOQQ ,S@'WMMDA5B?3;DV!^H'-K-^>![3531+J;]LH"25
MMS8$\"_]JP]AO4*/-*\<7AB:1VBBUM)XHV9BD?D:S/H7C4>3:_OWN$\++]+D
M?T_/_&_;3+3/'R.1_7_??3W']^]X?<;W[W[W[W[W[W[WVK,K!E)5E(964D,K
M W!!'((/ODCO&Z21NT<D;*Z.C%71U(971E(965A<$<@^Y%)5U5!54U=0U-11
M5U%40U='64DTE-54E532+-3U--40LDT%1!,@='0AE8 @@CW[V9KK#N*5I:;;
MN[Z@R^5HZ?'9R9O6'8Z(Z?*2$^L.;*LYY!_SA()<6'_'/Y75,E3CMA=I5[5'
MW,D-#@=Y5;WF2:0^.GH=R3N?W4E<JD=:WJ5C^^2"95WZ?^$_/_"H'<59N#K_
M .#W\R_>U1GUW!D,/LKI'Y=;GK0^6I,K6R#'8/97R'S57*&RM'D:IX*6BWC.
M?N8)F!S4DL<DN3IO>S.^[%_?T!_?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?
MO?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?
MO?O?O?O?O?O?O?O?O?O?O:*[&['V+U'LG</8_9>Z<1LO8VU*)<AN'<V=J12X
MW&4TE3!14_EDL\DM165U5%3T\,:O-45$J11JTCJI2&_=_;,ZNVAG=_\ 86Y,
M7M'9NV:1:[.[AS-0*;'X^GDGAI(/(]F>2>KK*F.""*-7EGGE2.-6=U4I'?F_
M=F]7[0SN_NP=QXO:6SMM4BUV<W#F:@4V/Q]/)/#20>1[,\D]565$<$$4:O+/
M/(D<:L[JI9=Q;BP>TL+D-Q;DRE)AL'BH149#)5T@BIJ:-I$ACU-8LTDT\JQQ
MHH+R2,JJ"Q (3_'GY<?'+Y6XW/93X_=IX3L6#:T]%!N.EHZ+.X3,85LE]V,;
M+DMO[HQ.#SM+1Y$X^<4\[4P@G,$@1V*-8,NB?E#T)\F,?FLET=V3A]^P[;FI
M(<]3TM'FL/E<0<A]T,?+D,'N/&8;-4U+7FAG$$S4XAF,+A&8HU@SZ+^3_0OR
M6Q^:R72'9&(WY#MR:DASU/2TF9P^5Q!R'W0Q\N0P>X\9A\S34M>:&803-3B&
M8PN$9BK62O7W;/7?:E-7U6P=T46XH\6\,>1BAAKJ*LHC4^;[9ZF@RE)0UT4-
M2:>3QN8]#E&TDV/LQOL?/8]>Q$]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^
M]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^
M]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^
M]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^
M]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^
M]^]^]^]^]^]^]^]A7OKO3I+J]WC[,[BZKZ[DC1))(]]=A;2VDZ)(=,;NN?R^
M/94=N 3P3]/8;;S[FZ?ZX=H^P^UNMMAR(J.Z;SWUM?:[HDATH[+G,I0LJNW
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MBBDIRS*-?J6X,=&?+/X[?)2?.4G27:&%WS7[;19LUC(*+.X3+4=*]0:1*_\
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ML'\Q[YQ4TT4\?R1[!9X761%GEP]5"64W EIJK%34\Z'\JZLI_(]E7C^4'?\
M%(DB]H[D+(P8"1J&:,D&X#Q2T;Q2+_4,"#[$##_SD_YD6%9!%\D*NOA%3'42
MT^8ZUZ>RRSA"FJG>IK>OY:^&FF1-++#-$1<E2K'5[6^*_FP_/[$E1%W]55L(
MJ$J)(,KU]U5DQ.%*:H&J*O8TE;#3RJEF6*6,BY*D,;^UMBOYKGSZQ)41=^U5
M;"*A*B2#*]?]5Y,3A2FJ!JBKV/)6PT\JI9EBEC(N2I#&_M_H_F'\C*,C1V-+
M.GD61HZS;>T*H26TWC,DV :=(W"V(1U^I(L>?8G8[^>M_,)HH&BJ=[=>9B1I
M6D%3D>K]LQ3HA1%$"KB8L73&)60L"T9>[&[$6 $6@_G.?.FCA:*HWAL3*NTI
MD%17]<[>CF12J*(57%QXVG,2E2P)0O=C=B+ ")0?SE_G+1PM'4;OV+E':0N*
MBOZZV_',BE440JN,CQT!C4J6!*%[L;L18!34_P Y/D! A27-;>K&+EA+4;8Q
MJNH(4: *1:6/0"+\J6N3S:P"RIOY_OSN@@AAEH.BJR2.-4>JJ>O<XL]0RBQE
MF6DWM2TJR.>2(XT2_P!%'M5T_P#._P#FC##%%)1=,U4D:*CU-1L7,+-.RBQE
ME6EW?34X=SR=$:+_ $ ]JN#^=Q\SH88HI*/IJJ>-%1ZF?8V76:=@+&65:7=U
M-3AW^IT1HO\ 0#V\1_/?O-(T1J?8TS*H!EDV_7"20@<NXBS<409OSI51_A[:
MLA_/M^?-;.)J:MZ?Q,8C5/M<?UP9("REB92V5SV3JO(X8 CR:+ 64<W;:[^=
MC\VZN82T]9U7BX]"I]M0[ ,D)8%B92V3S61J-; V/[FG@6 YNVUW\ZOYL5<P
ME@K.K,8FA4^VH=@F2$L"Q,I;)9K(5&MKV/[FG@6 YO%J/G?WS-)KCFVA2+I
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M;- \4'K/[2D1CCT\"P<9+^9M\[<LKK5?(O=D0DG-0QQN'V9A6$A+G2CX?;-
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M3;BU[_\ % /?O;A' !:XN?Z#_?7)]J*FH;D6%S_7B]O\/PH]B_@]IZM!:/\
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MG]"QNBQCA H]L^6^-70V9CDBK.J]HPK(SLQQ./.!D!D-V\<V#EQTT2@_I"L
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M]^]^]^]^]^]^]^]^]IG=^R]G=@X"MVKOS:FW-Z[8R2:,AMW=>$QNX<)7* P
MJL7EJ:KH9](8VU(;7X]I[=.T=J;YPE9MK>NV<!N[;N07178'<V'Q^=P]8H!
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M/JH_V)%_]XY]]ICN.;F_]!>P/^-A]/\ 7]P*;9MP+0,?]<6_WW^'OWL7NMZ
M/C\\6 TU?@I-7JL0L%1J )7^E2+_ %_UO9DNCL(IPV\-2V7)_:XXEKVM'2UV
ML7LP^E<+_7\<?2^VA_PG0Z/CS'0OSMFJJ5$INUO[F=4BHJ ZP&+';-[#:OA\
MK4$\:)H[$B,V@S,1H+1"R:_>PD:FL;,H# D$-J!%C]#J M[+D^+TL0RN&!(8
M%2"I'!!'-F!_P]ZH%9L6>DFFIJJBFIJFFEE@J*>:-H9X)X7:.:&:&15>*:*1
M2K*0"I%CS[][Q-3?X'_7'(_WCCW%?''FUC_@>?\ >#;\?X>TW6;-L#^T0?\
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M^]^]^][9_P#PG>^0_P#'NN.W_C'FJ[7D=@YJ#M'8\$\VN9]I[L:'$;MH**
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MWOWOWOWOWOZ"'\JC9-!L+^7U\8L70TL5.<SL%M[5KH5>2KK]^YS+[PGJJB8
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MW[W[W[W[W[W[W[W[W[W[W[W[W[W[W[W[W[W[W64[M([R.=3R.SN; 79R68V
M %R?Q[UW)II*B:6HF;7+/+)-*]E75)*Q=VTJ%5=3,38  >_@+Y;*U^<RN3S>
M5G^ZR>8R%;E<C4^*&#[BOR%3)5UD_AIXX:>'S5$S-IC146]E %A[][Z5=3 ?
M[?\ UOS[XQH78*!?VW^_>W2*.UE _I_L!QQ_K^U)14VHJ .!:_'ZCQ?_ &_N
M13PF1QP;7_I]3_3W[VZ0Q?0 ?\C_ .*#VL:*E^@'^O\ 3Z#Z7_XI[$G;V',K
M(Y2Y)%N/K?\ WH#W[V[0QE2-)LPL=8XTD<W!^HL?:PH*4AHV74I0JRLMU8,.
M05(L0]_S^/9B]H82:DGI:JE:6GJX)HIX*F!WBGIYX7$D4T,L162*6)U!5E(*
MD"W/OWL4:"@@WO 54QTV[J:/62^F.#<4$:B\DALJ0Y6%%]3?28<GG4RF/PV&
MI.V*1T1Z>A[+H:<R$R%8:/>]'"OJDD;T0TFX:2%!Y)+::I?6]V,DB;)72_2^
MS?YQ>S:[&8RNV[L#^:?L#;K9)WR34>!V9\^]F8&C J,GDZ@"BPNT/DMM#"T2
M_P 0R&E8-UP**RL!J#D,A1^]IPT,U+,\%3#)#41.4D@E0I)&Z_59%8 AA_3V
MB?X-54%3-25U--25=+(T-13U$3Q3PRH;/&\;@.C*?K>WNMC(]1[MZYW5F]C[
M_P!JYS9N]MK92IPNY-J[FQ59A<]@<O0R&.JQ^6Q=?#!6457"_P"I'0&UC]"#
M[][FQ07^HN?]X'^)/X]OE+0\#BR_CZ\G_B3[$;![5U:+QW)M9;<_X7XX]^]J
MW:E1_#L[C:F]D-0L$I^BB*J!@=B+<JGDU?CZ<>Q-Z\JOX'NW"5OZ(C5K25!_
M IZX-22._P" D0FU_P!?3[M,_E9]B2_'GYS?'+L26?[+#3;[HMB[HE8E:6/;
M'9,%1L3+UM<-+F2EPT6X!7D %@](I4:@/?O:^W]@ [IFX%/.B"O4"_( 2GJ+
M?3Z6C;_D'_'V,';VSQ))%NJCBN6\5+EE11>XM%25I)^@M:)S_P $_P ?=[?\
M^OX()D,IAOFKL'$AVJ4PNR>\J:EA M) D.)V+OVI(^JO$L.#K'/Z2N/"@ZI6
M'O8:K3"PX/\ O _/]/8(+1W_ +(_PN2?]O\ CWK<4FQB0I,8'_(/^M]+V%_?
MO8T;$IA!A"]@/N*R>6X_(58H!^+V!B/LSW4E#]GM5I"JAJS)U=1J  NJ)!2@
M<<V#4YL/\3_7WN:_R)>NUV-\):S*F"-)NP.Y-\;H$X$9FEI,=C=L;+AB9U02
M+#!4[5G*1L6"M(["VLCW[V%.6HE@R>0A"@".MJE6Q ](F?0?H!RMO9>MP8K[
M3.9BF"H%@R==$@  ]"U,HC/HL "EOP+>]4SY3=-#8GR1[^V='3I%!MKN3LK#
MT21K (SCJ/>&8BQLD:P101)'-CQ&ZJL<856 T+^D>]XL;A9<K7P44%U:5QKD
M(N(HEYEE)XOH07 N+GCWAP>VJC<&6H\53J5:ID'DEL'2GIU]4]0X8BXBC!(%
MQJ:P')'MC^-WQ$W=\HN\MA])[0B-/5[NR\:9G.-3&>FVMM:B_P JW+NBMB+P
MK)!AL3%)(D1=#4S^.!6#RK[][$7?C18[;]#AZ5=$4LL<80'DTU$@<ZC;EC.T
M;$GZFY]C3VV:?#;-Q.V,>GAIZB>&%(OU7HL7&LC:[6+.U4\+,WU)N3]?>Q3_
M #T*O:7QW^ W17P[ZOI1@=M[IW%@<%08=7$DDW7/3&+I,E5BND2)#69&JWCD
M\%5U%2]GJ*A9)&#.Y(][!.2"]^+_ .PY_(^GY _K[*I44 Y(%C^/K8_ZQ_/^
M\'WI>YO:=M>J+GGD*!]?ZC_7]^]M\L/X(O\ T/Y'^Q]IZKH?U#38\_ZQ_P"*
M'_;>P;S^U^'#17!O9K7^GY!_(]^]N^(VH*JGFS68E?'[>H[/-5!?\HK6#:12
M8U&XDEE?T:CZ$)_-B/:AVUURN2H:K=6YYIL)LK%^NKKA'>LRTBR:!C,)$]A/
M4U,H\?E-XXV)OJ*D Z?Q-_EFP]J=>;M^8/RNW#E^B/@;U.WWN[.Q%QNO>W<V
M5IJ\4--U3T'AZT1Q9[=6Y<PO\+.6</C,74NY?SR4\T">]I;/9%LG.GA@2BQU
M&C08W&Q<Q4E*6+?J(#3U,Q]4TK7>1^3Q8 -MZ9=]PU40IZ.+%X3&1-1X'"4Y
M+4^,H=9?2TA >JKZE_W*BI>\D\IN38*HK?\ FQWS5?(W>.(BVULG$=1="]6X
MJKV9\>NB-LR-/MWJGK]JYJUH*C)2QQUV\=_[JK/]R&YMR9 R9+.Y5VEE=84I
MX(/>TG/%^1]/]Z/_ !OV%5;2_J-O]?C_ 'D<?4'Z^ZR]SX#QF3T<<_BP!Y^H
M']??O;5-';G_ %[C_?<>T?7TGU(%B+V_Q_-O]L./8(Y2A:&1P1R";'Z?2_OW
MMJGCMZA_L?\ $?@_[#VD:R&QU@?4V/\ KV_XGVP>_>XOMO\ ?O?O9L?CO*3A
M-PP:P1'E:>71Q=3-2!"Y_M6?P6%^/3Q^?=G/P/J2VS]]T?D4B#<N/J1#Z=2&
MKQ8B,AL->F7[, 7-O0;?GW](+_A$1N)ZGXH?-O:9R$,D>$^0VQ-Q)BE%/]Q1
M/NCK9<;)D)65!5&')KM!8XP[&,-2/H )D+>]F']GO][NWOWOWOWOWOWOWOWO
MWOWOWOWOWOWOWOWOWOWOWOWOWOWOWOWOWOWOWOWOWOWOWOWOWOWOWOWOWOWO
MWOWOWOWOWOWOWOWO1U_G??)@=[?,G+[#P>2^\V/\=\:_6F+2%W:CFWK).F1[
M*R:1R$Z*V+."+#3%0$<82-EN#J;3D_G#_(4=T?+'*;*P^0^[V=T/CWZ]QR1.
MYI)=WO,M=V#D$1S=*N+,B+$S$ *XPZ$7!U-IW_S@OD&.Y_E=E-EX>O\ N]G=
M$X]^OL<D3N:27=SSK7=@9!$<^BKCS BQ4Q "N,0A%P=34D?-CLD;Y[BJ\%15
M/FPG7M,VVJ949C"^::05&Y*D*WZ9DK@E&Y%@PHE(_J:B<OM[.8!,/)FL578M
M-P8:GW#A&K:>2G&4P=745=)2Y6C\@!FH:FHH9E20>EC&;<>ZM\I@LQA$Q4F7
MQE9C4SF*@SN(:L@> 9'#U4]52TV3I-8!FHZB>BE5)!Z6*&WNKS*8/,85,5)E
M\;68Y,YBH,YB&K('@&1P]5/54M-DJ36 9:.>>BE5''I8H;>RE5>/KJ!:-JVE
MGI5R%''D*(SQM']U0RR2Q154.H#7!)) X5AP=)M[9_;5[:O</V?G^61\B#\9
MOFITQORNKC0[1S^='6N_V:18Z3^Z&_VBP5379%FDC_R';>8FHLN]C>^.'#?I
M8[7\N[O<_'GY==2;TK*TT6U\WFAU]O=F<1TO]U=[M'A:BLKV+Q_Y%M_*RTF5
M:QO>@'#?I)U_Y>7>I^/?RWZEWG65IH]L9O-+U_O9F<1TO]UM[M'A:BLKV+Q_
MY'@,I+291K&]Z <-^DCS\:.PO]&O<^S<[/.8,37UPVWGR6"P_P (SY6ADGJ"
M67]C&UCPUAY^M..#]#]!_P![SWO>1]W_ /OWOWOWOWOWOWOWOWOWOWOWOWOW
MOWOWOWOWOWOWOWOWOWOWOWOWOWOWOWOWOWOWOWOWOWOWOWOWOWOWOWOWOWOW
MOWO2H_X4!?\ 9=>'_P#$"=?_ /O2;]]ZB/\ /#_[+.Q7_B$]C_\ O0;V]ZC?
M\[W_ +++Q?\ XA78_P#[O]Z^Z8?GU_S/&C_\,/ ?^[+/>Z/O=.ONGOV27W[W
M[W[W[W]$W^7=_P!D*?$K_P 0)UM_[S=%[WQO@?\ ]D8_&'_Q"?7_ /[S]'[W
MN/@E_P!D:?&/_P 0KL'_ -T%)[V%OCW_ ,R.ZG_\,/;?_NM@]G+]FR]FP]C%
M[][][][][][][][][][][][][][][][][^>E_,QZ?I.C?G1\C=B8NBBQ^#DW
MU)O3;])31"&AI<+V/C,?OZCH,?&H5$HL3_>-J-%7TQ_;E/[/O15_F%]5TO3?
MS,[\V7C:2*APTF\WW=@Z6GC$5'38C?\ CJ'>])14,:A42DQ?\?:D15X3P%?[
M/O1B_F#]64O3GS)[ZV7C:2.BPTF\GW;@Z6GC$5'38G?V/H=[4E%0H $2DQG\
M?:E15X3P%?[/O7Y^2FT(=D=X]B8*EA2"A;.-FJ"*)-$$5'N.FI\]#!3J %6&
MD_B)A '"^.WX]D4]DQ]DT]@;[][][][][^AW_+D[ZK/DE\+NB>S\S5_>[IFV
MG_=/>52Y=JBIW7L.OJ]GY?)5FLD_=9V3#+D&L=/^5BUAP-[;X#=UU?R ^)'2
M_8V6JOO-R3;9_NSNRH8N9ZC<NRZVJVKE,A5:R?\ *<T^)6O:QT_Y4+6' WJ?
M@5W35]_?$OIGL7+57W>XYMLG;.ZZABYGJ-R[,K:K:N4R%5K)/W.9?$K7-8Z?
M\J%K#@;!OQVWW-V/TUL;<]9+YLH^*_A68D))DERN"GFP]74S7O\ NUS48J#^
M/W>/Z>SN^SA>S?\ L:_?O?O?O?O?O?O?O?O?O?O?O?O:0W_OW:'5NR=T]B[_
M ,]0[8V7LO"5^X=RY[(NR4F-Q6-@:>IF98UDGJ)F"Z(H8E>:>9ECC1Y'52EM
M[[VVKUOM#<>_=[YJCV[M':6(K<[N#-5[LM-C\;00M-43,J*\T\K!=$4,:O--
M*RQQJSLJE+[VWKM;KC:.X]^;VS5'MW:6T\16YW<&:KW9:;'XV@A::>5E17FG
ME8+IBBC5YII66.-6=E4M&>SV(VOA<IN'/U\&,PV&HI\ADJ^I)$5-2TR%Y'(4
M,\CD"R(@9Y'(506(!T&/YAWSUWW\Z>XJO<=;)DL#U%M.JK\=U'UY/,@CPF%D
MD6.3<&<@II)*2HWGN:.!)JZ4-*M.NBEBD>&%7?22^=OS7WI\S>UJG/U<F0PG
M5NV*FMH.KMB33*(\/B'=8Y,YF(:>22EGW;N%(4EK) TH@71312/%"KMI/?.G
MYJ;S^97:M3GZN3(87J_;-36T/5^Q9IE$>(Q+NL;YS,0T[O2S[LW D*2UD@:4
M0+HIHY'BA5VH;^0?>^=[QWA+D9FJ:#:6*EGI]I;?D<!:*B9@K9"N2-FBDS.2
M6-7G8%Q&+1(Q1 37[[([[)![ +V._P :?CSV!\I^Z=D](]:T8FW#O#(F.HR5
M1'*V+VU@:-#59W=&<EB!,&)PF.C>5^0\TFB&/5-+&C#1\>^B=\?)/MS:'3W7
MU*)<[NJO,<^0GCE;&[>PM(AJ<UN3,21@F'&8>@C>5_HTKZ(8]4LD:L,_Q]Z+
MWO\ )'MO:'3_ %_2B7.[IKC'/7SQRMC=OX6E0U.9W'F)(@3#C,/01O(_T:5]
M$,>J62-6776W7V?[1WGA=D[;A#Y#+U&F2ID5S2XV@A4RUV4KF0>BDHJ=2Q_+
MM9%N[*#]!CXL?&/K/XC=,[8Z7ZNQ_AQ.%B%7G,Y4Q1KFMZ;KJH*>/-[OW#-'
M<397+24ZV0'Q4U/'%3PA888T7>8^-OQVZ\^+G4NW>I.N*'PXO$1"JS.9J(XU
MR^[=S5,,$>8W3G94N)<EE)(%LH/CIX$C@B"PQ1J-XKXW_'CKWXO=3[=ZEZYH
M?%B\1']UF,Q41QC+[MW+4PP)E]TYR5+B7)9.2!;*#XZ>!(X(@L42*+_.KNM-
MM=2[-QFS-KT^BDHD\U;72*HK<SE98XUK<OD'7]=55M&.!Z8HU6- $10#$^QX
M]CO[$+W[W[W[W[W[W[W[W[W[W[W[W[W[W[W[W[W[W[W[W[W[W[W[W[W[W[W[
MW[W[W[W[W[W65_-0^#V,^9WQSS$6!Q4,G=W5E'E=W=1Y**-17Y*JBI5GSO7[
MRB-GDH=[T=$D42$HB92&DE9@B2!J\/YDWPZQ_P M>A,K%A,;#)W!UO2Y+=/5
MV0CC45M?4QTZS9K8SRA&>2BWC24:11(2BID8J65F"(X:O3^9%\/<?\LNALI%
MA<;#)V_UQ2Y+='6&0CC45M?4QTZS9G8[RA&>2CWA24BQ1(2J)D8J65F"(X8M
M7RCZ2INY.NZM*"E1MZ[7AJLOM*I51YZB58@]=@&?22T&;A@"*MP%J4A<D*K
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MJ6LA2HIY0#8@20R _P"Q]_0YQ]?2Y7'T.4H91/19*CIJ^CG4$":EK(4J*>4
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M,ZW43TLB?J0@4[5V'RN,I<-6Y#'U=%2;AQLN8P534P/%#EL5!E\K@)LA02.
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MG_\ G1U#0;7VQU7N?;M'X\9MG%4W6E:P%Y%H:*F:LVS)-H !-X:X2RM^J21
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M^GOWMZIHAQ<< ?\ (O\ ;GVL:&GU$6'^MQ_O/X]F@VEA0YC)3TJ!Q;_7L/\
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M_45BO^M5=[L4^!7_ !9^RO\ M9;9_P#<7,^_H:?\(=/^95_S$O\ Q('QQ_\
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M'U"HJ@B+&RL20.-@[^1+WL,=NCM?XZ9>L"4VY*&#L_9D$KE4_C6&6EP>\*.
M,Y62JR.'EQ]0J*H(BQTK$D#BR?\ EZ]A?:Y;>/6-;/:+*4\>[<%&[$+]]0B'
M'YN&,%K--543TT@  .BE<\_C:X][,7O9:]VH^_>_>_>_>_>_>_>_>_>_>_>_
M>_>_>_>_>_>_>_>_>_>_>_>_>_>_>_>_>_>_>_>_>_>_>_>_>_>_>_>_>]*C
M_A0%_P!EUX?_ ,0)U_\ ^])OWWJ(_P \/_LL[%?^(3V/_P"]!O;WJ-_SO?\
MLLO%_P#B%=C_ /N_WK[IA^?7_,\:/_PP\!_[LL][H^]TZ^Z>_9)??O?O?O?O
M?T3?Y=W_ &0I\2O_ ! G6W_O-T7O?&^!_P#V1C\8?_$)]?\ _O/T?O>X^"7_
M &1I\8__ !"NP?\ W04GO86^/?\ S([J?_PP]M_^ZV#V<OV;+V;#V,7OWOWO
MWOWOWOWOWOWOWOWOWOWOWOWOWOWO3"_X4+Y""L^;FPZ:$2"3$_&K8V/JM:A5
M,\G8W;F54Q$,2\?VV3CN2 =5Q;BYU*/YZM=#5_,'94$0?7C/CYLVAJ=:@*9I
M-_=HY)3$0QU)]OD(^3;U7%N+G4R_GGUT-7\O]EP1!]>,^/VSJ&IUJ IFDW[V
MADE,1#'4GV^0CY-O5<6XN:;OY@<Z3=UX*--6JEZVPD$MQ8:VW%NVJ&DW-U\=
M2O\ 3F_NB3W2][ID]D8]^]^]^]^][D?_  G@V_D<=\0^TL_5Q>*BW'\@,XN*
MU AZB##[#V#25-6O&DT[5LTD*\W\D#W %B=L#^1%@Z^@^+79&;JH_%29[O#,
MKC=0.J>'%;*V335%4O&DP-62O$.;ZX7N+6)VMOY%.#KZ'XN=CYNIC\5)GN[L
MPN-U7U3PXK9>RJ:HJEXTF!JN5XAS?7"]Q:Q-PO\ +XQ]13]1[HKY5T0Y'?U<
M*6][R1T>"P,4DP_'C,SL@_.I&_PO?K[NX]W9>SY^_>_>_>_>_>_>_>_>RH_-
MWY*8WXE?&+M3NZJ>C?,[=P+X[8^-K"6CS._\^ZXC:&.:!09:FF7+U25%6J"Z
MT-/,Y(5"P+-\POD%C_C#\=>RNX:EJ5\M@<*U#L['U9U1Y;>^<<8O:U T*@R5
M%.N4J4GJ5076C@F<D*I(+1\O_D!0?&/X[]D]OU+4KY;!89J'9]!5&\>6WMFW
M&+VO0F%09*BG7*5*3U*J+K1P3.;*I("ONOLBFZHZSW3O64PM68ZA-/A*:;E:
MS/U["DQ%.4'JEC%7*LDH'(@C=N "1\ZO/9W,;HSF:W-N+)5F9W!N++9'.YW,
M9"9JBORN8R]9-D,GDJZH<EYZRNK:AY97/+.Q)^OO0SS>:RVX\SEMPY[(566S
MF>R=?FLSE:Z5IZW)Y;*54M=D<A63O=YJJMK)WDD<\L[$GWH@YK,Y7<>9RVX<
M[D*K+9S/9.OS.9RE=*T];DLKE*J6NR.0K)WNTU565<[R2.>6=B?>O-7UU9E*
MZLR>1J9JS(9&KJ*ZNK*AS)/55E7,]14U,\C<O-/-(S,3R6)/MI]MGML]Q/9W
M_P"73\9O]FR^7?5'560HY*O9<&5.]>R[1R/"O7VSFBRN<HJJ2)D>ECW+,M/A
MXY@?VI\C&W-K$XGP+^/'^S.?*3K+K2NI'JMI0Y,[O["(CD>%=C;4,>3S-'4O
M$R/31[AE6#%)*#^W/7QGFUO9P?@=\>O]F:^476?6M=2O4[2BR9W=V"1&[PKL
M?:ICR68HZAXV5Z>/<$JP8I)0?VYJ]#S:WL;?CQUK_I6[;VKM:HA:7#)5'-;D
MLK,@P&'*U5=!*R$-$N2<1T:O_9DJ5/OZ&D$$%+!#34T,5/34\4<%/3P1I%!!
M!$@CBAABC"QQ111J%55 "@6'O>PAAAIX8J>GBC@@@C2&""%%BAAAB4)'%%&@
M5(XXT4!5   %A[WHX88:>&*GIXHX(((TA@@A18H888E"1Q11H%2..-% 50
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M:.Z<)OG:FV-Z[9K4R.V]X;>PNZ=OY",62OPFX,;39;%5J#\)54%7&X_P;W]
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M/HJV)'^Q/OWM944 L#:_T _XK;V)F+I 0IM^K\_TM:Y]VV=/;(BJ?M5\0(]
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M^J_Z_P#Q"^ZW=O\ T7_$BW^WO[^7=TPZ?Y)R!S"?]AQ_3W[VNL>1=/Z"]_\
M8BUO]X]C?@2-*_[Z_-[_ .V]VR],2)KI+D?6+_H;_;^_>UI0$:U_UK7_ ,>.
M/8OX<_I_UA_O9_WKW<!T9+$#27*_B_/YU7O;Z?3W[VM:,C0O^N>/I]?I[%'$
MLMD_UA_O%[G^OY]W&='U-,K4NHK]1Q>_U"D<GW[VKJ1E\:?G@7_VW^\V]KNF
M9-*D\BP_WCZC_"_NWOJ#*8J*"G,OCL%4D&QN-('T/UT^_>\\[+I8C@$?[S^?
M>:H>-B2H 7ZV_P!AS[6G9N8P\U#+X/&+Q$"UOJ?\#];6/OWM)U9'K/\ K\_[
M;_B?:+RC+S]/JQ_'TL;?3W4OWE54K"LTE>?-;_>0/]Y]^]\=M59BR4U(3Z*J
M)F4?\W8/4+#\7C+7_P!8>\6R,@8<S44!;]NN@9T'X\]-9UM_2\)DO_6P]ROY
M97;$FWOD7NSJN>I;^$=E;4K,C14ID8H-T;,/\0IY(HB3&AGV]4Y'RD ,_AC!
MN%%O>\>Z,[7PU,N.IS]M&@022HQ\THDC$@TO8>)+-;T^JX^OX]XM];IRU/4U
M.(HR:&*)8_+41,?N:A)8UD]$HMX(R' ]/JN#ZOQ[@_S-?G%WKM3?F\?CWL"H
M;K/ X:#%PYG=.#JY?[X[JI<W@J#-I]CFT6$[:Q3T^42-DHK5ADB96J0C/"/>
MPSG'))O?ZF_/-['V ]>I.H_DW/\ T5<_U)/O60WO2L[UAE+22.[N[NQ9W9R=
M;LS$LS,W))^I]^]L=0MBX'_$?@C_ (@GVD:Y?U?['_;E;_[V/9/=ZTP'D/\
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M][][][][][][][][][][][][][TJ/^% 7_9=>'_\0)U__P"])OWWJ(_SP_\
MLL[%?^(3V/\ ^]!O;WJ-_P [W_LLO%_^(5V/_P"[_>ONF'Y]?\SQH_\ PP\!
M_P"[+/>Z/O=.ONGOV27W[W[W[W[W]$W^7=_V0I\2O_$"=;?^\W1>]\;X'_\
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M::J**F%F&7QS$*2%$66U,0/H+XP+<_3D@>PRRF(QX21ANC!.RJS+&M/N8.Y
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M JB'(5L8 *A5JI@O _U&O2?I_3V(^*W!G*32*;,Y.!0@4)%75*I_J;&/RZ"
M /Q^/=E_3?RH^26Q5IHMG]_]S;;IX(Q%%0XCLO>-'CA"(DB6%L;%F!CY852)
M J-&570MA=1;WM44NZLW'IO5B9=0NL\437! XUJB2?7_ &KV)&-WYN>(HKY
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M]W\EWYJ'8^[V^)_8F7\>T-^9"?(=25U=,WBP._:IA)7;0225O'38W>JAI:5
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M7BQ.&@D6%S$DDGGJ2C+!'*XT^_>Q@PNTJ3'A)JPK6U0LPU+_ )/$PY&B-O\
M.,I^C-_K@ ^S+;8Z]H,,L51D63)9!=+ %3]G3N+']J)N9F4_1W'X!"J?>WU\
M+OY3?5GQZI\3O#MZIH.X>U*<4U;%#44;CKS:6015D PF%K!Y-Q5M'-?17Y%
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M^M^3_O7M"Y&2P_I^IO\ 8_3_ !_Q]E.WE6#1.;VO=?Z_U)Y_K[][3]0WZO\
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M\=3>CW6?ZU>*/^WBKO9_O@8;XGLL_P#5SVU_[BYGW]#/_A#I_P RK_F)?^)
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ME'%>NW5MQUBJ-T[(81HTM;455+2_=XR.S/\ Q" 0QZ!53$U=_P U#X;#Y/\
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MU1W7D:_)Q04D9%'M7L+3][N7;^E=24M'FR[Y.@3T+9ZF&)!'2CW2Q\T.D?\
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M$&5Z.%"&.BUW?\CWO:+9'?6\ND<Q6^'%=S;;3(;?BE:\9WOL.+(9."FA##3
MV2VK69(NP(\KTD*$,=%C\_ +L),#V)G-@UL_CH]\XM:G&HY]/\?VZE35I$@/
M$9JL//5%B"-;01KR;6W%_>UM[VK?=O\ [][][][][][][][][][][][][][]
M[][][][][][][][][][][][][][][][][][][][][][][][][][][][][][]
M[][][][][;ZW+XK&RTD&1R>/H)J^0Q4,-;6TU++6RJT2-'21SR1O42*\R A
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M_KC_ 'UOK[,]M;.<1.K\C3?G_8W_ -M[][>X9?H1^?J/Z'\^UA0U?Z;-R/\
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M-C=2X8F5/#M#'5C8W;PIZ6IT&DK-S54KY&HC:Q2JKG6^E5MHU_-;Y#9OY?\
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M0KF.'&T<\E1(UCICB8VX]^]CAN?,)A<;IA8+55(-/2(#8H  ))AR"!"A%O\
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M[F_^%OZG\#_BOLKFZL_?R*)+L;W(/_$#W[VTS2?7_'\?X'_B3[1]=5 !N?\
M7_Q)XN+?U_'LO6>RAFD<!C8$WO\ G_"Y_K[][:IY-(///^]G_C7M%UM1PQOR
MWT_P'Y/^Q]H=W+L6/]>/?O;=[92;F_OA[][-5\=HR,;N>:XL]=CHP/R#%3U+
M$G\6(F%O];W99\#(&7;_ &)4DKHFS."@5>=0:FHJ^1B>+:6%4+?ZQ]_16_X0
M^82HI^B?G]N1I86I<KVUTAA(8%U_<1U&W]G;[KZF66Z"/PS1[FB$=F+:HWN
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MWOWOWOWOWOWOWOWOWO2H_P"% 7_9=>'_ /$"=?\ _O2;]]ZB/\\/_LL[%?\
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MV*WRDDWLLU/&/]@+P'V9GI+(+-@,S S6%+DQ4M<6TI4T<2W/UX_R0GWN&_\
M"=/M"DS'QD^06V*RM18=C=Q1;NJI)7+"BQ^[-AX2D,C'EDIPVQ9GL.-08@7)
MO[V$,]:TTTTQ:QEE>0@M<WD<L?H#SS[+A5Y0U%34U+<-45$T[7"@WED:0WN3
MSZO>I'OGMF;>.\-V;NJI&^YW3N7.[CJ [ZG$^;RE5DY@S D%_)4F_)%_?O<9
MI[_DGDG_  _/Y/\ Q3VWR5P_+"W^O<?[Q91[#FNWFQ!M);Z_4@?ZWY^GOWL5
M1D?[T[&KT=B^3PT22S>HEW^U!D2HOR6:HI$D4_DN&_P]C^,XO8/4V8C=O-G-
ML015%3J.J248]6FCK2#<NU7C8YD/Y,JM_A[VEXN_4_F@_P D3N_"9FL.;^1G
MP^P.$W5NLSU#U.5RT?5\%1G<5O\ <2&6JK:S>W4^-SE#,Y8RU&:IZMP-+(C>
M]@K)/]>;#^OY/_$GV52IK[WNUS_0<V_US?CZ^].#,[LN&O,%7G\FW^VO<^_>
MVZ:H^H4V_K?ZF_\ O7^]^T_55Q-_5_7Z?0>P>SVZRP=4D-N;DMR1^?SQ[][;
M6JGC=9(W>-T97C>-BD@=2"K1LI#(587!X(_'M@DR,E/(D\,TD,T,B313QNT<
ML4L;!HI(I$*NDB,H*D$$'Z>PBJM_Y3;N5Q^>P&8R.%SV$R%)E\-FL175.-RN
M(RV-J(ZS'93&9&CEAJZ#(4%9"DL,\3I)%*H96# 'W[VZ5U<FY$\TVB/<<:*O
MI72F>1> S >F/,1K_K"J L+2@"5US6:BWW%]Q4>.#>\$<<;-''ICWG&MD5F5
M!HBW5$EOP%R"BPM4A5J3%=S]SXG^8+B1N;<PQN#^>6#QN-QE;6XS&FDQWS=Q
MU(4HXJVMBHT%!B/EEB* +J;3#2]D4L(CC$>Z8X(-R^]H2:3DW/\ K_CD?C_
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MO+N4HMN[:H)'5E&2W+GZJFH*>XTB6H4M902 B[Z[EVK\?.G]_=Q;SF5,'L7
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M5L[SND*$GQT\.O1&@X1%"C@>[U/^$[_4-+NKY&]O]Q5T(GCZBZWQV!Q6H?\
M 3<7:.4K*>GKT-K^1=N;/RM/:]BM2W]!:YK^1%U;3;E[\[4[6K(A,G5W7]!A
M,;J_Y1<]V/DJJ""M0VOK7 ;4R4%OIIJ#_0>[E?Y%'5U/N3OKM/M6LB$R=7[
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MT[\F]RT&T>U<;#!B<'V/G*BGQVUNQ:>&..&B_CF5J)8Z7 [WE T2F?QTF1D
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M*RCJX9*:JI*JFD:&HIJFGF5)H*B"9"CHX#*P((!'OWOKWQ]Q_?O?)6*FX/\
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MJ%OZ!R/]X:P]RUKA;ZG_ %A_OC?VHH-YQ6'[I'T_M?['\GW[VMMHUS1TF\$
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M[>Q%$L4$4?:>!ER696DC5$9&W3MW([;W#D:ME4D5&0J*Z76UWU@:?=H'4/\
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M2^8W2%/28S9W=FY,CMZC"1Q;9WPE#OW#1TL?Z*&C&ZZ7*9'#4:GZ)CZBDM]
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M=^#S^/K,1GZ#,[QW9G-PQ4F<Q5?#35N,R>/PU=24LE/+%'+#X DBZPQ.X_\
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M9#_$?TX8B_\ L&]JRDW@P M-_L"?]\/]X]^]Y!4#\V_V!]RER''U8?[ &_\
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M8BW#+B@RG_$$$>PZS7\LKX"9]62N^*?4< >G:F)PN!DVVPC8L2ROMVKQ3I4
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MT>W),YA]X[NVO)78G&RU$V.AR-)@,S04%9441JY$2=XO.8BL;.R1QJA,._\
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M4"EN+WL/:AIOBO\ 'VE+F+K#!-K !^YGRU8!IO;0*S(SB,\\Z;7_ #[%+&_
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MQI+%C_N0V_0Y;ED"&_\ %8JRXLO / /(Y)/M6_[([\*O^\/_ (N?^D_]3_\
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M-5F<[M%86>, "1H7"LURC!;,87:7\@[?-3)"V^OD5M/#1!D:>':6Q<QN:21
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M1^ 7L/P![%*B^%_Q!H(!3P?%SX^R1AF8-6]/[!R4]V-R#59' U525'X!>P_
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M_L2]^_V3GXB?]XK_ !P_]$?UE_\ 8Q[]_LG?Q'_[Q9^.7_HD.L__ +&/?O\
M0CTQ_P ^BZP_] ':G_UI]A[F/Y:'P'SB".M^*/3T"B*:$'#[:3;SZ)P%<F7
M3XR0RJ!Z)"=<9Y0J?:&RO\O7X2YA E7\9^J85$4L5\5MY<$^F8 .3)A)L?(9
M0!Z')UQGE2#[0V4_E\_"C,($J_C3U7"HCEBOB]OK@WTS !R9,+-CY#( /2Y.
MM#RI!]L%7\;.AZY=,W5>ST 1T_R3&KCVLXLQU4#TS%Q^&OJ7\$>PMR/\F_\
MEM92=:BI^-%!%(D2PA<=V;W3AX"BN[@M38GL>BIGEU2&\C(7(L";*  WK_Y4
M'\O[)3+/4?'NAC=(A$%H.P^W,5"55G<%J?%[^HZ=Y;R&[E2Y%@38  .:_P#E
M2_ +)3+/4?'RAC=(A$%H.PNVL5"55G<%J?%[]HZ=Y;R&[E2Y%@38 !+U'P]^
M.-4XDEZVIU8($ I]R[SHTL"S7,5)N*"-GNWZB-1%A>P'M+P?R3/Y<M/E(<E'
MTIF62"OCKDQ<_:?9]5BV2*H%0M!-#4[LFJ*B@(7QLLDK.\?#.22?:;A_E _
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MEG8F[%Y'9FI"WAN_=/:&[JO<&<FGRN=SE8D%+24Z2R) DLQCH,/B:35*\5)
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M. 1$'GH'V[11N]K>0U>=61%N"WB)Y56'L)_AKMN7.=VXG(^-VIMJ8C-9RH8
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MS<\ZB75S_D4<)5@)I%]VL?#?I]MO[?F[3W)3L^Y-WPE<&*I"9\=MQWU_> N
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M1G<K$#<:IG84D;BS*$G4\,/::^#'5<8ARW;66IE:5Y*C;^TO(+F*-%T9W*Q
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M*>C@"Q1C\1H!^/= N[]T9/>VZ,[NS,R>3)9_)U.2J=))CB,\A,5+#JY6FHX
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M==3TD.*I*V/4G]WH\O44\!F!"U]=)%'&3#9IZQOE'W]-OG^,=<]=51J-J82
MUF]]QTK'[7)FFJX:>/'4U4FI/X*F2G@B\H(%95R1HA\5C-6#\IOD!-OK^,=<
M=<U1J-IX2 UF^-QTK$TF3--5P4T6.IJI-2?P2/)SP1>4$+65<D:(3%9IO>ZP
M55G94169V8*JJ"S,S&RJJBY+$G@>R JI8A5!9F(554$EB38  <DD^Z_E4L0J
M@LS$*JJ"2Q)L  .22??O>PAU9CMJ?$?XT8FJWQ4#&28_'_WBW6%6,Y');PSZ
M)4/@Z"G:2-:W)P6BQT !4-'2B1RJAW%TW7M#MWXV=#XVIW9.*!Z*B_CFXP%0
MUU=N;,JDSXFDA,B+55\-HZ&( J&2G#N54.PNLZ\H=N?&KH7&U.[9Q0/147\<
MW&%5#75VY\RJ3-B*.$R(M57P@14,0!4,E.'<JH=A[V]_%SN7??>6SL[O;=VT
M,;M;#R[DK*394F/>M/\ %,'3C1,U0:Z:9JR?'5BM ]9$L$%1*KJL,9B8%U^/
MO:&[^V]L9C=>Y=LT.WL9)G:FFVJ]$U4?XAB81HE:8U<LC54U#4@PO4QK%#-(
MKA8T,; NWQ[[1WAV[MC,;LW+MFAV[BY,[4TVU'HFJC_$<3"-$K3FKED-5-0U
M(,+U48BAFD5PL2&-@?>S-^Q\]C[[][][][][][][][][][][][][][][][][
M][][][][][][][][][][][][][][][][][][][][][][][][][][][][][][
M][][][][][][][][][][][][][][][][][][][][][][][][][][][][][][
M][][][][][][][][][][][][][][][][][][][][][][][][][][][][][][
M][][][][][][][][][][][][][][][][][][][][][][][][][][][3.]<?6
MY?9V[<5C6*9')[9SV/H'"HY6MK<554U*P23]MRL\BFS>D_GCVP[JHJK);8W'
MCJ%BM;7X',45&P5&*U55CZB"G8+)Z&(FD'#<'\^V#==%59+:^Y,=0L5KLA@,
MQ14;!48K556.J8*=@LGH8B:0<-P?S[][U89H9J>:6GJ(I()X)'AG@F1HIH9H
MF*212QN%>.2-U(92 018^]>B6*2&22&:-X9H7>*6*5&CDBDC8H\<B. R.C @
M@@$$>]>&6*2&22&:-X9H7>*6*5&CDBDC8H\<B. R.C @@@$$>_>[@>B_G5T]
MLKIO96U=WP[HIMR;1P,&!J*+%85*Z"OCQ0-/0U-#5OD(8+U=$L9<3-#IFUBV
MC2QLSZC^7?66U>L-J[>W+%N"#.;:P\.'GI,=BDK(:Q,</!23TE2];%#>II50
ML)6BTRZA^G2QLWZA^7O6.U.KMJ;=W-#N&#.[:P\6'GI,=BDK(:Q,<##23TE2
M];##>II50L)6BTRZA^G2Q][!/MOY>=K_ "0KFZKZ4VIF\+A<X'HZBDQI:MWC
MN*BD/CJ%RE71D46W\&T<@%4B2-&(]7FJ3"S( I[(^2W8W>=6W7G56W,MBL7E
M@U--34!:JW/FZ5SHF7(5-*12X7$,C@5"(Y0)?RSF)F3V%'9/R8['[UJVZ[ZI
MVYEL5BLN'IIJ:@+56Z,Y2.=$RY"II2*7"XAHW J$1R@2_EG,3,OOWLV_Q9^%
M>&ZB:AWSV$*+<79*A9\=2QVJ,'LURIL: N N2SBAO55LNB!N( "IFD,G\>_B
MMBNM32;MWK]IG-] +-14Z6GQ.UV(-C1E@!79< ^JI8:8CQ" 097,K\>?BIBN
MM#2;NWM]IG-]J%FHJ=+3XC:[$&QHRP"UV74'U5+#3$>(1<>5_>S\>SB^SD>_
M>_>_>_>_>_>_>_>_>_>_>_>_>]9#O?=M?OCN3LK<V1DD>:NWAFX:=)""U-C,
M9628O#T5U])%#BJ*&&X^NB_Y]T'=O[DK-V]H;[SU<[M+5[FRL4*N06@H*"J?
M'XRDN.#]ICJ6*.X^NF_N@?N#<E9N[M#?F?KG=I:S<^6B@60@M!CZ"J?'XRDN
M.#]ICJ6**X^NF_OWL:?CC\@MR=5;3W7L'K+8TF>[5[(SE!3X7.QG[QJ*GAH)
M:6BA@PB4TK9*NH*FHJ)H1(ZTZF8O*&1"CBIT=W1G>N]N;BV=L':,F8[#WSEZ
M.#%9=#]T:6&*CDIZ6*'$K3R-75='43S2Q!W6!3(6D#*A5A5Z,[JSO76V]Q[-
MV#M%\SV)OK+T<&*RZ'[IJ6&*CDIZ6*'$K3R-7U='43S2Q!W6%3*6D#*A5O>[
M-OBY\76ZL-3V5V34G<O=&YQ4U>4R575?Q,;:&3+25U%25S/**[-5GD(KJX,P
M:YAA/BUO.??X^_'YNO3/OO?<YSW:>?\ /4Y"OJ9_OQ@A7ZGJZ2FJV:0564JM
M9%75@D-<QQ'QZGE/W\>_CXW7AGWYON<Y[M3<'GJ<A7U-1]^,"*_4]724U6S2
M"KRM5K(JZL$AKF*(^/4\WO9T/9IO9J/?O?O?O?O?O>*H@AJH)J6IC2:GJ89(
M)X9!JCEAF1HY8W4\,DB,01^0?>.:&*HAE@GC66&>-X9HG&I)(I%*21NIX*NC
M$$?T]XYH8JB&6GGC66">*2&:)QJ22*52DD;C\JZ,01_0^_>]:/OSJ#+])=F[
M@V5D(IFQL=3)7[7R4BMX\OMFLED?%UB2$!7J(H@8*D"X2IBD4$@ FAWN/K/)
M=4;]S6U:R.4T"3O6;?KW5M&3P-3([8^I5R KS11CPS@7"5$;K<@ FA;N3K+)
M=3[^S6U*V.4T"3R5FWJ]U;1D\#4R.V/J5<@*\T<8\,X%PE1&ZW( )][V(\3V
M9LG)[!QW9+;EP='M*NP]+EY,U59.D@QU''/3)/+3U55-(D<%72NQBDB?3*DJ
ME&4."ON[7&[]VID-G4.^VSV)I=MU>,I\D^5J*^FAHJ5)H%ED@J*B21$AJ:=V
M,;QM:1)%*E0P(]W=XW?VT\ALVAWXV>Q-+MJKQE/DY,K49"FBH:5)H%ED@J*B
M5T2&IIW8QO$UI%D4H5# CW[W2S\Q/E,>\<U3[,V2]5'UOMZO::GE9)89]X9I
M ]/'F)J1D2:#'TZ2.E% X\A#M+(%=ECBJN^3OR%/;64@VMM1JB/8N%K#+#(R
MR13;FRBAH4R<M,RI+#10([+2Q.-9#&1P&94CJJ^3_P ACVYE8-K;4:ICV)A*
MPRPR,LD4VY\HH:%,I+3,J2PT4".RTD3C60YD<!F"1^]C_P##KX7U<%7C.V.X
ML1-1O1S4^0V;L?(Q&*I^YB*3TN?W+2/:2G%/( U-0R .7&N90H5'&7XP_%FI
MAJ:#L;L[&RTS4TL-;M?:==&8Y_/&5EI\SGJ9[/"(7 :"D<!RXUR@ !&&;XO_
M !7J8JG']C]H8R6E:EEAK=K[2KHS'/YXRLU/F<]3/9X1"X#04C@.7&N50 $;
MWNV7W8[[LA]^]^]^]^]^]^]^]^]^]UI_S)NQ1B=A;1ZTHZ@+6;OS,F>R\4<G
MK&#VX%%+#4Q W\-?FJR.6,G@O0M;Z>R'_.O>XQNS]M;#I9[5.YLH^8R<:.-0
MQ&#"BGBGC^OBK,K5)(A/U:D;^GLAGSNWP,;L[;.PJ6?35;FRCYC)QHXU#$8,
M**>*>/Z^*LRM4DB$_5J-OZ>_>Z951V#LJLRQJ'D*J2$0NL89R!95,CJMSQ<@
M?4^ZN0K,&*JS!%U.0"0BEE0,Q'"J7<"Y_) _/NK0*S!BJLP1=3D D(I94#,1
MPJEW N?R0/S[][V<>H.QMG]@];;9W1MK+XR;'KM_%KDH(:J /M^L@H8DK,7E
M(KHU!/031.A$BHK*FM+H58WY=9[XVSO38N!W!@LECY:)<-CQ70Q5$(;"U,5'
M&E5C\A%=3134<L;(0X4%5U+="&-_/66^=L;UV)@-P8')T$M$N%QXKX8JB$/A
M:J&CC2JQ^0BNIHIJ*6-D(<*"JZENA#'WLCGR^^9^W\9@,MUCU%FZ?-[BS$$^
M,W'N[$5"SXS;V.F41UE#ALA#JI\AF:V%FB::%FCHT+:6\]O$4KY+_*7"X_#9
M+8/6N6@RV;RD,U!G-RXV834&%HI5"5-)BZV/5#6Y2KB9HVEB9DIE)LWFMXRC
M_)KY486@PV2V!UGEH,MF\I#-09S<N-F$U!A:*50E328NMBU0UN4JXF:-I8F9
M*92;-YK>/WL"/B/\,,KONNQ/9':F+EQNP::2'(8;;=?$T5?O1T*34LU72RJ&
MIMK.;,Q<!ZU!I1?$_D(0?&SXM9'=]9CM\]AX^2@V= \5;B\'6QM'6;I9=,M-
M+44\BAH-O.;,2]FJU&E1XVU^P?\ C5\6,CO"LQN^NQ,?)0;-@>.MQ>"K8VCK
M-U,I62FEJ:>10U/MYSZF+V:K4:5'C;R>_>[K(XXXHTBB1(XHT6...-0D<<:
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M1[DZRV)\5^C=K2;;CIL')1;^W.:]_%4T$U54U&8J:JLIZ51@-OY&IK'DJ_\
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M''''&H5(XT4!41%      ]WR111PQQPPQI##"B1111(L<<4<:A$CC1 %1$4
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MQ^,&1B$>;.UJ>NQZ3T1(CJJG.Y:LKJ]\;A5#?N)&T?EOXSY2ZQGWM1?*;I_
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M#%S9'/Z#&VY,])%7Y9%8%72B*04]'C4=6*DT\,;NATNSCV.?5OQWZSZE=:[
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M[JCH/KSI^%I=N8^6MSLT1BJ]S9AXJO,31L!Y(*=XXH:;'TC$<QP1IK%O(SD
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M#EEFJ9I)I7>:>>5Y99')>26:5RSNS&[.\CL23]23[][V7?CYUVO5G3>P=EO
MM/D<?@J>LSJ^,)(=PY<MELVLK?KE-/D:R2%&;GQ1J.  !?%TMLD=>]7[-VL\
M(AK:+$05.770$<YK)ELCEA(?U.8:VJ>)2W/C11P  +Z>E=D+UYU=LW:KPB&M
MHL/!59== 5SF\F6R66$A_5(8:ZJ>)2W/CC4<  #WL9?8H^Q2]^]^]^]^]^]^
M]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^
M]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^
M]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^
M]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^
M]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^
M]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^
M]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^
M]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^
M]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^
M]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^
M]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^
M]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^
M]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^
M]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]U3?S'.Y\7)B\'TK@LA%59,Y.#
M<F]5I9DD&.IZ2GD&"PE9H+@5-;-5FL>(Z7B6"!C=91[KL^<7:6/?'XGJK$5L
M=17FOASNZA3RHXHH::%QB,55:=0$]5+4&J>,Z7C6&%N1(/=='SE[3Q[X_$=4
MX>MCJ*\U\.=W6M/*KBBAIH7&(Q55IU 3U4M2:IXSI>-886^D@]^]D,^+NS:/
M?W?_ %?MK(*LE!-N+^+UD#@&.JI=KX^MW1/1R@D7BK8L,8FMSI<VY]D]^/VU
MZ;>/<O7^!K0KT<N;_B55$_*5%/M^BJ]P34L@XO'51XLQM^;,;>R=?'S:U-O+
MN?K[ UJJ]'+G/XG51.+I44^WZ*KW#-2R"XO'51XLQM^=+&W/OWO9,]WJ^[W/
M?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O
M?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O
M?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O
M?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O
M?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O
M?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O
M?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O
M?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O
M?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O
M?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O
M?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O
M?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O
M?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O
M?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O?O=</R#Q?S@R&:WC
M-M#<='@>LQ631X.CV?$U1N5\1'$$AG9\%MW*;V%?.JL\JT\@59&(4:0GLC?=
M&/\ EG6Y7<\NV<Y2X?80J9$Q--MF,SYYL:D82.9GQ.#R&ZQ63*I>00/97:RB
MP7V1?NK'_+6MRNYY=LYREP^PA52IB:;;$9GSS8U(PD4S/B,)D-V"LF52\BP/
M97:RBP7W[W3WE,5X\GD$R6Y:";(K6U2Y"6K@W2*N2N$[BK>J%=@(JT5+5&KR
M>95DUWU &_NLG(8_17UJ5V=HY:Y:NH%9+4P[@%0]6)7^Y:H%9AHJL3F;5K\B
MA]5]0O?W6+D,?HKZU*[.T<M<M74"LEJ8=P"H>K$K_<M4"LPT56)S-JU^10^J
M^H7O[][=>N5WTG8&V4ZODR,V^TS,2[6EP8M5RY!=862$5:11BD>G#F;[E5A^
MW+^<"/6/;CL==W+O/ KU^];)N]<I&NWI,2+5,E:-85XA4I'&*9H=1E\ZK%X-
M7E 35[<MC+N]=Z8!>OWKI-X+E(UV])B!:IDK1K"O$*E(XQ3-#J,OG58O!J\H
M":O?O=ZWQ_W!\NJ[/3XKOS8NU,-MFGP=1/3;GQ]?@7S=;FTJJ&*FHIJ3;NZL
MQ0F.>EEGD9EHJ9%\?Z[E4:W?IG-?)2KS$V.[CVCMW%X&'$S34^?HJS#MEJO+
M)44D<%++38/<.3I#'+3R2N2*6!%T?KN0IM\Z7S7R6J\Q-CNY=H;<Q> @Q$\T
M&?HJS#OEJO+)44D<%++38/<64I"DM/)*Y(I:=%T?KN54^]FW]F2]F4]^]^]^
M]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^
M]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^
M]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^
M]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^
M]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^
M]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^
M]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^]^
/]^]^]^]^]^]^]^]^]__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>gubvrvugbnha000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gubvrvugbnha000001.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  # (0# 2(  A$! Q$!_\0
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M .:NBB@ _P"&V?VS/^CM_P!IS_P_7Q4_^:NC_AMG]LS_ *.W_:<_\/U\5/\
MYJZ** #_ (;9_;,_Z.W_ &G/_#]?%3_YJZ/^&V?VS/\ H[?]IS_P_7Q4_P#F
MKHHH /\ AMG]LS_H[?\ :<_\/U\5/_FKH_X;9_;,_P"CM_VG/_#]?%3_ .:N
MBB@ _P"&V?VS/^CM_P!IS_P_7Q4_^:NC_AMG]LS_ *.W_:<_\/U\5/\ YJZ*
<* #_ (;9_;,_Z.W_ &G/_#]?%3_YJZ*** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>gneflb3r2gmg000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gneflb3r2gmg000001.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  (! 0$! 0(! 0$" @(" @0# @("
M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_
MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P  1" "N =\# 2(  A$! Q$!_\0
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MG@>SM?A-X'B6T;5H_M>K/"3EH,[43.>C%6R/1?1C7!^ K2,JI(%?8<0<5XK
MYM]1PG*L1&*C6JQ7Q/1V5U;:W-*U[Z*R6OEX++:=7"^WJWY&VXQ?1=W^BVMK
MU/5]+^*7Q.U*7S?[2@CC_P"?>.S38/;D%OUKJ]/^(5Q=6$FC^)M-6WAN(FC-
MSIXV^6&&"=ISZYR/R-8?@G2()452%KK=3\.6L5CY@"_=KZ#)O[>EAG7]O*6F
MJDW)-=K/9>ECS<5+"*IR<B7IH5])\+^"/ACH<GBXLMY,J;H[IL9?/18QT&?7
MKUYQT\)^(&I:IXNUNXUW5Y-TTS?=7[J+V4>P'^<U[3X3ETR_OY/ _B"!;BUN
M/WMO'(WW9%Y(&.>1D]>Q]34/B_X@>!OAPDECX.\.6<VH+E6D2(!(V_VF^\Q!
M[ _B*Y\\R_!YIE%-^VAAL-"]XI-R=3KIIS.UK:WL]3;!UZF'Q+]UU*CV=[+E
M]>GF?/TWP=\<:I9R:H^B-964:AI+[5)%M80I. =TA&>HZ9->?^*=)\,Z0[10
MZBVJ3#!WV\;16X.>>7 =QV^ZGL37I/Q+\7^)_&U[]L\2:K)<;2?+BSB.,>BJ
M.!_,]R:\SU^ #=@5^"<00RVDW'"0;_O3M=^D5I'T;GY-'VV!EB):U6O1?JWJ
M_E8XO6/WD[.L21KD[4C7A1G./4_B2<=Z_1KX(?\ )%O"'_8KZ?\ ^DT=?G7J
MT>&-?HI\$>/@OX1'_4KZ?_Z31U^@^ [?]JXV_P#)'_TH\;C3_=:/J_R.HHHH
MK^FC\\"BBB@ KY+_ ."T'[4'_#-W[$6NV&BZB\&O^.6_X1[1VA*[D292;J7D
MY %NLBAARKRQ].H^M*_$[_@M)\9=;_:\_;_T3]F#X:7*WT'A6Z@\.:9%&25E
MUB[EC%P>G4/Y,)'8P-ZU%27+$NFKR/J3_@WA_9Q_X0+]FO7/VA]9L(UOO'NK
M&#3)MP9AIUFSQ _[!:X-QD=Q'&?2OAS_ (+;?L_)\"OV]?$6J:9;JFF>.;:+
MQ)9A(R LDQ9+E2<8+&XBEDXZ"5<\U^Y'P4^%7A[X'_"3PS\(/"D2+I_AG0[;
M3K5EB">:(HU0R,!_$Y!=CU+,2222:^(_^#A[X O\0/V6=#^.>FPR-=^ -<VW
M6U?E%C?&.&1CWR)TM<=L,U3*/[LJ,OWA^<__  2D_:,/[,_[<G@SQ=?ZE]GT
M?6KO^P?$!V@J;6[(0,WHJ3>3*2.<1=^0?Z&T;<,XK^5E'>-Q)&Q5E.59>H-?
MT>_\$\OVBO\ AJ;]CKP/\8;NYEEU*ZT=;/7FG*[VU"V)M[ASCH'DC,@[[9%S
M2I2Z#JKJ>U4445L8A1110 5^#/\ P79_Y20>*_\ L#Z3_P"D45?O-7X,_P#!
M=G_E)!XK_P"P/I/_ *115G5^$UH_$SPS]B3_ )/.^$7_ &4_0/\ TXP5_2S7
M\TW[$G_)YWPB_P"RGZ!_Z<8*_I9J:/4=;H%%%<7\?OCU\-/V:OA1J_QD^+&O
MKI^CZ/;-)*<CS+B3'R01*2-\KMA57/)/) R1L8GXN?\ !>_X@1^-/^"AFJ:!
M$V[_ (17PQIFE,<=VC:\(Z<_\??OSQVP/D[X4?#?Q+\8OB;X?^%/@ZR:XU3Q
M%K%OI]C$O>260("3T &<DG@ $G@5I_M ?&3Q1^T?\<_$_P :O$Z.VH>*-;FO
M/L^\R>2KMB*!3C)6./9&O'1!7ZK_ /!%G_@E=KWP(GA_:R_:,T)[3Q9=6C1^
M$_#=U#B31X9%VO<S@\K<.A**G'EHS;LL^V/FMSR.J_)$_1;2=-L]&TRWTC3H
M?+M[6%8;>/<3M15"J,GDX [\U8HI&8+UKI.4_'+_ (.(?VH+SQE\<M!_98T+
M4!_9?@VQ74M;CCF;]YJ5RF8TD7[I\NVV,IZ_Z5(*_.S3--O]9U*WT?2[5I[J
M[G2&WAC&6DD9@JJ/<D@5Z/\ MJ?%&X^-/[6WQ&^)TTC,FJ^,+Y[3=U6V29HX
M%/TB1%_"NJ_X)A?#S3_BE^W]\*_"6JQ[[=?%,>H21E=P<6:/=[2.X)@P?8FN
M5^](ZE[L3]Z?V2?V?]$_9>_9O\'? K0X85_X1_18HKZ2!F9;B\;]Y=3 MS^\
MG>1\=!NP   !Z/2+TI:ZCE"BBB@ HHHH *A%E:K<M>+!&)F4*TH0;BH/ SZ<
MU-10 4444 %%%% 'S;_P5A_::?\ 9<_8B\5^+=*O9+?6]>C'A_P[)']Y+NZ1
MP9 ?X62%9Y0?[T8'>OF7_@W*_9Q'AOX5^+OVH-<TO;=>);X:-H,[YW"RMSNG
M9>VV2<JISSFU[=_#_P#@O;\?=3^/7[7?AW]E?P"?ML7@Z..V:WMF9C<:Q?&,
MF/ .UBD?V=!QE6>49[#]7OV7O@9H_P"S5^SYX/\ @7H?D-'X:T."TN)[:+8E
MS<[=T\^WL9)C)(>^7-9_%4]#3X:?J?CC_P %[/V>F^#_ .VW-\2=,A8:7\1-
M)BU5"MJ(XX[R("WN8@1P['9',QX.;GGU/A__  3L_:+/[+7[8_@?XM7FHM;Z
M5%JRV7B!ADJ=/N/W,Y8?Q!%?S /[T:]Q7ZK_ /!?C]GT_%C]B\?%'2K)I=3^
M'FL1ZA^[CW,;&<B"X7U !:&5CV6 YXY'X>5E/W9&L/>B?U4!L\BBOG3_ ()3
M_M%#]I?]AOP7XQOKV2?5]'L1H6OR37'FR-=V@$?F.W4M)'Y4QSS^][]3]%UT
MIW5SG>CL%%%% C\SO#UOX>>%7OM4O(YOXDAL$=1SQ@F52>/85Z'X6TKX6.JF
MY\;:VC;ONKX<B/''?[5_2O+=*;GFNNT"7!45_ &5XJC1K+FHQEZN?Z21^W8J
MG.4=)->EOU3/=/!'A?X#W!4ZC\2=37I\CZ48C^8\P"O5?"G@OX$OM_L[7([Q
MOX5N;_:Q_P" C;G\J^;O#"SW4T=M:P-))(P$<<:[F8^@ ZFO>/AI\#-6GC35
M/&;-9P_>%FI'FL/]H_P#VZ_2OW?@O%5,=55/#Y;2G;=VE9>LI2DE]WHF?$YM
M3C1BY3KR7EIKZ))'A_[5^I7@_:1U2WNMWE6]M:1VF3QY?D(W'MO9ZF\":LBJ
MHW5TG[>/@"5-2TOXOZ"XN+1(5TS5#"0RP,K%HF)!S\V]E.>FU?[PKR/PEXI\
MH*-]?!\3>WR7CC&0K_;FYQ?1QF^96?5*_+ZIK='MX#DQ>3TG#I%)^JT?^?S/
MI;PAXG2!%_>#BNFO_&RR6NPRCIZUX+H?C<(@_>8K3F\> QX\[]:^QP/%KHX7
MD4CQJV5<U6[1Z#H6O/<?$+2DA;YFOD'X$\_IFNQ\:>$/@W/<SW6OZK#:7$DC
M--Y5]\Y8G).WG'/M7G?[/%A+XE\7R>,;XK'I^DJ?W\IVJT[C:JY/!P"3[';Z
MBNP^)GP6O-8\[7O!USYTDS&22TED'SDG)*,>.O."?Q[5]?DJQV(X9J8J.%C7
MYIN2C+5\J27-%;N[36COII<\W%>QIYA&DZCA9)-KOO9_(\^\;>%/@#$&-A\2
M]2W?\\UT\S?KM0?K7E?BG2?A2BNUMXWUQF_A4^'8L'\?M7]*U_%UM?:5=R6&
MIV<EO-$</#-&58?4&N"U^4'=7XSQ%FF'JSE?!TX/:R]HK/T]IO\ +Y'UF P]
M2,5:K)^O*_\ VTPO$=KX503?8=9U"5AGRA+IJ(&^I$S8_(U^@/P1_P"2,>$?
M^Q7T_P#])HZ_.S5GRQ(K]$_@B<_!?PB?^I7T_P#])HZ^R\"I1J9QC7&*7N1V
MO_,^[9YG&2<<'1N[ZO\ (ZBBBBOZ8/SX***#0!Y[^U9\>=&_9B_9W\7?'?7$
M62/PWHLEQ;V[/M%Q<G"00Y[;YFC3/.-W>OR4_P""%/P5\2?M'_MRZQ^TQ\0K
MF[U)?!\-QJ]_J=PP8W>L7S2)&9">68AKJ;(Z/$N>O/LO_!QK^T\MIH?@_P#9
M(\/WR^=>R?\ "1>)$56W+"A>&TCSG:0S_:'92"08HCP",^0_LB?\$H?^"GFK
M?!71_BM\ ?VF=)\!:/XTT^'58]+M_'&K:?/+$ZYADF2TMFC+-&0R_,Q"N <'
M(&,GS3]#:*M#U/VF'2N3^/'PET3X\_!;Q5\&?$<C1V?B?0;K39IE7+0^;&RB
M1<_Q(Q##W45^:O\ PZK_ ."V7_20VW_\.MXB_P#D2C_AU7_P6R_Z2&V__AUO
M$7_R)5<S[$\J[GY?^,?"?B'P#XMU3P-XMTR6QU71=1FL=2LYEP\%Q%(8Y(V'
M8AE(/TK]./\ @W _:(^RZIXZ_99U:[55NHU\2:&KR8_>+Y=O=* >I*_9F ':
M-S]/BG]OK]C/]HO]CGXK6NG?M'^)['Q!JWBNSDU9?$6FZE<WB7LAE990\MS%
M'(TP;#/D'B5#DY.,']AW]H*X_9;_ &L/ _QO$_EVFD:W&FL9C+9L)@8+H8'4
M^3)(5]&"GM6,?=D;2]Z)_2E14=K=6U[;1W=G<1S12QAXY(V#*ZD9!!'!!'>I
M*ZCE"BBB@ K\&?\ @NS_ ,I(/%?_ &!])_\ 2**OWFK\&?\ @NS_ ,I(/%?_
M &!])_\ 2**LZOPFM'XF?,/P:\9>)_AU\8/"GQ!\$Z,NI:UH7B2QU'2-/D@>
M5;JZAN$DBB*1D.X9U5=JD,<X!!K](+G_ (+_ '[7W@.&.Y^*_P"Q38VD:_+-
M)(NH:>K-CC!F1]O4<'.?;-?!7[$G_)YWPB_[*?H'_IQ@K^E#5=(TO6],N-&U
MG38+RSNH6ANK6ZA62.:-AAD=6!#*02"",$&LZ<9/9EU)16Z/QP\=?\''?[4^
ML126_P /_@UX)T,/N"S7PNKZ6,9XP?-C3('<H0?0=OGW2OB'^T?_ ,%6OVH/
M#/PQ^//[2-K9SZQ?-!I4VN9ATZQ)49CM[:!1&)G5 JCY3*X16DW,#7OW_!;#
M_@F+HG[.FJQ_M0_L_>%Q9^"]8O/)\2:+90XAT2\<_))&H_U=O*25"@!(WVJ,
M"1$7\^M,U/4M%U*WUG1]0FM+RTG2:UNK:4QR0R*0RNK+@JP(!!!R",TI<U[,
MJ/+:Z/WS_8E_X)!?LN?L:WEKXU33Y?&/C*W4-'XG\00IBUD_O6MN,K;G_:)>
M0<X?!(KZMVKZ5\R?\$KOV[]/_;B_9SM]7\07<,?C;PSY>G^,+-2BF67;^[O%
M0'(CF4$] !(DJ@84$_3F:WCR\NASRYKZA37Z9IU-?G'%42?RPZQ/-<ZO=7-P
M?WDEQ(TF?[Q8DU]6?\$/((IO^"E_@!Y$!,=KK#1^Q_LJZ&?R)KYU^.G@F^^&
MOQL\8?#K4X&CN-!\4:AI\T;8X:&X>,]/]WMQ7M'_  2$\76G@K_@H]\+=6OK
MM88[C5[FPW,>&>ZLKBV1?J7E4#W(KEC\2.J7PL_H6 QT%%"G(HKJ.4**** "
MBBB@ HHHH **** "N1^//Q?\.? #X,^)OC7XNW-I_AC1;C4+B&.15>?RT)6%
M"W&]VVHN>K,!77&OS8_X.*?VGU\*?"+PW^RIH&I+]N\5W8U;Q!"I.Y-/MW_<
M*W;$EP-P[YM#TSS,I<L;E17-*Q\R?\$>/A=XK_;(_P""C]U^T+\2$FOH_#EU
M=>+-<O6M\Q2:E+*?LT9/1&\YVF0#M;,  !D?N$O Q7XD_L4?\$K_ /@I1XP^
M"NF_'+]G/]HS2_A_I?C2U6Y^PKXRU73;JXBCDD2)YEM+9D8$;G3YV^27/!8B
MO8/^'5?_  6R_P"DAMO_ .'6\1?_ ")6<+QCL:32E+<_3OXD^ ?#?Q4^'NN_
M#+QA;/-I/B+1[G3-2CC?:S6\\312 'L=K'![&OYDOBO\./$7P>^)WB#X4^+;
M8PZEX<UFYTZ^0_\ /2&1D)'J#C((X(((K],O^'57_!;+_I(;;_\ AUO$7_R)
M7QG_ ,%#/V(?VH?V/O'FE:Q^T[XUT_Q1J'C2&:ZA\1Z?K%S?&YDA*)(DLES%
M'(9%#Q'D$%77#$@@*I>6MAT[1TN?47_!N9^T:/#/Q;\7?LQZW?1I;>)]/76-
M$66?;_IMM\LL2+_$TD#[SW"VG?M^P%?S*_LL_'#5?V;/VBO!OQSTAFW^&]>A
MNKB-%R9K;.R>+_@<+2)_P*OZ7] UW2/$^AV7B3P_J$=U8ZA:1W-C=0ME9H9%
M#(X]BI!'UJZ3]VQ%5>]<MT445H9GY<Z4)I)Q%!$SL>BJN37;>%H-$MW6;Q!J
MS1JNT_9[*,22,#SUR$7WY)!_A/-<#&Y1LULZ5>$;3NK_ #SHUHX>LIN-_6]O
MPM^=O(_=JU-SCO8]U\*_&7_A%+7['\._"]GI;'&[4K@?:KQQWR[@( >X5%%:
MT/CKQ9XKN575=<O+R29P%A:5F!8] JCC\ *\=T74\*HW5[3\.M1T3X4Z9#XX
M\50+<:Q=0A]#TA^/+0]+F7^Z"/NCJ1R.H8?IV19IC\UY:-:OR4(ZRZ0BNK4(
MV3D]DDKR=EYGS.-PU'#WG&%YO;JV_5ZV_!(]ETSPAX3\*?#2XT;XB^3+#JD1
M74+69LJ^1_JU Y) [CG/.>!CY[\>?L6>+[0CQ1\$+S^VM(N27AL;J4174 _N
MY?:L@&",Y!Z<'K6QJGQ$USQAJIU77=0::5N$3HL8_NJ.P_R>:]B^(?C%?AQX
M*T_P=976W4)+1$=T/,: 89_4$MD#\>XK]&Q,.%>+\OJK$T7"AA8)0FG:K=O1
M7UC[S3?*U)7UN>#3EF65UH^SE>=1ZIZQLO+?3NFCY/M?AW\;K*4VTOPI\1[E
M;'RZ/,1^87!KTGP%^S!\3=<7^U_B&1X?TJ&/SK@R.)+AHQR0J*3M. ?O8(_N
MGI7N?ASQI,_P7G\1WNHR27$%O,GGLYW>9N(3)]>5K/\ @O\ $=?$AG\&^(+H
MW$SJSV[S-N,J'[R$GKCK]"?2N/*^ >%<+C\-3KXBI4]M!3A&348W>T9\NKN[
MK1QU5NIKB,\S*I1J.%.,>5V;5V_-J^GWW-+1?#/@'Q%\.6\%^!)E@AMAF-=Q
MWI+V9P>3N.<DY]N@QXKJ_B#Q7X*U2:Q@U*\T^YMY2LD<-PRX8?0X(_0BDU'Q
M#K?@;Q-.+&_DM[RPN'BW1GNI((]P<=#P:O>+_$6D?'#2OM=E#':^++2+YK2/
M[FIQ*,GR\_\ +0#D+U(! SQB,VS;#YQAXPHQ]CBJ*Y5&.BG%?9CVG'I'JM$V
M[(,+A:F%J-S?/3GJV]6F^K[I]^G7N<]XB^.&J>(++^S/'^A6.N19Q'/-%Y-S
M"/1)8\8]>0PSU!Z5YCXJC\-7\C2>'-3EAW, MGJ6 PSZ2K\C#U+"/J.#1K6I
MD%@6YKE=5O<[CNK\<SO/L5CM,2_:/O+XO_ OB?DI-I=CZO!X.G1_AKE\EM]V
MWW6,W5_.C?9-$R[ERNY<9'K[BOT:^"'_ "1;PA_V*^G_ /I-'7YMW$ADDSFO
MTD^"&1\%_"((_P"97T__ -)HZ_4/ ?\ Y&F,_P $?_2CP>-=,+1]7^1U%%%%
M?TT?G85#J6I:?H^G7&KZO?0VMK:PM-=75Q($CAC4$L[,>%4 $DG@ 5-7QM_P
M7$_:;_X4!^Q3JG@W1=1$.N?$28Z#9J%!86;+F]?!_A\G]UGJ#<*1ZA2?*KCB
MN9V/RX\3ZGXB_P""H_\ P4VV6TMS';>._&26UG\NY['1H1C=MZ9CM(3(P& 6
M#'C)-?T#Z1H^E^']+MM#T/3X;.RL[=(+.TMHPD<,2*%5%4<*H4  #@ 8K\E/
M^#<K]F^76_B'XQ_:FUS3Y?LNAV:Z#H,TD0\N2ZFVRW+*W4/'$L2\?PW1K]=*
MBFM+EU'K8****T,SX/\ ^#@7]GB/XI?L?6OQDTK2XY-6^'>L1W,EQD^8-.N2
M(+A% X/[TVLAST6)B,<Y_$>OZB/BO\.- ^,'PS\0?"OQ7"LFF^(]%N=-OE*Y
MQ'-$T;$>X#9!Z@@&OYD?B1X#U[X6?$/7OAEXIC1=3\.ZU=:9J*QME1/!*T4F
M#W&Y#BL*J]ZYT4G[MC][O^"/?[1H_:/_ &%/">IZEJ37&M>%4;PYKC2+@^;:
MA1"<_P 1:V>W8MW9F[@U]05^-/\ P;L?M%'P1^T1XC_9UUB]D^Q^-M'^V:5$
MTGRKJ%F&<A5Z O;M,2PY/D(#GC'[+ Y&:UIN\3*HK2"BBBJ("OP9_P""[/\
MRD@\5_\ 8'TG_P!(HJ_>:OP9_P""[/\ RD@\5_\ 8'TG_P!(HJSJ_":T?B9X
M9^Q)_P GG?"+_LI^@?\ IQ@K^EFOYIOV)/\ D\[X1?\ 93] _P#3C!7]+-31
MZCK=#G_BI\,?!GQH^'.M?"GXAZ.E_HGB#39;+4K63^*-UQD'^%@<,K#E6 (P
M0#7\XO[8?[,'C3]CW]H3Q!\"?&BM(VF7/F:7J!3:NH6+Y,%RN,CYD^\ 3M<.
MI.5-?TM5\3_\%LOV$6_:F_9[/Q:\ :0LOC?P!;RW=LD,>9-1TT M<6O4990/
M.3AB61D49ER*J1YE<FG+E=C\F?V _P!LCQ3^Q!^T;I/Q?TD7%UH\C?8_%6CP
MM_Q_Z>Y'F*!N4&1.)(R2 '1<_*6!_HH\">-_"OQ*\&:7\0? VMPZEH^M6,=Y
MIM];MN2>&10RL/P/0\@\'FOY;:_3[_@@5^W^V@ZS_P ,/_%/5_\ 0=0EDNO
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M3W'PLUNXATV^,FF>,/ LLEY&C1D,MPKP?OK;!P5:5(SD<<BL?>ILV]VH?T+
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MM^&_A[P+_P $Z_"_B#1P6NO%FJ:EJVK2%L@SBZDM% ] (K6(8_O!CWK\;?\
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M</)U-?HA_P ,P?L_?]$FT?\ \!__ *]"_LQ?L_JP8?";1^/6VS_6E_Q G/\
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M?\$KO^">?B&Y:[O_ -E#PK&S-N*V-O):KT[+"ZJ![ 8KZ HI<J'S2/%?"/\
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M%6GW+++JL_VS4%5NMO&<(I'HTGS?6&L/X3?%WPC^R-\!M-L)--DU7QAXJ/\
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M'&W55D0, ??!KX<\33W_ .V5^UHNGZ8[_P!DM<"WAE5B?)TV DM(#M^4O\[
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MX4OO!?@6QN/.DDUJ'9=WD@XW"+KD!B%'W!\Q+,<*,:;Y8:;FU1<TU?9'#?\
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M@HHHH *-H]*** #:/2C ]*** "C&>U%% !@9SBBBB@ HP#SBBB@ HP/2BB@
HP!VHP/2BB@   Z4444 &T>E&T>E%% !@>E'2BB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>9
<FILENAME>abio-20210331.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Instance Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-05-10T20:34:29.4323035+00:00 -->
<!-- Version            : 5.0.1.615 -->
<!-- Package ID         : beedb4a101e74518954371bca82a94aa -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xbrli:xbrl xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:dei-ent-std="http://xbrl.sec.gov/dei-ent-std/2020-01-31" xmlns:dei-std="http://xbrl.sec.gov/dei-std/2020-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:abio="http://www.arcabiopharma.com/20210331" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:schemaRef xlink:type="simple" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xlink:href="abio-20210331.xsd" />
  <xbrli:unit id="U_xbrlishares">
    <xbrli:measure>xbrli:shares</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U_iso4217USD">
    <xbrli:measure>iso4217:USD</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U_iso4217USD_xbrlishares">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:USD</xbrli:measure>
      </xbrli:unitNumerator>
      <xbrli:unitDenominator>
        <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>
  <xbrli:unit id="U_utrsqft">
    <xbrli:measure>utr:sqft</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U_xbrlipure">
    <xbrli:measure>xbrli:pure</xbrli:measure>
  </xbrli:unit>
  <xbrli:context id="C_0000907654_20210101_20210331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0000907654_20210510">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-05-10</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0000907654_20210331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0000907654_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0000907654_20200101_20200331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0000907654_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20200331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20200331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0000907654_20200331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200401_20200630">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200401_20200630">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0000907654_20200401_20200630">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200401_20200630">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200630">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200630">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200630">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0000907654_20200630">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200701_20200930">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-07-01</xbrli:startDate>
      <xbrli:endDate>2020-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200701_20200930">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-07-01</xbrli:startDate>
      <xbrli:endDate>2020-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0000907654_20200701_20200930">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-07-01</xbrli:startDate>
      <xbrli:endDate>2020-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200701_20200930">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-07-01</xbrli:startDate>
      <xbrli:endDate>2020-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200930">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200930">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200930">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0000907654_20200930">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201001_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-10-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201001_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-10-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0000907654_20201001_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-10-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201001_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-10-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20210331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210101_20210331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0000907654_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapStockOptionMember_20210101_20210331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0000907654_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapStockOptionMember_20200101_20200331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0000907654_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapWarrantMember_20210101_20210331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0000907654_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapWarrantMember_20200101_20200331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0000907654_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0000907654_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0000907654_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20210101_20210331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0000907654_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20210101_20210331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0000907654_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20210101_20210331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0000907654_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapSoftwareAndSoftwareDevelopmentCostsMember_20210101_20210331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0000907654_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20210331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0000907654_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0000907654_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20210331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0000907654_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0000907654_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20210331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0000907654_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0000907654_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapSoftwareAndSoftwareDevelopmentCostsMember_20210331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0000907654_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapSoftwareAndSoftwareDevelopmentCostsMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0000907654_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_srtChiefExecutiveOfficerMember_20210101_20210331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0000907654_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_srtChiefExecutiveOfficerMember_20200101_20200331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0000907654_20130801">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-08-01</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0000907654_20200829">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-08-29</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0000907654_20200828_20200829">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-08-28</xbrli:startDate>
      <xbrli:endDate>2020-08-29</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0000907654_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20210101_20210331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0000907654_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20200101_20200331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0000907654_us-gaapSubsidiarySaleOfStockAxis_abioDirectOfferingMember_20200603_20200603">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">abio:DirectOfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-06-03</xbrli:startDate>
      <xbrli:endDate>2020-06-03</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0000907654_us-gaapSubsidiarySaleOfStockAxis_abioDirectOfferingMember_20200603">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">abio:DirectOfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-06-03</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0000907654_deiLegalEntityAxis_abioJonesTradingInstitutionalServicesLLCMember_us-gaapTypeOfArrangementAxis_abioCapitalOnDemandSalesAgreementMember_20170111">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:CapitalOnDemandSalesAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">abio:JonesTradingInstitutionalServicesLLCMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-01-11</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0000907654_deiLegalEntityAxis_abioJonesTradingInstitutionalServicesLLCMember_us-gaapTypeOfArrangementAxis_abioCapitalOnDemandSalesAgreementMember_20200714">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:CapitalOnDemandSalesAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">abio:JonesTradingInstitutionalServicesLLCMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-07-14</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0000907654_deiLegalEntityAxis_abioJonesTradingInstitutionalServicesLLCMember_20170111">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">abio:JonesTradingInstitutionalServicesLLCMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-01-11</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0000907654_us-gaapTypeOfArrangementAxis_abioCapitalOnDemandSalesAgreementMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:CapitalOnDemandSalesAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0000907654_us-gaapTypeOfArrangementAxis_abioCapitalOnDemandSalesAgreementMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:CapitalOnDemandSalesAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0000907654_us-gaapTypeOfArrangementAxis_abioNewCapitalOnDemandSalesAgreementMember_20200722">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:NewCapitalOnDemandSalesAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-07-22</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0000907654_us-gaapTypeOfArrangementAxis_abioNewCapitalOnDemandSalesAgreementMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:NewCapitalOnDemandSalesAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0000907654_us-gaapTypeOfArrangementAxis_abioNewCapitalOnDemandSalesAgreementMember_20210101_20210331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:NewCapitalOnDemandSalesAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0000907654_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_abioNewCapitalOnDemandSalesAgreementMember_20210430">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:NewCapitalOnDemandSalesAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-04-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0000907654_us-gaapClassOfWarrantOrRightAxis_abioWarrantExpirationTwoThousandAndTwentyTwoMember_20210101_20210331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">abio:WarrantExpirationTwoThousandAndTwentyTwoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0000907654_us-gaapClassOfWarrantOrRightAxis_abioWarrantExpirationTwoThousandAndTwentyTwoMember_20210331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">abio:WarrantExpirationTwoThousandAndTwentyTwoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0000907654_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210101_20210331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0000907654_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20200331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0000907654_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <dei:EntityRegistrantName id="F_000000" contextRef="C_0000907654_20210101_20210331">ARCA Biopharma, Inc.</dei:EntityRegistrantName>
  <dei:EntityCentralIndexKey id="F_000001" contextRef="C_0000907654_20210101_20210331">0000907654</dei:EntityCentralIndexKey>
  <dei:EntityCurrentReportingStatus id="F_000002" contextRef="C_0000907654_20210101_20210331">Yes</dei:EntityCurrentReportingStatus>
  <dei:DocumentType id="F_000003" contextRef="C_0000907654_20210101_20210331">10-Q</dei:DocumentType>
  <dei:AmendmentFlag id="F_000004" contextRef="C_0000907654_20210101_20210331">false</dei:AmendmentFlag>
  <dei:DocumentPeriodEndDate id="F_000005" contextRef="C_0000907654_20210101_20210331">2021-03-31</dei:DocumentPeriodEndDate>
  <dei:DocumentFiscalPeriodFocus id="F_000006" contextRef="C_0000907654_20210101_20210331">Q1</dei:DocumentFiscalPeriodFocus>
  <dei:TradingSymbol id="F_000007" contextRef="C_0000907654_20210101_20210331">ABIO</dei:TradingSymbol>
  <dei:DocumentFiscalYearFocus id="F_000008" contextRef="C_0000907654_20210101_20210331">2021</dei:DocumentFiscalYearFocus>
  <dei:CurrentFiscalYearEndDate id="F_000009" contextRef="C_0000907654_20210101_20210331">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:EntityFilerCategory id="F_000010" contextRef="C_0000907654_20210101_20210331">Non-accelerated Filer</dei:EntityFilerCategory>
  <dei:EntitySmallBusiness id="F_000011" contextRef="C_0000907654_20210101_20210331">true</dei:EntitySmallBusiness>
  <dei:EntityEmergingGrowthCompany id="F_000012" contextRef="C_0000907654_20210101_20210331">false</dei:EntityEmergingGrowthCompany>
  <dei:EntityCommonStockSharesOutstanding id="F_000013" contextRef="C_0000907654_20210510" decimals="INF" unitRef="U_xbrlishares">14410143</dei:EntityCommonStockSharesOutstanding>
  <dei:EntityShellCompany id="F_000014" contextRef="C_0000907654_20210101_20210331">false</dei:EntityShellCompany>
  <dei:EntityFileNumber id="F_000015" contextRef="C_0000907654_20210101_20210331">000-22873</dei:EntityFileNumber>
  <dei:EntityTaxIdentificationNumber id="F_000016" contextRef="C_0000907654_20210101_20210331">36-3855489</dei:EntityTaxIdentificationNumber>
  <dei:EntityAddressAddressLine1 id="F_000017" contextRef="C_0000907654_20210101_20210331">10170 Church Ranch Way</dei:EntityAddressAddressLine1>
  <dei:EntityAddressAddressLine2 id="F_000018" contextRef="C_0000907654_20210101_20210331">Suite 100</dei:EntityAddressAddressLine2>
  <dei:EntityAddressCityOrTown id="F_000019" contextRef="C_0000907654_20210101_20210331">Westminster</dei:EntityAddressCityOrTown>
  <dei:EntityAddressStateOrProvince id="F_000020" contextRef="C_0000907654_20210101_20210331">CO</dei:EntityAddressStateOrProvince>
  <dei:EntityAddressPostalZipCode id="F_000021" contextRef="C_0000907654_20210101_20210331">80021</dei:EntityAddressPostalZipCode>
  <dei:CityAreaCode id="F_000022" contextRef="C_0000907654_20210101_20210331">720</dei:CityAreaCode>
  <dei:LocalPhoneNumber id="F_000023" contextRef="C_0000907654_20210101_20210331">940-2200</dei:LocalPhoneNumber>
  <dei:DocumentQuarterlyReport id="F_000024" contextRef="C_0000907654_20210101_20210331">true</dei:DocumentQuarterlyReport>
  <dei:DocumentTransitionReport id="F_000025" contextRef="C_0000907654_20210101_20210331">false</dei:DocumentTransitionReport>
  <dei:Security12bTitle id="F_000026" contextRef="C_0000907654_20210101_20210331">Common Stock, par value $0.001 per share</dei:Security12bTitle>
  <dei:SecurityExchangeName id="F_000027" contextRef="C_0000907654_20210101_20210331">NASDAQ</dei:SecurityExchangeName>
  <dei:EntityIncorporationStateCountryCode id="F_000028" contextRef="C_0000907654_20210101_20210331">DE</dei:EntityIncorporationStateCountryCode>
  <dei:EntityInteractiveDataCurrent id="F_000029" contextRef="C_0000907654_20210101_20210331">Yes</dei:EntityInteractiveDataCurrent>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="F_000030" contextRef="C_0000907654_20210331" decimals="-3" unitRef="U_iso4217USD">66933000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="F_000031" contextRef="C_0000907654_20201231" decimals="-3" unitRef="U_iso4217USD">49071000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:OtherAssetsCurrent id="F_000032" contextRef="C_0000907654_20210331" decimals="-3" unitRef="U_iso4217USD">1797000</us-gaap:OtherAssetsCurrent>
  <us-gaap:OtherAssetsCurrent id="F_000033" contextRef="C_0000907654_20201231" decimals="-3" unitRef="U_iso4217USD">897000</us-gaap:OtherAssetsCurrent>
  <us-gaap:AssetsCurrent id="F_000034" contextRef="C_0000907654_20210331" decimals="-3" unitRef="U_iso4217USD">68730000</us-gaap:AssetsCurrent>
  <us-gaap:AssetsCurrent id="F_000035" contextRef="C_0000907654_20201231" decimals="-3" unitRef="U_iso4217USD">49968000</us-gaap:AssetsCurrent>
  <us-gaap:OperatingLeaseRightOfUseAsset id="F_000036" contextRef="C_0000907654_20210331" decimals="-3" unitRef="U_iso4217USD">414000</us-gaap:OperatingLeaseRightOfUseAsset>
  <us-gaap:OperatingLeaseRightOfUseAsset id="F_000037" contextRef="C_0000907654_20201231" decimals="-3" unitRef="U_iso4217USD">428000</us-gaap:OperatingLeaseRightOfUseAsset>
  <us-gaap:PropertyPlantAndEquipmentNet id="F_000038" contextRef="C_0000907654_20210331" decimals="-3" unitRef="U_iso4217USD">27000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet id="F_000039" contextRef="C_0000907654_20201231" decimals="-3" unitRef="U_iso4217USD">21000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:OtherAssetsNoncurrent id="F_000040" contextRef="C_0000907654_20210331" decimals="-3" unitRef="U_iso4217USD">12000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:OtherAssetsNoncurrent id="F_000041" contextRef="C_0000907654_20201231" decimals="-3" unitRef="U_iso4217USD">12000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:Assets id="F_000042" contextRef="C_0000907654_20210331" decimals="-3" unitRef="U_iso4217USD">69183000</us-gaap:Assets>
  <us-gaap:Assets id="F_000043" contextRef="C_0000907654_20201231" decimals="-3" unitRef="U_iso4217USD">50429000</us-gaap:Assets>
  <us-gaap:AccountsPayableCurrent id="F_000044" contextRef="C_0000907654_20210331" decimals="-3" unitRef="U_iso4217USD">1578000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccountsPayableCurrent id="F_000045" contextRef="C_0000907654_20201231" decimals="-3" unitRef="U_iso4217USD">1773000</us-gaap:AccountsPayableCurrent>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent id="F_000046" contextRef="C_0000907654_20210331" decimals="-3" unitRef="U_iso4217USD">255000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent id="F_000047" contextRef="C_0000907654_20201231" decimals="-3" unitRef="U_iso4217USD">815000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:OtherAccruedLiabilitiesCurrent id="F_000048" contextRef="C_0000907654_20210331" decimals="-3" unitRef="U_iso4217USD">1047000</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:OtherAccruedLiabilitiesCurrent id="F_000049" contextRef="C_0000907654_20201231" decimals="-3" unitRef="U_iso4217USD">911000</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent id="F_000050" contextRef="C_0000907654_20210331" decimals="-3" unitRef="U_iso4217USD">2880000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent id="F_000051" contextRef="C_0000907654_20201231" decimals="-3" unitRef="U_iso4217USD">3499000</us-gaap:LiabilitiesCurrent>
  <us-gaap:OperatingLeaseLiabilityNoncurrent id="F_000052" contextRef="C_0000907654_20210331" decimals="-3" unitRef="U_iso4217USD">394000</us-gaap:OperatingLeaseLiabilityNoncurrent>
  <us-gaap:OperatingLeaseLiabilityNoncurrent id="F_000053" contextRef="C_0000907654_20201231" decimals="-3" unitRef="U_iso4217USD">409000</us-gaap:OperatingLeaseLiabilityNoncurrent>
  <us-gaap:Liabilities id="F_000054" contextRef="C_0000907654_20210331" decimals="-3" unitRef="U_iso4217USD">3274000</us-gaap:Liabilities>
  <us-gaap:Liabilities id="F_000055" contextRef="C_0000907654_20201231" decimals="-3" unitRef="U_iso4217USD">3908000</us-gaap:Liabilities>
  <us-gaap:CommitmentsAndContingencies id="F_000056" xsi:nil="true" contextRef="C_0000907654_20210331" unitRef="U_iso4217USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:CommitmentsAndContingencies id="F_000057" xsi:nil="true" contextRef="C_0000907654_20201231" unitRef="U_iso4217USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:CommonStockValue id="F_000058" contextRef="C_0000907654_20210331" decimals="-3" unitRef="U_iso4217USD">14000</us-gaap:CommonStockValue>
  <us-gaap:CommonStockValue id="F_000059" contextRef="C_0000907654_20201231" decimals="-3" unitRef="U_iso4217USD">10000</us-gaap:CommonStockValue>
  <us-gaap:AdditionalPaidInCapitalCommonStock id="F_000060" contextRef="C_0000907654_20210331" decimals="-3" unitRef="U_iso4217USD">224149000</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:AdditionalPaidInCapitalCommonStock id="F_000061" contextRef="C_0000907654_20201231" decimals="-3" unitRef="U_iso4217USD">200665000</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:RetainedEarningsAccumulatedDeficit id="F_000062" contextRef="C_0000907654_20210331" decimals="-3" unitRef="U_iso4217USD">-158254000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RetainedEarningsAccumulatedDeficit id="F_000063" contextRef="C_0000907654_20201231" decimals="-3" unitRef="U_iso4217USD">-154154000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:StockholdersEquity id="F_000064" contextRef="C_0000907654_20210331" decimals="-3" unitRef="U_iso4217USD">65909000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000065" contextRef="C_0000907654_20201231" decimals="-3" unitRef="U_iso4217USD">46521000</us-gaap:StockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity id="F_000066" contextRef="C_0000907654_20210331" decimals="-3" unitRef="U_iso4217USD">69183000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity id="F_000067" contextRef="C_0000907654_20201231" decimals="-3" unitRef="U_iso4217USD">50429000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:CommonStockParOrStatedValuePerShare id="F_000068" contextRef="C_0000907654_20210331" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare id="F_000069" contextRef="C_0000907654_20201231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized id="F_000070" contextRef="C_0000907654_20210331" decimals="INF" unitRef="U_xbrlishares">100000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized id="F_000071" contextRef="C_0000907654_20201231" decimals="INF" unitRef="U_xbrlishares">100000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesIssued id="F_000072" contextRef="C_0000907654_20210331" decimals="INF" unitRef="U_xbrlishares">14410143</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued id="F_000073" contextRef="C_0000907654_20201231" decimals="INF" unitRef="U_xbrlishares">9548150</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding id="F_000074" contextRef="C_0000907654_20210331" decimals="INF" unitRef="U_xbrlishares">14410143</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding id="F_000075" contextRef="C_0000907654_20201231" decimals="INF" unitRef="U_xbrlishares">9548150</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000076" contextRef="C_0000907654_20210101_20210331" decimals="-3" unitRef="U_iso4217USD">2876000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000077" contextRef="C_0000907654_20200101_20200331" decimals="-3" unitRef="U_iso4217USD">365000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="F_000078" contextRef="C_0000907654_20210101_20210331" decimals="-3" unitRef="U_iso4217USD">1226000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="F_000079" contextRef="C_0000907654_20200101_20200331" decimals="-3" unitRef="U_iso4217USD">975000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:OperatingExpenses id="F_000080" contextRef="C_0000907654_20210101_20210331" decimals="-3" unitRef="U_iso4217USD">4102000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses id="F_000081" contextRef="C_0000907654_20200101_20200331" decimals="-3" unitRef="U_iso4217USD">1340000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingIncomeLoss id="F_000082" contextRef="C_0000907654_20210101_20210331" decimals="-3" unitRef="U_iso4217USD">-4102000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss id="F_000083" contextRef="C_0000907654_20200101_20200331" decimals="-3" unitRef="U_iso4217USD">-1340000</us-gaap:OperatingIncomeLoss>
  <us-gaap:InterestAndOtherIncome id="F_000084" contextRef="C_0000907654_20210101_20210331" decimals="-3" unitRef="U_iso4217USD">2000</us-gaap:InterestAndOtherIncome>
  <us-gaap:InterestAndOtherIncome id="F_000085" contextRef="C_0000907654_20200101_20200331" decimals="-3" unitRef="U_iso4217USD">24000</us-gaap:InterestAndOtherIncome>
  <us-gaap:InterestExpense id="F_000086" contextRef="C_0000907654_20200101_20200331" decimals="-3" unitRef="U_iso4217USD">4000</us-gaap:InterestExpense>
  <us-gaap:NetIncomeLoss id="F_000087" contextRef="C_0000907654_20210101_20210331" decimals="-3" unitRef="U_iso4217USD">-4100000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="F_000088" contextRef="C_0000907654_20200101_20200331" decimals="-3" unitRef="U_iso4217USD">-1320000</us-gaap:NetIncomeLoss>
  <us-gaap:EarningsPerShareBasicAndDiluted id="F_000089" contextRef="C_0000907654_20210101_20210331" decimals="2" unitRef="U_iso4217USD_xbrlishares">-0.33</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted id="F_000090" contextRef="C_0000907654_20200101_20200331" decimals="2" unitRef="U_iso4217USD_xbrlishares">-0.83</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="F_000091" contextRef="C_0000907654_20210101_20210331" decimals="0" unitRef="U_xbrlishares">12356928</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="F_000092" contextRef="C_0000907654_20200101_20200331" decimals="0" unitRef="U_xbrlishares">1594070</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:CommonStockSharesOutstanding id="F_000093" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">1594070</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:StockholdersEquity id="F_000094" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231" decimals="-3" unitRef="U_iso4217USD">2000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000095" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231" decimals="-3" unitRef="U_iso4217USD">152024000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000096" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231" decimals="-3" unitRef="U_iso4217USD">-144416000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000097" contextRef="C_0000907654_20191231" decimals="-3" unitRef="U_iso4217USD">7610000</us-gaap:StockholdersEquity>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000098" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20200331" decimals="-3" unitRef="U_iso4217USD">16000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000099" contextRef="C_0000907654_20200101_20200331" decimals="-3" unitRef="U_iso4217USD">16000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:NetIncomeLoss id="F_000100" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20200331" decimals="-3" unitRef="U_iso4217USD">-1320000</us-gaap:NetIncomeLoss>
  <us-gaap:CommonStockSharesOutstanding id="F_000101" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200331" decimals="INF" unitRef="U_xbrlishares">1594070</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:StockholdersEquity id="F_000102" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200331" decimals="-3" unitRef="U_iso4217USD">2000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000103" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200331" decimals="-3" unitRef="U_iso4217USD">152040000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000104" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200331" decimals="-3" unitRef="U_iso4217USD">-145736000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000105" contextRef="C_0000907654_20200331" decimals="-3" unitRef="U_iso4217USD">6306000</us-gaap:StockholdersEquity>
  <abio:IssuanceOfCommonStockAndExerciseOfPrefundedWarrantsShares id="F_000106" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200401_20200630" decimals="INF" unitRef="U_xbrlishares">673500</abio:IssuanceOfCommonStockAndExerciseOfPrefundedWarrantsShares>
  <abio:IssuanceOfCommonStockAndExerciseOfPrefundedWarrants id="F_000107" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200401_20200630" decimals="-3" unitRef="U_iso4217USD">5297000</abio:IssuanceOfCommonStockAndExerciseOfPrefundedWarrants>
  <abio:IssuanceOfCommonStockAndExerciseOfPrefundedWarrants id="F_000108" contextRef="C_0000907654_20200401_20200630" decimals="-3" unitRef="U_iso4217USD">5297000</abio:IssuanceOfCommonStockAndExerciseOfPrefundedWarrants>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000109" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200401_20200630" decimals="-3" unitRef="U_iso4217USD">4000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000110" contextRef="C_0000907654_20200401_20200630" decimals="-3" unitRef="U_iso4217USD">4000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:NetIncomeLoss id="F_000111" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200401_20200630" decimals="-3" unitRef="U_iso4217USD">-1302000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="F_000112" contextRef="C_0000907654_20200401_20200630" decimals="-3" unitRef="U_iso4217USD">-1302000</us-gaap:NetIncomeLoss>
  <us-gaap:CommonStockSharesOutstanding id="F_000113" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200630" decimals="INF" unitRef="U_xbrlishares">2267570</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:StockholdersEquity id="F_000114" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200630" decimals="-3" unitRef="U_iso4217USD">2000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000115" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200630" decimals="-3" unitRef="U_iso4217USD">157341000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000116" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200630" decimals="-3" unitRef="U_iso4217USD">-147038000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000117" contextRef="C_0000907654_20200630" decimals="-3" unitRef="U_iso4217USD">10305000</us-gaap:StockholdersEquity>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000118" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200701_20200930" decimals="INF" unitRef="U_xbrlishares">7018054</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000119" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200701_20200930" decimals="-3" unitRef="U_iso4217USD">7000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000120" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200701_20200930" decimals="-3" unitRef="U_iso4217USD">42129000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000121" contextRef="C_0000907654_20200701_20200930" decimals="-3" unitRef="U_iso4217USD">42136000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000122" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200701_20200930" decimals="-3" unitRef="U_iso4217USD">5000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000123" contextRef="C_0000907654_20200701_20200930" decimals="-3" unitRef="U_iso4217USD">5000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:NetIncomeLoss id="F_000124" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200701_20200930" decimals="-3" unitRef="U_iso4217USD">-1991000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="F_000125" contextRef="C_0000907654_20200701_20200930" decimals="-3" unitRef="U_iso4217USD">-1991000</us-gaap:NetIncomeLoss>
  <us-gaap:CommonStockSharesOutstanding id="F_000126" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200930" decimals="INF" unitRef="U_xbrlishares">9285624</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:StockholdersEquity id="F_000127" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200930" decimals="-3" unitRef="U_iso4217USD">9000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000128" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200930" decimals="-3" unitRef="U_iso4217USD">199475000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000129" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200930" decimals="-3" unitRef="U_iso4217USD">-149029000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000130" contextRef="C_0000907654_20200930" decimals="-3" unitRef="U_iso4217USD">50455000</us-gaap:StockholdersEquity>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000131" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201001_20201231" decimals="INF" unitRef="U_xbrlishares">262526</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000132" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201001_20201231" decimals="-3" unitRef="U_iso4217USD">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000133" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201001_20201231" decimals="-3" unitRef="U_iso4217USD">1172000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000134" contextRef="C_0000907654_20201001_20201231" decimals="-3" unitRef="U_iso4217USD">1173000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000135" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201001_20201231" decimals="-3" unitRef="U_iso4217USD">18000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000136" contextRef="C_0000907654_20201001_20201231" decimals="-3" unitRef="U_iso4217USD">18000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:NetIncomeLoss id="F_000137" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201001_20201231" decimals="-3" unitRef="U_iso4217USD">-5125000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="F_000138" contextRef="C_0000907654_20201001_20201231" decimals="-3" unitRef="U_iso4217USD">-5125000</us-gaap:NetIncomeLoss>
  <us-gaap:CommonStockSharesOutstanding id="F_000139" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231" decimals="INF" unitRef="U_xbrlishares">9548150</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:StockholdersEquity id="F_000140" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231" decimals="-3" unitRef="U_iso4217USD">10000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000141" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231" decimals="-3" unitRef="U_iso4217USD">200665000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000142" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231" decimals="-3" unitRef="U_iso4217USD">-154154000</us-gaap:StockholdersEquity>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000143" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210331" decimals="INF" unitRef="U_xbrlishares">4861993</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000144" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210331" decimals="-3" unitRef="U_iso4217USD">4000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000145" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20210331" decimals="-3" unitRef="U_iso4217USD">23343000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000146" contextRef="C_0000907654_20210101_20210331" decimals="-3" unitRef="U_iso4217USD">23347000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000147" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20210331" decimals="-3" unitRef="U_iso4217USD">141000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000148" contextRef="C_0000907654_20210101_20210331" decimals="-3" unitRef="U_iso4217USD">141000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:NetIncomeLoss id="F_000149" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210101_20210331" decimals="-3" unitRef="U_iso4217USD">-4100000</us-gaap:NetIncomeLoss>
  <us-gaap:CommonStockSharesOutstanding id="F_000150" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210331" decimals="INF" unitRef="U_xbrlishares">14410143</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:StockholdersEquity id="F_000151" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210331" decimals="-3" unitRef="U_iso4217USD">14000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000152" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210331" decimals="-3" unitRef="U_iso4217USD">224149000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000153" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210331" decimals="-3" unitRef="U_iso4217USD">-158254000</us-gaap:StockholdersEquity>
  <us-gaap:DepreciationAndAmortization id="F_000154" contextRef="C_0000907654_20210101_20210331" decimals="-3" unitRef="U_iso4217USD">3000</us-gaap:DepreciationAndAmortization>
  <us-gaap:DepreciationAndAmortization id="F_000155" contextRef="C_0000907654_20200101_20200331" decimals="-3" unitRef="U_iso4217USD">3000</us-gaap:DepreciationAndAmortization>
  <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense id="F_000156" contextRef="C_0000907654_20210101_20210331" decimals="-3" unitRef="U_iso4217USD">14000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
  <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense id="F_000157" contextRef="C_0000907654_20200101_20200331" decimals="-3" unitRef="U_iso4217USD">22000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
  <us-gaap:ShareBasedCompensation id="F_000158" contextRef="C_0000907654_20210101_20210331" decimals="-3" unitRef="U_iso4217USD">141000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation id="F_000159" contextRef="C_0000907654_20200101_20200331" decimals="-3" unitRef="U_iso4217USD">16000</us-gaap:ShareBasedCompensation>
  <us-gaap:IncreaseDecreaseInOtherCurrentAssets id="F_000160" contextRef="C_0000907654_20210101_20210331" decimals="-3" unitRef="U_iso4217USD">840000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
  <us-gaap:IncreaseDecreaseInOtherCurrentAssets id="F_000161" contextRef="C_0000907654_20200101_20200331" decimals="-3" unitRef="U_iso4217USD">75000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
  <us-gaap:IncreaseDecreaseInAccountsPayable id="F_000162" contextRef="C_0000907654_20210101_20210331" decimals="-3" unitRef="U_iso4217USD">56000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccountsPayable id="F_000163" contextRef="C_0000907654_20200101_20200331" decimals="-3" unitRef="U_iso4217USD">-293000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities id="F_000164" contextRef="C_0000907654_20210101_20210331" decimals="-3" unitRef="U_iso4217USD">-560000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
  <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities id="F_000165" contextRef="C_0000907654_20200101_20200331" decimals="-3" unitRef="U_iso4217USD">60000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
  <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities id="F_000166" contextRef="C_0000907654_20210101_20210331" decimals="-3" unitRef="U_iso4217USD">61000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
  <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities id="F_000167" contextRef="C_0000907654_20200101_20200331" decimals="-3" unitRef="U_iso4217USD">-99000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities id="F_000168" contextRef="C_0000907654_20210101_20210331" decimals="-3" unitRef="U_iso4217USD">-5225000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities id="F_000169" contextRef="C_0000907654_20200101_20200331" decimals="-3" unitRef="U_iso4217USD">-1686000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="F_000170" contextRef="C_0000907654_20210101_20210331" decimals="-3" unitRef="U_iso4217USD">6000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="F_000171" contextRef="C_0000907654_20200101_20200331" decimals="-3" unitRef="U_iso4217USD">3000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities id="F_000172" contextRef="C_0000907654_20210101_20210331" decimals="-3" unitRef="U_iso4217USD">-6000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities id="F_000173" contextRef="C_0000907654_20200101_20200331" decimals="-3" unitRef="U_iso4217USD">-3000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:ProceedsFromIssuanceOfCommonStock id="F_000174" contextRef="C_0000907654_20210101_20210331" decimals="-3" unitRef="U_iso4217USD">24070000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:PaymentsOfStockIssuanceCosts id="F_000175" contextRef="C_0000907654_20210101_20210331" decimals="-3" unitRef="U_iso4217USD">977000</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities id="F_000176" contextRef="C_0000907654_20210101_20210331" decimals="-3" unitRef="U_iso4217USD">23093000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect id="F_000177" contextRef="C_0000907654_20210101_20210331" decimals="-3" unitRef="U_iso4217USD">17862000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect id="F_000178" contextRef="C_0000907654_20200101_20200331" decimals="-3" unitRef="U_iso4217USD">-1689000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents id="F_000179" contextRef="C_0000907654_20201231" decimals="-3" unitRef="U_iso4217USD">49071000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents id="F_000180" contextRef="C_0000907654_20191231" decimals="-3" unitRef="U_iso4217USD">8363000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents id="F_000181" contextRef="C_0000907654_20210331" decimals="-3" unitRef="U_iso4217USD">66933000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents id="F_000182" contextRef="C_0000907654_20200331" decimals="-3" unitRef="U_iso4217USD">6674000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
  <us-gaap:CapitalExpendituresIncurredButNotYetPaid id="F_000183" contextRef="C_0000907654_20210101_20210331" decimals="-3" unitRef="U_iso4217USD">3000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
  <abio:VendorFinanceAgreement id="F_000184" contextRef="C_0000907654_20200101_20200331" decimals="-3" unitRef="U_iso4217USD">408000</abio:VendorFinanceAgreement>
  <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability id="F_000185" contextRef="C_0000907654_20200101_20200331" decimals="-3" unitRef="U_iso4217USD">49000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
  <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock id="F_000186" contextRef="C_0000907654_20210101_20210331">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1) The Company and Summary of Significant Accounting Policies &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Description of Business &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;ARCA biopharma, Inc. (the Company or ARCA), a Delaware corporation, is headquartered in Westminster, Colorado. The Company is a clinical-stage biopharmaceutical company applying a precision medicine approach to the development and commercialization of genetically targeted therapies for cardiovascular diseases. The Company&amp;#8217;s lead product candidates are rNAPc2 (AB201) as a potential treatment for diseases caused by ribonucleic acid, or RNA, viruses, initially focusing on COVID-19, the disease caused by SARS-CoV-2 virus, and Gencaro&amp;#8482; (bucindolol hydrochloride) for the treatment of atrial fibrillation (AF) in patients with chronic heart failure (HF).&amp;nbsp;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;rNAPc2 is a protein therapeutic in clinical development as a potential treatment for patients hospitalized with COVID-19. Based on its unique mechanism of action, development history and the clinical evidence from the SARS&amp;#8209;CoV-2 pandemic, the Company believes rNAPc2 has potential to be a beneficial therapy for patients with this serious viral disease. The Company initiated the Phase 2b clinical trial of rNAPc2 as a potential treatment for patients hospitalized with COVID-19 in the fourth quarter of 2020.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company continues to evaluate the feasibility and potential timing for initiating PRECISION-AF relative to the COVID-19 pandemic and prioritizing the development of rNAPc2.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&amp;#8217;s other product candidate, AB171, is a thiol-substituted isosorbide mononitrate, which ARCA plans to develop as a genetically-targeted treatment for HF and peripheral arterial disease. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In March 2020, the World Health Organization declared the outbreak of COVID-19, a novel strain of Coronavirus, a global pandemic. This outbreak is causing major disruptions to businesses and markets worldwide as the virus spreads. The Company does not expect a material financial effect as a result of the pandemic. However, if the pandemic continues to be a severe worldwide crisis, it could have a material adverse effect on the Company&amp;#8217;s business, results of operations, financial condition and cash flows.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Liquidity and Going Concern &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company devotes substantially all of its efforts towards obtaining regulatory approval and raising capital necessary to fund its operations and it is subject to a number of risks associated with clinical research and development, including dependence on key individuals, the development of and regulatory approval of commercially viable products, the need to raise adequate additional financing necessary to fund the development and commercialization of its products, and competition from larger companies. The Company has not generated revenue to date and has incurred substantial losses and negative cash flows from operations since its inception.&amp;nbsp;&amp;nbsp;The Company has historically funded its operations through issuances of common and preferred stock.&amp;nbsp;&amp;nbsp; &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company believes that its current cash and cash equivalents as of March 31, 2021&lt;font style="Background-color:#FFFFFF;color:#000000;"&gt; &lt;/font&gt;will be sufficient to fund its operations through &lt;font style="Background-color:#FFFFFF;color:#000000;"&gt;the end of fiscal year &lt;/font&gt;2022. &lt;font style="Background-color:#FFFFFF;color:#000000;"&gt;Conducting a Phase 3 rNAPc2 clinical trial or the Phase 3 PRECISION-AF trial would likely require additional financing&lt;/font&gt;. &lt;font style="Background-color:#FFFFFF;color:#000000;"&gt;However, changing circumstances may cause us to consume capital significantly faster or slower than currently anticipated. The Company has based these estimates on assumptions that may prove to be wrong, and the Company could exhaust its available financial resources sooner than the Company currently anticipates. Therefore, the Company may have to raise additional capital for clinical trials of &lt;/font&gt;rNAPc2&lt;font style="Background-color:#FFFFFF;color:#000000;"&gt; and will have to raise additional capital for clinical trials of Gencaro. The Company may not be able to raise sufficient capital on acceptable terms, or at all, to continue development of &lt;/font&gt;rNAPc2&lt;font style="Background-color:#FFFFFF;color:#000000;"&gt; or Gencaro or to otherwise continue operations and may not be able to execute any strategic transaction&lt;/font&gt;.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&amp;#8217;s liquidity, and its ability to raise additional capital or complete any strategic transaction, depends on a number of factors, including, but not limited to, the following: &lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-family:&apos;Times New Roman&apos;;font-size:15pt;line-height:11pt;"&gt;&amp;#x2022;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;the costs and timing for the potential additional clinical trials in order to gain possible regulatory approval for rNAPc2, Gencaro or any other product candidate; &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-family:&apos;Times New Roman&apos;;font-size:15pt;line-height:11pt;"&gt;&amp;#x2022;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;the market price of the Company&amp;#8217;s stock and the availability and cost of additional equity capital from existing and potential new investors; &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-family:&apos;Times New Roman&apos;;font-size:15pt;line-height:11pt;"&gt;&amp;#x2022;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;the Company&amp;#8217;s ability to retain the listing of its common stock on the Nasdaq Capital Market; &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-family:&apos;Times New Roman&apos;;font-size:15pt;line-height:11pt;"&gt;&amp;#x2022;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;general economic and industry conditions affecting the availability and cost of capital, including as a result of the COVID-19 pandemic; &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-family:&apos;Times New Roman&apos;;font-size:15pt;line-height:11pt;"&gt;&amp;#x2022;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; and &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-family:&apos;Times New Roman&apos;;font-size:15pt;line-height:11pt;"&gt;&amp;#x2022;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;the terms and conditions of the Company&amp;#8217;s existing collaborative and licensing agreements. &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The sale of additional equity or convertible debt securities would likely result in substantial additional dilution to the Company&amp;#8217;s stockholders. If the Company raises additional funds through the incurrence of indebtedness, the obligations related to such indebtedness would be senior to rights of holders of the Company&amp;#8217;s capital stock and could contain covenants that would restrict the Company&amp;#8217;s operations. The Company also cannot predict what consideration might be available, if any, to the Company or its stockholders, in connection with any strategic transaction. Should strategic alternatives or additional capital not be available to the Company, or not be available on acceptable terms, the Company may be unable to realize value from its assets and discharge its liabilities in the normal course of business which may, among other alternatives, cause the Company to further delay, substantially reduce or discontinue operational activities to conserve its cash resources.&amp;nbsp;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Basis of Presentation &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The accompanying unaudited financial statements of the Company were prepared in accordance with generally accepted accounting principles for interim financial information and instructions to Form 10-Q and pursuant to Regulation S-X.&amp;nbsp;&amp;nbsp;Accordingly, these financial statements do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America (GAAP) for complete financial statements.&amp;#160; In the opinion of management, these financial statements include all normal and recurring adjustments considered necessary for a fair presentation of these interim financial statements.&amp;nbsp;&amp;nbsp;The results of operations for the three months ended March 31, 2021 are not necessarily indicative of results expected for the full year ending December&amp;#160;31, 2021.&amp;#160; The Company has generated no revenue to date and its activities have consisted of seeking regulatory approval, research and development, exploring strategic alternatives for further developing and commercializing rNAPc2 and Gencaro, and raising capital. These unaudited financial statements should be read in conjunction with the audited financial statements and footnotes thereto for the year ended December&amp;#160;31, 2020 included in the Company&amp;#8217;s Annual Report on Form 10-K filed with the Securities and Exchange Commission. Amounts presented are rounded to the nearest thousand, where indicated, except per share data and par values.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Concentrations of Credit Risk &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company has no off-balance-sheet concentrations of credit risk, such as foreign exchange contracts, option contracts, or foreign currency hedging arrangements. The Company maintains cash and cash equivalent balances in the form of bank demand deposits and money market fund accounts with financial institutions that management believes are creditworthy. Such balances may at times exceed the insured amount. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Comprehensive Loss&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Comprehensive loss is defined as the change in equity during a period from transactions and other events and/or circumstances from non-owner sources. If the Company had comprehensive gains (losses), they would be reflected in the statement of operations and comprehensive loss and as a separate component in the statement of stockholders&amp;#8217; equity. There were no elements of comprehensive loss during the three months ended March 31, 2021&amp;#160;and&amp;#160;2020.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Leases&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company determines if an arrangement is a lease at inception.&amp;nbsp;&amp;nbsp;Operating leases are included in right-of-use (ROU) asset &amp;#8211; operating and lease obligations are included in accrued expenses and other liabilities and operating lease liability on the Company&amp;#8217;s March 31, 2021 and December&amp;#160;31, 2020 balance sheets.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;ROU lease assets represent the Company&amp;#8217;s right to use an underlying asset for the lease term and lease obligations represent the Company&amp;#8217;s obligation to make lease payments arising from the lease. Operating ROU lease assets are recognized at the commencement date based on the present value of lease payments over the lease term. As the Company&amp;#8217;s lease does not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments.&amp;nbsp;&amp;nbsp;The Company&amp;#8217;s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Accrued Outsourcing Expenses &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As part of the process of preparing its financial statements, the Company is required to estimate accrued outsourcing expenses. This process involves identifying services that third parties have performed on the Company&amp;#8217;s behalf and estimating the level of service performed and the associated cost incurred for these services as of the balance sheet date. Examples of estimated accrued outsourcing expenses include contract service fees, such as fees payable to contract manufacturers in connection with the production of materials related to the Company&amp;#8217;s drug product, and service fees and pass through costs from clinical research organizations. The Company develops estimates of liabilities using its judgment based upon the facts and circumstances known at the time. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Recent Accounting Pronouncements&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company reviewed recently issued accounting pronouncements and concluded that they were either not applicable or not expected to have a significant impact to the financial statements.&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
  <us-gaap:EarningsPerShareTextBlock id="F_000187" contextRef="C_0000907654_20210101_20210331">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2) Net Loss Per Share &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company calculates basic earnings per share by dividing net loss by the weighted average common shares outstanding during the period. Diluted earnings per share is computed by dividing net loss by the weighted average number of common shares outstanding during the period increased to include, if dilutive, the number of additional common shares that would have been outstanding if the potential common shares had been issued. The Company&amp;#8217;s potentially dilutive shares include stock options and warrants for common stock&lt;font style="letter-spacing:-0.1pt;"&gt;. &lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Because the Company reported a net loss for the three months ended March 31, 2021 and 2020, all potentially dilutive shares of common stock have been excluded from the computation of the dilutive net loss per share for all periods presented.&lt;font style="font-size:12pt;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;Such potentially dilutive shares of common stock consist of the following:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.18%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.8%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;March 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.18%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Potentially dilutive securities, excluded:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding stock options&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;596,497&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30,890&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.18%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Warrants to purchase common stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;133,401&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;133,401&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.18%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;729,898&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;164,291&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
  <us-gaap:FairValueDisclosuresTextBlock id="F_000188" contextRef="C_0000907654_20210101_20210331">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3) Fair Value Disclosures &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;There were no marketable securities as of March 31, 2021 or December 31, 2020.&amp;nbsp;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). Inputs used to measure fair value are classified into the following hierarchy: &lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-family:&apos;Times New Roman&apos;;font-size:15pt;line-height:11pt;"&gt;&amp;#x2022;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&amp;#8212;Unadjusted quoted prices in active markets for identical assets or liabilities.&amp;nbsp;&amp;nbsp;The Company&amp;#8217;s Level 1 assets consist of money market investments.&amp;nbsp;&amp;nbsp;The Company does not have any Level 1 liabilities.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-family:&apos;Times New Roman&apos;;font-size:15pt;line-height:11pt;"&gt;&amp;#x2022;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&amp;#8212;Unadjusted quoted prices in active markets for similar assets or liabilities; unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active; or inputs other than quoted prices that are observable for the asset or liability.&amp;nbsp;&amp;nbsp;The Company does not have any Level 2 assets or liabilities. &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-family:&apos;Times New Roman&apos;;font-size:15pt;line-height:11pt;"&gt;&amp;#x2022;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&amp;#8212;Unobservable inputs for the asset or liability.&amp;nbsp;&amp;nbsp;The Company does not have any Level 3 assets or liabilities. &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of March 31, 2021 and December 31, 2020, the Company had $66.9 million and $49.1 million, respectively, of cash equivalents consisting of money market funds with original maturities of 90 days or less. The Company has the ability to liquidate these investments without restriction. The Company determines fair value for these money market funds with Level 1 inputs through quoted market prices. There were no transfers of assets between fair value hierarchy levels during the three-month period ended March&amp;#160;31,&amp;#160;2021. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt; Fair Value of Other Financial Instruments &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The carrying amount of other financial instruments, including accounts payable and a vendor finance agreement, which are included in accounts payable and accrued expenses and other liabilities, approximated fair value due to their short maturities. &lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
  <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock id="F_000189" contextRef="C_0000907654_20210101_20210331">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4) Property and Equipment&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment consist of the following (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.52%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimated Life&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;March 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.52%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computer equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.1%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3 years&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;37&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;31&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.52%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lab equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.1%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5 years&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;146&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.1%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;146&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.52%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.1%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5 years&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;38&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.1%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;38&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.52%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computer software&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:20.1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3 years&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;59&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;56&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.52%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.1%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;280&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;271&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.52%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accumulated depreciation and amortization&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:20.1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(253&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(250&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.52%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment, net&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:20.1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;27&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the three months ended March 31, 2021 and 2020, depreciation and amortization expense was $3,000 and $3,000, respectively. &lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
  <us-gaap:RelatedPartyTransactionsDisclosureTextBlock id="F_000190" contextRef="C_0000907654_20210101_20210331">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5) Related Party Arrangements &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Transactions with the Company&amp;#8217;s President and Chief Executive Officer &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has entered into unrestricted research grants with its President and Chief Executive Officer&amp;#8217;s academic research laboratory at the University of Colorado. Funding of any unrestricted research grants is contingent upon the Company&amp;#8217;s financial condition, and can be deferred or terminated at the Company&amp;#8217;s discretion. Total expense under these arrangements for the three months ended March 31, 2021 and 2020 was $107,000 and $70,000 respectively.&amp;nbsp;&amp;nbsp; &lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock id="F_000191" contextRef="C_0000907654_20210101_20210331">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6) Commitments and Contingencies &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has or is subject to the following commitments and contingencies. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Employment Agreements &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company maintains employment agreements with several key executive employees. The agreements may be terminated at any time by the Company with or without cause upon written notice to the employee, and entitle the employee to wages in lieu of notice for periods not exceeding one calendar year from the date of termination without cause or by the employee for good reason. Certain of these agreements also provide for payments to be made under certain conditions related to a change in control of the Company. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Operating Lease &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On August&amp;#160;1, 2013 the Company entered into a lease agreement for approximately 5,300 square feet of office facilities in Westminster, Colorado which served as the Company&amp;#8217;s primary business office from October&amp;#160;1, 2013 until September 30, 2020.&amp;nbsp;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On August&amp;#160;29, 2020 the Company entered into a lease agreement for approximately 5,200 square feet of office facilities in Westminster, Colorado which serves as the Company&amp;#8217;s primary business office effective October&amp;#160;1, 2020 (October 2020 Lease). The lease term is 42 months beginning October 1, 2020 and includes an option to renew for an additional 36 month term at the then prevailing rental rate. The exercise of the lease renewal option is at the Company&amp;#8217;s sole discretion.&amp;nbsp;&amp;nbsp;The amounts recorded assume the Company will exercise its renewal option. The lease includes real estate taxes and insurance, which is not a lease component and is not included in the lease obligation.&amp;nbsp;&amp;nbsp;In addition, common area maintenance charges are based on actual costs incurred and are a non-lease component that is not included in the lease obligation.  &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Future minimum commitments due under the October 2020 Lease agreement as of March 31, 2021 are as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:55.82%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remainder of 2021&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.56%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;64&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.56%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;88&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.56%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;90&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2024&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.56%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;93&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2025&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.56%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;96&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.78%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;125&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total remaining lease payments&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.56%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;556&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: imputed lease interest&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.56%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(106&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.78%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: Current portion&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(56&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.78%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease liability, net of current portion&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;394&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Rent expense, which is included in general and administrative expense, for the three months ended March 31, 2021 and 2020 was $22,000 and $23,000, respectively. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of March 31, 2021, the lease liability was $450,000, and the current portion is included in accrued expenses and other liabilities and the non-current portion is in operating lease liability, net of current portion in the accompanying balance sheet. Cash paid for amounts included in the measurement of lease liabilities and the operating cash flows from operating leases for the three months ended March 31, 2021 and 2020 were $7,000 and $25,000, respectively. The weighted-average remaining lease term for the operating lease as of March&amp;#160;31, 2021 is 6.0&amp;#160;years. The discount rate for the operating lease is 7%.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <abio:EquityFinancingsAndWarrantsDisclosureTextBlock id="F_000192" contextRef="C_0000907654_20210101_20210331">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(7) &lt;font style="font-style:italic;"&gt;Equity Financings and Warrants&lt;/font&gt; &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Registered Direct Financing&lt;/p&gt;
&lt;p style="margin-bottom:12pt;margin-top:6pt;line-height:11pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On June 3, 2020, the Company closed a registered direct offering with certain institutional and accredited investors of 348,000 shares of the Company&amp;#8217;s common stock, at a purchase price of $9.00 per share, and pre-funded warrants to purchase 325,500 shares of common stock at a purchase price of $8.999 per warrant. All warrants were exercised by the closing date. The net proceeds were approximately $5.3 million, after deducting placement agent fees and other offering expenses. The Company paid JonesTrading a placement agent fee equal to 8.0% of the aggregate gross proceeds and agreed to provide JonesTrading with customary indemnification and contribution rights.&amp;nbsp;&amp;nbsp;&lt;font style="font-size:12pt;"&gt; &lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;At the Market Equity Financing &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;text-indent:0%;font-weight:bold;;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On January&amp;#160;11, 2017, the Company entered into a Capital on Demand&lt;font style="font-size:8.5pt;"&gt;&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt; TM&lt;/sup&gt;&lt;/font&gt;&amp;#160;Sales Agreement (the Sales Agreement) with JonesTrading Institutional Services LLC, as agent (JonesTrading), pursuant to which the Company may offer and sell, from time to time through JonesTrading, shares of the Company&amp;#8217;s common stock, par value $0.001 per share (the Common Stock), having an aggregate offering price of up to $7.3&amp;#160;million.&amp;nbsp;&amp;nbsp;On August&amp;#160;21, 2017, January 25, 2019, March 11, 2019, May 9, 2019, May 20, 2019, June 28, 2019, July&amp;#160;2, 2020 and July 14, 2020, the Company amended its Capital on Demand Sales Agreement. The amendments, among other things, increased the maximum aggregate offering value of shares of the Company&amp;#8217;s common stock which the Company may issue and sell from time to time under the Sales Agreement&lt;font style="font-size:12pt;"&gt;&amp;#160;&lt;/font&gt;from $7.3 million to $32.4&amp;#160;million (the Shares).&amp;nbsp;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the amended Sales Agreement, JonesTrading may sell the Shares by any method permitted by law and deemed to be an &amp;#8220;at the market offering&amp;#8221; as defined in Rule 415 promulgated under the Securities Act of 1933, as amended, including sales made directly on or through the Nasdaq Capital Market, on any other existing trading market for the Common Stock or to or through a market maker. In addition, under the amended Sales Agreement, JonesTrading may sell the Shares by any other method permitted by law, including in negotiated transactions. The Company may instruct JonesTrading not to sell Shares if the sales cannot be effected at or above the price designated by the Company from time to time. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is not obligated to make any sales of the Shares under the amended Sales Agreement. The offering of Shares pursuant to the amended Sales Agreement will terminate upon the earlier of (a)&amp;#160;the sale of all of the Shares subject to the amended Sales Agreement or (b)&amp;#160;the termination of the amended Sales Agreement by JonesTrading or the Company, as permitted therein. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company paid JonesTrading a commission rate equal to 3.0% of the aggregate gross proceeds from each sale of Shares and agreed to provide JonesTrading with customary indemnification and contribution rights. The Company will also reimburse JonesTrading for certain specified expenses in connection with entering into and amending the Sales Agreement. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the amended Sales Agreement, the Company sold an aggregate of 2,214,301 &lt;font style="font-size:6pt;"&gt;&amp;#160;&lt;/font&gt;shares of Common Stock, for net proceeds of approximately $14.4 million, during the year ended December 31, 2020, including initial expenses for executing the &amp;#8220;at the market offering&amp;#8221; and commissions to the placement agent. This sales agreement terminated in July 2020.&amp;nbsp;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;line-height:11pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On July 22, 2020, the Company entered into a new Capital on Demand&lt;font style="font-size:8.5pt;"&gt;&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt; TM&lt;/sup&gt;&lt;/font&gt;&amp;#160;Sales Agreement (the 2020 Sales Agreement) with JonesTrading, pursuant to which the Company may offer and sell, from time to time through JonesTrading, shares of the Company&amp;#8217;s Common Stock, having an aggregate offering price of up to $54.0&amp;#160;million. During the three months ended March 31, 2021 and the year ended December 31, 2020, the Company had sold an aggregate of 4,861,993 and 5,066,279 shares of its Common Stock pursuant to the terms of the 2020 Sales Agreement for net proceeds of approximately $23.3 million and $28.9&amp;#160;million, respectively, after deducting expenses for executing the &amp;#8220;at the market offering&amp;#8221; and commissions paid to the placement agent.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In April 2021, the Company amended the 2020 Sales Agreement and has $50.0 million available for the offering under its prospectus to the Company&amp;#8217;s registration statement on Form S-3 (No. 333-254585).&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:16pt;line-height:11pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Warrants &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Warrants to purchase shares of common stock were previously granted as part of various financing and business agreements.&amp;nbsp;&amp;nbsp;All outstanding warrants were recorded in additional paid-in capital at their estimated fair market value at the date of grant using a Black-Scholes option-pricing model. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of March 31, 2021, these warrants, by year of expiration, are summarized below:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:60%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.16%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year of Expiration&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.92%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.36%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;of Warrants&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.92%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.62%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise Price&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.16%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.36%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;133,401&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.62%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;109.80&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;</abio:EquityFinancingsAndWarrantsDisclosureTextBlock>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock id="F_000193" contextRef="C_0000907654_20210101_20210331">
&lt;p style="margin-bottom:0pt;margin-top:0pt;line-height:11pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(8) Share-based Compensation &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the three month periods ended March 31, 2021 and 2020, the Company recognized the following non-cash, share-based compensation expense in the statements of operations (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.54%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three Months&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Ended March 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.54%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.54%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;36&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.54%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.54%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;105&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.54%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.54%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.88%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;141&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.54%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.54%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock option transactions for the three month period ended March 31, 2021 under the Company&amp;#8217;s stock incentive plans were as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;of Options&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted Average Exercise Price&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remaining&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contractual&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Term&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in years)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options outstanding at December&amp;#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;531,238&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.71&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.68&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;67,200&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.30&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited and cancelled&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,941&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;72.33&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options outstanding at March 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;596,497&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.01&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.51&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options exercisable at March 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;66,125&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;38.02&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.68&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options vested and expected to vest&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;595,774&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.01&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.51&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <us-gaap:IncomeTaxDisclosureTextBlock id="F_000194" contextRef="C_0000907654_20210101_20210331">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(9) Income Taxes &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In accordance with GAAP, a valuation allowance should be provided if it is more likely than not that some or all of the Company&amp;#8217;s deferred tax assets will not be realized.&amp;nbsp;&amp;nbsp;The Company&amp;#8217;s ability to realize the benefit of its deferred tax assets will depend on the generation of future taxable income. Due to the uncertainty of future profitable operations and taxable income, the Company has recorded a full valuation allowance against its net deferred tax assets.&amp;nbsp;&amp;nbsp;The Company believes its tax filing positions and deductions related to tax periods subject to examination will be sustained upon audit and, therefore, has no reserve for uncertain tax positions.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
  <abio:DescriptionOfBusinessPolicyTextBlock id="F_000195" contextRef="C_0000907654_20210101_20210331">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Description of Business &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;ARCA biopharma, Inc. (the Company or ARCA), a Delaware corporation, is headquartered in Westminster, Colorado. The Company is a clinical-stage biopharmaceutical company applying a precision medicine approach to the development and commercialization of genetically targeted therapies for cardiovascular diseases. The Company&amp;#8217;s lead product candidates are rNAPc2 (AB201) as a potential treatment for diseases caused by ribonucleic acid, or RNA, viruses, initially focusing on COVID-19, the disease caused by SARS-CoV-2 virus, and Gencaro&amp;#8482; (bucindolol hydrochloride) for the treatment of atrial fibrillation (AF) in patients with chronic heart failure (HF).&amp;nbsp;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;rNAPc2 is a protein therapeutic in clinical development as a potential treatment for patients hospitalized with COVID-19. Based on its unique mechanism of action, development history and the clinical evidence from the SARS&amp;#8209;CoV-2 pandemic, the Company believes rNAPc2 has potential to be a beneficial therapy for patients with this serious viral disease. The Company initiated the Phase 2b clinical trial of rNAPc2 as a potential treatment for patients hospitalized with COVID-19 in the fourth quarter of 2020.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company continues to evaluate the feasibility and potential timing for initiating PRECISION-AF relative to the COVID-19 pandemic and prioritizing the development of rNAPc2.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&amp;#8217;s other product candidate, AB171, is a thiol-substituted isosorbide mononitrate, which ARCA plans to develop as a genetically-targeted treatment for HF and peripheral arterial disease. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In March 2020, the World Health Organization declared the outbreak of COVID-19, a novel strain of Coronavirus, a global pandemic. This outbreak is causing major disruptions to businesses and markets worldwide as the virus spreads. The Company does not expect a material financial effect as a result of the pandemic. However, if the pandemic continues to be a severe worldwide crisis, it could have a material adverse effect on the Company&amp;#8217;s business, results of operations, financial condition and cash flows.&lt;/p&gt;</abio:DescriptionOfBusinessPolicyTextBlock>
  <abio:LiquidityAndGoingConcernPolicyTextBlock id="F_000196" contextRef="C_0000907654_20210101_20210331">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Liquidity and Going Concern &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company devotes substantially all of its efforts towards obtaining regulatory approval and raising capital necessary to fund its operations and it is subject to a number of risks associated with clinical research and development, including dependence on key individuals, the development of and regulatory approval of commercially viable products, the need to raise adequate additional financing necessary to fund the development and commercialization of its products, and competition from larger companies. The Company has not generated revenue to date and has incurred substantial losses and negative cash flows from operations since its inception.&amp;nbsp;&amp;nbsp;The Company has historically funded its operations through issuances of common and preferred stock.&amp;nbsp;&amp;nbsp; &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company believes that its current cash and cash equivalents as of March 31, 2021&lt;font style="Background-color:#FFFFFF;color:#000000;"&gt; &lt;/font&gt;will be sufficient to fund its operations through &lt;font style="Background-color:#FFFFFF;color:#000000;"&gt;the end of fiscal year &lt;/font&gt;2022. &lt;font style="Background-color:#FFFFFF;color:#000000;"&gt;Conducting a Phase 3 rNAPc2 clinical trial or the Phase 3 PRECISION-AF trial would likely require additional financing&lt;/font&gt;. &lt;font style="Background-color:#FFFFFF;color:#000000;"&gt;However, changing circumstances may cause us to consume capital significantly faster or slower than currently anticipated. The Company has based these estimates on assumptions that may prove to be wrong, and the Company could exhaust its available financial resources sooner than the Company currently anticipates. Therefore, the Company may have to raise additional capital for clinical trials of &lt;/font&gt;rNAPc2&lt;font style="Background-color:#FFFFFF;color:#000000;"&gt; and will have to raise additional capital for clinical trials of Gencaro. The Company may not be able to raise sufficient capital on acceptable terms, or at all, to continue development of &lt;/font&gt;rNAPc2&lt;font style="Background-color:#FFFFFF;color:#000000;"&gt; or Gencaro or to otherwise continue operations and may not be able to execute any strategic transaction&lt;/font&gt;.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&amp;#8217;s liquidity, and its ability to raise additional capital or complete any strategic transaction, depends on a number of factors, including, but not limited to, the following: &lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-family:&apos;Times New Roman&apos;;font-size:15pt;line-height:11pt;"&gt;&amp;#x2022;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;the costs and timing for the potential additional clinical trials in order to gain possible regulatory approval for rNAPc2, Gencaro or any other product candidate; &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-family:&apos;Times New Roman&apos;;font-size:15pt;line-height:11pt;"&gt;&amp;#x2022;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;the market price of the Company&amp;#8217;s stock and the availability and cost of additional equity capital from existing and potential new investors; &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-family:&apos;Times New Roman&apos;;font-size:15pt;line-height:11pt;"&gt;&amp;#x2022;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;the Company&amp;#8217;s ability to retain the listing of its common stock on the Nasdaq Capital Market; &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-family:&apos;Times New Roman&apos;;font-size:15pt;line-height:11pt;"&gt;&amp;#x2022;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;general economic and industry conditions affecting the availability and cost of capital, including as a result of the COVID-19 pandemic; &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-family:&apos;Times New Roman&apos;;font-size:15pt;line-height:11pt;"&gt;&amp;#x2022;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; and &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-family:&apos;Times New Roman&apos;;font-size:15pt;line-height:11pt;"&gt;&amp;#x2022;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;the terms and conditions of the Company&amp;#8217;s existing collaborative and licensing agreements. &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The sale of additional equity or convertible debt securities would likely result in substantial additional dilution to the Company&amp;#8217;s stockholders. If the Company raises additional funds through the incurrence of indebtedness, the obligations related to such indebtedness would be senior to rights of holders of the Company&amp;#8217;s capital stock and could contain covenants that would restrict the Company&amp;#8217;s operations. The Company also cannot predict what consideration might be available, if any, to the Company or its stockholders, in connection with any strategic transaction. Should strategic alternatives or additional capital not be available to the Company, or not be available on acceptable terms, the Company may be unable to realize value from its assets and discharge its liabilities in the normal course of business which may, among other alternatives, cause the Company to further delay, substantially reduce or discontinue operational activities to conserve its cash resources.&amp;nbsp;&amp;nbsp;&lt;/p&gt;</abio:LiquidityAndGoingConcernPolicyTextBlock>
  <us-gaap:BasisOfAccountingPolicyPolicyTextBlock id="F_000197" contextRef="C_0000907654_20210101_20210331">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Basis of Presentation &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The accompanying unaudited financial statements of the Company were prepared in accordance with generally accepted accounting principles for interim financial information and instructions to Form 10-Q and pursuant to Regulation S-X.&amp;nbsp;&amp;nbsp;Accordingly, these financial statements do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America (GAAP) for complete financial statements.&amp;#160; In the opinion of management, these financial statements include all normal and recurring adjustments considered necessary for a fair presentation of these interim financial statements.&amp;nbsp;&amp;nbsp;The results of operations for the three months ended March 31, 2021 are not necessarily indicative of results expected for the full year ending December&amp;#160;31, 2021.&amp;#160; The Company has generated no revenue to date and its activities have consisted of seeking regulatory approval, research and development, exploring strategic alternatives for further developing and commercializing rNAPc2 and Gencaro, and raising capital. These unaudited financial statements should be read in conjunction with the audited financial statements and footnotes thereto for the year ended December&amp;#160;31, 2020 included in the Company&amp;#8217;s Annual Report on Form 10-K filed with the Securities and Exchange Commission. Amounts presented are rounded to the nearest thousand, where indicated, except per share data and par values.&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
  <us-gaap:ConcentrationRiskCreditRisk id="F_000198" contextRef="C_0000907654_20210101_20210331">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Concentrations of Credit Risk &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company has no off-balance-sheet concentrations of credit risk, such as foreign exchange contracts, option contracts, or foreign currency hedging arrangements. The Company maintains cash and cash equivalent balances in the form of bank demand deposits and money market fund accounts with financial institutions that management believes are creditworthy. Such balances may at times exceed the insured amount. &lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
  <abio:ComprehensiveLossPolicyPolicyTextBlock id="F_000199" contextRef="C_0000907654_20210101_20210331">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Comprehensive Loss&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Comprehensive loss is defined as the change in equity during a period from transactions and other events and/or circumstances from non-owner sources. If the Company had comprehensive gains (losses), they would be reflected in the statement of operations and comprehensive loss and as a separate component in the statement of stockholders&amp;#8217; equity. There were no elements of comprehensive loss during the three months ended March 31, 2021&amp;#160;and&amp;#160;2020.&lt;/p&gt;</abio:ComprehensiveLossPolicyPolicyTextBlock>
  <us-gaap:LesseeLeasesPolicyTextBlock id="F_000200" contextRef="C_0000907654_20210101_20210331">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Leases&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company determines if an arrangement is a lease at inception.&amp;nbsp;&amp;nbsp;Operating leases are included in right-of-use (ROU) asset &amp;#8211; operating and lease obligations are included in accrued expenses and other liabilities and operating lease liability on the Company&amp;#8217;s March 31, 2021 and December&amp;#160;31, 2020 balance sheets.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;ROU lease assets represent the Company&amp;#8217;s right to use an underlying asset for the lease term and lease obligations represent the Company&amp;#8217;s obligation to make lease payments arising from the lease. Operating ROU lease assets are recognized at the commencement date based on the present value of lease payments over the lease term. As the Company&amp;#8217;s lease does not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments.&amp;nbsp;&amp;nbsp;The Company&amp;#8217;s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term.&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
  <abio:AccruedOutsourcingExpensesPolicyTextBlock id="F_000201" contextRef="C_0000907654_20210101_20210331">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Accrued Outsourcing Expenses &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As part of the process of preparing its financial statements, the Company is required to estimate accrued outsourcing expenses. This process involves identifying services that third parties have performed on the Company&amp;#8217;s behalf and estimating the level of service performed and the associated cost incurred for these services as of the balance sheet date. Examples of estimated accrued outsourcing expenses include contract service fees, such as fees payable to contract manufacturers in connection with the production of materials related to the Company&amp;#8217;s drug product, and service fees and pass through costs from clinical research organizations. The Company develops estimates of liabilities using its judgment based upon the facts and circumstances known at the time. &lt;/p&gt;</abio:AccruedOutsourcingExpensesPolicyTextBlock>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock id="F_000202" contextRef="C_0000907654_20210101_20210331">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Recent Accounting Pronouncements&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company reviewed recently issued accounting pronouncements and concluded that they were either not applicable or not expected to have a significant impact to the financial statements.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock id="F_000203" contextRef="C_0000907654_20210101_20210331">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Because the Company reported a net loss for the three months ended March 31, 2021 and 2020, all potentially dilutive shares of common stock have been excluded from the computation of the dilutive net loss per share for all periods presented.&lt;font style="font-size:12pt;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;Such potentially dilutive shares of common stock consist of the following:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.18%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.8%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;March 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.18%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Potentially dilutive securities, excluded:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding stock options&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;596,497&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30,890&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.18%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Warrants to purchase common stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;133,401&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;133,401&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.18%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;729,898&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;164,291&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
  <us-gaap:PropertyPlantAndEquipmentTextBlock id="F_000204" contextRef="C_0000907654_20210101_20210331">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment consist of the following (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.52%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimated Life&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;March 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.52%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computer equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.1%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3 years&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;37&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;31&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.52%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lab equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.1%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5 years&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;146&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.1%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;146&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.52%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.1%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5 years&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;38&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.1%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;38&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.52%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computer software&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:20.1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3 years&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;59&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;56&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.52%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.1%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;280&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;271&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.52%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accumulated depreciation and amortization&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:20.1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(253&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(250&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.52%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment, net&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:20.1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;27&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
  <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock id="F_000205" contextRef="C_0000907654_20210101_20210331">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Future minimum commitments due under the October 2020 Lease agreement as of March 31, 2021 are as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:55.82%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remainder of 2021&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.56%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;64&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.56%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;88&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.56%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;90&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2024&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.56%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;93&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2025&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.56%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;96&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.78%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;125&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total remaining lease payments&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.56%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;556&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: imputed lease interest&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.56%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(106&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.78%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: Current portion&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(56&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.78%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease liability, net of current portion&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;394&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
  <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock id="F_000206" contextRef="C_0000907654_20210101_20210331">
&lt;p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of March 31, 2021, these warrants, by year of expiration, are summarized below:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:60%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.16%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year of Expiration&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.92%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.36%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;of Warrants&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.92%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.62%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise Price&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.16%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.36%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;133,401&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.62%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;109.80&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
  <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock id="F_000207" contextRef="C_0000907654_20210101_20210331">
&lt;p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the three month periods ended March 31, 2021 and 2020, the Company recognized the following non-cash, share-based compensation expense in the statements of operations (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.54%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three Months&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Ended March 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.54%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.54%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;36&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.54%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.54%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;105&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.54%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.54%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.88%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;141&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.54%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.54%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock id="F_000208" contextRef="C_0000907654_20210101_20210331">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock option transactions for the three month period ended March 31, 2021 under the Company&amp;#8217;s stock incentive plans were as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;of Options&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted Average Exercise Price&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remaining&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contractual&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Term&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in years)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options outstanding at December&amp;#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;531,238&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.71&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.68&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;67,200&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.30&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited and cancelled&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,941&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;72.33&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options outstanding at March 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;596,497&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.01&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.51&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options exercisable at March 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;66,125&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;38.02&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.68&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options vested and expected to vest&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;595,774&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.01&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.51&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
  <us-gaap:Revenues id="F_000209" contextRef="C_0000907654_20210101_20210331" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:Revenues>
  <us-gaap:FairValueDisclosureOffbalanceSheetRisksAmountAsset id="F_000210" contextRef="C_0000907654_20210331" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:FairValueDisclosureOffbalanceSheetRisksAmountAsset>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000211" contextRef="C_0000907654_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapStockOptionMember_20210101_20210331" decimals="0" unitRef="U_xbrlishares">596497</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000212" contextRef="C_0000907654_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapStockOptionMember_20200101_20200331" decimals="0" unitRef="U_xbrlishares">30890</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000213" contextRef="C_0000907654_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapWarrantMember_20210101_20210331" decimals="0" unitRef="U_xbrlishares">133401</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000214" contextRef="C_0000907654_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapWarrantMember_20200101_20200331" decimals="0" unitRef="U_xbrlishares">133401</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000215" contextRef="C_0000907654_20210101_20210331" decimals="0" unitRef="U_xbrlishares">729898</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000216" contextRef="C_0000907654_20200101_20200331" decimals="0" unitRef="U_xbrlishares">164291</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities id="F_000217" contextRef="C_0000907654_20210331" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities id="F_000218" contextRef="C_0000907654_20201231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure id="F_000219" contextRef="C_0000907654_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210331" decimals="-5" unitRef="U_iso4217USD">66900000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure id="F_000220" contextRef="C_0000907654_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-5" unitRef="U_iso4217USD">49100000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <abio:FairValueAssetsBetweenHierarchyLevelsTransfersAmount id="F_000221" contextRef="C_0000907654_20210101_20210331" decimals="INF" unitRef="U_iso4217USD">0</abio:FairValueAssetsBetweenHierarchyLevelsTransfersAmount>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife id="F_000222" contextRef="C_0000907654_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20210101_20210331">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife id="F_000223" contextRef="C_0000907654_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20210101_20210331">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife id="F_000224" contextRef="C_0000907654_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20210101_20210331">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife id="F_000225" contextRef="C_0000907654_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapSoftwareAndSoftwareDevelopmentCostsMember_20210101_20210331">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000226" contextRef="C_0000907654_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20210331" decimals="-3" unitRef="U_iso4217USD">37000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000227" contextRef="C_0000907654_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20201231" decimals="-3" unitRef="U_iso4217USD">31000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000228" contextRef="C_0000907654_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20210331" decimals="-3" unitRef="U_iso4217USD">146000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000229" contextRef="C_0000907654_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20201231" decimals="-3" unitRef="U_iso4217USD">146000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000230" contextRef="C_0000907654_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20210331" decimals="-3" unitRef="U_iso4217USD">38000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000231" contextRef="C_0000907654_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20201231" decimals="-3" unitRef="U_iso4217USD">38000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000232" contextRef="C_0000907654_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapSoftwareAndSoftwareDevelopmentCostsMember_20210331" decimals="-3" unitRef="U_iso4217USD">59000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000233" contextRef="C_0000907654_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapSoftwareAndSoftwareDevelopmentCostsMember_20201231" decimals="-3" unitRef="U_iso4217USD">56000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000234" contextRef="C_0000907654_20210331" decimals="-3" unitRef="U_iso4217USD">280000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000235" contextRef="C_0000907654_20201231" decimals="-3" unitRef="U_iso4217USD">271000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment id="F_000236" contextRef="C_0000907654_20210331" decimals="-3" unitRef="U_iso4217USD">253000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment id="F_000237" contextRef="C_0000907654_20201231" decimals="-3" unitRef="U_iso4217USD">250000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty id="F_000238" contextRef="C_0000907654_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_srtChiefExecutiveOfficerMember_20210101_20210331" decimals="-3" unitRef="U_iso4217USD">107000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
  <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty id="F_000239" contextRef="C_0000907654_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_srtChiefExecutiveOfficerMember_20200101_20200331" decimals="-3" unitRef="U_iso4217USD">70000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
  <us-gaap:AreaOfRealEstateProperty id="F_000240" contextRef="C_0000907654_20130801" decimals="-2" unitRef="U_utrsqft">5300</us-gaap:AreaOfRealEstateProperty>
  <us-gaap:AreaOfRealEstateProperty id="F_000241" contextRef="C_0000907654_20200829" decimals="-2" unitRef="U_utrsqft">5200</us-gaap:AreaOfRealEstateProperty>
  <us-gaap:LesseeOperatingLeaseTermOfContract id="F_000242" contextRef="C_0000907654_20200829">P42M</us-gaap:LesseeOperatingLeaseTermOfContract>
  <us-gaap:LesseeOperatingLeaseRenewalTerm id="F_000243" contextRef="C_0000907654_20200829">P36M</us-gaap:LesseeOperatingLeaseRenewalTerm>
  <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent id="F_000244" contextRef="C_0000907654_20200829" decimals="2" unitRef="U_xbrlipure">0.07</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
  <us-gaap:LesseeOperatingLeaseOptionToExtend id="F_000245" contextRef="C_0000907654_20200828_20200829">option to renew for an additional 36 month term at the then prevailing rental rate.</us-gaap:LesseeOperatingLeaseOptionToExtend>
  <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend id="F_000246" contextRef="C_0000907654_20200828_20200829">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
  <us-gaap:LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent id="F_000247" contextRef="C_0000907654_20210101_20210331">The lease includes real estate taxes and insurance, which is not a lease component and is not included in the lease obligation.  In addition, common area maintenance charges are based on actual costs incurred and are a non-lease component that is not included in the lease obligation.</us-gaap:LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear id="F_000248" contextRef="C_0000907654_20210331" decimals="-3" unitRef="U_iso4217USD">64000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths id="F_000249" contextRef="C_0000907654_20210331" decimals="-3" unitRef="U_iso4217USD">88000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo id="F_000250" contextRef="C_0000907654_20210331" decimals="-3" unitRef="U_iso4217USD">90000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree id="F_000251" contextRef="C_0000907654_20210331" decimals="-3" unitRef="U_iso4217USD">93000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour id="F_000252" contextRef="C_0000907654_20210331" decimals="-3" unitRef="U_iso4217USD">96000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
  <abio:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour id="F_000253" contextRef="C_0000907654_20210331" decimals="-3" unitRef="U_iso4217USD">125000</abio:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue id="F_000254" contextRef="C_0000907654_20210331" decimals="-3" unitRef="U_iso4217USD">556000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
  <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount id="F_000255" contextRef="C_0000907654_20210331" decimals="-3" unitRef="U_iso4217USD">106000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
  <us-gaap:OperatingLeaseLiabilityCurrent id="F_000256" contextRef="C_0000907654_20210331" decimals="-3" unitRef="U_iso4217USD">56000</us-gaap:OperatingLeaseLiabilityCurrent>
  <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList id="F_000257" contextRef="C_0000907654_20210331">us-gaap:OtherAccruedLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
  <us-gaap:OperatingLeaseCost id="F_000258" contextRef="C_0000907654_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20210101_20210331" decimals="-3" unitRef="U_iso4217USD">22000</us-gaap:OperatingLeaseCost>
  <us-gaap:OperatingLeaseCost id="F_000259" contextRef="C_0000907654_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20200101_20200331" decimals="-3" unitRef="U_iso4217USD">23000</us-gaap:OperatingLeaseCost>
  <us-gaap:OperatingLeasePayments id="F_000260" contextRef="C_0000907654_20210101_20210331" decimals="-3" unitRef="U_iso4217USD">7000</us-gaap:OperatingLeasePayments>
  <us-gaap:OperatingLeasePayments id="F_000261" contextRef="C_0000907654_20200101_20200331" decimals="-3" unitRef="U_iso4217USD">25000</us-gaap:OperatingLeasePayments>
  <us-gaap:OperatingLeaseLiability id="F_000262" contextRef="C_0000907654_20210331" decimals="-3" unitRef="U_iso4217USD">450000</us-gaap:OperatingLeaseLiability>
  <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList id="F_000263" contextRef="C_0000907654_20210331">us-gaap:OperatingLeaseLiabilityNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
  <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 id="F_000264" contextRef="C_0000907654_20210331">P6Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
  <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent id="F_000265" contextRef="C_0000907654_20210331" decimals="2" unitRef="U_xbrlipure">0.07</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
  <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices id="F_000266" contextRef="C_0000907654_us-gaapSubsidiarySaleOfStockAxis_abioDirectOfferingMember_20200603_20200603" decimals="INF" unitRef="U_xbrlishares">348000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
  <us-gaap:SaleOfStockPricePerShare id="F_000267" contextRef="C_0000907654_us-gaapSubsidiarySaleOfStockAxis_abioDirectOfferingMember_20200603" decimals="2" unitRef="U_iso4217USD_xbrlishares">9.00</us-gaap:SaleOfStockPricePerShare>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights id="F_000268" contextRef="C_0000907654_us-gaapSubsidiarySaleOfStockAxis_abioDirectOfferingMember_20200603" decimals="INF" unitRef="U_xbrlishares">325500</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="F_000269" contextRef="C_0000907654_us-gaapSubsidiarySaleOfStockAxis_abioDirectOfferingMember_20200603" decimals="3" unitRef="U_iso4217USD_xbrlishares">8.999</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ProceedsFromIssuanceOfCommonStock id="F_000270" contextRef="C_0000907654_us-gaapSubsidiarySaleOfStockAxis_abioDirectOfferingMember_20200603_20200603" decimals="-5" unitRef="U_iso4217USD">5300000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <abio:SellingCommissionPerAdditionalSharesSoldPercentage id="F_000271" contextRef="C_0000907654_us-gaapSubsidiarySaleOfStockAxis_abioDirectOfferingMember_20200603" decimals="3" unitRef="U_xbrlipure">0.080</abio:SellingCommissionPerAdditionalSharesSoldPercentage>
  <us-gaap:CommonStockParOrStatedValuePerShare id="F_000272" contextRef="C_0000907654_deiLegalEntityAxis_abioJonesTradingInstitutionalServicesLLCMember_us-gaapTypeOfArrangementAxis_abioCapitalOnDemandSalesAgreementMember_20170111" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <abio:CommonStockAuthorizedOfferingAmountUnderAgreementToSell id="F_000273" contextRef="C_0000907654_deiLegalEntityAxis_abioJonesTradingInstitutionalServicesLLCMember_us-gaapTypeOfArrangementAxis_abioCapitalOnDemandSalesAgreementMember_20170111" decimals="-5" unitRef="U_iso4217USD">7300000</abio:CommonStockAuthorizedOfferingAmountUnderAgreementToSell>
  <abio:CommonStockAuthorizedOfferingAmountUnderAgreementToSell id="F_000274" contextRef="C_0000907654_deiLegalEntityAxis_abioJonesTradingInstitutionalServicesLLCMember_us-gaapTypeOfArrangementAxis_abioCapitalOnDemandSalesAgreementMember_20200714" decimals="-5" unitRef="U_iso4217USD">32400000</abio:CommonStockAuthorizedOfferingAmountUnderAgreementToSell>
  <abio:SellingCommissionPerAdditionalSharesSoldPercentage id="F_000275" contextRef="C_0000907654_deiLegalEntityAxis_abioJonesTradingInstitutionalServicesLLCMember_20170111" decimals="3" unitRef="U_xbrlipure">0.030</abio:SellingCommissionPerAdditionalSharesSoldPercentage>
  <us-gaap:CommonStockSharesIssued id="F_000276" contextRef="C_0000907654_us-gaapTypeOfArrangementAxis_abioCapitalOnDemandSalesAgreementMember_20201231" decimals="INF" unitRef="U_xbrlishares">2214301</us-gaap:CommonStockSharesIssued>
  <abio:NetProceedsFromIssuanceOfCommonStock id="F_000277" contextRef="C_0000907654_us-gaapTypeOfArrangementAxis_abioCapitalOnDemandSalesAgreementMember_20200101_20201231" decimals="-5" unitRef="U_iso4217USD">14400000</abio:NetProceedsFromIssuanceOfCommonStock>
  <abio:CommonStockAuthorizedOfferingAmountUnderAgreementToSell id="F_000278" contextRef="C_0000907654_us-gaapTypeOfArrangementAxis_abioNewCapitalOnDemandSalesAgreementMember_20200722" decimals="-5" unitRef="U_iso4217USD">54000000</abio:CommonStockAuthorizedOfferingAmountUnderAgreementToSell>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000279" contextRef="C_0000907654_us-gaapTypeOfArrangementAxis_abioNewCapitalOnDemandSalesAgreementMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">5066279</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000280" contextRef="C_0000907654_us-gaapTypeOfArrangementAxis_abioNewCapitalOnDemandSalesAgreementMember_20210101_20210331" decimals="INF" unitRef="U_xbrlishares">4861993</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:ProceedsFromIssuanceOfCommonStock id="F_000281" contextRef="C_0000907654_us-gaapTypeOfArrangementAxis_abioNewCapitalOnDemandSalesAgreementMember_20200101_20201231" decimals="-5" unitRef="U_iso4217USD">28900000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfCommonStock id="F_000282" contextRef="C_0000907654_us-gaapTypeOfArrangementAxis_abioNewCapitalOnDemandSalesAgreementMember_20210101_20210331" decimals="-5" unitRef="U_iso4217USD">23300000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <abio:CommonStockAuthorizedOfferingAmountUnderAgreementToSell id="F_000283" contextRef="C_0000907654_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_abioNewCapitalOnDemandSalesAgreementMember_20210430" decimals="-5" unitRef="U_iso4217USD">50000000</abio:CommonStockAuthorizedOfferingAmountUnderAgreementToSell>
  <abio:WarrantsExpirationYear id="F_000284" contextRef="C_0000907654_us-gaapClassOfWarrantOrRightAxis_abioWarrantExpirationTwoThousandAndTwentyTwoMember_20210101_20210331">2022</abio:WarrantsExpirationYear>
  <us-gaap:ClassOfWarrantOrRightOutstanding id="F_000285" contextRef="C_0000907654_us-gaapClassOfWarrantOrRightAxis_abioWarrantExpirationTwoThousandAndTwentyTwoMember_20210331" decimals="0" unitRef="U_xbrlishares">133401</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="F_000286" contextRef="C_0000907654_us-gaapClassOfWarrantOrRightAxis_abioWarrantExpirationTwoThousandAndTwentyTwoMember_20210331" decimals="2" unitRef="U_iso4217USD_xbrlishares">109.80</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000287" contextRef="C_0000907654_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210101_20210331" decimals="-3" unitRef="U_iso4217USD">36000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000288" contextRef="C_0000907654_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20200331" decimals="-3" unitRef="U_iso4217USD">9000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000289" contextRef="C_0000907654_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20210101_20210331" decimals="-3" unitRef="U_iso4217USD">105000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000290" contextRef="C_0000907654_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20200101_20200331" decimals="-3" unitRef="U_iso4217USD">7000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000291" contextRef="C_0000907654_20210101_20210331" decimals="-3" unitRef="U_iso4217USD">141000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000292" contextRef="C_0000907654_20200101_20200331" decimals="-3" unitRef="U_iso4217USD">16000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="F_000293" contextRef="C_0000907654_20201231" decimals="INF" unitRef="U_xbrlishares">531238</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="F_000294" contextRef="C_0000907654_20210101_20210331" decimals="INF" unitRef="U_xbrlishares">67200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod id="F_000295" contextRef="C_0000907654_20210101_20210331" decimals="INF" unitRef="U_xbrlishares">1941</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="F_000296" contextRef="C_0000907654_20210331" decimals="INF" unitRef="U_xbrlishares">596497</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber id="F_000297" contextRef="C_0000907654_20210331" decimals="INF" unitRef="U_xbrlishares">66125</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber id="F_000298" contextRef="C_0000907654_20210331" decimals="INF" unitRef="U_xbrlishares">595774</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="F_000299" contextRef="C_0000907654_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">8.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice id="F_000300" contextRef="C_0000907654_20210101_20210331" decimals="2" unitRef="U_iso4217USD_xbrlishares">4.30</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice id="F_000301" contextRef="C_0000907654_20210101_20210331" decimals="2" unitRef="U_iso4217USD_xbrlishares">72.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="F_000302" contextRef="C_0000907654_20210331" decimals="2" unitRef="U_iso4217USD_xbrlishares">8.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice id="F_000303" contextRef="C_0000907654_20210331" decimals="2" unitRef="U_iso4217USD_xbrlishares">38.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice id="F_000304" contextRef="C_0000907654_20210331" decimals="2" unitRef="U_iso4217USD_xbrlishares">8.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 id="F_000305" contextRef="C_0000907654_20200101_20201231">P9Y8M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 id="F_000306" contextRef="C_0000907654_20210101_20210331">P9Y6M3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 id="F_000307" contextRef="C_0000907654_20210101_20210331">P7Y8M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 id="F_000308" contextRef="C_0000907654_20210101_20210331">P9Y6M3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
  <us-gaap:LiabilityForUncertainTaxPositionsCurrent id="F_000309" contextRef="C_0000907654_20210331" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:LiabilityForUncertainTaxPositionsCurrent>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>abio-20210331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-05-10T20:34:29.4323035+00:00 -->
<!-- Version            : 5.0.1.615 -->
<!-- Package ID         : beedb4a101e74518954371bca82a94aa -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:abio="http://www.arcabiopharma.com/20210331" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.arcabiopharma.com/20210331" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd" namespace="http://xbrl.sec.gov/country/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd" namespace="http://xbrl.sec.gov/currency/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" namespace="http://xbrl.sec.gov/dei/2020-01-31" />
  <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
  <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd" namespace="http://xbrl.sec.gov/exch/2020-01-31" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/negated" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/net" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" namespace="http://xbrl.sec.gov/naics/2017-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd" namespace="http://xbrl.sec.gov/sic/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd" namespace="http://fasb.org/srt/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd" namespace="http://fasb.org/srt-roles/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd" namespace="http://fasb.org/srt-types/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" namespace="http://xbrl.sec.gov/stpr/2018-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" namespace="http://fasb.org/us-gaap/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd" namespace="http://fasb.org/us-roles/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd" namespace="http://fasb.org/us-types/2020-01-31" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType id="TemplateLink" roleURI="http://www.arcabiopharma.com/20210331/role/TemplateLink" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>00000 - Document - Template Link</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="abio-20210331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation Links, all" xlink:type="simple" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="abio-20210331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="abio-20210331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="abio-20210331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.arcabiopharma.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/20210331/taxonomy/role/StatementBALANCESHEETSUnaudited" id="Role_StatementBALANCESHEETSUnaudited">
        <link:definition>100010 - Statement - BALANCE SHEETS (Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/20210331/taxonomy/role/StatementBALANCESHEETSUnauditedParenthetical" id="Role_StatementBALANCESHEETSUnauditedParenthetical">
        <link:definition>100020 - Statement - BALANCE SHEETS (Unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/20210331/taxonomy/role/StatementSTATEMENTSOFOPERATIONSUnaudited" id="Role_StatementSTATEMENTSOFOPERATIONSUnaudited">
        <link:definition>100030 - Statement - STATEMENTS OF OPERATIONS (Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/20210331/taxonomy/role/StatementSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" id="Role_StatementSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited">
        <link:definition>100040 - Statement - STATEMENTS OF STOCKHOLDERS&apos; EQUITY (Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/20210331/taxonomy/role/StatementSTATEMENTSOFCASHFLOWSUnaudited" id="Role_StatementSTATEMENTSOFCASHFLOWSUnaudited">
        <link:definition>100050 - Statement - STATEMENTS OF CASH FLOWS (Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPolicies" id="Role_DisclosureTheCompanyAndSummaryOfSignificantAccountingPolicies">
        <link:definition>100060 - Disclosure - The Company and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureNetLossPerShare" id="Role_DisclosureNetLossPerShare">
        <link:definition>100070 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureFairValueDisclosures" id="Role_DisclosureFairValueDisclosures">
        <link:definition>100080 - Disclosure - Fair Value Disclosures</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosurePropertyAndEquipment" id="Role_DisclosurePropertyAndEquipment">
        <link:definition>100090 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureRelatedPartyArrangements" id="Role_DisclosureRelatedPartyArrangements">
        <link:definition>100100 - Disclosure - Related Party Arrangements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingencies" id="Role_DisclosureCommitmentsAndContingencies">
        <link:definition>100110 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureEquityFinancingsAndWarrants" id="Role_DisclosureEquityFinancingsAndWarrants">
        <link:definition>100120 - Disclosure - Equity Financings and Warrants</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureShareBasedCompensation" id="Role_DisclosureShareBasedCompensation">
        <link:definition>100130 - Disclosure - Share-based Compensation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>100140 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesPolicies" id="Role_DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>100150 - Disclosure - The Company and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureNetLossPerShareTables" id="Role_DisclosureNetLossPerShareTables">
        <link:definition>100160 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosurePropertyAndEquipmentTables" id="Role_DisclosurePropertyAndEquipmentTables">
        <link:definition>100170 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" id="Role_DisclosureCommitmentsAndContingenciesTables">
        <link:definition>100180 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureEquityFinancingsAndWarrantsTables" id="Role_DisclosureEquityFinancingsAndWarrantsTables">
        <link:definition>100190 - Disclosure - Equity Financings and Warrants (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureShareBasedCompensationTables" id="Role_DisclosureShareBasedCompensationTables">
        <link:definition>100200 - Disclosure - Share-based Compensation (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesDetailsTextual" id="Role_DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesDetailsTextual">
        <link:definition>100210 - Disclosure - The Company and Summary of Significant Accounting Policies (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureNetLossPerShareSummaryOfPotentiallyDilutiveSharesOfCommonStockDetails" id="Role_DisclosureNetLossPerShareSummaryOfPotentiallyDilutiveSharesOfCommonStockDetails">
        <link:definition>100220 - Disclosure - Net Loss Per Share - Summary of Potentially Dilutive Shares of Common Stock (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureFairValueDisclosuresDetailsTextual" id="Role_DisclosureFairValueDisclosuresDetailsTextual">
        <link:definition>100230 - Disclosure - Fair Value Disclosures (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails" id="Role_DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails">
        <link:definition>100240 - Disclosure - Property and Equipment - Summary of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosurePropertyAndEquipmentDetailsTextual" id="Role_DisclosurePropertyAndEquipmentDetailsTextual">
        <link:definition>100250 - Disclosure - Property and Equipment (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureRelatedPartyArrangementsDetailsTextual" id="Role_DisclosureRelatedPartyArrangementsDetailsTextual">
        <link:definition>100260 - Disclosure - Related Party Arrangements (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingenciesDetailsTextual" id="Role_DisclosureCommitmentsAndContingenciesDetailsTextual">
        <link:definition>100270 - Disclosure - Commitments and Contingencies (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumCommitmentsDueUnderOctober2020LeaseAgreementDetails" id="Role_DisclosureCommitmentsAndContingenciesFutureMinimumCommitmentsDueUnderOctober2020LeaseAgreementDetails">
        <link:definition>100280 - Disclosure - Commitments and Contingencies - Future Minimum Commitments due Under October 2020 Lease Agreement (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumCommitmentsDueUnderOctober2020LeaseAgreementDetails2" id="Role_DisclosureCommitmentsAndContingenciesFutureMinimumCommitmentsDueUnderOctober2020LeaseAgreementDetails2">
        <link:definition>100290 - Disclosure - Commitments and Contingencies - Future Minimum Commitments due Under October 2020 Lease Agreement (Details)2</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureEquityFinancingsAndWarrantsDetailsTextual" id="Role_DisclosureEquityFinancingsAndWarrantsDetailsTextual">
        <link:definition>100300 - Disclosure - Equity Financings and Warrants (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureEquityFinancingsAndWarrantsSummaryOfWarrantsByYearOfExpirationDetails" id="Role_DisclosureEquityFinancingsAndWarrantsSummaryOfWarrantsByYearOfExpirationDetails">
        <link:definition>100310 - Disclosure - Equity Financings and Warrants - Summary of Warrants by Year of Expiration (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureShareBasedCompensationSummaryOfNonCashShareBasedCompensationExpenseDetails" id="Role_DisclosureShareBasedCompensationSummaryOfNonCashShareBasedCompensationExpenseDetails">
        <link:definition>100320 - Disclosure - Share-based Compensation - Summary of Non-cash, Share-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureShareBasedCompensationSummaryOfStockOptionActivitiesDetails" id="Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivitiesDetails">
        <link:definition>100330 - Disclosure - Share-based Compensation - Summary of Stock Option Activities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureIncomeTaxesDetailsTextual" id="Role_DisclosureIncomeTaxesDetailsTextual">
        <link:definition>100340 - Disclosure - Income Taxes (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="abio_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" name="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="abio_IssuanceOfCommonStockAndExerciseOfPrefundedWarrantsShares" name="IssuanceOfCommonStockAndExerciseOfPrefundedWarrantsShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="abio_IssuanceOfCommonStockAndExerciseOfPrefundedWarrants" name="IssuanceOfCommonStockAndExerciseOfPrefundedWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="abio_VendorFinanceAgreement" name="VendorFinanceAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="abio_EquityFinancingsAndWarrantsDisclosureTextBlock" name="EquityFinancingsAndWarrantsDisclosureTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="abio_DescriptionOfBusinessPolicyTextBlock" name="DescriptionOfBusinessPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="abio_LiquidityAndGoingConcernPolicyTextBlock" name="LiquidityAndGoingConcernPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="abio_ComprehensiveLossPolicyPolicyTextBlock" name="ComprehensiveLossPolicyPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="abio_AccruedOutsourcingExpensesPolicyTextBlock" name="AccruedOutsourcingExpensesPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount" name="FairValueAssetsBetweenHierarchyLevelsTransfersAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="abio_CommitmentsAndContingenciesLineItems" name="CommitmentsAndContingenciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="abio_CommitmentsAndContingenciesTable" name="CommitmentsAndContingenciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="abio_SellingCommissionPerAdditionalSharesSoldPercentage" name="SellingCommissionPerAdditionalSharesSoldPercentage" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="abio_EquityFinancingAndWarrantsLineItems" name="EquityFinancingAndWarrantsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="abio_EquityFinancingAndWarrantsTable" name="EquityFinancingAndWarrantsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="abio_DirectOfferingMember" name="DirectOfferingMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="abio_CapitalOnDemandSalesAgreementMember" name="CapitalOnDemandSalesAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="abio_JonesTradingInstitutionalServicesLLCMember" name="JonesTradingInstitutionalServicesLLCMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="abio_NewCapitalOnDemandSalesAgreementMember" name="NewCapitalOnDemandSalesAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="abio_CommonStockAuthorizedOfferingAmountUnderAgreementToSell" name="CommonStockAuthorizedOfferingAmountUnderAgreementToSell" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="abio_NetProceedsFromIssuanceOfCommonStock" name="NetProceedsFromIssuanceOfCommonStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="abio_WarrantsExpirationYear" name="WarrantsExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="abio_WarrantExpirationTwoThousandAndTwentyTwoMember" name="WarrantExpirationTwoThousandAndTwentyTwoMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>11
<FILENAME>abio-20210331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-05-10T20:34:29.4323035+00:00 -->
<!-- Version            : 5.0.1.615 -->
<!-- Package ID         : beedb4a101e74518954371bca82a94aa -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef xlink:type="simple" xlink:href="abio-20210331.xsd#TemplateLink" roleURI="http://www.arcabiopharma.com/20210331/role/TemplateLink" />
  <link:roleRef roleURI="http://www.arcabiopharma.com/20210331/taxonomy/role/StatementBALANCESHEETSUnaudited" xlink:href="abio-20210331.xsd#Role_StatementBALANCESHEETSUnaudited" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20210331/taxonomy/role/StatementBALANCESHEETSUnaudited">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10130.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10140.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="10150.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10160.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent" order="10170.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arcabiopharma.com/20210331/taxonomy/role/StatementSTATEMENTSOFOPERATIONSUnaudited" xlink:href="abio-20210331.xsd#Role_StatementSTATEMENTSOFOPERATIONSUnaudited" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20210331/taxonomy/role/StatementSTATEMENTSOFOPERATIONSUnaudited">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:type="locator" xlink:label="us-gaap_InterestExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestAndOtherIncome" xlink:type="locator" xlink:label="us-gaap_InterestAndOtherIncome" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_InterestAndOtherIncome" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_InterestExpense" order="10030.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="10040.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10060.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arcabiopharma.com/20210331/taxonomy/role/StatementSTATEMENTSOFCASHFLOWSUnaudited" xlink:href="abio-20210331.xsd#Role_StatementSTATEMENTSOFCASHFLOWSUnaudited" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20210331/taxonomy/role/StatementSTATEMENTSOFCASHFLOWSUnaudited">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="10050.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="10060.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationAndAmortization" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets" order="10110.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" order="10130.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="10140.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails" xlink:href="abio-20210331.xsd#Role_DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10600.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10610.00" priority="2" use="optional" weight="-1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumCommitmentsDueUnderOctober2020LeaseAgreementDetails" xlink:href="abio-20210331.xsd#Role_DisclosureCommitmentsAndContingenciesFutureMinimumCommitmentsDueUnderOctober2020LeaseAgreementDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumCommitmentsDueUnderOctober2020LeaseAgreementDetails">
    <link:loc xlink:href="abio-20210331.xsd#abio_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:type="locator" xlink:label="abio_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="abio_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" order="10060.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumCommitmentsDueUnderOctober2020LeaseAgreementDetails2" xlink:href="abio-20210331.xsd#Role_DisclosureCommitmentsAndContingenciesFutureMinimumCommitmentsDueUnderOctober2020LeaseAgreementDetails2" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumCommitmentsDueUnderOctober2020LeaseAgreementDetails2">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="10030.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>12
<FILENAME>abio-20210331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-05-10T20:34:29.4323035+00:00 -->
<!-- Version            : 5.0.1.615 -->
<!-- Package ID         : beedb4a101e74518954371bca82a94aa -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <link:roleRef xlink:type="simple" xlink:href="abio-20210331.xsd#TemplateLink" roleURI="http://www.arcabiopharma.com/20210331/role/TemplateLink" />
  <link:roleRef roleURI="http://www.arcabiopharma.com/20210331/taxonomy/role/StatementSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" xlink:href="abio-20210331.xsd#Role_StatementSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20210331/taxonomy/role/StatementSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="abio-20210331.xsd#abio_IssuanceOfCommonStockAndExerciseOfPrefundedWarrantsShares" xlink:type="locator" xlink:label="abio_IssuanceOfCommonStockAndExerciseOfPrefundedWarrantsShares" />
    <link:loc xlink:href="abio-20210331.xsd#abio_IssuanceOfCommonStockAndExerciseOfPrefundedWarrants" xlink:type="locator" xlink:label="abio_IssuanceOfCommonStockAndExerciseOfPrefundedWarrants" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="abio_IssuanceOfCommonStockAndExerciseOfPrefundedWarrants" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="abio_IssuanceOfCommonStockAndExerciseOfPrefundedWarrantsShares" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="10540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="10660.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureNetLossPerShareSummaryOfPotentiallyDilutiveSharesOfCommonStockDetails" xlink:href="abio-20210331.xsd#Role_DisclosureNetLossPerShareSummaryOfPotentiallyDilutiveSharesOfCommonStockDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureNetLossPerShareSummaryOfPotentiallyDilutiveSharesOfCommonStockDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:type="locator" xlink:label="us-gaap_WarrantMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockOptionMember" xlink:type="locator" xlink:label="us-gaap_StockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_StockOptionMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10140.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureFairValueDisclosuresDetailsTextual" xlink:href="abio-20210331.xsd#Role_DisclosureFairValueDisclosuresDetailsTextual" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureFairValueDisclosuresDetailsTextual">
    <link:loc xlink:href="abio-20210331.xsd#abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount" xlink:type="locator" xlink:label="abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount" order="10350.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails" xlink:href="abio-20210331.xsd#Role_DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:type="locator" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquipmentMember" xlink:type="locator" xlink:label="us-gaap_EquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10860.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10900.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureRelatedPartyArrangementsDetailsTextual" xlink:href="abio-20210331.xsd#Role_DisclosureRelatedPartyArrangementsDetailsTextual" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureRelatedPartyArrangementsDetailsTextual">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ChiefExecutiveOfficerMember" xlink:type="locator" xlink:label="srt_ChiefExecutiveOfficerMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="srt_ChiefExecutiveOfficerMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_2" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" order="10180.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingenciesDetailsTextual" xlink:href="abio-20210331.xsd#Role_DisclosureCommitmentsAndContingenciesDetailsTextual" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingenciesDetailsTextual">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:type="locator" xlink:label="us-gaap_AreaOfRealEstateProperty" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="abio-20210331.xsd#abio_CommitmentsAndContingenciesTable" xlink:type="locator" xlink:label="abio_CommitmentsAndContingenciesTable" />
    <link:loc xlink:href="abio-20210331.xsd#abio_CommitmentsAndContingenciesLineItems" xlink:type="locator" xlink:label="abio_CommitmentsAndContingenciesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="abio_CommitmentsAndContingenciesLineItems" xlink:to="abio_CommitmentsAndContingenciesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_CommitmentsAndContingenciesTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_AreaOfRealEstateProperty" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_OperatingLeaseCost" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_OperatingLeasePayments" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" order="10490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="10570.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureEquityFinancingsAndWarrantsDetailsTextual" xlink:href="abio-20210331.xsd#Role_DisclosureEquityFinancingsAndWarrantsDetailsTextual" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureEquityFinancingsAndWarrantsDetailsTextual">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="abio-20210331.xsd#abio_NetProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="abio_NetProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="abio-20210331.xsd#abio_CommonStockAuthorizedOfferingAmountUnderAgreementToSell" xlink:type="locator" xlink:label="abio_CommonStockAuthorizedOfferingAmountUnderAgreementToSell" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="abio-20210331.xsd#abio_SellingCommissionPerAdditionalSharesSoldPercentage" xlink:type="locator" xlink:label="abio_SellingCommissionPerAdditionalSharesSoldPercentage" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:loc xlink:href="abio-20210331.xsd#abio_NewCapitalOnDemandSalesAgreementMember" xlink:type="locator" xlink:label="abio_NewCapitalOnDemandSalesAgreementMember" />
    <link:loc xlink:href="abio-20210331.xsd#abio_JonesTradingInstitutionalServicesLLCMember" xlink:type="locator" xlink:label="abio_JonesTradingInstitutionalServicesLLCMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain_2" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <link:loc xlink:href="abio-20210331.xsd#abio_CapitalOnDemandSalesAgreementMember" xlink:type="locator" xlink:label="abio_CapitalOnDemandSalesAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="abio-20210331.xsd#abio_DirectOfferingMember" xlink:type="locator" xlink:label="abio_DirectOfferingMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="abio-20210331.xsd#abio_EquityFinancingAndWarrantsTable" xlink:type="locator" xlink:label="abio_EquityFinancingAndWarrantsTable" />
    <link:loc xlink:href="abio-20210331.xsd#abio_EquityFinancingAndWarrantsLineItems" xlink:type="locator" xlink:label="abio_EquityFinancingAndWarrantsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="abio_EquityFinancingAndWarrantsLineItems" xlink:to="abio_EquityFinancingAndWarrantsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_EquityFinancingAndWarrantsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="abio_DirectOfferingMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_EquityFinancingAndWarrantsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="abio_CapitalOnDemandSalesAgreementMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_EquityFinancingAndWarrantsTable" xlink:to="dei_LegalEntityAxis" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_2" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="abio_JonesTradingInstitutionalServicesLLCMember" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="abio_NewCapitalOnDemandSalesAgreementMember" order="10490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_EquityFinancingAndWarrantsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_2" order="10550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="10590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_EquityFinancingAndWarrantsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="10620.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_EquityFinancingAndWarrantsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="10640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_EquityFinancingAndWarrantsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="10660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_EquityFinancingAndWarrantsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="10680.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_EquityFinancingAndWarrantsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="10700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_EquityFinancingAndWarrantsLineItems" xlink:to="abio_SellingCommissionPerAdditionalSharesSoldPercentage" order="10720.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_EquityFinancingAndWarrantsLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10770.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_EquityFinancingAndWarrantsLineItems" xlink:to="abio_CommonStockAuthorizedOfferingAmountUnderAgreementToSell" order="10810.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_EquityFinancingAndWarrantsLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="10990.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_EquityFinancingAndWarrantsLineItems" xlink:to="abio_NetProceedsFromIssuanceOfCommonStock" order="11010.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_EquityFinancingAndWarrantsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="11120.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureEquityFinancingsAndWarrantsSummaryOfWarrantsByYearOfExpirationDetails" xlink:href="abio-20210331.xsd#Role_DisclosureEquityFinancingsAndWarrantsSummaryOfWarrantsByYearOfExpirationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureEquityFinancingsAndWarrantsSummaryOfWarrantsByYearOfExpirationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <link:loc xlink:href="abio-20210331.xsd#abio_WarrantsExpirationYear" xlink:type="locator" xlink:label="abio_WarrantsExpirationYear" />
    <link:loc xlink:href="abio-20210331.xsd#abio_WarrantExpirationTwoThousandAndTwentyTwoMember" xlink:type="locator" xlink:label="abio_WarrantExpirationTwoThousandAndTwentyTwoMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="abio_WarrantExpirationTwoThousandAndTwentyTwoMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="abio_WarrantsExpirationYear" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="10200.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureShareBasedCompensationSummaryOfNonCashShareBasedCompensationExpenseDetails" xlink:href="abio-20210331.xsd#Role_DisclosureShareBasedCompensationSummaryOfNonCashShareBasedCompensationExpenseDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureShareBasedCompensationSummaryOfNonCashShareBasedCompensationExpenseDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10140.00" priority="2" use="optional" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>13
<FILENAME>abio-20210331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-05-10T20:34:29.4323035+00:00 -->
<!-- Version            : 5.0.1.615 -->
<!-- Package ID         : beedb4a101e74518954371bca82a94aa -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/axisDefault" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd#axisDefault" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:href="abio-20210331.xsd#abio_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:type="locator" xlink:label="abio_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" />
    <link:label xml:lang="en-US" xlink:label="abio_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating lease liability payments due after year four.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:to="abio_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:type="locator" xlink:label="dei_EntitySmallBusiness" />
    <link:label xml:lang="en-US" xlink:label="dei_EntitySmallBusiness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntitySmallBusiness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:type="locator" xlink:label="dei_EntityShellCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityShellCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityShellCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line1</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line2</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address City Or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address State Or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport" xlink:type="locator" xlink:label="dei_DocumentQuarterlyReport" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentQuarterlyReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Quarterly Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentQuarterlyReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Quarterly Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:type="locator" xlink:label="dei_DocumentTransitionReport" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentTransitionReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentTransitionReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Financial Position [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASSETS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents At Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use asset - operating</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Right Of Use Asset</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued compensation and employee benefits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Related Liabilities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liability, net of current portion</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Liabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Liabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&#8217; equity:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.001 par value; 100 million shares authorized at March 31, 2021 and December 31, 2020; 14,410,143 and 9,548,150 shares issued and outstanding at March 31, 2021 and December 31, 2020, respectively</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings Accumulated Deficit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders&#8217; equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders&#8217; equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Par Or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Costs and expenses:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total costs and expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestAndOtherIncome" xlink:type="locator" xlink:label="us-gaap_InterestAndOtherIncome" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestAndOtherIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest and other income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestAndOtherIncome" xlink:to="us-gaap_InterestAndOtherIncome_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestAndOtherIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest And Other Income</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:type="locator" xlink:label="us-gaap_InterestExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Interest expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Basic And Diluted [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basic and diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Basic And Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average shares outstanding:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Basic And Diluted Other Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basic and diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Share Outstanding Basic And Diluted</link:label>
    <link:loc xlink:href="abio-20210331.xsd#abio_IssuanceOfCommonStockAndExerciseOfPrefundedWarrantsShares" xlink:type="locator" xlink:label="abio_IssuanceOfCommonStockAndExerciseOfPrefundedWarrantsShares" />
    <link:label xml:lang="en-US" xlink:label="abio_IssuanceOfCommonStockAndExerciseOfPrefundedWarrantsShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of common stock and exercise of prefunded warrants shares.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_IssuanceOfCommonStockAndExerciseOfPrefundedWarrantsShares" xlink:to="abio_IssuanceOfCommonStockAndExerciseOfPrefundedWarrantsShares_lbl" />
    <link:loc xlink:href="abio-20210331.xsd#abio_IssuanceOfCommonStockAndExerciseOfPrefundedWarrants" xlink:type="locator" xlink:label="abio_IssuanceOfCommonStockAndExerciseOfPrefundedWarrants" />
    <link:label xml:lang="en-US" xlink:label="abio_IssuanceOfCommonStockAndExerciseOfPrefundedWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of common stock and exercise of prefunded warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_IssuanceOfCommonStockAndExerciseOfPrefundedWarrants" xlink:to="abio_IssuanceOfCommonStockAndExerciseOfPrefundedWarrants_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Stockholders Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-In Capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance, shares</link:label>
    <link:label xml:lang="en-US" xlink:label="abio_IssuanceOfCommonStockAndExerciseOfPrefundedWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock and exercise of prefunded warrants for cash, net of offering costs</link:label>
    <link:label xml:lang="en-US" xlink:label="abio_IssuanceOfCommonStockAndExerciseOfPrefundedWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Common Stock And Exercise Of Prefunded Warrants</link:label>
    <link:label xml:lang="en-US" xlink:label="abio_IssuanceOfCommonStockAndExerciseOfPrefundedWarrantsShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock and exercise of prefunded warrants for cash, net of offering costs, shares</link:label>
    <link:label xml:lang="en-US" xlink:label="abio_IssuanceOfCommonStockAndExerciseOfPrefundedWarrantsShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Common Stock And Exercise Of Prefunded Warrants Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock for cash, net of offering costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock for cash, net of offering costs, shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance, shares</link:label>
    <link:loc xlink:href="abio-20210331.xsd#abio_VendorFinanceAgreement" xlink:type="locator" xlink:label="abio_VendorFinanceAgreement" />
    <link:label xml:lang="en-US" xlink:label="abio_VendorFinanceAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Remaining amount of asset increase which was financed under an agreement with the vendor.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_VendorFinanceAgreement" xlink:to="abio_VendorFinanceAgreement_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Cash Flows [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation And Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of right-of-use asset - operating</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Right Of Use Asset Amortization Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in operating assets and liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Other Current Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued compensation and employee benefits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Employee Related Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accrued Liabilities And Other Operating Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from investing activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Property Plant And Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in investing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from the issuance of common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Common stock offering costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments Of Stock Issuance Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and cash equivalents, beginning of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and cash equivalents, end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental cash flow information:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet" xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest paid</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest Paid Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIncomeTaxRefunds" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIncomeTaxRefunds" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIncomeTaxRefunds_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax refund received</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIncomeTaxRefunds" xlink:to="us-gaap_ProceedsFromIncomeTaxRefunds_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIncomeTaxRefunds_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Income Tax Refunds</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosure of noncash investing and financing transactions:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="locator" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchases of property and equipment in accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Capital Expenditures Incurred But Not Yet Paid</link:label>
    <link:label xml:lang="en-US" xlink:label="abio_VendorFinanceAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vendor finance agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="abio_VendorFinanceAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Vendor Finance Agreement</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leased assets obtained in exchange for operating lease liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Right Of Use Asset Obtained In Exchange For Operating Lease Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">The Company and Summary of Significant Accounting Policies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements Disclosure And Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Disclosures</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Arrangements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:href="abio-20210331.xsd#abio_EquityFinancingsAndWarrantsDisclosureTextBlock" xlink:type="locator" xlink:label="abio_EquityFinancingsAndWarrantsDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="abio_EquityFinancingsAndWarrantsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Description of equity financings during the periods presented and information related to outstanding warrants of company stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_EquityFinancingsAndWarrantsDisclosureTextBlock" xlink:to="abio_EquityFinancingsAndWarrantsDisclosureTextBlock_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="abio_EquityFinancingsAndWarrantsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Financings and Warrants</link:label>
    <link:label xml:lang="en-US" xlink:label="abio_EquityFinancingsAndWarrantsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Financings And Warrants Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Share Based Payments [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:href="abio-20210331.xsd#abio_DescriptionOfBusinessPolicyTextBlock" xlink:type="locator" xlink:label="abio_DescriptionOfBusinessPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="abio_DescriptionOfBusinessPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Description of business.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_DescriptionOfBusinessPolicyTextBlock" xlink:to="abio_DescriptionOfBusinessPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="abio_DescriptionOfBusinessPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description of Business</link:label>
    <link:label xml:lang="en-US" xlink:label="abio_DescriptionOfBusinessPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Description Of Business Policy [Text Block]</link:label>
    <link:loc xlink:href="abio-20210331.xsd#abio_LiquidityAndGoingConcernPolicyTextBlock" xlink:type="locator" xlink:label="abio_LiquidityAndGoingConcernPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="abio_LiquidityAndGoingConcernPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Liquidity and going concern.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_LiquidityAndGoingConcernPolicyTextBlock" xlink:to="abio_LiquidityAndGoingConcernPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="abio_LiquidityAndGoingConcernPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liquidity and Going Concern</link:label>
    <link:label xml:lang="en-US" xlink:label="abio_LiquidityAndGoingConcernPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liquidity And Going Concern Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Basis Of Accounting Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentrations of Credit Risk</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Credit Risk</link:label>
    <link:loc xlink:href="abio-20210331.xsd#abio_ComprehensiveLossPolicyPolicyTextBlock" xlink:type="locator" xlink:label="abio_ComprehensiveLossPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="abio_ComprehensiveLossPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Comprehensive loss policy.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ComprehensiveLossPolicyPolicyTextBlock" xlink:to="abio_ComprehensiveLossPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="abio_ComprehensiveLossPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive Loss</link:label>
    <link:label xml:lang="en-US" xlink:label="abio_ComprehensiveLossPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Loss Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Leases Policy [Text Block]</link:label>
    <link:loc xlink:href="abio-20210331.xsd#abio_AccruedOutsourcingExpensesPolicyTextBlock" xlink:type="locator" xlink:label="abio_AccruedOutsourcingExpensesPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="abio_AccruedOutsourcingExpensesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued outsourcing expenses.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_AccruedOutsourcingExpensesPolicyTextBlock" xlink:to="abio_AccruedOutsourcingExpensesPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="abio_AccruedOutsourcingExpensesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Outsourcing Expenses</link:label>
    <link:label xml:lang="en-US" xlink:label="abio_AccruedOutsourcingExpensesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Outsourcing Expenses Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recent Accounting Pronouncements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Potentially Dilutive Shares of Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Property and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Future Minimum Commitments due Under October 2020 Lease Agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Future Minimum Rental Payments For Operating Leases Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Warrants by Year of Expiration</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Stockholders Equity Note Warrants Or Rights [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Non-cash, Share-based Compensation Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock Option Activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:type="locator" xlink:label="us-gaap_Revenues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Revenues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenues</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Revenues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosureOffbalanceSheetRisksAmountAsset" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosureOffbalanceSheetRisksAmountAsset" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosureOffbalanceSheetRisksAmountAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentrations of credit risk</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosureOffbalanceSheetRisksAmountAsset" xlink:to="us-gaap_FairValueDisclosureOffbalanceSheetRisksAmountAsset_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosureOffbalanceSheetRisksAmountAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosure Offbalance Sheet Risks Amount Asset</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockOptionMember" xlink:type="locator" xlink:label="us-gaap_StockOptionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:type="locator" xlink:label="us-gaap_WarrantMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WarrantMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants to purchase common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WarrantMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrant [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Measurement Frequency [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Frequency [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements, Recurring</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements Recurring [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Fair Value Hierarchy Level [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements Fair Value Hierarchy [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 1</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level1 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Asset Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation By Asset Class [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money Market Funds</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Marketable securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Debt Securities</link:label>
    <link:loc xlink:href="abio-20210331.xsd#abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount" xlink:type="locator" xlink:label="abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount" />
    <link:label xml:lang="en-US" xlink:label="abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value assets between hierarchy levels transfers amount.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount" xlink:to="abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash equivalents consisting of money market funds and commercial paper</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Fair Value Disclosure</link:label>
    <link:label xml:lang="en-US" xlink:label="abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transfers of assets between fair value hierarchy levels</link:label>
    <link:label xml:lang="en-US" xlink:label="abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets Between Hierarchy Levels Transfers Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment By Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Computer Equipment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquipmentMember" xlink:type="locator" xlink:label="us-gaap_EquipmentMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lab Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equipment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture and Fixtures</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Furniture And Fixtures [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:type="locator" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer Software</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Software And Software Development Costs [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property Plant And Equipment [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated Life</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Useful Life</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated Life</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Estimated Useful Lives</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment, Gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accumulated depreciation and amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation Depletion And Amortization Property Plant And Equipment</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property and equipment, net</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Depreciation and amortization expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Related Party Transactions By Related Party [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Related Party Transactions By Related Party [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions By Related Party [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ChiefExecutiveOfficerMember" xlink:type="locator" xlink:label="srt_ChiefExecutiveOfficerMember" />
    <link:label xml:lang="en-US" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Chief Executive Officer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Chief Executive Officer [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research Grants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction Expenses From Transactions With Related Party</link:label>
    <link:loc xlink:href="abio-20210331.xsd#abio_CommitmentsAndContingenciesLineItems" xlink:type="locator" xlink:label="abio_CommitmentsAndContingenciesLineItems" />
    <link:label xml:lang="en-US" xlink:label="abio_CommitmentsAndContingenciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitments and contingencies.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_CommitmentsAndContingenciesLineItems" xlink:to="abio_CommitmentsAndContingenciesLineItems_lbl" />
    <link:loc xlink:href="abio-20210331.xsd#abio_CommitmentsAndContingenciesTable" xlink:type="locator" xlink:label="abio_CommitmentsAndContingenciesTable" />
    <link:label xml:lang="en-US" xlink:label="abio_CommitmentsAndContingenciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitments and contingencies.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_CommitmentsAndContingenciesTable" xlink:to="abio_CommitmentsAndContingenciesTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="abio_CommitmentsAndContingenciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments And Contingencies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="abio_CommitmentsAndContingenciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="abio_CommitmentsAndContingenciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments And Contingencies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="abio_CommitmentsAndContingenciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:type="locator" xlink:label="us-gaap_AreaOfRealEstateProperty" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AreaOfRealEstateProperty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Area of office facilities taken on lease</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfRealEstateProperty" xlink:to="us-gaap_AreaOfRealEstateProperty_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AreaOfRealEstateProperty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Area Of Real Estate Property</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Term Of Contract</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional operating lease term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Renewal Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average discount rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Weighted Average Discount Rate Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease renewal option</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Option To Extend</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee, Operating Lease, Existence of Option to Extend [true false]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Existence Of Option To Extend</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee, operating lease, assumptions and judgments, allocation of lease and nonlease component</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent" xlink:to="us-gaap_LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Assumptions And Judgments Allocation Of Lease And Nonlease Component</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remainder of 2021</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Remainder Of Fiscal Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Four</link:label>
    <link:label xml:lang="en-US" xlink:label="abio_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
    <link:label xml:lang="en-US" xlink:label="abio_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due After Year Four</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total remaining lease payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: imputed lease interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Undiscounted Excess Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: Current portion</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability Current Statement Of Financial Position Extensible List</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rent expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, cash paid for measurement of lease liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Payments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Lease liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average remaining lease term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Weighted Average Remaining Lease Term1</link:label>
    <link:loc xlink:href="abio-20210331.xsd#abio_SellingCommissionPerAdditionalSharesSoldPercentage" xlink:type="locator" xlink:label="abio_SellingCommissionPerAdditionalSharesSoldPercentage" />
    <link:label xml:lang="en-US" xlink:label="abio_SellingCommissionPerAdditionalSharesSoldPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Selling commission per additional shares sold percentage.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_SellingCommissionPerAdditionalSharesSoldPercentage" xlink:to="abio_SellingCommissionPerAdditionalSharesSoldPercentage_lbl" />
    <link:loc xlink:href="abio-20210331.xsd#abio_EquityFinancingAndWarrantsLineItems" xlink:type="locator" xlink:label="abio_EquityFinancingAndWarrantsLineItems" />
    <link:label xml:lang="en-US" xlink:label="abio_EquityFinancingAndWarrantsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Equity financing and warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_EquityFinancingAndWarrantsLineItems" xlink:to="abio_EquityFinancingAndWarrantsLineItems_lbl" />
    <link:loc xlink:href="abio-20210331.xsd#abio_EquityFinancingAndWarrantsTable" xlink:type="locator" xlink:label="abio_EquityFinancingAndWarrantsTable" />
    <link:label xml:lang="en-US" xlink:label="abio_EquityFinancingAndWarrantsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Equity financing and warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_EquityFinancingAndWarrantsTable" xlink:to="abio_EquityFinancingAndWarrantsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="abio_EquityFinancingAndWarrantsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Financing And Warrants [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="abio_EquityFinancingAndWarrantsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Financing And Warrants [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary Sale Of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Name Of Transaction [Domain]</link:label>
    <link:loc xlink:href="abio-20210331.xsd#abio_DirectOfferingMember" xlink:type="locator" xlink:label="abio_DirectOfferingMember" />
    <link:label xml:lang="en-US" xlink:label="abio_DirectOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Direct offering.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_DirectOfferingMember" xlink:to="abio_DirectOfferingMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="abio_DirectOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Direct Offering</link:label>
    <link:label xml:lang="en-US" xlink:label="abio_DirectOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Direct Offering [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Type Of Arrangement [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Arrangements And Nonarrangement Transactions [Member]</link:label>
    <link:loc xlink:href="abio-20210331.xsd#abio_CapitalOnDemandSalesAgreementMember" xlink:type="locator" xlink:label="abio_CapitalOnDemandSalesAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="abio_CapitalOnDemandSalesAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Capital on demand sales agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_CapitalOnDemandSalesAgreementMember" xlink:to="abio_CapitalOnDemandSalesAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="abio_CapitalOnDemandSalesAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="abio_CapitalOnDemandSalesAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Capital On Demand Sales Agreement [Member]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <link:label xml:lang="en-US" xlink:label="dei_LegalEntityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Legal Entity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LegalEntityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Legal Entity [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity [Domain]</link:label>
    <link:loc xlink:href="abio-20210331.xsd#abio_JonesTradingInstitutionalServicesLLCMember" xlink:type="locator" xlink:label="abio_JonesTradingInstitutionalServicesLLCMember" />
    <link:label xml:lang="en-US" xlink:label="abio_JonesTradingInstitutionalServicesLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">JonesTrading Institutional Services LLC.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_JonesTradingInstitutionalServicesLLCMember" xlink:to="abio_JonesTradingInstitutionalServicesLLCMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="abio_JonesTradingInstitutionalServicesLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">JonesTrading</link:label>
    <link:label xml:lang="en-US" xlink:label="abio_JonesTradingInstitutionalServicesLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Jones Trading Institutional Services L L C [Member]</link:label>
    <link:loc xlink:href="abio-20210331.xsd#abio_NewCapitalOnDemandSalesAgreementMember" xlink:type="locator" xlink:label="abio_NewCapitalOnDemandSalesAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="abio_NewCapitalOnDemandSalesAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">New Capital on Demand Sales Agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_NewCapitalOnDemandSalesAgreementMember" xlink:to="abio_NewCapitalOnDemandSalesAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="abio_NewCapitalOnDemandSalesAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 Sales Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="abio_NewCapitalOnDemandSalesAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">New Capital On Demand Sales Agreement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="abio_EquityFinancingAndWarrantsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Financing And Warrants [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="abio_EquityFinancingAndWarrantsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Financing And Warrants [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Issued For Services</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase price per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Price Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-funded warrants to purchase shares of common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase price per warrant</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net proceeds from issuance of common stock</link:label>
    <link:label xml:lang="en-US" xlink:label="abio_SellingCommissionPerAdditionalSharesSoldPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of selling commission per additional shares sold</link:label>
    <link:label xml:lang="en-US" xlink:label="abio_SellingCommissionPerAdditionalSharesSoldPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Selling Commission Per Additional Shares Sold Percentage</link:label>
    <link:loc xlink:href="abio-20210331.xsd#abio_CommonStockAuthorizedOfferingAmountUnderAgreementToSell" xlink:type="locator" xlink:label="abio_CommonStockAuthorizedOfferingAmountUnderAgreementToSell" />
    <link:label xml:lang="en-US" xlink:label="abio_CommonStockAuthorizedOfferingAmountUnderAgreementToSell_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock, authorized offering amount under agreement to sell.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_CommonStockAuthorizedOfferingAmountUnderAgreementToSell" xlink:to="abio_CommonStockAuthorizedOfferingAmountUnderAgreementToSell_lbl" />
    <link:label xml:lang="en-US" xlink:label="abio_CommonStockAuthorizedOfferingAmountUnderAgreementToSell_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate offering price of common stock authorized</link:label>
    <link:label xml:lang="en-US" xlink:label="abio_CommonStockAuthorizedOfferingAmountUnderAgreementToSell_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Authorized Offering Amount Under Agreement To Sell</link:label>
    <link:loc xlink:href="abio-20210331.xsd#abio_NetProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="abio_NetProceedsFromIssuanceOfCommonStock" />
    <link:label xml:lang="en-US" xlink:label="abio_NetProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">The cash inflow associated with the amount received from entity&apos;s raising of capital, net of related financing costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_NetProceedsFromIssuanceOfCommonStock" xlink:to="abio_NetProceedsFromIssuanceOfCommonStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="abio_NetProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net proceeds from issuance of common stock</link:label>
    <link:label xml:lang="en-US" xlink:label="abio_NetProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Proceeds From Issuance Of Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Sale of common stock</link:label>
    <link:loc xlink:href="abio-20210331.xsd#abio_WarrantsExpirationYear" xlink:type="locator" xlink:label="abio_WarrantsExpirationYear" />
    <link:label xml:lang="en-US" xlink:label="abio_WarrantsExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Year during which outstanding warrants of company stock will expire.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_WarrantsExpirationYear" xlink:to="abio_WarrantsExpirationYear_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Warrant Or Right [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Warrant or Right</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Warrant or Right</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right [Domain]</link:label>
    <link:loc xlink:href="abio-20210331.xsd#abio_WarrantExpirationTwoThousandAndTwentyTwoMember" xlink:type="locator" xlink:label="abio_WarrantExpirationTwoThousandAndTwentyTwoMember" />
    <link:label xml:lang="en-US" xlink:label="abio_WarrantExpirationTwoThousandAndTwentyTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrant expiration two thousand and twenty two.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_WarrantExpirationTwoThousandAndTwentyTwoMember" xlink:to="abio_WarrantExpirationTwoThousandAndTwentyTwoMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="abio_WarrantExpirationTwoThousandAndTwentyTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022</link:label>
    <link:label xml:lang="en-US" xlink:label="abio_WarrantExpirationTwoThousandAndTwentyTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrant Expiration Two Thousand And Twenty Two [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Warrant Or Right [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="abio_WarrantsExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Year of Expiration</link:label>
    <link:label xml:lang="en-US" xlink:label="abio_WarrantsExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Expiration Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of Warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Research and development</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">General and administrative</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Allocated Share Based Compensation Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Stock Options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Roll Forward</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of Options, Options outstanding, beginning of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Options, Granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Options, Exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Options, Forfeited and cancelled</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Options, Options outstanding, end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Options, Options exercisable, end of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Options, Options vested and expected to vest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Options, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price Rollforward</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted Average Exercise Price, Options outstanding, beginning of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Forfeited and cancelled</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted Average Exercise Price, Options outstanding, end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Options exercisable, end of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Options vested and expected to vest, end of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Options, Weighted Average Remaining Contractual Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Term (in years), Options outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Term (in years), Options exercisable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Term (in years), Options vested and expected to vest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reserve for uncertain tax positions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:to="us-gaap_LiabilityForUncertainTaxPositionsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liability For Uncertain Tax Positions Current</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>14
<FILENAME>abio-20210331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-05-10T20:34:29.4323035+00:00 -->
<!-- Version            : 5.0.1.615 -->
<!-- Package ID         : beedb4a101e74518954371bca82a94aa -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.arcabiopharma.com/20210331/role/TemplateLink" xlink:href="abio-20210331.xsd#TemplateLink" xlink:type="simple" />
  <link:roleRef roleURI="http://www.arcabiopharma.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="abio-20210331.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:type="locator" xlink:label="dei_DocumentTransitionReport" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport" xlink:type="locator" xlink:label="dei_DocumentQuarterlyReport" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:type="locator" xlink:label="dei_EntityShellCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:type="locator" xlink:label="dei_EntitySmallBusiness" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="10930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentQuarterlyReport" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="11050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="11090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="11130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="11170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arcabiopharma.com/20210331/taxonomy/role/StatementBALANCESHEETSUnaudited" xlink:href="abio-20210331.xsd#Role_StatementBALANCESHEETSUnaudited" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20210331/taxonomy/role/StatementBALANCESHEETSUnaudited">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="10780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="10820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="10860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="10900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="10940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_Liabilities" order="10980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="11020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="11060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="11140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="11180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="11220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="11260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="11300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arcabiopharma.com/20210331/taxonomy/role/StatementBALANCESHEETSUnauditedParenthetical" xlink:href="abio-20210331.xsd#Role_StatementBALANCESHEETSUnauditedParenthetical" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20210331/taxonomy/role/StatementBALANCESHEETSUnauditedParenthetical">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arcabiopharma.com/20210331/taxonomy/role/StatementSTATEMENTSOFOPERATIONSUnaudited" xlink:href="abio-20210331.xsd#Role_StatementSTATEMENTSOFOPERATIONSUnaudited" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20210331/taxonomy/role/StatementSTATEMENTSOFOPERATIONSUnaudited">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:type="locator" xlink:label="us-gaap_InterestExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestAndOtherIncome" xlink:type="locator" xlink:label="us-gaap_InterestAndOtherIncome" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_InterestAndOtherIncome" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_InterestExpense" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedAbstract" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arcabiopharma.com/20210331/taxonomy/role/StatementSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" xlink:href="abio-20210331.xsd#Role_StatementSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20210331/taxonomy/role/StatementSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="abio-20210331.xsd#abio_IssuanceOfCommonStockAndExerciseOfPrefundedWarrantsShares" xlink:type="locator" xlink:label="abio_IssuanceOfCommonStockAndExerciseOfPrefundedWarrantsShares" />
    <link:loc xlink:href="abio-20210331.xsd#abio_IssuanceOfCommonStockAndExerciseOfPrefundedWarrants" xlink:type="locator" xlink:label="abio_IssuanceOfCommonStockAndExerciseOfPrefundedWarrants" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="abio_IssuanceOfCommonStockAndExerciseOfPrefundedWarrants" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="abio_IssuanceOfCommonStockAndExerciseOfPrefundedWarrantsShares" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_li0l2" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding_li0l2" order="10790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arcabiopharma.com/20210331/taxonomy/role/StatementSTATEMENTSOFCASHFLOWSUnaudited" xlink:href="abio-20210331.xsd#Role_StatementSTATEMENTSOFCASHFLOWSUnaudited" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20210331/taxonomy/role/StatementSTATEMENTSOFCASHFLOWSUnaudited">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
    <link:loc xlink:href="abio-20210331.xsd#abio_VendorFinanceAgreement" xlink:type="locator" xlink:label="abio_VendorFinanceAgreement" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="locator" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIncomeTaxRefunds" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIncomeTaxRefunds" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet" xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="10750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="10830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="10870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="10990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="11030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="11070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="11110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="11150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_li0l2" order="11190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="11230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="11310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_ProceedsFromIncomeTaxRefunds" order="11350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="11390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" order="11470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="abio_VendorFinanceAgreement" order="11510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="11550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPolicies" xlink:href="abio-20210331.xsd#Role_DisclosureTheCompanyAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPolicies">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureNetLossPerShare" xlink:href="abio-20210331.xsd#Role_DisclosureNetLossPerShare" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureNetLossPerShare">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureFairValueDisclosures" xlink:href="abio-20210331.xsd#Role_DisclosureFairValueDisclosures" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureFairValueDisclosures">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosurePropertyAndEquipment" xlink:href="abio-20210331.xsd#Role_DisclosurePropertyAndEquipment" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosurePropertyAndEquipment">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureRelatedPartyArrangements" xlink:href="abio-20210331.xsd#Role_DisclosureRelatedPartyArrangements" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureRelatedPartyArrangements">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingencies" xlink:href="abio-20210331.xsd#Role_DisclosureCommitmentsAndContingencies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingencies">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureEquityFinancingsAndWarrants" xlink:href="abio-20210331.xsd#Role_DisclosureEquityFinancingsAndWarrants" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureEquityFinancingsAndWarrants">
    <link:loc xlink:href="abio-20210331.xsd#abio_EquityFinancingsAndWarrantsDisclosureTextBlock" xlink:type="locator" xlink:label="abio_EquityFinancingsAndWarrantsDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="abio_EquityFinancingsAndWarrantsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureShareBasedCompensation" xlink:href="abio-20210331.xsd#Role_DisclosureShareBasedCompensation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureShareBasedCompensation">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureIncomeTaxes" xlink:href="abio-20210331.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureIncomeTaxes">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="abio-20210331.xsd#Role_DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesPolicies">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:loc xlink:href="abio-20210331.xsd#abio_AccruedOutsourcingExpensesPolicyTextBlock" xlink:type="locator" xlink:label="abio_AccruedOutsourcingExpensesPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
    <link:loc xlink:href="abio-20210331.xsd#abio_ComprehensiveLossPolicyPolicyTextBlock" xlink:type="locator" xlink:label="abio_ComprehensiveLossPolicyPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <link:loc xlink:href="abio-20210331.xsd#abio_LiquidityAndGoingConcernPolicyTextBlock" xlink:type="locator" xlink:label="abio_LiquidityAndGoingConcernPolicyTextBlock" />
    <link:loc xlink:href="abio-20210331.xsd#abio_DescriptionOfBusinessPolicyTextBlock" xlink:type="locator" xlink:label="abio_DescriptionOfBusinessPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="abio_DescriptionOfBusinessPolicyTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="abio_LiquidityAndGoingConcernPolicyTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="abio_ComprehensiveLossPolicyPolicyTextBlock" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="abio_AccruedOutsourcingExpensesPolicyTextBlock" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureNetLossPerShareTables" xlink:href="abio-20210331.xsd#Role_DisclosureNetLossPerShareTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureNetLossPerShareTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosurePropertyAndEquipmentTables" xlink:href="abio-20210331.xsd#Role_DisclosurePropertyAndEquipmentTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosurePropertyAndEquipmentTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" xlink:href="abio-20210331.xsd#Role_DisclosureCommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingenciesTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureEquityFinancingsAndWarrantsTables" xlink:href="abio-20210331.xsd#Role_DisclosureEquityFinancingsAndWarrantsTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureEquityFinancingsAndWarrantsTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureShareBasedCompensationTables" xlink:href="abio-20210331.xsd#Role_DisclosureShareBasedCompensationTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureShareBasedCompensationTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesDetailsTextual" xlink:href="abio-20210331.xsd#Role_DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesDetailsTextual" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesDetailsTextual">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosureOffbalanceSheetRisksAmountAsset" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosureOffbalanceSheetRisksAmountAsset" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:type="locator" xlink:label="us-gaap_Revenues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_Revenues" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueDisclosureOffbalanceSheetRisksAmountAsset" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureNetLossPerShareSummaryOfPotentiallyDilutiveSharesOfCommonStockDetails" xlink:href="abio-20210331.xsd#Role_DisclosureNetLossPerShareSummaryOfPotentiallyDilutiveSharesOfCommonStockDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureNetLossPerShareSummaryOfPotentiallyDilutiveSharesOfCommonStockDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:type="locator" xlink:label="us-gaap_WarrantMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockOptionMember" xlink:type="locator" xlink:label="us-gaap_StockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_StockOptionMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureFairValueDisclosuresDetailsTextual" xlink:href="abio-20210331.xsd#Role_DisclosureFairValueDisclosuresDetailsTextual" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureFairValueDisclosuresDetailsTextual">
    <link:loc xlink:href="abio-20210331.xsd#abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount" xlink:type="locator" xlink:label="abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails" xlink:href="abio-20210331.xsd#Role_DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:type="locator" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquipmentMember" xlink:type="locator" xlink:label="us-gaap_EquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosurePropertyAndEquipmentDetailsTextual" xlink:href="abio-20210331.xsd#Role_DisclosurePropertyAndEquipmentDetailsTextual" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosurePropertyAndEquipmentDetailsTextual">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureRelatedPartyArrangementsDetailsTextual" xlink:href="abio-20210331.xsd#Role_DisclosureRelatedPartyArrangementsDetailsTextual" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureRelatedPartyArrangementsDetailsTextual">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ChiefExecutiveOfficerMember" xlink:type="locator" xlink:label="srt_ChiefExecutiveOfficerMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="srt_ChiefExecutiveOfficerMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingenciesDetailsTextual" xlink:href="abio-20210331.xsd#Role_DisclosureCommitmentsAndContingenciesDetailsTextual" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingenciesDetailsTextual">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:type="locator" xlink:label="us-gaap_AreaOfRealEstateProperty" />
    <link:loc xlink:href="abio-20210331.xsd#abio_CommitmentsAndContingenciesLineItems" xlink:type="locator" xlink:label="abio_CommitmentsAndContingenciesLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="abio-20210331.xsd#abio_CommitmentsAndContingenciesTable" xlink:type="locator" xlink:label="abio_CommitmentsAndContingenciesTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="abio_CommitmentsAndContingenciesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_CommitmentsAndContingenciesTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_CommitmentsAndContingenciesTable" xlink:to="abio_CommitmentsAndContingenciesLineItems" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_AreaOfRealEstateProperty" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_OperatingLeaseCost" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_OperatingLeasePayments" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumCommitmentsDueUnderOctober2020LeaseAgreementDetails" xlink:href="abio-20210331.xsd#Role_DisclosureCommitmentsAndContingenciesFutureMinimumCommitmentsDueUnderOctober2020LeaseAgreementDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumCommitmentsDueUnderOctober2020LeaseAgreementDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:loc xlink:href="abio-20210331.xsd#abio_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:type="locator" xlink:label="abio_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="abio_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureEquityFinancingsAndWarrantsDetailsTextual" xlink:href="abio-20210331.xsd#Role_DisclosureEquityFinancingsAndWarrantsDetailsTextual" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureEquityFinancingsAndWarrantsDetailsTextual">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="abio-20210331.xsd#abio_NetProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="abio_NetProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="abio-20210331.xsd#abio_CommonStockAuthorizedOfferingAmountUnderAgreementToSell" xlink:type="locator" xlink:label="abio_CommonStockAuthorizedOfferingAmountUnderAgreementToSell" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="abio-20210331.xsd#abio_SellingCommissionPerAdditionalSharesSoldPercentage" xlink:type="locator" xlink:label="abio_SellingCommissionPerAdditionalSharesSoldPercentage" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
    <link:loc xlink:href="abio-20210331.xsd#abio_EquityFinancingAndWarrantsLineItems" xlink:type="locator" xlink:label="abio_EquityFinancingAndWarrantsLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:loc xlink:href="abio-20210331.xsd#abio_NewCapitalOnDemandSalesAgreementMember" xlink:type="locator" xlink:label="abio_NewCapitalOnDemandSalesAgreementMember" />
    <link:loc xlink:href="abio-20210331.xsd#abio_JonesTradingInstitutionalServicesLLCMember" xlink:type="locator" xlink:label="abio_JonesTradingInstitutionalServicesLLCMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <link:loc xlink:href="abio-20210331.xsd#abio_CapitalOnDemandSalesAgreementMember" xlink:type="locator" xlink:label="abio_CapitalOnDemandSalesAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="abio-20210331.xsd#abio_DirectOfferingMember" xlink:type="locator" xlink:label="abio_DirectOfferingMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="abio-20210331.xsd#abio_EquityFinancingAndWarrantsTable" xlink:type="locator" xlink:label="abio_EquityFinancingAndWarrantsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="abio_EquityFinancingAndWarrantsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_EquityFinancingAndWarrantsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="abio_DirectOfferingMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_EquityFinancingAndWarrantsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="abio_CapitalOnDemandSalesAgreementMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_EquityFinancingAndWarrantsTable" xlink:to="dei_LegalEntityAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="abio_JonesTradingInstitutionalServicesLLCMember" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="abio_NewCapitalOnDemandSalesAgreementMember" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_EquityFinancingAndWarrantsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_EquityFinancingAndWarrantsTable" xlink:to="abio_EquityFinancingAndWarrantsLineItems" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_EquityFinancingAndWarrantsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_EquityFinancingAndWarrantsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_EquityFinancingAndWarrantsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_EquityFinancingAndWarrantsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_EquityFinancingAndWarrantsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_EquityFinancingAndWarrantsLineItems" xlink:to="abio_SellingCommissionPerAdditionalSharesSoldPercentage" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_EquityFinancingAndWarrantsLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_EquityFinancingAndWarrantsLineItems" xlink:to="abio_CommonStockAuthorizedOfferingAmountUnderAgreementToSell" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_EquityFinancingAndWarrantsLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="10980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_EquityFinancingAndWarrantsLineItems" xlink:to="abio_NetProceedsFromIssuanceOfCommonStock" order="11000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_EquityFinancingAndWarrantsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="11110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureEquityFinancingsAndWarrantsSummaryOfWarrantsByYearOfExpirationDetails" xlink:href="abio-20210331.xsd#Role_DisclosureEquityFinancingsAndWarrantsSummaryOfWarrantsByYearOfExpirationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureEquityFinancingsAndWarrantsSummaryOfWarrantsByYearOfExpirationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <link:loc xlink:href="abio-20210331.xsd#abio_WarrantsExpirationYear" xlink:type="locator" xlink:label="abio_WarrantsExpirationYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" />
    <link:loc xlink:href="abio-20210331.xsd#abio_WarrantExpirationTwoThousandAndTwentyTwoMember" xlink:type="locator" xlink:label="abio_WarrantExpirationTwoThousandAndTwentyTwoMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="abio_WarrantExpirationTwoThousandAndTwentyTwoMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="abio_WarrantsExpirationYear" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureShareBasedCompensationSummaryOfNonCashShareBasedCompensationExpenseDetails" xlink:href="abio-20210331.xsd#Role_DisclosureShareBasedCompensationSummaryOfNonCashShareBasedCompensationExpenseDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureShareBasedCompensationSummaryOfNonCashShareBasedCompensationExpenseDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureShareBasedCompensationSummaryOfStockOptionActivitiesDetails" xlink:href="abio-20210331.xsd#Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivitiesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureShareBasedCompensationSummaryOfStockOptionActivitiesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_li0l2" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="11050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="11130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_li0l2" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="11290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="11370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" order="11450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="11610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="11770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="11850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureIncomeTaxesDetailsTextual" xlink:href="abio-20210331.xsd#Role_DisclosureIncomeTaxesDetailsTextual" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureIncomeTaxesDetailsTextual">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_LiabilityForUncertainTaxPositionsCurrent" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140460226388088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>May 10, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ARCA Biopharma, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000907654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ABIO<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,410,143<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-22873<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">36-3855489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">10170 Church Ranch Way<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Westminster<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CO<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">80021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">940-2200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140460228051176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEETS (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 66,933<span></span>
</td>
<td class="nump">$ 49,071<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">1,797<span></span>
</td>
<td class="nump">897<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">68,730<span></span>
</td>
<td class="nump">49,968<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use asset - operating</a></td>
<td class="nump">414<span></span>
</td>
<td class="nump">428<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">69,183<span></span>
</td>
<td class="nump">50,429<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,578<span></span>
</td>
<td class="nump">1,773<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation and employee benefits</a></td>
<td class="nump">255<span></span>
</td>
<td class="nump">815<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued expenses and other liabilities</a></td>
<td class="nump">1,047<span></span>
</td>
<td class="nump">911<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">2,880<span></span>
</td>
<td class="nump">3,499<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, net of current portion</a></td>
<td class="nump">394<span></span>
</td>
<td class="nump">409<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">3,274<span></span>
</td>
<td class="nump">3,908<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 100 million shares authorized at March 31, 2021 and December 31, 2020; 14,410,143 and 9,548,150 shares issued and outstanding at March 31, 2021 and December 31, 2020, respectively</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">224,149<span></span>
</td>
<td class="nump">200,665<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(158,254)<span></span>
</td>
<td class="num">(154,154)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">65,909<span></span>
</td>
<td class="nump">46,521<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 69,183<span></span>
</td>
<td class="nump">$ 50,429<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140460232260664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEETS (Unaudited) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement Of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">14,410,143<span></span>
</td>
<td class="nump">9,548,150<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">14,410,143<span></span>
</td>
<td class="nump">9,548,150<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140460228027416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STATEMENTS OF OPERATIONS (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 2,876<span></span>
</td>
<td class="nump">$ 365<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">1,226<span></span>
</td>
<td class="nump">975<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total costs and expenses</a></td>
<td class="nump">4,102<span></span>
</td>
<td class="nump">1,340<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(4,102)<span></span>
</td>
<td class="num">(1,340)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestAndOtherIncome', window );">Interest and other income</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (4,100)<span></span>
</td>
<td class="num">$ (1,320)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Net loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted</a></td>
<td class="num">$ (0.33)<span></span>
</td>
<td class="num">$ (0.83)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract', window );"><strong>Weighted average shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Basic and diluted</a></td>
<td class="nump">12,356,928<span></span>
</td>
<td class="nump">1,594,070<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndOtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndOtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140460226926200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2019</a></td>
<td class="nump">$ 7,610<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 152,024<span></span>
</td>
<td class="num">$ (144,416)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning Balance, shares at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,594,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(1,320)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,320)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Mar. 31, 2020</a></td>
<td class="nump">6,306<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">152,040<span></span>
</td>
<td class="num">(145,736)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending Balance, shares at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,594,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2019</a></td>
<td class="nump">7,610<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">152,024<span></span>
</td>
<td class="num">(144,416)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning Balance, shares at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,594,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 46,521<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">200,665<span></span>
</td>
<td class="num">(154,154)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending Balance, shares at Dec. 31, 2020</a></td>
<td class="nump">9,548,150<span></span>
</td>
<td class="nump">9,548,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Mar. 31, 2020</a></td>
<td class="nump">$ 6,306<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">152,040<span></span>
</td>
<td class="num">(145,736)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning Balance, shares at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,594,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_IssuanceOfCommonStockAndExerciseOfPrefundedWarrants', window );">Issuance of common stock and exercise of prefunded warrants for cash, net of offering costs</a></td>
<td class="nump">5,297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_IssuanceOfCommonStockAndExerciseOfPrefundedWarrantsShares', window );">Issuance of common stock and exercise of prefunded warrants for cash, net of offering costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">673,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(1,302)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,302)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Jun. 30, 2020</a></td>
<td class="nump">10,305<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">157,341<span></span>
</td>
<td class="num">(147,038)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending Balance, shares at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,267,570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock for cash, net of offering costs</a></td>
<td class="nump">42,136<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">42,129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock for cash, net of offering costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,018,054<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(1,991)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,991)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Sep. 30, 2020</a></td>
<td class="nump">50,455<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">199,475<span></span>
</td>
<td class="num">(149,029)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending Balance, shares at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,285,624<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock for cash, net of offering costs</a></td>
<td class="nump">1,173<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">1,172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock for cash, net of offering costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">262,526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(5,125)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,125)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 46,521<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">200,665<span></span>
</td>
<td class="num">(154,154)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending Balance, shares at Dec. 31, 2020</a></td>
<td class="nump">9,548,150<span></span>
</td>
<td class="nump">9,548,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock for cash, net of offering costs</a></td>
<td class="nump">$ 23,347<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">23,343<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock for cash, net of offering costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,861,993<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(4,100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,100)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Mar. 31, 2021</a></td>
<td class="nump">$ 65,909<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">$ 224,149<span></span>
</td>
<td class="num">$ (158,254)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending Balance, shares at Mar. 31, 2021</a></td>
<td class="nump">14,410,143<span></span>
</td>
<td class="nump">14,410,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_IssuanceOfCommonStockAndExerciseOfPrefundedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock and exercise of prefunded warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_IssuanceOfCommonStockAndExerciseOfPrefundedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_IssuanceOfCommonStockAndExerciseOfPrefundedWarrantsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock and exercise of prefunded warrants shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_IssuanceOfCommonStockAndExerciseOfPrefundedWarrantsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140460226748088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (4,100)<span></span>
</td>
<td class="num">$ (5,125)<span></span>
</td>
<td class="num">$ (1,302)<span></span>
</td>
<td class="num">$ (1,320)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of right-of-use asset - operating</a></td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Change in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets', window );">Other current assets</a></td>
<td class="num">(840)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(75)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(293)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued compensation and employee benefits</a></td>
<td class="num">(560)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="nump">61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(99)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(5,225)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,686)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock</a></td>
<td class="nump">24,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Common stock offering costs</a></td>
<td class="num">(977)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">23,093<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">17,862<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,689)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of period</a></td>
<td class="nump">49,071<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,674<span></span>
</td>
<td class="nump">8,363<span></span>
</td>
<td class="nump">$ 8,363<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of period</a></td>
<td class="nump">66,933<span></span>
</td>
<td class="nump">$ 49,071<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,674<span></span>
</td>
<td class="nump">$ 49,071<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of noncash investing and financing transactions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchases of property and equipment in accounts payable</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_VendorFinanceAgreement', window );">Vendor finance agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">408<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Leased assets obtained in exchange for operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_VendorFinanceAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining amount of asset increase which was financed under an agreement with the vendor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_VendorFinanceAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140460305540440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The Company and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">The Company and Summary of Significant Accounting Policies</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(1) The Company and Summary of Significant Accounting Policies </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Description of Business </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARCA biopharma, Inc. (the Company or ARCA), a Delaware corporation, is headquartered in Westminster, Colorado. The Company is a clinical-stage biopharmaceutical company applying a precision medicine approach to the development and commercialization of genetically targeted therapies for cardiovascular diseases. The Company&#8217;s lead product candidates are rNAPc2 (AB201) as a potential treatment for diseases caused by ribonucleic acid, or RNA, viruses, initially focusing on COVID-19, the disease caused by SARS-CoV-2 virus, and Gencaro&#8482; (bucindolol hydrochloride) for the treatment of atrial fibrillation (AF) in patients with chronic heart failure (HF).&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rNAPc2 is a protein therapeutic in clinical development as a potential treatment for patients hospitalized with COVID-19. Based on its unique mechanism of action, development history and the clinical evidence from the SARS&#8209;CoV-2 pandemic, the Company believes rNAPc2 has potential to be a beneficial therapy for patients with this serious viral disease. The Company initiated the Phase 2b clinical trial of rNAPc2 as a potential treatment for patients hospitalized with COVID-19 in the fourth quarter of 2020.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company continues to evaluate the feasibility and potential timing for initiating PRECISION-AF relative to the COVID-19 pandemic and prioritizing the development of rNAPc2.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s other product candidate, AB171, is a thiol-substituted isosorbide mononitrate, which ARCA plans to develop as a genetically-targeted treatment for HF and peripheral arterial disease. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2020, the World Health Organization declared the outbreak of COVID-19, a novel strain of Coronavirus, a global pandemic. This outbreak is causing major disruptions to businesses and markets worldwide as the virus spreads. The Company does not expect a material financial effect as a result of the pandemic. However, if the pandemic continues to be a severe worldwide crisis, it could have a material adverse effect on the Company&#8217;s business, results of operations, financial condition and cash flows.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Liquidity and Going Concern </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company devotes substantially all of its efforts towards obtaining regulatory approval and raising capital necessary to fund its operations and it is subject to a number of risks associated with clinical research and development, including dependence on key individuals, the development of and regulatory approval of commercially viable products, the need to raise adequate additional financing necessary to fund the development and commercialization of its products, and competition from larger companies. The Company has not generated revenue to date and has incurred substantial losses and negative cash flows from operations since its inception.&nbsp;&nbsp;The Company has historically funded its operations through issuances of common and preferred stock.&nbsp;&nbsp; </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company believes that its current cash and cash equivalents as of March 31, 2021<font style="Background-color:#FFFFFF;color:#000000;"> </font>will be sufficient to fund its operations through <font style="Background-color:#FFFFFF;color:#000000;">the end of fiscal year </font>2022. <font style="Background-color:#FFFFFF;color:#000000;">Conducting a Phase 3 rNAPc2 clinical trial or the Phase 3 PRECISION-AF trial would likely require additional financing</font>. <font style="Background-color:#FFFFFF;color:#000000;">However, changing circumstances may cause us to consume capital significantly faster or slower than currently anticipated. The Company has based these estimates on assumptions that may prove to be wrong, and the Company could exhaust its available financial resources sooner than the Company currently anticipates. Therefore, the Company may have to raise additional capital for clinical trials of </font>rNAPc2<font style="Background-color:#FFFFFF;color:#000000;"> and will have to raise additional capital for clinical trials of Gencaro. The Company may not be able to raise sufficient capital on acceptable terms, or at all, to continue development of </font>rNAPc2<font style="Background-color:#FFFFFF;color:#000000;"> or Gencaro or to otherwise continue operations and may not be able to execute any strategic transaction</font>.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s liquidity, and its ability to raise additional capital or complete any strategic transaction, depends on a number of factors, including, but not limited to, the following: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the costs and timing for the potential additional clinical trials in order to gain possible regulatory approval for rNAPc2, Gencaro or any other product candidate; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the market price of the Company&#8217;s stock and the availability and cost of additional equity capital from existing and potential new investors; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the Company&#8217;s ability to retain the listing of its common stock on the Nasdaq Capital Market; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">general economic and industry conditions affecting the availability and cost of capital, including as a result of the COVID-19 pandemic; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the terms and conditions of the Company&#8217;s existing collaborative and licensing agreements. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The sale of additional equity or convertible debt securities would likely result in substantial additional dilution to the Company&#8217;s stockholders. If the Company raises additional funds through the incurrence of indebtedness, the obligations related to such indebtedness would be senior to rights of holders of the Company&#8217;s capital stock and could contain covenants that would restrict the Company&#8217;s operations. The Company also cannot predict what consideration might be available, if any, to the Company or its stockholders, in connection with any strategic transaction. Should strategic alternatives or additional capital not be available to the Company, or not be available on acceptable terms, the Company may be unable to realize value from its assets and discharge its liabilities in the normal course of business which may, among other alternatives, cause the Company to further delay, substantially reduce or discontinue operational activities to conserve its cash resources.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Basis of Presentation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying unaudited financial statements of the Company were prepared in accordance with generally accepted accounting principles for interim financial information and instructions to Form 10-Q and pursuant to Regulation S-X.&nbsp;&nbsp;Accordingly, these financial statements do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America (GAAP) for complete financial statements.&#160; In the opinion of management, these financial statements include all normal and recurring adjustments considered necessary for a fair presentation of these interim financial statements.&nbsp;&nbsp;The results of operations for the three months ended March 31, 2021 are not necessarily indicative of results expected for the full year ending December&#160;31, 2021.&#160; The Company has generated no revenue to date and its activities have consisted of seeking regulatory approval, research and development, exploring strategic alternatives for further developing and commercializing rNAPc2 and Gencaro, and raising capital. These unaudited financial statements should be read in conjunction with the audited financial statements and footnotes thereto for the year ended December&#160;31, 2020 included in the Company&#8217;s Annual Report on Form 10-K filed with the Securities and Exchange Commission. Amounts presented are rounded to the nearest thousand, where indicated, except per share data and par values.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentrations of Credit Risk </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company has no off-balance-sheet concentrations of credit risk, such as foreign exchange contracts, option contracts, or foreign currency hedging arrangements. The Company maintains cash and cash equivalent balances in the form of bank demand deposits and money market fund accounts with financial institutions that management believes are creditworthy. Such balances may at times exceed the insured amount. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Comprehensive Loss</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive loss is defined as the change in equity during a period from transactions and other events and/or circumstances from non-owner sources. If the Company had comprehensive gains (losses), they would be reflected in the statement of operations and comprehensive loss and as a separate component in the statement of stockholders&#8217; equity. There were no elements of comprehensive loss during the three months ended March 31, 2021&#160;and&#160;2020.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Leases</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determines if an arrangement is a lease at inception.&nbsp;&nbsp;Operating leases are included in right-of-use (ROU) asset &#8211; operating and lease obligations are included in accrued expenses and other liabilities and operating lease liability on the Company&#8217;s March 31, 2021 and December&#160;31, 2020 balance sheets.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ROU lease assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease obligations represent the Company&#8217;s obligation to make lease payments arising from the lease. Operating ROU lease assets are recognized at the commencement date based on the present value of lease payments over the lease term. As the Company&#8217;s lease does not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments.&nbsp;&nbsp;The Company&#8217;s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Accrued Outsourcing Expenses </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of the process of preparing its financial statements, the Company is required to estimate accrued outsourcing expenses. This process involves identifying services that third parties have performed on the Company&#8217;s behalf and estimating the level of service performed and the associated cost incurred for these services as of the balance sheet date. Examples of estimated accrued outsourcing expenses include contract service fees, such as fees payable to contract manufacturers in connection with the production of materials related to the Company&#8217;s drug product, and service fees and pass through costs from clinical research organizations. The Company develops estimates of liabilities using its judgment based upon the facts and circumstances known at the time. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Recent Accounting Pronouncements</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company reviewed recently issued accounting pronouncements and concluded that they were either not applicable or not expected to have a significant impact to the financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140460232502120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(2) Net Loss Per Share </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company calculates basic earnings per share by dividing net loss by the weighted average common shares outstanding during the period. Diluted earnings per share is computed by dividing net loss by the weighted average number of common shares outstanding during the period increased to include, if dilutive, the number of additional common shares that would have been outstanding if the potential common shares had been issued. The Company&#8217;s potentially dilutive shares include stock options and warrants for common stock<font style="letter-spacing:-0.1pt;">. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because the Company reported a net loss for the three months ended March 31, 2021 and 2020, all potentially dilutive shares of common stock have been excluded from the computation of the dilutive net loss per share for all periods presented.<font style="font-size:12pt;">&nbsp;&nbsp;</font>Such potentially dilutive shares of common stock consist of the following:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.8%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Potentially dilutive securities, excluded:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding stock options</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">596,497</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,890</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants to purchase common stock</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">133,401</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">133,401</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.18%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">729,898</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">164,291</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140460305542104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Disclosures<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Disclosures</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(3) Fair Value Disclosures </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There were no marketable securities as of March 31, 2021 or December 31, 2020.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). Inputs used to measure fair value are classified into the following hierarchy: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 1&#8212;Unadjusted quoted prices in active markets for identical assets or liabilities.&nbsp;&nbsp;The Company&#8217;s Level 1 assets consist of money market investments.&nbsp;&nbsp;The Company does not have any Level 1 liabilities.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2&#8212;Unadjusted quoted prices in active markets for similar assets or liabilities; unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active; or inputs other than quoted prices that are observable for the asset or liability.&nbsp;&nbsp;The Company does not have any Level 2 assets or liabilities. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 3&#8212;Unobservable inputs for the asset or liability.&nbsp;&nbsp;The Company does not have any Level 3 assets or liabilities. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March 31, 2021 and December 31, 2020, the Company had $66.9 million and $49.1 million, respectively, of cash equivalents consisting of money market funds with original maturities of 90 days or less. The Company has the ability to liquidate these investments without restriction. The Company determines fair value for these money market funds with Level 1 inputs through quoted market prices. There were no transfers of assets between fair value hierarchy levels during the three-month period ended March&#160;31,&#160;2021. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"> Fair Value of Other Financial Instruments </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The carrying amount of other financial instruments, including accounts payable and a vendor finance agreement, which are included in accounts payable and accrued expenses and other liabilities, approximated fair value due to their short maturities. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140460305690760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property Plant And Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(4) Property and Equipment</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment consist of the following (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Estimated Life</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2021</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.1%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 years</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lab equipment</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5 years</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">146</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">146</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and fixtures</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5 years</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer software</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:20.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 years</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">280</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">271</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated depreciation and amortization</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:20.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(253</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(250</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.52%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:20.1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the three months ended March 31, 2021 and 2020, depreciation and amortization expense was $3,000 and $3,000, respectively. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140460305555240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Arrangements</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(5) Related Party Arrangements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Transactions with the Company&#8217;s President and Chief Executive Officer </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has entered into unrestricted research grants with its President and Chief Executive Officer&#8217;s academic research laboratory at the University of Colorado. Funding of any unrestricted research grants is contingent upon the Company&#8217;s financial condition, and can be deferred or terminated at the Company&#8217;s discretion. Total expense under these arrangements for the three months ended March 31, 2021 and 2020 was $107,000 and $70,000 respectively.&nbsp;&nbsp; </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140460232488152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(6) Commitments and Contingencies </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has or is subject to the following commitments and contingencies. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Employment Agreements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company maintains employment agreements with several key executive employees. The agreements may be terminated at any time by the Company with or without cause upon written notice to the employee, and entitle the employee to wages in lieu of notice for periods not exceeding one calendar year from the date of termination without cause or by the employee for good reason. Certain of these agreements also provide for payments to be made under certain conditions related to a change in control of the Company. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Operating Lease </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On August&#160;1, 2013 the Company entered into a lease agreement for approximately 5,300 square feet of office facilities in Westminster, Colorado which served as the Company&#8217;s primary business office from October&#160;1, 2013 until September 30, 2020.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On August&#160;29, 2020 the Company entered into a lease agreement for approximately 5,200 square feet of office facilities in Westminster, Colorado which serves as the Company&#8217;s primary business office effective October&#160;1, 2020 (October 2020 Lease). The lease term is 42 months beginning October 1, 2020 and includes an option to renew for an additional 36 month term at the then prevailing rental rate. The exercise of the lease renewal option is at the Company&#8217;s sole discretion.&nbsp;&nbsp;The amounts recorded assume the Company will exercise its renewal option. The lease includes real estate taxes and insurance, which is not a lease component and is not included in the lease obligation.&nbsp;&nbsp;In addition, common area maintenance charges are based on actual costs incurred and are a non-lease component that is not included in the lease obligation.  </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Future minimum commitments due under the October 2020 Lease agreement as of March 31, 2021 are as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:55.82%;">
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Remainder of 2021</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">125</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total remaining lease payments</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.56%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">556</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: imputed lease interest</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(106</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: Current portion</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(56</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.78%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liability, net of current portion</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">394</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rent expense, which is included in general and administrative expense, for the three months ended March 31, 2021 and 2020 was $22,000 and $23,000, respectively. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March 31, 2021, the lease liability was $450,000, and the current portion is included in accrued expenses and other liabilities and the non-current portion is in operating lease liability, net of current portion in the accompanying balance sheet. Cash paid for amounts included in the measurement of lease liabilities and the operating cash flows from operating leases for the three months ended March 31, 2021 and 2020 were $7,000 and $25,000, respectively. The weighted-average remaining lease term for the operating lease as of March&#160;31, 2021 is 6.0&#160;years. The discount rate for the operating lease is 7%.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;">&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140460226356856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Financings and Warrants<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_EquityFinancingsAndWarrantsDisclosureTextBlock', window );">Equity Financings and Warrants</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(7) <font style="font-style:italic;">Equity Financings and Warrants</font> </p>
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Registered Direct Financing</p>
<p style="margin-bottom:12pt;margin-top:6pt;line-height:11pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On June 3, 2020, the Company closed a registered direct offering with certain institutional and accredited investors of 348,000 shares of the Company&#8217;s common stock, at a purchase price of $9.00 per share, and pre-funded warrants to purchase 325,500 shares of common stock at a purchase price of $8.999 per warrant. All warrants were exercised by the closing date. The net proceeds were approximately $5.3 million, after deducting placement agent fees and other offering expenses. The Company paid JonesTrading a placement agent fee equal to 8.0% of the aggregate gross proceeds and agreed to provide JonesTrading with customary indemnification and contribution rights.&nbsp;&nbsp;<font style="font-size:12pt;"> </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">At the Market Equity Financing </p>
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January&#160;11, 2017, the Company entered into a Capital on Demand<font style="font-size:8.5pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top"> TM</sup></font>&#160;Sales Agreement (the Sales Agreement) with JonesTrading Institutional Services LLC, as agent (JonesTrading), pursuant to which the Company may offer and sell, from time to time through JonesTrading, shares of the Company&#8217;s common stock, par value $0.001 per share (the Common Stock), having an aggregate offering price of up to $7.3&#160;million.&nbsp;&nbsp;On August&#160;21, 2017, January 25, 2019, March 11, 2019, May 9, 2019, May 20, 2019, June 28, 2019, July&#160;2, 2020 and July 14, 2020, the Company amended its Capital on Demand Sales Agreement. The amendments, among other things, increased the maximum aggregate offering value of shares of the Company&#8217;s common stock which the Company may issue and sell from time to time under the Sales Agreement<font style="font-size:12pt;">&#160;</font>from $7.3 million to $32.4&#160;million (the Shares).&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the amended Sales Agreement, JonesTrading may sell the Shares by any method permitted by law and deemed to be an &#8220;at the market offering&#8221; as defined in Rule 415 promulgated under the Securities Act of 1933, as amended, including sales made directly on or through the Nasdaq Capital Market, on any other existing trading market for the Common Stock or to or through a market maker. In addition, under the amended Sales Agreement, JonesTrading may sell the Shares by any other method permitted by law, including in negotiated transactions. The Company may instruct JonesTrading not to sell Shares if the sales cannot be effected at or above the price designated by the Company from time to time. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is not obligated to make any sales of the Shares under the amended Sales Agreement. The offering of Shares pursuant to the amended Sales Agreement will terminate upon the earlier of (a)&#160;the sale of all of the Shares subject to the amended Sales Agreement or (b)&#160;the termination of the amended Sales Agreement by JonesTrading or the Company, as permitted therein. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company paid JonesTrading a commission rate equal to 3.0% of the aggregate gross proceeds from each sale of Shares and agreed to provide JonesTrading with customary indemnification and contribution rights. The Company will also reimburse JonesTrading for certain specified expenses in connection with entering into and amending the Sales Agreement. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the amended Sales Agreement, the Company sold an aggregate of 2,214,301 <font style="font-size:6pt;">&#160;</font>shares of Common Stock, for net proceeds of approximately $14.4 million, during the year ended December 31, 2020, including initial expenses for executing the &#8220;at the market offering&#8221; and commissions to the placement agent. This sales agreement terminated in July 2020.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;line-height:11pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July 22, 2020, the Company entered into a new Capital on Demand<font style="font-size:8.5pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top"> TM</sup></font>&#160;Sales Agreement (the 2020 Sales Agreement) with JonesTrading, pursuant to which the Company may offer and sell, from time to time through JonesTrading, shares of the Company&#8217;s Common Stock, having an aggregate offering price of up to $54.0&#160;million. During the three months ended March 31, 2021 and the year ended December 31, 2020, the Company had sold an aggregate of 4,861,993 and 5,066,279 shares of its Common Stock pursuant to the terms of the 2020 Sales Agreement for net proceeds of approximately $23.3 million and $28.9&#160;million, respectively, after deducting expenses for executing the &#8220;at the market offering&#8221; and commissions paid to the placement agent.</p>
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2021, the Company amended the 2020 Sales Agreement and has $50.0 million available for the offering under its prospectus to the Company&#8217;s registration statement on Form S-3 (No. 333-254585).</p>
<p style="margin-bottom:0pt;margin-top:16pt;line-height:11pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Warrants </p>
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants to purchase shares of common stock were previously granted as part of various financing and business agreements.&nbsp;&nbsp;All outstanding warrants were recorded in additional paid-in capital at their estimated fair market value at the date of grant using a Black-Scholes option-pricing model. </p>
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March 31, 2021, these warrants, by year of expiration, are summarized below:</p>
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:60%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.16%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year of Expiration</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.36%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Number</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">of Warrants</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.62%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Weighted Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exercise Price</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.16%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.36%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">133,401</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.62%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109.80</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;text-indent:0%;font-size:10pt;">&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_EquityFinancingsAndWarrantsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of equity financings during the periods presented and information related to outstanding warrants of company stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_EquityFinancingsAndWarrantsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140460305381080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-based Compensation</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;line-height:11pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(8) Share-based Compensation </p>
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the three month periods ended March 31, 2021 and 2020, the Company recognized the following non-cash, share-based compensation expense in the statements of operations (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Three Months</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Ended March 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.88%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">141</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock option transactions for the three month period ended March 31, 2021 under the Company&#8217;s stock incentive plans were as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Number</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">of Options</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Weighted Average Exercise Price</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Term</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(in years)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options outstanding at December&#160;31, 2020</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">531,238</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.71</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.68</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67,200</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.30</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited and cancelled</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,941</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72.33</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options outstanding at March 31, 2021</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">596,497</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.01</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.51</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options exercisable at March 31, 2021</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66,125</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38.02</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.68</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options vested and expected to vest</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">595,774</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.01</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.51</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140460305529272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(9) Income Taxes </p>
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In accordance with GAAP, a valuation allowance should be provided if it is more likely than not that some or all of the Company&#8217;s deferred tax assets will not be realized.&nbsp;&nbsp;The Company&#8217;s ability to realize the benefit of its deferred tax assets will depend on the generation of future taxable income. Due to the uncertainty of future profitable operations and taxable income, the Company has recorded a full valuation allowance against its net deferred tax assets.&nbsp;&nbsp;The Company believes its tax filing positions and deductions related to tax periods subject to examination will be sustained upon audit and, therefore, has no reserve for uncertain tax positions.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140460311970312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The Company and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_DescriptionOfBusinessPolicyTextBlock', window );">Description of Business</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Description of Business </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARCA biopharma, Inc. (the Company or ARCA), a Delaware corporation, is headquartered in Westminster, Colorado. The Company is a clinical-stage biopharmaceutical company applying a precision medicine approach to the development and commercialization of genetically targeted therapies for cardiovascular diseases. The Company&#8217;s lead product candidates are rNAPc2 (AB201) as a potential treatment for diseases caused by ribonucleic acid, or RNA, viruses, initially focusing on COVID-19, the disease caused by SARS-CoV-2 virus, and Gencaro&#8482; (bucindolol hydrochloride) for the treatment of atrial fibrillation (AF) in patients with chronic heart failure (HF).&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rNAPc2 is a protein therapeutic in clinical development as a potential treatment for patients hospitalized with COVID-19. Based on its unique mechanism of action, development history and the clinical evidence from the SARS&#8209;CoV-2 pandemic, the Company believes rNAPc2 has potential to be a beneficial therapy for patients with this serious viral disease. The Company initiated the Phase 2b clinical trial of rNAPc2 as a potential treatment for patients hospitalized with COVID-19 in the fourth quarter of 2020.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company continues to evaluate the feasibility and potential timing for initiating PRECISION-AF relative to the COVID-19 pandemic and prioritizing the development of rNAPc2.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s other product candidate, AB171, is a thiol-substituted isosorbide mononitrate, which ARCA plans to develop as a genetically-targeted treatment for HF and peripheral arterial disease. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2020, the World Health Organization declared the outbreak of COVID-19, a novel strain of Coronavirus, a global pandemic. This outbreak is causing major disruptions to businesses and markets worldwide as the virus spreads. The Company does not expect a material financial effect as a result of the pandemic. However, if the pandemic continues to be a severe worldwide crisis, it could have a material adverse effect on the Company&#8217;s business, results of operations, financial condition and cash flows.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_LiquidityAndGoingConcernPolicyTextBlock', window );">Liquidity and Going Concern</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Liquidity and Going Concern </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company devotes substantially all of its efforts towards obtaining regulatory approval and raising capital necessary to fund its operations and it is subject to a number of risks associated with clinical research and development, including dependence on key individuals, the development of and regulatory approval of commercially viable products, the need to raise adequate additional financing necessary to fund the development and commercialization of its products, and competition from larger companies. The Company has not generated revenue to date and has incurred substantial losses and negative cash flows from operations since its inception.&nbsp;&nbsp;The Company has historically funded its operations through issuances of common and preferred stock.&nbsp;&nbsp; </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company believes that its current cash and cash equivalents as of March 31, 2021<font style="Background-color:#FFFFFF;color:#000000;"> </font>will be sufficient to fund its operations through <font style="Background-color:#FFFFFF;color:#000000;">the end of fiscal year </font>2022. <font style="Background-color:#FFFFFF;color:#000000;">Conducting a Phase 3 rNAPc2 clinical trial or the Phase 3 PRECISION-AF trial would likely require additional financing</font>. <font style="Background-color:#FFFFFF;color:#000000;">However, changing circumstances may cause us to consume capital significantly faster or slower than currently anticipated. The Company has based these estimates on assumptions that may prove to be wrong, and the Company could exhaust its available financial resources sooner than the Company currently anticipates. Therefore, the Company may have to raise additional capital for clinical trials of </font>rNAPc2<font style="Background-color:#FFFFFF;color:#000000;"> and will have to raise additional capital for clinical trials of Gencaro. The Company may not be able to raise sufficient capital on acceptable terms, or at all, to continue development of </font>rNAPc2<font style="Background-color:#FFFFFF;color:#000000;"> or Gencaro or to otherwise continue operations and may not be able to execute any strategic transaction</font>.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s liquidity, and its ability to raise additional capital or complete any strategic transaction, depends on a number of factors, including, but not limited to, the following: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the costs and timing for the potential additional clinical trials in order to gain possible regulatory approval for rNAPc2, Gencaro or any other product candidate; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the market price of the Company&#8217;s stock and the availability and cost of additional equity capital from existing and potential new investors; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the Company&#8217;s ability to retain the listing of its common stock on the Nasdaq Capital Market; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">general economic and industry conditions affecting the availability and cost of capital, including as a result of the COVID-19 pandemic; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the terms and conditions of the Company&#8217;s existing collaborative and licensing agreements. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The sale of additional equity or convertible debt securities would likely result in substantial additional dilution to the Company&#8217;s stockholders. If the Company raises additional funds through the incurrence of indebtedness, the obligations related to such indebtedness would be senior to rights of holders of the Company&#8217;s capital stock and could contain covenants that would restrict the Company&#8217;s operations. The Company also cannot predict what consideration might be available, if any, to the Company or its stockholders, in connection with any strategic transaction. Should strategic alternatives or additional capital not be available to the Company, or not be available on acceptable terms, the Company may be unable to realize value from its assets and discharge its liabilities in the normal course of business which may, among other alternatives, cause the Company to further delay, substantially reduce or discontinue operational activities to conserve its cash resources.&nbsp;&nbsp;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Basis of Presentation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying unaudited financial statements of the Company were prepared in accordance with generally accepted accounting principles for interim financial information and instructions to Form 10-Q and pursuant to Regulation S-X.&nbsp;&nbsp;Accordingly, these financial statements do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America (GAAP) for complete financial statements.&#160; In the opinion of management, these financial statements include all normal and recurring adjustments considered necessary for a fair presentation of these interim financial statements.&nbsp;&nbsp;The results of operations for the three months ended March 31, 2021 are not necessarily indicative of results expected for the full year ending December&#160;31, 2021.&#160; The Company has generated no revenue to date and its activities have consisted of seeking regulatory approval, research and development, exploring strategic alternatives for further developing and commercializing rNAPc2 and Gencaro, and raising capital. These unaudited financial statements should be read in conjunction with the audited financial statements and footnotes thereto for the year ended December&#160;31, 2020 included in the Company&#8217;s Annual Report on Form 10-K filed with the Securities and Exchange Commission. Amounts presented are rounded to the nearest thousand, where indicated, except per share data and par values.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentrations of Credit Risk </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company has no off-balance-sheet concentrations of credit risk, such as foreign exchange contracts, option contracts, or foreign currency hedging arrangements. The Company maintains cash and cash equivalent balances in the form of bank demand deposits and money market fund accounts with financial institutions that management believes are creditworthy. Such balances may at times exceed the insured amount. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_ComprehensiveLossPolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Comprehensive Loss</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive loss is defined as the change in equity during a period from transactions and other events and/or circumstances from non-owner sources. If the Company had comprehensive gains (losses), they would be reflected in the statement of operations and comprehensive loss and as a separate component in the statement of stockholders&#8217; equity. There were no elements of comprehensive loss during the three months ended March 31, 2021&#160;and&#160;2020.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Leases</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determines if an arrangement is a lease at inception.&nbsp;&nbsp;Operating leases are included in right-of-use (ROU) asset &#8211; operating and lease obligations are included in accrued expenses and other liabilities and operating lease liability on the Company&#8217;s March 31, 2021 and December&#160;31, 2020 balance sheets.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ROU lease assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease obligations represent the Company&#8217;s obligation to make lease payments arising from the lease. Operating ROU lease assets are recognized at the commencement date based on the present value of lease payments over the lease term. As the Company&#8217;s lease does not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments.&nbsp;&nbsp;The Company&#8217;s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_AccruedOutsourcingExpensesPolicyTextBlock', window );">Accrued Outsourcing Expenses</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Accrued Outsourcing Expenses </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of the process of preparing its financial statements, the Company is required to estimate accrued outsourcing expenses. This process involves identifying services that third parties have performed on the Company&#8217;s behalf and estimating the level of service performed and the associated cost incurred for these services as of the balance sheet date. Examples of estimated accrued outsourcing expenses include contract service fees, such as fees payable to contract manufacturers in connection with the production of materials related to the Company&#8217;s drug product, and service fees and pass through costs from clinical research organizations. The Company develops estimates of liabilities using its judgment based upon the facts and circumstances known at the time. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Recent Accounting Pronouncements</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company reviewed recently issued accounting pronouncements and concluded that they were either not applicable or not expected to have a significant impact to the financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_AccruedOutsourcingExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued outsourcing expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_AccruedOutsourcingExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_ComprehensiveLossPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Comprehensive loss policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_ComprehensiveLossPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_DescriptionOfBusinessPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_DescriptionOfBusinessPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_LiquidityAndGoingConcernPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liquidity and going concern.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_LiquidityAndGoingConcernPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140460313453256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Summary of Potentially Dilutive Shares of Common Stock</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because the Company reported a net loss for the three months ended March 31, 2021 and 2020, all potentially dilutive shares of common stock have been excluded from the computation of the dilutive net loss per share for all periods presented.<font style="font-size:12pt;">&nbsp;&nbsp;</font>Such potentially dilutive shares of common stock consist of the following:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.8%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Potentially dilutive securities, excluded:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding stock options</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">596,497</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,890</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants to purchase common stock</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">133,401</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">133,401</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.18%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">729,898</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">164,291</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140460232329192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property Plant And Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Summary of Property and Equipment</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment consist of the following (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Estimated Life</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2021</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.1%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 years</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lab equipment</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5 years</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">146</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">146</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and fixtures</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5 years</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer software</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:20.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 years</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">280</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">271</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated depreciation and amortization</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:20.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(253</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(250</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.52%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:20.1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140460305529272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Future Minimum Commitments due Under October 2020 Lease Agreement</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Future minimum commitments due under the October 2020 Lease agreement as of March 31, 2021 are as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:55.82%;">
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Remainder of 2021</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">125</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total remaining lease payments</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.56%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">556</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: imputed lease interest</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(106</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: Current portion</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(56</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.78%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liability, net of current portion</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">394</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140460232356904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Financings and Warrants (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Summary of Warrants by Year of Expiration</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March 31, 2021, these warrants, by year of expiration, are summarized below:</p>
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:60%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.16%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year of Expiration</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.36%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Number</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">of Warrants</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.62%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Weighted Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exercise Price</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.16%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.36%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">133,401</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.62%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109.80</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140460305561528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Non-cash, Share-based Compensation Expense</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the three month periods ended March 31, 2021 and 2020, the Company recognized the following non-cash, share-based compensation expense in the statements of operations (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Three Months</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Ended March 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.88%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">141</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activities</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock option transactions for the three month period ended March 31, 2021 under the Company&#8217;s stock incentive plans were as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Number</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">of Options</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Weighted Average Exercise Price</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Term</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(in years)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options outstanding at December&#160;31, 2020</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">531,238</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.71</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.68</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67,200</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.30</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited and cancelled</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,941</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72.33</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options outstanding at March 31, 2021</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">596,497</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.01</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.51</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options exercisable at March 31, 2021</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66,125</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38.02</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.68</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options vested and expected to vest</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">595,774</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.01</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.51</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140460333634360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The Company and Summary of Significant Accounting Policies (Details Textual)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosureOffbalanceSheetRisksAmountAsset', window );">Concentrations of credit risk</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosureOffbalanceSheetRisksAmountAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of financial assets, which are not recognized in the financial statements (off-balance sheet) because they fail to meet some other criterion for recognition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13433-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosureOffbalanceSheetRisksAmountAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140460228035160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Summary of Potentially Dilutive Shares of Common Stock (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="nump">729,898<span></span>
</td>
<td class="nump">164,291<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember', window );">Outstanding stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="nump">596,497<span></span>
</td>
<td class="nump">30,890<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="nump">133,401<span></span>
</td>
<td class="nump">133,401<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140460307592152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Disclosures (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount', window );">Transfers of assets between fair value hierarchy levels</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring | Level 1 | Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents consisting of money market funds and commercial paper</a></td>
<td class="nump">$ 66,900,000<span></span>
</td>
<td class="nump">$ 49,100,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value assets between hierarchy levels transfers amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140460226796120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment - Summary of Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, Gross</a></td>
<td class="nump">$ 280<span></span>
</td>
<td class="nump">$ 271<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation and amortization</a></td>
<td class="num">(253)<span></span>
</td>
<td class="num">(250)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">$ 27<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, Gross</a></td>
<td class="nump">$ 37<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Lab Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, Gross</a></td>
<td class="nump">$ 146<span></span>
</td>
<td class="nump">146<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, Gross</a></td>
<td class="nump">$ 38<span></span>
</td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Computer Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, Gross</a></td>
<td class="nump">$ 59<span></span>
</td>
<td class="nump">$ 56<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140460330520840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Details Textual) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property Plant And Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140460229684728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Arrangements (Details Textual) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefExecutiveOfficerMember', window );">Chief Executive Officer | Research Grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Total expense</a></td>
<td class="nump">$ 107<span></span>
</td>
<td class="nump">$ 70<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140460225462920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details Textual)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 29, 2020 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 01, 2013 </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of office facilities taken on lease | ft&#178;</a></td>
<td class="nump">5,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease term</a></td>
<td class="text">42 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Additional operating lease term</a></td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Lease renewal option</a></td>
<td class="text">option to renew for an additional 36 month term at the then prevailing rental rate.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend', window );">Lessee, Operating Lease, Existence of Option to Extend [true false]</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent', window );">Lessee, operating lease, assumptions and judgments, allocation of lease and nonlease component</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The lease includes real estate taxes and insurance, which is not a lease component and is not included in the lease obligation.  In addition, common area maintenance charges are based on actual costs incurred and are a non-lease component that is not included in the lease obligation.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating lease, cash paid for measurement of lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Accrued expenses and other liabilities<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Operating lease liability, net of current portion<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22<span></span>
</td>
<td class="nump">$ 23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_CommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_CommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of assumptions and judgments used by lessee for allocating contract between lease and nonlease components for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee has option to extend operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140460226636040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Future Minimum Commitments due Under October 2020 Lease Agreement (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">Remainder of 2021</a></td>
<td class="nump">$ 64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2025</a></td>
<td class="nump">96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour', window );">Thereafter</a></td>
<td class="nump">125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total remaining lease payments</a></td>
<td class="nump">556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed lease interest</a></td>
<td class="num">(106)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: Current portion</a></td>
<td class="num">$ (56)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Accrued expenses and other liabilities<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, net of current portion</a></td>
<td class="nump">$ 394<span></span>
</td>
<td class="nump">$ 409<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease liability payments due after year four.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140460223081752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Financings and Warrants (Details Textual) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 03, 2020</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Apr. 30, 2021</div></th>
<th class="th"><div>Jul. 22, 2020</div></th>
<th class="th"><div>Jul. 14, 2020</div></th>
<th class="th"><div>Jan. 11, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_EquityFinancingAndWarrantsLineItems', window );"><strong>Equity Financing And Warrants [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,410,143<span></span>
</td>
<td class="nump">9,548,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=abio_JonesTradingInstitutionalServicesLLCMember', window );">JonesTrading</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_EquityFinancingAndWarrantsLineItems', window );"><strong>Equity Financing And Warrants [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_SellingCommissionPerAdditionalSharesSoldPercentage', window );">Percentage of selling commission per additional shares sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=abio_CapitalOnDemandSalesAgreementMember', window );">Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_EquityFinancingAndWarrantsLineItems', window );"><strong>Equity Financing And Warrants [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,214,301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_NetProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=abio_CapitalOnDemandSalesAgreementMember', window );">Sales Agreement | JonesTrading</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_EquityFinancingAndWarrantsLineItems', window );"><strong>Equity Financing And Warrants [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_CommonStockAuthorizedOfferingAmountUnderAgreementToSell', window );">Aggregate offering price of common stock authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,400<span></span>
</td>
<td class="nump">$ 7,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=abio_NewCapitalOnDemandSalesAgreementMember', window );">2020 Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_EquityFinancingAndWarrantsLineItems', window );"><strong>Equity Financing And Warrants [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,300<span></span>
</td>
<td class="nump">$ 28,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_CommonStockAuthorizedOfferingAmountUnderAgreementToSell', window );">Aggregate offering price of common stock authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,861,993<span></span>
</td>
<td class="nump">5,066,279<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=abio_NewCapitalOnDemandSalesAgreementMember', window );">2020 Sales Agreement | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_EquityFinancingAndWarrantsLineItems', window );"><strong>Equity Financing And Warrants [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_CommonStockAuthorizedOfferingAmountUnderAgreementToSell', window );">Aggregate offering price of common stock authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=abio_DirectOfferingMember', window );">Direct Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_EquityFinancingAndWarrantsLineItems', window );"><strong>Equity Financing And Warrants [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Common stock issued</a></td>
<td class="nump">348,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Purchase price per share</a></td>
<td class="nump">$ 9.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Pre-funded warrants to purchase shares of common stock</a></td>
<td class="nump">325,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Purchase price per warrant</a></td>
<td class="nump">$ 8.999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of common stock</a></td>
<td class="nump">$ 5,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_SellingCommissionPerAdditionalSharesSoldPercentage', window );">Percentage of selling commission per additional shares sold</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_CommonStockAuthorizedOfferingAmountUnderAgreementToSell">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock, authorized offering amount under agreement to sell.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_CommonStockAuthorizedOfferingAmountUnderAgreementToSell</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_EquityFinancingAndWarrantsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity financing and warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_EquityFinancingAndWarrantsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_NetProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital, net of related financing costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_NetProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_SellingCommissionPerAdditionalSharesSoldPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Selling commission per additional shares sold percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_SellingCommissionPerAdditionalSharesSoldPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=abio_JonesTradingInstitutionalServicesLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=abio_JonesTradingInstitutionalServicesLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abio_CapitalOnDemandSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abio_CapitalOnDemandSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abio_NewCapitalOnDemandSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abio_NewCapitalOnDemandSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=abio_DirectOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=abio_DirectOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140460232573880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Financings and Warrants - Summary of Warrants by Year of Expiration (Details) - 2022<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class Of Warrant Or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_WarrantsExpirationYear', window );">Year of Expiration</a></td>
<td class="text">2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants | shares</a></td>
<td class="nump">133,401<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Weighted Average Exercise Price | $ / shares</a></td>
<td class="nump">$ 109.80<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_WarrantsExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Year during which outstanding warrants of company stock will expire.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_WarrantsExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=abio_WarrantExpirationTwoThousandAndTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=abio_WarrantExpirationTwoThousandAndTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140460228030088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation - Summary of Non-cash, Share-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total expenses</a></td>
<td class="nump">$ 141<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total expenses</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total expenses</a></td>
<td class="nump">$ 105<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140460226860968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation - Summary of Stock Option Activities (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Stock Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Options outstanding, beginning of period</a></td>
<td class="nump">531,238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options, Granted</a></td>
<td class="nump">67,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Number of Options, Forfeited and cancelled</a></td>
<td class="num">(1,941)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Options outstanding, end of period</a></td>
<td class="nump">596,497<span></span>
</td>
<td class="nump">531,238<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options, Options exercisable, end of period</a></td>
<td class="nump">66,125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of Options, Options vested and expected to vest</a></td>
<td class="nump">595,774<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Stock Options, Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Options outstanding, beginning of period</a></td>
<td class="nump">$ 8.71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="nump">4.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Forfeited and cancelled</a></td>
<td class="nump">72.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Options outstanding, end of period</a></td>
<td class="nump">8.01<span></span>
</td>
<td class="nump">$ 8.71<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Options exercisable, end of period</a></td>
<td class="nump">38.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Options vested and expected to vest, end of period</a></td>
<td class="nump">$ 8.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Stock Options, Weighted Average Remaining Contractual Term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term (in years), Options outstanding</a></td>
<td class="text">9 years 6 months 3 days<span></span>
</td>
<td class="text">9 years 8 months 4 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term (in years), Options exercisable</a></td>
<td class="text">7 years 8 months 4 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term (in years), Options vested and expected to vest</a></td>
<td class="text">9 years 6 months 3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140460232354744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Details Textual)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUncertainTaxPositionsCurrent', window );">Reserve for uncertain tax positions</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUncertainTaxPositionsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for uncertainty in income taxes classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUncertainTaxPositionsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>49
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MAAK(W1N(W8T6M3W$KX36HK27.:, W1C _QLA].'&O!=HWP,M_@502P,$%
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M37\Z[<!<:P]^67Q>;+I6R$,+SZ0I.DN;&0XF':L:UX*"W8K2%&>>WC/U!JW
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M*/1_O$$F\E/CDD24K51^2/=^W]@MB4E*$,N^/&FA)),G36@C]QZP.C)KED.
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M43AS=_ZPS%."T<6-")GYHPEWH@ 3YIY_\1S.<MQ^HMX,X=C7>UA2!")X@,4
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MVD#S7WS-:>!&QP+T?64II9H% W0C_.(O4$L#!!0    ( +: JU(UM8^4W@(
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M9G%2N4.Y)<-O)>-H>H.%($QA*0SM8&:,4&ODHI,=A\3\SBM,6JYYPQ6_PC6
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M;:<<>,^MT[_"K3'/)(MU#TJ+Q/^1=/<CBEF3VELL JI:(-?WC'"3=SN KZF
M?KC4C1]N)M@P[7(=/8J<G!J-29GCX(1$ N%,WZ^[O\#/^YWAK2Z97W>0 K1\
MF$]FPVDV25L/J"[/'UI[[LT+@^O"@S,#)'6)%M5QW3Q4T3G)[]C G\J,56"W
MP*#/1EDWZ87<2*7E CGN:+/OM=2;*L2R8(Q#X[L.N+\VI77-I0S[@/!30QC!
MMQ-Q?3P5SS]:K,K3Z7$^G\U/YB]&NW7QZT/[TB-[4EQ=L&MME&T\ %VQ)#,9
MW)0NCI^-=/RC6/8#FV-?--B("$4N.TA\6J5P&83'J1(.URJ,)^O*- 2[X8"4
M<+L=<X6U*4JS5&$B81Y5D?>6$H_M@-E(W5![*"YD[&-T6S0^->L5EJ&;X^MB
M;2-%UFSHF+DX#A=;DH:K$0M,0C1E=^.()0"L.K>'3"9WH#8^BF90*2/@$$23
M;K;JO\SJ?-U]=?3O]N2[_N31QZ9:)%;LDG+T-=X=(76Y(8=E#<?3MBD^\;0X
M@B/YT003?Y9-CIX=3;+3T4GVT+UEO'<1K,BMXG675^[&A'0G[-_V-^K+=)'<
M'4_7<<"PPA 4FI80S48OYX/$(]U#L'6\5BYL  _%KVO"TN'X 'Y?6ANZ!S;0
M_Y_AXG]02P,$%     @ MH"K4OZEMRJI P  _ <  !D   !X;"]W;W)K<VAE
M971S+W-H965T,30N>&ULK55-;^,V$+WS5Q!J422 U_JR+3MK&\C'=MO#=@TG
M[1Z*'FAI9!&12)>DXJ2_OC.4K770.*<>+).CF3=O'D?#^5Z;1UL!./[<U,HN
M@LJYW548VKR"1MBAWH'"-Z4VC7"X-=O0[@R(P@<U=9A$T21LA%3!<NYM*[.<
MZ];54L'*<-LVC3 O-U#K_2*(@Z-A+;>5(T.XG._$%N[!_;Y;&=R%/4HA&U!6
M:L4-E(O@.KZZ&9&_=_A#PMZ>K#E5LM'ZD3:_%HL@(D)00^X(0>#?$]Q"71,0
MTOC[@!GT*2GP='U$_]G7CK5LA(5;77^3A:L6P33@!92BK=U:[W^!0SUCPLMU
M;?V3[SO?+ EXWEJGFT,P,FBDZO[%\T&'DX!I="8@.00DGG>7R+.\$TXLYT;O
MN2%O1*.%+]5'(SFIZ%#NG<&W$N/<\KX2!CY0706_U0V>M14DUSQTB$X^87Y
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M%48M@Z_Y)U(Z><WY]Z]$]7"CTM2V$"OE %F8RF*#F#6QQLD&Y_(8@),NX,7
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MX>,TD5-4QQ[&8G&"?#1F,I/N$P7,:%V7E VW=12U8U*'BQ,9R')*$JC2P=/
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M4L<_S>>?I8/>$;HIB;D3QU"[ 962:KC63J^,5/X'SCH\9 HSJ?4)TSEKE5]
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MT #\3KV4_($VZ/Z%QMO_ U!+ P04    " "V@*M2G$[.HM "   *!@  &0
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M%Z.8V6YH=!LT36C4E4%J^["L:<Z"]0YT7AF#NXTGZ"?W["]02P,$%     @
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M#R-JFB+33)RNPL?>:(=E(@Q+K,M@? #N%UJ[_<0+=)5^\1=02P,$%     @
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MH V@^ZU2YFC8!,,CN/@+4$L#!!0    ( +: JU+KY?4GT@,  )L(   9
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M&V\'1M:N$]Y* WW5O59P]2'*!L!Z*:';=0.[@;],3?\ 4$L#!!0    ( +:
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MI!]ND.X,"KI9#VK6@Y=W%YKNYJ"Z> XZ^K;!<K#%DNSH[%'-\<C)<<*S5:%
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M;LJ!XBM[/[CE2M\V[.-27PA!F #]?LZY>AJ8!>HKYO@O4$L#!!0    ( +:
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M+9$)>QD$U(T?[95&6A1_K.@I ^,,Z'ZM->X%YZ!_'/,_4$L#!!0    ( +:
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MK,P9-LJY<6Y5*'#IW&W]7F=$LY2"#XPL) &U8:J)P#:!7(? 11"8 9.@_1-
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MJ"P![4^E-.N%O0M6_UT8_PM02P,$%     @ MH"K4FO(DSA> P  ]PD  !D
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MZ['V $0E%S338,D@2_+-)W[0A6@!H-L#0!J #@4X&N <"G UP#T4X&F =RC
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MQ>/F1M"B>HUU0X6@676Y(C@F3 V0WR\H%=L;]6:L?OT[^1]02P,$%     @
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M*AM UZ=2FM7&WJ#^+NG_ U!+ P04    " "V@*M28M3KENH#  "'$   &0
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M7JS3E"B[WG*B^-8VCDNN=!MJAQN@*0BS03]?<:Z.$Z.@_N]A^@]02P,$%
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M<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ MH"K4NEZ!BQ[ P  :!<
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M              "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%
M  @ MH"K4O?N/G93!0  '!8  !@              ("!#0@  'AL+W=O<FMS
M:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( +: JU+1IJ<U_ 0  !,2   8
M              " @98-  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"
M% ,4    " "V@*M2W:;30'0"  "0!@  &               @('($@  >&PO
M=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ MH"K4L0Q"'9J P
MMPH  !@              ("!<A4  'AL+W=O<FMS:&5E=',O<VAE970T+GAM
M;%!+ 0(4 Q0    ( +: JU(;V8;$!P8  ,D?   8              " @1(9
M  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    " "V@*M2WC(G
M +P%  !6%@  &               @(%/'P  >&PO=V]R:W-H965T<R]S:&5E
M=#8N>&UL4$L! A0#%     @ MH"K4E.1/OSW$   [BT  !@
M ("!024  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( +:
MJU)?D:#,9 ,   D(   8              " @6XV  !X;"]W;W)K<VAE971S
M+W-H965T."YX;6Q02P$"% ,4    " "V@*M2G;O?R\@$  #."P  &
M        @($(.@  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%
M  @ MH"K4C6UCY3> @  808  !D              ("!!C\  'AL+W=O<FMS
M:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    " "V@*M2[6;;$_4"  "U!@
M&0              @($;0@  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+
M 0(4 Q0    ( +: JU(@W*5:5P8  ,</   9              " @4=%  !X
M;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ MH"K4H="1I'$
M!@  <Q   !D              ("!U4L  'AL+W=O<FMS:&5E=',O<VAE970Q
M,RYX;6Q02P$"% ,4    " "V@*M2_J6W*JD#  #\!P  &0
M@('04@  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( +:
MJU*W=0U:(0,  .D&   9              " @;!6  !X;"]W;W)K<VAE971S
M+W-H965T,34N>&UL4$L! A0#%     @ MH"K4K_-5AN2$0  K3$  !D
M         ("!"%H  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4
M    " "V@*M2G$[.HM "   *!@  &0              @('1:P  >&PO=V]R
M:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( +: JU+Q2%LBH@(  ,4%
M   9              " @=AN  !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL
M4$L! A0#%     @ MH"K4GT<NK/& @  ]04  !D              ("!L7$
M 'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    " "V@*M2& )E
MK%@"   0!0  &0              @(&N=   >&PO=V]R:W-H965T<R]S:&5E
M=#(P+GAM;%!+ 0(4 Q0    ( +: JU+KY?4GT@,  )L(   9
M  " @3UW  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @
MMH"K4I^Z#^XS @  [ 0  !D              ("!1GL  'AL+W=O<FMS:&5E
M=',O<VAE970R,BYX;6Q02P$"% ,4    " "V@*M2[\UO1.8"  !8"0  &0
M            @(&P?0  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4
M Q0    ( +: JU*87@YF[0(  +X'   9              " @<V   !X;"]W
M;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ MH"K4@X%B!R  P
M;@X  !D              ("!\8,  'AL+W=O<FMS:&5E=',O<VAE970R-2YX
M;6Q02P$"% ,4    " "V@*M2YVM[$C\"   H!0  &0              @(&H
MAP  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( +: JU)O
M2DA[80(  ((%   9              " @1Z*  !X;"]W;W)K<VAE971S+W-H
M965T,C<N>&UL4$L! A0#%     @ MH"K4KZ4&>S=!   :1   !D
M     ("!MHP  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( +: JU)BU.N6Z@,  (<0   9              "
M@3.@  !X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ MH"K
M4GT;R!;G 0  S0,  !D              ("!5*0  'AL+W=O<FMS:&5E=',O
M<VAE970S-"YX;6Q02P$"% ,4    " "V@*M2^XB8V! #   P$0  #0
M        @ %RI@  >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( +: JU*7BKL<
MP    !,"   +              "  :VI  !?<F5L<R\N<F5L<U!+ 0(4 Q0
M   ( +: JU+I>@8L>P,  &@7   /              "  9:J  !X;"]W;W)K
M8F]O:RYX;6Q02P$"% ,4    " "V@*M2C-]?K6X!  #=%   &@
M    @ $^K@  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4
M" "V@*M2!E="=X\!  !P%0  $P              @ 'DKP  6T-O;G1E;G1?
@5'EP97-=+GAM;%!+!08     *@ J %T+  "DL0     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>85</ContextCount>
  <ElementCount>233</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>21</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="abio-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="abio-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - BALANCE SHEETS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/20210331/taxonomy/role/StatementBALANCESHEETSUnaudited</Role>
      <ShortName>BALANCE SHEETS (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="abio-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100020 - Statement - BALANCE SHEETS (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/20210331/taxonomy/role/StatementBALANCESHEETSUnauditedParenthetical</Role>
      <ShortName>BALANCE SHEETS (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="abio-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100030 - Statement - STATEMENTS OF OPERATIONS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/20210331/taxonomy/role/StatementSTATEMENTSOFOPERATIONSUnaudited</Role>
      <ShortName>STATEMENTS OF OPERATIONS (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="abio-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100040 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/20210331/taxonomy/role/StatementSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited</Role>
      <ShortName>STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="abio-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100050 - Statement - STATEMENTS OF CASH FLOWS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/20210331/taxonomy/role/StatementSTATEMENTSOFCASHFLOWSUnaudited</Role>
      <ShortName>STATEMENTS OF CASH FLOWS (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="abio-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100060 - Disclosure - The Company and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>The Company and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="abio-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100070 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureNetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="abio-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100080 - Disclosure - Fair Value Disclosures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureFairValueDisclosures</Role>
      <ShortName>Fair Value Disclosures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="abio-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100090 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosurePropertyAndEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="abio-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100100 - Disclosure - Related Party Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureRelatedPartyArrangements</Role>
      <ShortName>Related Party Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="abio-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="abio-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Equity Financings and Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureEquityFinancingsAndWarrants</Role>
      <ShortName>Equity Financings and Warrants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="abio-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Share-based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureShareBasedCompensation</Role>
      <ShortName>Share-based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="abio-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="abio-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100150 - Disclosure - The Company and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>The Company and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="abio-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100160 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureNetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureNetLossPerShare</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="abio-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100170 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosurePropertyAndEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosurePropertyAndEquipment</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="abio-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100180 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="abio-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Equity Financings and Warrants (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureEquityFinancingsAndWarrantsTables</Role>
      <ShortName>Equity Financings and Warrants (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureEquityFinancingsAndWarrants</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="abio-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Share-based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureShareBasedCompensationTables</Role>
      <ShortName>Share-based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureShareBasedCompensation</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="abio-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100210 - Disclosure - The Company and Summary of Significant Accounting Policies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesDetailsTextual</Role>
      <ShortName>The Company and Summary of Significant Accounting Policies (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="abio-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100220 - Disclosure - Net Loss Per Share - Summary of Potentially Dilutive Shares of Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureNetLossPerShareSummaryOfPotentiallyDilutiveSharesOfCommonStockDetails</Role>
      <ShortName>Net Loss Per Share - Summary of Potentially Dilutive Shares of Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="abio-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Fair Value Disclosures (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureFairValueDisclosuresDetailsTextual</Role>
      <ShortName>Fair Value Disclosures (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureFairValueDisclosures</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="abio-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Property and Equipment - Summary of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails</Role>
      <ShortName>Property and Equipment - Summary of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="abio-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Property and Equipment (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosurePropertyAndEquipmentDetailsTextual</Role>
      <ShortName>Property and Equipment (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosurePropertyAndEquipmentTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="abio-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Related Party Arrangements (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureRelatedPartyArrangementsDetailsTextual</Role>
      <ShortName>Related Party Arrangements (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureRelatedPartyArrangements</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="abio-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Commitments and Contingencies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingenciesDetailsTextual</Role>
      <ShortName>Commitments and Contingencies (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingenciesTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="abio-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Commitments and Contingencies - Future Minimum Commitments due Under October 2020 Lease Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumCommitmentsDueUnderOctober2020LeaseAgreementDetails</Role>
      <ShortName>Commitments and Contingencies - Future Minimum Commitments due Under October 2020 Lease Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="abio-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Equity Financings and Warrants (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureEquityFinancingsAndWarrantsDetailsTextual</Role>
      <ShortName>Equity Financings and Warrants (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureEquityFinancingsAndWarrantsTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="abio-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Equity Financings and Warrants - Summary of Warrants by Year of Expiration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureEquityFinancingsAndWarrantsSummaryOfWarrantsByYearOfExpirationDetails</Role>
      <ShortName>Equity Financings and Warrants - Summary of Warrants by Year of Expiration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="abio-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Share-based Compensation - Summary of Non-cash, Share-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureShareBasedCompensationSummaryOfNonCashShareBasedCompensationExpenseDetails</Role>
      <ShortName>Share-based Compensation - Summary of Non-cash, Share-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="abio-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100330 - Disclosure - Share-based Compensation - Summary of Stock Option Activities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureShareBasedCompensationSummaryOfStockOptionActivitiesDetails</Role>
      <ShortName>Share-based Compensation - Summary of Stock Option Activities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="abio-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100340 - Disclosure - Income Taxes (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureIncomeTaxesDetailsTextual</Role>
      <ShortName>Income Taxes (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/20210331/taxonomy/role/DisclosureIncomeTaxes</ParentRole>
      <Position>34</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>abio-20210331.xml</File>
    <File>abio-20210331.xsd</File>
    <File>abio-20210331_cal.xml</File>
    <File>abio-20210331_def.xml</File>
    <File>abio-20210331_lab.xml</File>
    <File>abio-20210331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>54
<FILENAME>0001564590-21-026534-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001564590-21-026534-xbrl.zip
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M#]**"O1K[((*;#8:\Z%HS8#B"OZ\";\%CWX>AA75Z.]<1"/,)!3UU[,I9L!
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M@<"AG;,UW-F9J]R4PS9/2:PB@9U^H\P]67=]BWJNK:;D.]TM1Q)S.ZR]7))
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M]D86!"_8G#OB.@Q&I4=Y\^O82H]$;$]19+9%()7+S,T@W3G -ZX"4?#'%[4
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MV0)23X<R^60BW-".1ZA.4&)';"+33E9,/@_X&2(>\=20B"R=C'J "8J20TN
MLN&X8N8GC(<V#%24[8Y1J3W7>70 $'&$OA%$ R/*PJ&N /TQ2AQ%Y&8$"C4_
M5U[8(_BA][4TR9&%@(A/_C0$^*4(L ?F>F0:,L\)+!7$^+A6$8!X*9@+XY3
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MB4_L[L6)B1UM;Q]CWJ'[HKS#]O<&3-Y!%TH8"Z,I961^P7AHN-IFIZ<KF8P
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M>#?7#%>V6#ZKS6OW>\7&R G8 O4]N'Z^,YM]SS%WH- '#XEX7/),]V]%"K4
M->!:1B!)GDK^  *E$'S[E9 / Z52D(I$NHJOS /DI8WXK5>XF*DO7TOY+4CT
MQX+._\K#!U"4POKTZ:J&?JO4):_RK[RNH5H5,?/IX@,9KN91A[WM28&1/A#<
M\VJJ3SSVML<6]?3O81C$]T5H:BL;E#$+,6$4@R/? !O2S(R(Q,"5?/HK/@V
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M113X]2#PO.!1'NWQ3[&-BRJB5)BU\YA5)7I)GYBT>(L*.U3;$RRY>T4/!+$
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M#&E%F0Q*K3(&8K87XQ:#RI^1=PSR])VC]^FXX##'S!.U,GM.2RE9(OR4A;&
MJP>74F7*)*JQ?"Z34(@+4!0._Y-<%=SOP#5GR@M >XZ?I4-G1&0VL7IL# :3
M'J PP$.C&:KXW9V*F552*TH2BAR7_,!]F3ET"&3?H:< E3&E[W*<8GE!JMM]
M?B^=J$Q/20!RA :V /PCT/@'J:N%*4"<6T8\*D6 &.+/>"B"R#6^'P(3B1C3
MCR*AD]*>8%I4^A&&LK^73KLM\9ZYB;(!OWQOVX>E:5K*LB-EB%?\2#)#:KU
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MF4=9MZQB(Y?@?4)_8OFU58Y^M+&!I4/2TF9)7$K=I-G=O+Q/613,9Z&0H'+
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M)J#!!Z7ZYICIYM&8:84>*X<?*T'0@:0J0&.,L;%=TALF###7BQ_E7@4N&15
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MYI+!WJYZ(^?Y^ Y$]H7VZ07L_[^*JS^D7*V%;6K7^WN_ITT?(BV94 'X "-
MG=;)/N6MW:BWC;S-(.7G>'27KZ$\JL6#GDG\$2VTS"XOZ]2'"MIL,!I57WE5
MWZGW%A#O>%7][P0$A 67#Q#.W?,C5?H?GGAHNQ!-?0E=FVNA<HS>UW%O?-D
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M1. 2"?. .X\!YXMQ.Q*^H!JXTL ]$-7,5U4H8,(Y9@N=J"3ONE3B' "[G1B
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MWSP BF3H%27G.52\39:0T3?#7A6:'_D*N'1"#;LZ(*U$X&&U9^WGB6&!&%2
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MDEF>A5EUZ?9U$XBYEQ: ZUM>ELM=$?<#^WWIW__QSC\DPN!4YPOC^:4C*(,
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MSV5>.UOIR0RU=#K:9L\<6R9=[_6IRG*7TE-EZVL=7(^@2WU#:/:!8U.HR,?
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M,&""N0(PL\*10K@L6?,5L RI4OT YA>Q3;@CJML?Z=);<DS+TRZK'T?0AJ_
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MD.@#=.F2W8#0Y/5AC!;@_BF;<MCF;0N'1,6(:3H\+FS0Q\G'3P;V1!+*H>>
M6M=SYU2E_ 7-X70*^:'$_.#@3W1>.-V9 [GZGN QM"QAZ)7I:^Z-1^ ,'6ZC
M3'ZP<GC+NF+/))-3ZB4&"<6+FQO"PJ647M<TD:_P_6$PQI89+.6I$1'N(!72
MFHY.RS[[)8AI&6_LF/WA-# "0V?$['[_C2*+Z(K"08RIT$($OQ*I6D3%!DJ3
M_<%CCM5P&IV.?PLL"YHWRVTN,Z,@TY26'8J [:KPE07K&!6%DTQ#BP1I]M]_
MSJY"@,X+92T_SR*&LA9IO2?"[QQS^R]*A[XF$"B!=[4#45.(U%\&7;NO8QB0
M+8]()*'H9[_>@F?D FMH]^C"TS:94B$K=TQ\G$N14^+U%VQ#=JN%237"O4U<
MY'J!EQ)H@L'@5I)?&9+[QP<)!PB!QND,O[1,B/RQ0?_8'A+TT>>^35N4.#Y@
M]YL*,B4VEZ39&L 9L/QV1*=,[&=JRZ0<YT@.$R2ORL#HX",_DP&B)^L[LN2-
MG33IXY)7E[EAQF$X76-.UM@D$%":0SWD0,,-U_Z2DR;^8\V.^@-8T#_7NE/!
M Q&@=HA2Z72PD(F LUSC2<7%2B"B-/*W L%K<6"Y\M.]='+F;B!=?"I$2W_M
MJ8R(6!3L8Z@\%1VY6&CR5+'L-.V<A_W*!,OJP)H=]Y(S O4JOI6PD3C53:E,
MM6UADS[!3XPJH>IQL$NZOXPS^?O5*3@5FOE%05&/,M.L2T8LL]:O3,EI[NHA
M-@ 3B5OV2>'I2B$MZ(3CPU[5*99-G>.2DM6CHC4Q=(D58KUUNFHZJXX2C=E7
MIH:QT*5+;&HEJKZKS\(E+<V4+G.,/KNLS6HEJ]A*I9;E+5'V9D639=Z9UY?5
M5>XJ41S5:H+HUI>*;Q!4Q2.Q:B22O&PU5XSDF0N#ZG A4.X [:\?BV 1/I^Q
M5K (E ^N('A7=J0C7PB4:T0C0 Y3BPH5^T8@5->54!X5RJ7=T55AU5U<Y30T
M-BOTHSO"#LO3DMAD$4+0$4F:U0@"V4TQ*QS$3Z&HSGZNL;=8 &<9^0(WRS\@
M58+3_MLS<H(;!/D&IQ"B['N]Y-NLPSXP":F^[D_0+_O0<XD+;!8QS"SF!BVE
M0HT0F6ALL+$B7)N1]'D67B):DU<\F6./4 GI^)Z\4GN_I,\DR[QDR98V,N1K
MI%+)'(8<NHJ\8EF0+?)*(5*:#-+7D*51*4V*70=)59)!245CDN+MBZ <1\&8
MQ,C>!U@]R\7VJZ5]<M>V3BPOT>M5("9B4;&B9U.9FC%5')(C!4F.:!U.9LS9
M,FPL"B+YJYM=R%E^B=R"> FAYD )C^W< &J&V1EP5%GR(;U:V3]@^Q:0>?Q;
MP;&L:M&2_!NN3,@D1]%T;"SSSP6$9BI#,MZP*,6OQ^]GO2M9X'X^<<F$R'V]
M5B 7631>*Y#WG>1]JE_Q$L*@YB1^CJ\?-CJ"!I[9++_FIQ/8D9OB>\<*9D '
M=ODPK!28R+WI4B(910$8>\%ZKL/K2*(FQ6J'KQ=#"!BS.H4>"KZ)N 9!A\*O
MQBC],N[]&&C0ZJ(KD0@V8<V1M$X/GK/_>:+M_?!_4$L#!!0    ( +: JU*P
MA^3?5S\  !;/ P 5    86)I;RTR,#(Q,#,S,5]L86(N>&UL[7U[<^0X<N?_
M%W'? ==[X=B-D[JE[AGO]NSN.$J/'LO6J&1)L^N]B8L)BD2IZ$$1M21+4NVG
M/SSX %E\ "! @FK;84]UJ9B9S%]F(@$D$G_ZE]<- L\P3D(<_?G=Z?N3=P!&
M/@["Z.G/[W;)L9?X8?@.)*D7!1["$?SSNSU,WOW+]__S?_SI?QT?@XLO5S=@
MX:?A,[P($Q_A9!?#W][_^#OPGV=WU^ ZC'Y]]!((+K"_V\ H!<=@G:;;[SY\
M>'EY>1^LPBC!:)<2[LE['V\^@./CG/1Y##WZ!W#AI1"P__D.?#SY>'I\\NWQ
MZ<G#QY/O/GWSW<?/[[_Y]/'3R:=O_\_)R7<G)P*!O_#7 L+_? >^?7_R_O3]
M/Y]^*_SPUO-_]9X@N+H0?O@(8?#XC7=Z<@I__\VWIW_X_.TWGWY_^NA[?_CH
M??[&\T1)\78?AT_K%/S6_QT3D;QO%$&$X!Y\"2,O\D,/@?O\38_ 5>2_!PN$
MP!U]+ %W,('Q,PS>9U01T=MW*%<>P2A*V#___$[0WNMCC-[C^.G#QY.33Q_R
M7[_+?OYZ\/N73^S7IY\_?_[ _EK\- F;?DC(GG[XSQ^O[_TUW'C'!"IB!3YE
MD(3?)>S+:^PSC"3D JV_H/\ZSG]V3+\Z/OUX_.GT_6L2O"/: (#K(\8(WL$5
MH/_]Z>ZJE>?G#_07'R+X1 PGN/8>(2(R,Q+K&*Z:GT-Q7'F,RO&9RG'ZSU2.
MWS112_=;X@])N-DBHI4/@T6]@:E9:>L$30M\"^,0!Y>1824WD[4C_'WJQ8:U
MWD;8] L\D/@&S8I^2-*XT#CUD&&A#T@:%%K#-M)#.8<:PLI+'AD;,B0_>=Z6
MLT*4Z ?O-4PNX,K;H;113";B 0$R2IU\@"A-Z#>46G),OSH^.<TB[V\:Z+8+
MSD2AHWWV2TJQ8U#@XO,A2* ,7U,8!3"+^@5M[!^\5Y*_6 +]]T_X^4, 0_Y.
MY$/]3<A7OUQ&:9CNSTD*$GOHBC!Y_7>XKW)'=###<?XE>Z4_O^MX^$-53/I[
M.J*23S1[@M'Q3_>RQ'Y!CS7SB&&"=S$;;J4UFI;N^SUG S(^@#$"A-.?/I0"
M'<J_B/V*%%[LYP*0CSTR9+_XX&.2)FS38R0:_2K&FTYM9FQQKY8^=%J']QAB
M:@"G)Y]R0R;?_'(-DP3"Y1;&)&&)GJXAR36N0_(G1-C<>GN:G"87.[A8$27^
M#7KQ%Z)]&?L80EW=@/2YF;&P(,OC6=;W[GLN"<"Y* !160#*A0';3!H0["#P
MJ#Q@3P0"*\+Y_;2F:, L\'! NHU9*]2=8S*A6SPFQ'/\5#;$U1[2"VT5(F8,
MC@/W/:,,?LYI_[_IHUBSEG&K(BP S6/D'7P**:,HO?$V4&U(JS\[9$2KTK(V
MH)5L .4SO2%THH#[-.2:QI&^LJ?-?9!NVF,PN]S%,>%[![<XIN, F0*FNT0Q
MR6RA,2C7;*1I+^7D[$#!#W"&KKAJ#TQ85G6N0H(&HF'"(?+UW@?R%K(.4'U&
M3[LB#?,&7JQB4_+3FW.CDG&;(EQ1*%+2I0EC7! ^ >7U!7E/LM98>TA/>Q4B
MYNVQ( \H_>D-LEG1N%47SB@5J>G39(0L%KOI-I=JJ*P]/,S%*\0L!D_.!Q!&
M;&MO>K/MA@+W:LDYM==#K+3&31KVES#Q/<19?R'?22?"'02&:?J H$4CY[QR
MS3-N[AAZ.S182F-.PE W>B4$3!C^0^S1NHG[_>81(UECKSVDI]D*$?-&G9$'
MG/[T9MRL:-RJ"V>4BM3T:3X:\[5G[5@L/&XB!!3D[,=ARLK-*'P(26,,KNG*
M0?6WQ%\9S1O9]>#K'.6K*:;4[<]K[H6TT#-OZ_D*CZAP=Y+K7ERPC+Y<Q  -
M4;^Y5><O(8+Q.6'VA&/%BH;:HT,6-"NDK"TM,RX@9S.]<7<A@'O4XYBVD9:B
MS9GQ_<9#Z&R7A!%,%/=,:H\.46R%E#4S9EQ SL85,VY& />HQS%M(RU%FS/C
MRPV,GTAR_T.,7]+U.=YLO4@Q*K>0&*+H1I+6S#OG!C@[D/%SQ<Z[(<*2>G,4
M#C0,"8.;X7BSP=%]BOU?[]<>>97E+F7'2(@XBEOBG90&[<)V4+:W/<Z8 L;U
M"'"^0&#LBIM( 8C5U.DV6*@5)R68#.9$:XB0UAA2?7+0&"U0LI<042:NC1.-
MVL?=NG%+TTA'R69GIC>[S2.4*J1N?F[H+(G3L3HA!9R'*V;;H/6#J:BH%9<T
M?#@)[56N.7-]\%ZO D@^KD)^JE''=EN)#%%S"U%K5DWX@2I#QVR\#RHLK3UG
M84%#$3'G&(L@(&^09/^Y)G/I4S6G:"0P1/,-!,UH_1G&C[CN#AF;H_P#/=8.
MP3)R8'6]'R LI3<GP4!-*%1 .)W&_#\.-?^/IC7^T=I8T&S\#R_87>/_*&O\
M'VT8OR$H^HW_XXC&?TX^+N,'_!)IF;[XN %ME^3LFSWE!7 ,*#?'3+X!E":#
MKVO+00":C9VI?MFG>N.V3L]'P&5\&^/G,/*E"PBZ:1A0>HVF?=-G#*GMYRP=
ML_\VH)J<H%%YKH+2[ X<CJ4,',9]XA8GJ8?^;[@]QX&>1]0H&%!]A:)];^#L
M .$'*$/'?*$9H"9/:%";FV T>X$T#$:*RN@+QM!3L?KJ,YJ%2P(-"P5C3)^$
MO".&W*AEW*8)5S2*U)1IPAQINS5TN\:1XK+ZX7-Z2JS3,6^:C -@+)Q9<FS5
M.N[2BDL:1NK*-5E[_A\[+R8@HST_@RQKM:V/#RM^KI&S6'M><,H.7T]ORGV(
M8 E5.:A]I*UXHV?=8R]*0KHVKV?GA\\//+)=HV?S/'S!RCE3;T6E?E"^45LN
M(E"W=@7EFS#W>^CO8I+TG'Y\? A3))T7'SZGI]PZ'0OGW2A9@%?@].-O'W\'
M<H;3VW2KZG&7:EQ2<V:[ G' J(]CLI>O_IJ\-%1IE-7\[#"=BK3,FV_.!>1L
M'&F4U8D"[M.0:QI'>LHVMS)W%?DX)N&>50.PM<%SO(O2>*^^1-=#:LCR4"=I
M:XMV%:["0G;&VY%U#Q4<L:)2'<<,M<.5H24'E4EW(G;D\9L,O-3+3O6I^E$S
MC6%@--&TZ#D%.WJ"T<O[A[GC+9TP85G5N0I)W3%4T6AP"+D>X/2;NG=D7__"
M/)+.-9:KXCJ+6\SG'"J-9M7HJ4.D0M]L%I S!,N5<.-'SM.9QK5:@&(=Q?:W
MNQUNEHLD@6FB8X#U)_5-K4K)0HNW^_O+AWLWK*9%W[A;&V[I-G-83EK*+RV:
M;A;-]2WX@,!09=<(VFM6X3%VW[EDV&UH'-AWHY*<U'S5VG/=3V;UYUZR7D0!
M_<_EWW?ALX>(.,DB/??B>!]&3W_QT$YJZJI(4!\;*086O(3P UX4 )]^@"5G
M-_Q%#4>LI<Y98(8$N A+P#X(3,$B!3E;P/B.[''+= WC2H!1<:^FI_5Q.:1F
MWG$8#^!7!ADW?*8#"=RO(_>TCD2%5P>8*7,I[1S*V ANR*C+2\V^9Q><.6G4
MO?9LU)3M6?&D]EN]-XC="+I<_91 )I12N.XF-""&=!$V'\09@V.\.MXED)L[
M."[OF'+#\N5 PTHZ=!J@/-X75WTQ5OP"6[KJ1;CQ86!D[[F-J66D^UNBI93D
M8#3[VM(EJALUY^FFHP]-%UWSKI-S8Y,'F+,Z E$7+F/ZC11<6$5]+D.#:J@P
M3FRF4/ "-Z.[C) 2WA#$!LT+1 )&DM22H*W9@4L)5#<4S1.#NH:<5'O3]*#D
M,<D,07UJ,#Q9M349<,F&:]H]R/[-I/T6\OV1K3"_$32$"1D!6%^Q-48!B4]T
M,$CW.ML \C3U]2_+P\)ID*O%V=7UU</5Y3U8W%R ^X?E^;__Z_+ZXO+N_I]^
M\X>/I[__([C\CY^N'O[FAB<H(XQUM3P7-#-_$YBR[$=D"SC?Z78E!.$&;,AU
M43&"UFA;<ZCDZ<C^G 1"S9YD>*?.-AH-WC+YGMW"]VDE7G+K[;U'!'6665LH
M#,@(&BE:*+[(^-!KS"DC-[RA!Q$LIR<WM8]JBL]X3+0R>[G9(KR'\ XB+X7!
MH?NKN($$,7U,>HE;<8YX!P/@X\T61@FOW67+3IDLX!%&<!6Z,DV1!Q,KZ]5Y
MX#*_RKF!C!UH&&HF68SBMC3,P?HH#5TG::-LS[7@*_4L @UU*\R64H3DS VW
MDL3O8"FK6YMN8U5=W,K FMZ5AKF/69>QYB:M^^+.>8:<-YCW ,M6/[V=5W<[
M<WGVFGL9_<1,[<LV$+>PQU%LT"*V09N[Q9YM M)3S;G#T*/B)&=SPUGD,6W=
M4V]5K_/XM>RM%_RFVSD1G%US+#$4R6R-'BZ/&CW#A<%QPM8 ,79].=YLPG3#
MRGVCX!Q'U)E@Y"M:;R>9 77)[60M+.:6S'@AN<C.#4N700LKJ,]A9- A**Q<
M7 X42V<Z3>P_VMEQ''./4>25[RE"QM.1S0^U;41[&X<C;14ZM34HW#FF?C;I
MX-EA 4JD96>\P!%(^*UT__OD_<G)*=AZ,7BF_/X(3D].P"9$B"[R)OPR-&^7
MKG$<_@,&P$O!C\2DU^#3Z1$@NCQE8\X%]"'M,IA_>T+(?'/TS>G)T>DWG]@O
M/A]]^\T?CDZ_/<EIADE"UU+8>E=YUYHL_2- :&PA.R^/)N[7U&M"N ]>U\P%
M52R%WXLWQ9FF11"P ^<>NO7"X"HZ][8A2>6%EU;:G92@-F"OK)>ZA=7C@B=Q
MX# X#B/@<[9N>(0"?EA=D^YCA0Y@HOS 500RCI6K)T=VKCN8>F$$@TLOCDCD
M31:^O]OLV&;1!5R%?JB4'LI0TP>LG[J5K9F<!P@X$S>\2@$XK*Y"]T'*O"IG
M!W)^0$3LH@^QD:9:PZ989K-X6RMK2>O$R@V'Z4"E<SYE?AYE>_[D6)VSYD)R
M"RU[E; C+#FS:8SKCB*-IT(UL^TJYK&KEZ=;E[CUXF7,^G(%;#)V"V-V6;GF
M4D4[.2/3T3;RMA<TBI4,-UQ*!;_F=8)N1<X JZ;5!,*1WF_%>?*U!4"X L9V
M.A=C[)-%L=REZ5J'9(S 5"=KVY4.5O^<<ZE6O)I=J5F!#F/3Y#J<$UA(H#*.
MNURQE=Q!KI*3, @%)SF2B_#%;$?=HX9/EVN(2G,4BPZ7N.I!81QW6):[&8-\
MHD+'(!@"W9&\0]C?<=1%FC#K\I,#';J,3X?'+&60L>(VM!'\!A9=AG4J$EI)
MZ(/10M(H#IP'*!M)N]8RN@\:+*FO,1I#%X64E]D!"AU#ZB!BH*"T3M1&T$VR
MVJ_\&(DC!2W]Z#25^#8KS%DD,K<N2WIS-M,5L]S!!-(BBD447,!GB##K/Y3)
MI;:KUTEHR%Y1!V$+?>8R=LQ)@I*A&VXB!Q=6TI[3T* :*@M6XE/PRCUH9*_Y
M 4;$A1$19A%LPBBDODOKBS3\II>4/CP]I,W[3L:0N8Y78>F&]\C"AA5UZ#A$
MJ(H.=:$JMXF\Z&"T'92)&1WWK9U+/,B_W/",=BBZTB[CZ9;E-&LJ^^9SGVN<
MZ%FX^+@!99?DS%LYI0JH:>6M>7'DFH4W@-%DXW4M.:CX SO/U@LHA]'7:$@>
M !/:,)4=@.>2J"W1-%,8LD+31-%\UI/S$1HRA(R5&X;? PV64YB;,* : C2U
MX0T8KGH0L.H%&M. @T>'*]Q,#OF9:SJ"3ZP534WAL"]QG,+2.]+Y1MVXHNH6
MHYXF.;^!J5[:4GM07[D50N93%4(>H,Z1<DS;;58W[M2&4ZI%I5:G2T/R^NZ\
M*NG,2T*?KDZ%:$>BE\Z*OS3) >V^Y%B8SUQR%P D@^0[L([L!JCBB#65.1/,
M,M\J3B\4Y6^ L>6+HISQ=#L)/1HQZ',6<3/O8QPAMIG 6<S"PS0\R[)'C>Y)
M;KD/F]5<A(E/XO4NUMN\UF9A#=0VEN;=\*^0WDE$3Y$_P]A[@@T%1_,8^WH-
M0=YCN[4_4]!5QDJ^5""(,MWHF=OG@IOGS8[V,%BNF.1"Z=6 0567@[X=Z''\
M:H;@@9!C,XJ>)[RH%M4S&0 7@EX]QWU>D&/ ".\]AI@Z[NG)I\QMZ3>_T")B
MC\"\7 F5F?3*L%<8^V%"OK\EC^^B  9_]>+8B]*$%U/*N.U0#NJX#N-H!M<
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M<1&[T4[D.O7&H>H^TT;!7#-3:UZBTK-T3/?H :6CLZP9A[ )0.8)AQUD)W*
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MAZ6+F#%<PR@)GR$]QZP]Z"B1TTR%Y,A;26 KK &B)[ZWC*T+Z:LBBEA#G3-
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M V1_I-TD3O5CE QM2Z?Z&WB-T*^AOH/J3M,4;=!EVS:T*GQN +<X^D';AD(
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M1A7.$TMR,-M8<>-5Y#$SH$POAL!MU3.[(8:.V::I9!_)>5W_6/T+?4]Q+"T
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MTDQO4#F6]4XB&-S[A:C"E,:'7:97;U (&#O79%4:]@MV!6B9L^P&:UMTY&V
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M_OP:^0_0?R:LJ?,L<BA+V=0-[RSCG(V$2U]PT=(R)N$CAK^'Q% /GR%[2U8
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M,S,Q7V-A;"YX;6Q02P$"% ,4    " "V@*M2^>WQ<,01  "O! $ %0
M        @ '1C@  86)I;RTR,#(Q,#,S,5]D968N>&UL4$L! A0#%     @
MMH"K4K"'Y-]7/P  %L\# !4              ( !R*   &%B:6\M,C R,3 S
M,S%?;&%B+GAM;%!+ 0(4 Q0    ( +: JU+5>;3<-B4  )^L @ 5
M      "  5+@  !A8FEO+3(P,C$P,S,Q7W!R92YX;6Q02P4&      8 !@"*
) 0  NP4!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
